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Current agents used for pharmacological reactivation of foetal haemoglobin (HbF) have 
limited application due to moderate therapeutic properties, variable patient response and 
potential cytotoxic effects. Therefore, identification of novel HbF inducing agents is 
still a major research goal to this day.  
Identification of new potential HbF inducers has been mainly based on screening of 
drug libraries. However, this approach has not been very successful in generating new 
promising agents. In the current project, I employed two approaches for identifying 
potential HbF inducers: 1) screening of agents that are structurally similar to 
compounds with known HbF inducing activity; 2) investigating molecular pathways of 
a known HbF inducer with the aim of identifying suitable targets for therapeutic 
manipulation and target-based drug design.  
The first approach involved screening of eleven xanthines including caffeine and nine 
hydroxystilbenic derivatives of resveratrol as potential HbF inducers. However, none of 
the agents had a potent enough HbF inducing activity in order to be considered as 
promising therapeutic agents. In the second approach, decitabine was chosen based on 
its high HbF inducing activity and moderate cytotoxicity in K562 cells and primary 
human erythroid cultures. Chromatin immunoprecipitation was used to characterise 
epigenetic changes in the β-globin gene locus, and quantitative real-time PCR for 
investigation of changes in gene expression levels of ten erythroid-related genes, in the 
presence of the agent. A quantitative iTRAQ proteomic approach coupled with mass 
spectrometry was used for identification of changes in the proteome of decitabine-
treated and un-treated primary human erythroid cultures. The findings suggest that 
decitabine induces HbF production through activation of signal transduction pathways 
rather than through hypomethylation of gene promoters. One such possible pathway is 
the NF-κB pathway. Among the differentially expressed proteins, twenty-seven proteins 
were associated with the action of decitabine. Two of those proteins, ARHGAP4 and 
EGLN2, were previously implicated in hydroxyurea-mediated induction of γ-globin 
gene expression and hypoxia-mediated erythropoiesis, respectively. In addition, the de-
ubiquitinating enzyme USP11 was substantially modulated in the presence of 
decitabine. The exact role of these proteins in γ-globin expression remains to be 
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Red blood cells, the commonest cell type in blood, are responsible for the delivery of 
oxygen to different tissues around the body. Haemoglobin is the iron-containing protein 
within the red blood cells that is responsible for the transport and exchange of oxygen. 
Haemoglobin is a tetrameric protein composed of four polypeptide chains, two α-globin 
and two β-like globin polypeptide chains encoded by individual specific genes. 
Mutations in these genes can lead to a quantitative reduction in the respective globin 
gene or result in the production of haemoglobin variants, referred to as 
haemoglobinopathies.  
 
1.1. Haematopoiesis and Erythropoiesis 
Haematopoiesis refers to the continuous production of cellular blood components from 
haematopoietic stem cells (HSC). Within the haematopoietic system, HSCs form the top 
part of the hierarchy and have the ability to give rise to nine different functional cell 
types through their differentiation properties (Figure 1) (Orkin and Zon, 2008). 
However, despite the ability of self-renewal, HSCs have low proliferating potential and 
usually remain in the G0 phase of the cell cycle (Bradford et al., 1997). The homeostatic 
control thus relies on the highly proliferating and committed multi-potent (ST-HSC), 
oligo-potent (CMP, CLP, GMP, MEP) and lineage-restricted progenitor cells (Pro-T, 
Pro-NK, Pro-B, Pro-DC, erythroblasts, megakaryocytes) within the haematopoietic 
hierarchy (Bryder et al., 2006).   
In mammals, the location of haematopoiesis changes during development, starting in the 
yolk sac followed by sequential migration to the intraembryonic aorta-gonad-
mesonephros (AGM) region, foetal liver, thymus, spleen and finally bone marrow. The 
initial production of HSCs in yolk sac is known as “primitive erythropoiesis”, but it is 
only transient and is rapidly replaced by adult-type haematopoiesis known as “definitive 
haematopoiesis”. The AGM region produces the first adult type HSCs at around E11 in 
embryonic mice (Muller et al., 1994). Definitive haematopoiesis then continues with 
colonisation of HSCs in the foetal liver which serves as a temporary haematopoietic 
territory during the foetal stages of development until birth when the haematopoietic 
cells again migrate and colonise the bone marrow. It has been suggested that none of 
these sites can generate HSCs de novo, but rather expand populations of HSCs that have 
migrated to these sites (Houssaint, 1981). Moreover, HSCs have also been located in the 
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placenta around the same time as HSCs appear in AGM (Gekas et al., 2005). However, 
their exact role in haematopoiesis is still unknown. 
 
 
Figure 1, Haematopoiesis. All progenitors originate from pluripotent stem cells that have the 
ability for self renewal. Except for lymphocytes, all white and red blood cells originate from a 
single progenitor from the myeloid lineage. Abbreviations: LT-HSC, long-term haematopoietic 
stem cell; ST-HSC, short-term haematopoietic stem cell; CMP, common myeloid progenitor; 
CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, 
granulocyte/macrophage progenitor; RBCs, red blood cells. Adapted from Orkin and Zon 
(2008) Cell 132(4):631-644 and http://stemcells.nih.gov/info/basics/pages/basics4.aspx  
 
Adult haematopoiesis begins with the HSC and proceeds unidirectionally in a primarily 
irreversible process under normal physiological steady-state conditions. HSCs form 
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capacity for self-renewal. Multipotent progenitors then give rise to the oligopotent 
common lymphoid progenitor and common myeloid progenitor which have a more 
restricted developmental potential. Such oligopotent progenitors in turn give rise to 
more lineage-restricted progenitors from which all the mature blood cells arise (Bryder 
et al., 2006) (Figure 1).  
Mature enucleated erythrocytes are produced from such lineage-restricted erythroid 
progenitors in a process known as erythropoiesis. Primitive erythrocytes, originating in 
the blood island of the yolk sac, are relatively large cells characterised by the expression 
of embryonic globins and are the only erythrocytes that retain their nucleus when 
entering the circulation. During definitive erythropoiesis, enucleated erythropoietic cells 
are produced initially in foetal liver and later in blood, replacing the embryonic red 
blood cells. Near the time of birth, the site of erythropoiesis switches to the bone 
marrow and spleen, with the bone marrow being responsible for the steady-state 
regulation of adult erythropoiesis (Figure 2).  
The earliest recognizable erythroid committed progenitors are the proerythroblasts 
which are identified in the bone marrow. When stained with Giemsa or Wright stain, 
proerythroblasts appear as large cells with dark-blue cytoplasm and a central nucleus 
with slightly clumped chromatin. By a series of progressive cell divisions, 
proerythroblasts give rise to basophilic, polychromatic and orthochromatic erythroblasts 
which accumulate progressively more haemoglobin and decrease in size while the 
nuclear chromatin becomes more condensed and the RNA and protein producing 
apparatus are removed from the cytoplasm (Figure 3). Although protein synthesis is 
active throughout the erythroid maturation, haemoglobin production is activated at the 
polychromatic normoblast stage and continues to the reticulocyte stage of development 
after which no further protein synthesis occurs in red blood cells. RNA synthesis 
continues up to the orthochromatic stage after which nucleotide synthesis ceases. 
Similarly DNA synthesis is active in early stages and but not in the late polychromatic 
and orthochromatic erythroblasts (Borsook, 1964, Weatherall, 1974). When the nucleus 
is finally extruded from the erythroblasts, reticulocytes are formed within the bone 
marrow and are still able to synthesise haemoglobin and still contain some ribosomal 




       
Figure 2, Developmental regulation of globin gene expression during ontogeny. The site of 
erythropoiesis changes during development (top panel) while the levels of expression of 
embryonic (ζ & ε), foetal (α & γ) and adult (α & β) globin chains vary at different gestational 
ages. Adapted from the www.medicalbiochemistrypage.org  
                                           
       
Figure 3, Erythropoiesis. During foetal development, HSCs migrate to the bone marrow that 
constitute the main site of erythropoiesis for the rest of the adult life. The earliest recognisable 
erythroid progenitors are the proerythrolasts which are identified in the bone marrow. By a 
series of progressive cell divisions, proerythroblasts (Pro-EB) give rise to basophilic (Baso-EB), 
polychromatic (Poly-EB) and orthochromatic erythroblasts which accumulate progressively 
more haemoglobin and reduce in size while the nuclear chromatin becomes more condensed and 
the RNA and protein producing apparatus are removed from the cytoplasm. Early progenitors 
express high levels of proliferation markers (CD71) and minimal levels of differentiation 
markers (GPA), whereas the differentiated cells have low proliferation and high differentiation 








Once they are released into the circulation, they circulate in the peripheral blood for 1-2 
days before they mature, mainly in the spleen, with all the RNA being lost resulting in 
the formation of a non-nucleated biconcave disc known as the mature red blood cell 
(Figure 3). 
Schofield (1978) was the first to introduce the importance of stem cell 
microenvironment, the niche that can extrinsically influence stem cell behaviour. 
Subsequent studies have confirmed the importance of localised extracellular signals in 
regulating stem cell self-renewal and differentiation. Experiments in genetically 
modified mice have shown that HSCs reside adjacent to osteoblasts in the periosteal 
region of the bone marrow suggesting an important role of osteoblasts in the HSCs 
niche (Nilsson et al., 1997).  
Other studies have demonstrated that the HSCs reside next to vascular endothelium 
(Kim et al., 2005) suggesting that different anatomical locations represent different 
niches for HSCs, that can have a different impact on regulation of self-renewal or 
lineage outcome. For example, HSCs in foetal liver are proliferating while the HSCs in 
bone marrow are mostly quiescent (Orkin and Zon, 2008).    
In addition, the microenvironment contains factors that trigger developmental signalling 
pathways and activate genetic programs to direct haematopoietic development and 
lineage-restricted differentiation. Induction events are orchestrated by signalling 
pathways that turn on or off transcription factors that regulate the expression of specific 
panels of genes associated with haematopoietic fate and function (Figure 1). 
Remarkably, the majority of transcription factors in the haematopoietic system are 
involved in chromosomal translocation and somatic mutations in human haematopoietic 
malignancies. Stem cell leukemia (SCL)/ T-cell Acute lymphocytic leukemia 1(TAL-1) 
and LIM domain only 2 (LMO2) are among the transcription factors that are essential 
for development of both the primitive and definitive haematopoietic systems (Porcher et 
al., 1996, Gering et al., 1998) while Runx1 is important for developmental specification 
of HSCs’ fate (Burns et al., 2005).  Therefore, HSCs can be described as groups of cells 
with varying developmental potential based on intrinsic networks driven by 
transcription factors and inputs from the cellular niches in which they reside (Orkin and 




1.2. Regulation of globin gene expression  
In humans, globin gene expression is characterised by two different developmental 
switches, the embryonic switch and the foetal switch (Thein, 2004). These switches 
coincide with changes in the morphology of the erythroid cells, the site of 
erythropoiesis and haemoglobin composition (Figure 2). At approximately 6 to 8 weeks 
of gestation, the expression of the embryonic ε-globin gene switches to that of the two 
γ-globin (Αγ and Gγ) genes in the foetal liver (embryonic switch). This involves the 
silencing of the ε-globin gene and up-regulation of γ-globin expression (85-98%) which 
is maintained throughout foetal life (Thein, 2004, Stamatoyannopoulos, 2005, Testa, 
2009). Foetal haemoglobin (HbF, α2γ2) has a relatively high affinity for oxygen 
compared to adult haemoglobin, a property that favours the exchange of oxygen 
between adult haemoglobin in the maternal red blood cells and foetal haemoglobin in 
foetal blood through the placenta (Gambari and Fibach, 2007). Shortly after birth, γ-
globin expression is almost completely silenced (<5%) while the expression of β- and δ-
globin genes is up-regulated in a process known as foetal switching (Testa, 2009) 
(Figure 2). Expression of the γ-globin gene continues to decrease but is not silenced, 
with foetal haemoglobin reaching less than 1% of the total haemoglobin at around 2 
years of age (Rutland et al., 1983). In adult blood, the dominant haemoglobin is adult 
haemoglobin (HbA, α2β2) that comprises about 95% of the total haemoglobin. Each 
globin chain binds to a haem molecule via a histidine side chain which consists of a 
charged iron atom  in the centre of a large heterocyclic organic ring known as porphyrin 
(Perutz, 1976). In addition to the residual levels of HbF which reside in a subset of 
erythrocytes known as F cells (Boyer et al., 1975, Thein and Menzel, 2009), normal 
adult blood contains 2.5-3.5% HbA2 (α2δ2) (Kunkel et al., 1957).  
The genes responsible for the synthesis of globin chains are clustered in two regions 
(Figure 4). The α-like globin gene locus on the tip of chromosome 16, consists of three 
genes; α1, α2 and ζ genes (Deisseroth et al., 1977, Lauer et al., 1980). The β-like globin 
genes are found in another locus, a 100kb region on chromosome 11 that consists of 
five functional genes, ε, Gγ,  Αγ, δ and β (Fritsch et al., 1980). The globin genes are 
arranged in the order in which they are expressed during development. The two γ-globin 
genes are the result of a 5-kb tandem duplication, and their coding sequences differ only 
by a single nucleotide within codon 136 in exon 3 (Schroeder et al., 1968), giving rise 
to 
Gγ and Aγ respectively. In adults, HbF is composed of 40% Gγ and 60% Αγ whereas in 
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the newborn HbF is composed of 70% 
Gγ and 30% Aγ.  At the molecular level, all the 
globin genes consist of three exons separated by two intervening regions or introns 
(Testa, 2009, Thein, 2004).  
 
 




                             Embryonic Haemoglobins                             Foetal                   Adult  
                                                                                               Haemoglobin        Haemoglobins 
Figure 4, Haemoglobin expression. (A) Genes responsible for the expression of globin chains 
are clustered into two regions, the α-like globin gene locus on chromosome 16 and β-like globin 
gene locus on chromosome 11. The genes are arranged in the order they are expressed, leading 
to the formation of the different types of haemoglobins at different stages of development (B). 
Adapted from  http://itg.content-e.eu/Generated/pubx/173/hematology/sickle_cell_anaemia.htm 
 
Evidence suggests that switching between the expression of different globins relies on 
two mechanisms, gene silencing and gene competition. Expression of individual genes 
relies on direct physical interaction between the globin gene promoters and cis-acting 
elements such as the Locus Control Region (LCR), mediated by transcription factors 
         ζ2ε2                      ζ2γ2                      α2ε2                  α2γ2                 α2δ2           α2β2 




and chromatin remodelling activities. While the ε- and γ- globin genes are 
autonomously silenced at the appropriate developmental stage, expression of the adult 
β-globin gene (HBB) depends on the lack of competition between the γ-gene for the 
LCR sequence and direct interaction of HBB itself to the LCR. In addition, the restricted 
expression of the ε-globin gene in yolk sac when placed close to the LCR suggests that 
ε-globin gene expression is depended on the LCR (Raich et al., 1990). Mutations of 
GATA1, YY1 or Sp1 binding sites within the ε-promoter abolished ε-globin gene 
silencing suggesting that silencing of the embryonic gene might be combinatorial, 
requiring multiple transcription factors for the formation of the silencing complex 
(Raich et al., 1995). It is currently assumed that the silencing complex turns off ε-globin 
gene expression in the definitive erythropoiesis by inhibiting the interaction between the 
ε-globin gene and the LCR (Stamatoyannopoulos, 2005). 
Silencing of the γ-globin gene appears to involve both autonomous silencing (Dillon 
and Grosveld, 1991) and gene competition (Enver et al., 1990). The presence of 
developmental expression of γ-globin gene in transgenic mice carrying βYAC construct 
with a deleted β-globin gene suggests that the γ-globin gene is mainly regulated by 
autonomous silencing (Peterson et al., 1995). In addition, deletion of the -378 to -730 
region of the γ-promoter leads to continuous expression of the γ-globin gene suggesting 
the presence of a silencer within this deleted stretch of DNA upstream of the γ-globin 
gene (Stamatoyannopoulos et al., 1993). Although autonomous silencing appears to be 
the principal mechanism that switches off the expression of the foetal globin gene, 
increased γ-globin gene expression in patients with β-thalassaemia due to β-promoter 
deletions suggests that competition with the β-globin gene promoter might also 
contribute to γ-globin gene silencing (Stamatoyannopoulos, 2005). Gene competition 
between the β- and γ-globin gene has also been suggested after observations that 
developmental regulation is lost in transgenic mice carrying either the γ- or β-globin 
gene close to the LCR (Enver et al., 1990, Behringer et al., 1990). In situ hybridization 
methods have shown that the LCR interacts with only one promoter in the globin locus 
at a given time (Wijgerde et al., 1995), while more advanced techniques such as 3C and 
RNA trap assay, have shown that transcribed globin genes are in close proximity to the 
LCR, confirming the “looping model” of globin gene expression (Tolhuis et al., 2002) 
(Figure 5). Loop formation requires the presence of trans-activating erythroid specific 
transcription factors such as EKLF (also known as KLF1) (Drissen et al., 2004), 
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GATA1 and FOG-1, where binding within cis elements presides loop formation (Vakoc 





At least three different cis-acting DNA elements have been shown to have a role in the 
transcription of eukaryotic genes including core promoters, proximal regulatory 
elements, and distal regulatory elements. These cis-acting transcriptional regulatory 
elements contain recognition sites for trans-acting DNA–binding transcription factors 
that either enhance or repress transcription (Maston et al., 2006).  
There are four motifs commonly associated with core gene promoters, the TATA box 
along with the TFIIB-recognition element (BRE), the Initiator element (Inr) and 
Downstream Promoter Element (DPE) motifs. In contrast to most gene promoters which 
contain CpG islands with no obvious TATA box, globin gene promoters contain well-
defined TATA boxes without any CpG islands nearby. Mutations in all the positions of 
the TATA box have been associated with β-thalassaemias while mutations within the 
DPE and Inr motifs have also been associated at least once with β-thalassaemia. The 
upstream regulatory region adjacent to the basal promoters contains a CCAAT box 
Figure 5, The ‘looping model’ for 
globin gene expression. The model 
aims to explain haemoglobin 
switching and is based on the direct 
interaction of the LCR with the 
individual globin gene promoters. In 
the presence of trans-activating 
transcription factors, the LCR comes 
in close proximity to the promoters 
of γ-globin genes at the prenatal age, 
leading to the expression of foetal 
haemoglobin. Shortly after birth, the 
presence of chromatin remodelling 
complexes and trans-activating 
transcription factors shifts the 
interaction of the LCR with the β-
globin promoter leading to the 
expression of adult haemoglobin.  
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(Dierks et al., 1983), a conserved motif that allows binding of NF-Y and CP1 proteins 
(deBoer et al., 1988). In addition, two upstream regulatory elements were identified in 
the globin promoters and include a CCAAT box which acts as a binding site for 
transcription factors of the Krüppel-like zinc finger class (KLF), and GATA1 binding 
sites which are implicated in the positive regulation of GATA1 gene and related 
proteins. Phylogenetic footprinting led to the discovery of the stage selector element 
(SSE) in the human γ-globin gene promoter, a binding site for a factor implicated in the 
differential expression of γ-and β-globin genes (Jane et al., 1992). In contrast to the β-
like globin genes, α-globin gene promoters are composed of CpG islands and do not 
contain binding sites for GATA1. The regulated expression of α-globin in the presence 
of CpG islands suggested that CpG might be a key component of the cis-regulatory 
elements for the α-globin gene in humans (Shewchuk and Hardison, 1997).  
Earlier experiments demonstrated the presence of two proximal enhancers around the β-
globin gene, one within the gene and another downstream of the gene (Behringer et al., 
1987, Trudel and Costantini, 1987), and one at around 1kb downstream of the 
polyadenylation signal of the 
Aγ-globin gene (Bodine and Ley, 1987). Both enhancers of 
the β-globin gene are implicated in the expression of the gene in primates and contain 
binding sites for GATA1 (Wall et al., 1988). The γ-globin gene enhancer was mapped 
to a tissue-specific DNase I hypersensitive site and was the only DNA segment 
surrounding the γ-globin genes that could enhance reporter gene expression when 
driven by the γ-globin gene promoter in transfected erythroid cells (Bodine and Ley, 
1987). 
One important aspect that is commonly found in the α-like and β-like globin gene 
clusters is the presence of strong distal enhancers. Tuan et al. (1985) identified five 
DNAse I hypersensitive sites (HS) located 6 to 20kb upstream (5’) of the β-globin 
which were shown to be involved in embryonic, foetal and adult globin gene 
expression, now referred to as the locus control region (LCR) (Forrester et al., 1987). 
Each HS comprises of approximately a 250bp long sequence devoid of nucleosomes 
which is composed of arrays of multiple ubiquitous and lineage-specific transcription 
factor-binding sites (Li et al., 2002, Stamatoyannopoulos, 2005). HS1-4 are erythroid 
specific and act as enhancers of the β-globin LCR while HS5 is found in cells of 
multiple lineages and acts as an insulator (Li and Stamatoyannopoulos, 1994). HS2 is 
the most prominent enhancer element in the β-globin LCR as shown by close proximity 
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of HS2 to the actively transcribed β-globin gene (Carter et al., 2002). Moreover, 
experiments in transgenic mice (Roberts et al., 1997) and human erythroid cells 
(Sargent et al., 1999) showed a switch between the contacts of HS2 and HS3 with 
embryonic and foetal globin genes in yolk sac to contacts with adult globin genes in 
adult erythroid cells, confirming that interactions between the LCR and the various 
genes of the β-globin locus are developmentally controlled (Fraser et al., 1993). Almost 
all HS contain three transcription factor–binding motifs; Maf-response elements 
(MARE) to which transcription activator proteins of the basic leucine zipper class can 
bind, GATA motifs and CACC motif to which a family of zinc-finger proteins 
including KLF1 can bind (Ney et al., 1990, Philipsen et al., 1990, Talbot et al., 1990, 
Strauss and Orkin, 1992, Andrews et al., 1993). HS2 of the β-globin LCR also contains 
three E-boxes which act as binding sites for TAL-1 and its heretodimeric partners 
involved in haematopoiesis (Elnitski et al., 1997).  
For the α-globin cluster, there are four highly conserved, noncoding sequences called 
multispecies conserved sequences (MCS) R1-R4 which act as regulatory elements. The 
MCS R1, R2, R3 and R4 sequences were previously identified as DNase I 
hypersensitive sites and referred to as HS-48, HS-40, HS-33 and HS-10, respectively, 
corresponding to their position relative to the ζ-globin mRNA cap site. However, only 




Trans-regulation is mediated by nuclear DNA-binding proteins that recognise cis-acting 
regulatory elements. These transcription factors can enhance or inhibit gene expression 
by modifying chromatin structure either by direct binding on proximal or distal 
regulatory elements or by assembling multiprotein complexes that establish and 
maintain active or repressive chromatin states. This is facilitated by the formation of 
long-range chromatin loops which bring critical regulatory elements into physical 




1.2.2.1. Erythroid-specific transcription factors 
GATA1 is the founding member of the GATA family of proteins that comprise of zinc 
finger transcription factors. It was originally identified as a protein with binding 
specificity for the β-globin 3’ enhancer (Wall et al., 1988). Whole genome occupancy 
maps developed by multiple groups showed that only a minority of the GATA1 binding 
sites are located at proximal promoter regions close to the transcription initiation site 
while the majority occur at distant regulatory elements with equal distribution between 
intra- and intergenic regions (Fujiwara et al., 2009). GATA1 is essential for erythroid 
cell maturation, erythroid cells from gata1-deficient mice fail to mature beyond the 
proerythroblast stage (Pevny et al., 1995), while gata1-null mouse embryos die from 
severe anaemia between E10.5 and E11.5 (Fujiwara et al., 1996). The arrest in primitive 
and definitive erythropoiesis of embryonic stem cells lacking gata1 beyond the 
proerythroblast stage can be attributed to the apoptosis of the precursors (Weiss and 
Orkin, 1995). GATA1 is directly involved in cell survival due to its ability to activate 
erythropoietin (EPO) receptors (Zon et al., 1991), an important signalling pathway for 
survival of erythroid progenitors, as well as its ability to alter the expression of Bcl-XL 
(Gregory et al., 1999), a gene encoding an anti-apoptotic protein. A direct role of 
GATA1 in the regulation of foetal to adult switch in humans has been proposed by the 
identification of patients with congenital erythropoietic porphyria and elevated HbF 
who had a GATA1 zinc-finger mutation (Phillips et al., 2007). GATA1 appears to 
facilitate chromatin loop formation at both the c-kit and β-globin loci (Jing et al., 2008) 
through interactions with erythroid-specific and ubiquitous transcription factors. 
GATA1 interacts with the Friend of GATA1 (FOG-1) through its N-terminal finger, an 
interaction that is important for erythroid and megakaryocytic development (Tsang et 
al., 1997). In fact, GATA1 was shown to bind to a region upstream of both γ-globin 
gene promoters in a FOG-1 dependent manner which leads to recruitment of the 
repressive Nucleosome Remodelling Deacetylase (NuRD) complex (Harju-Baker et al., 
2008), suggesting a role in foetal to adult globin switching. Functional assays have 
shown GATA1 to physically interact with KLF1, Sp1 (Gregory et al., 1999) as well as 
with components of the basal transcription factor complex including p300 and CREB-
binding protein (CBP). The interaction leads to acetylation of GATA1 itself (Kasper et 
al., 2002) and recruitment of CBP to activated genes and erythroid specific transcription 
factors. More recently, miR-144/451 locus was shown to be a direct target of GATA1 
27 
 
and mice lacking miR-144/451 or miR-451 alone show impaired erythropoiesis, 
particularly under stress conditions (Dore et al., 2008).  
In erythroid cells, SCL/TAL1 transcription factor forms a complex with the basic helix-
loop-helix protein E2A and with the LIM domain (domains originally identified in 
Lin11, Isl-1 and Mec-3 proteins)-containing cofactors LIM domain only 2 (LMO2) and 
LIM domain-binding protein 1 (LDB1), which in turn interact with GATA1 to form a 
pentameric complex that binds to a short consensus DNA motif known as the E-box 
(Wadman et al., 1997). LDB1 directly binds to DNase-hypersensitive sites HS2, HS3 
and HS4 of the β-globin LCR and forms long-range interactions with the β-globin 
promoter, despite the absence of a functional LDB1 binding site at the β-globin 
promoter (Soler et al., 2010). Expression of SCL/TAL1 coincides with GATA1 
expression in erythroid cells and is highly expressed in erythroid precursors and 
erythroid cell lines (Green et al., 1991, Visvader et al., 1991). Forced expression of the 
SCL in human CD34
+
 cells stimulates formation of erythroid and megakaryocyte 
progenitors and an increase in the size of erythroid colonies (Elwood et al., 1998). 
Disruption of the SCL/TAL1 gene in adult haematopoietic stem cells causes erythroid 
and megakaryocytic defects suggesting a role of the SCL factor in the onset of 
haematopoiesis (Mikkola et al., 2003). Moreover, SCL/TAL1 can activate and repress 
transcription through recruitment of coactivators such as p300/CBP (Huang et al., 1999) 
or corepressors such as Sin3A or Eto-2 (Schuh et al., 2005). 
Nuclear factor-erythroid 2 (NF-E2) was first described as an activating protein-1 (AP-1) 
–like DNA-binding factor required for proper function of the erythroid-expressed 
promoter of the porphobilinogen deaminase gene (Mignotte et al., 1989). NF-E2 binds 
on the AP-1-like motifs (MAREs), important cis-elements within the HS2 of the β-
globin LCR (Ney et al., 1990), that lead to formation of DNA hypersensitive sites 
(Stamatoyannopoulos, 2005). NF-E2 binding sites were also found within the α-globin 
LCR (Jarman et al., 1991). NF-E2 is a heterodimeric protein composed of two basic-
leucine zipper DNA-binding polypeptides, the haematopoietic-restricted p45 subunit 
(Ney et al., 1993) and the non-haematopoietic specific subunit, p18 (Andrews et al., 
1993). p45 was suggested to have a critical regulatory role in globin gene expression 
due to its ability to restore α- and β-globin gene expression in p45 transduced murine 
erythroleukaemia cells that lacked both alleles of p45 (Lu et al., 1994). However, 
targeted inactivation of p45 in mice did not disrupt erythropoiesis and globin gene 
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expression, but rather severely affected megakaryocyte maturation (Shivdasani and 
Orkin, 1995). Similarly, p18 deficient mice developed normally and displayed no 
obvious defects in erythropoiesis, globin gene expression and platelet maturation 
(Kotkow and Orkin, 1996). However, the N-terminal domain of p45, which was found 
to be crucial for the NF-E2 activity, was shown to interact with other proteins including 
CBP/p300 (Cheng et al., 1997), ubiquitin ligase (Gavva et al., 1997) and the TBP-
associated factor TAFII130 (Amrolia et al., 1997), suggesting a chromatin modifying 
role for NF-E2 through interaction with the basal transcription machinery and 
recruitment of CBP/p300 associated histone acetyltransferases to the LCR.  
Kruppel-like factor 1 (KLF1), previously known as erythroid Kruppel-like factor, 
(EKLF) is a zinc finger transcription factor with three highly similar C-terminal C2H2-
type zinc fingers that acts as an activator of the adult β-globin gene through a highly 
conserved CACCC motif (Miller and Bieker, 1993). KLF1 is restricted to erythroid 
cells leading to embryonic lethality in klf1-null mice (Perkins et al., 1995). Although, it 
was initially thought that KLF1 was an adult-stage specific factor that facilitates foetal 
to adult haemoglobin switching, other studies have shown that an LCR-β-globin 
transgene normally expressed in primitive erythroid cells is not expressed in the absence 
of KLF1 (Tewari et al., 1998), suggesting a role of KLF1 in regulating both definitive 
and primitive erythropoiesis. Borg et al. (2010) identified a nonsense mutation in KLF1 
in a Maltese family with hereditary persistence of foetal haemoglobin (HPFH) which 
suggested that KLF1 is an activator of BCL11A. Independently, Zhou et al. (2010) 
demonstrated a role of KLF1 as a repressor of foetal globin gene and activator of 
BCL11A. KLF1 was shown to interact with HS1-3 of the human β-globin LCR (Im et 
al., 2005) and was able to physically and functionally interact with CBP/p300 (Zhang et 
al., 2001) and BRG1 (Armstrong et al., 1998). Studies has shown that KLF1 promotes 
the formation of a high-order chromatin loop at the β-globin locus (Drissen et al., 2004) 
and functions as a transcriptional repressor by recruiting Sin3A and histone deacetylase 
1 (HDAC1) (Chen and Bieker, 2001). Within the KLF family, KLF3 is a repressor of 
embryonic globin genes as shown by the derepression of the embryonic globin genes in 




1.2.2.2. Ubiquitous factors involved in globin gene switching 
Genome wide association studies showed that B-cell lymphoma/leukemia 11A 
(BCL11A) gene on chromosome 2 is associated with HbF levels in non-anaemic 
individuals (Menzel et al., 2007). The zinc finger transcription factor, which was 
initially identified as myeloid or B cell proto-oncogene in humans, exhibited stage-
specific expression in human ontogeny where primitive and foetal liver erythroid cells 
that expressed high levels of γ-globin had low or absent expression of the full-length 
form of BCL11A (Sankaran et al., 2008) but had notable expression of the shorter 
variant forms of the protein. Knock-down of BCL11A led to robust expression of HbF 
confirming its repressor function on γ-globin genes in both healthy and β-thalassaemic 
primary human erythroid progenitor cells (Wilber et al., 2011). BCL11A was found to 
directly interact with chromatin at the human β-globin locus in primary human erythroid 
progenitor cells and physically interact with NuRD chromatin remodelling complex and 
erythroid transcription factors GATA1 and FOG-1 (Sankaran et al., 2008). Moreover, 
BCL11A physically interacts with the transcription factor Sex determining region Y-
box 6 (SOX6) (Xu et al., 2010).  
SOX6 belongs to the family of Sry-related High mobility group (HMG) box 
transcription factors and was shown to have a potential role in haemoglobin gene 
regulation. SOX6 is widely expressed in a range of tissues. The lack of activating or 
repressive transcriptional regulatory domains in the SOX6 protein, allows the factor to 
be used in multiple tissues at variable developmental stages by interacting with different 
partners. SOX6 plays a critical role in cell cycle progression of lineage specific 
progenitors as well as control the terminal differentiation of post-mitotic cells 
(Hagiwara, 2011). Sox6 deficient mice demonstrated elevated embryonic β-like globin 
at the foetal liver stage that was rapidly down-regulated in late foetal livers (Yi et al., 
2006). SOX6 was shown to bind chromatin at the proximal γ-globin promoters and have 
long-range interactions with a variety of regions throughout the β-globin gene cluster 
(Xu et al., 2010), suggesting a role in γ-globin gene silencing. However, SOX6 has been 
suggested to enhance definitive erythropoiesis in mouse by stimulating erythroid cell 
survival, proliferation and terminal maturation (Dumitriu et al., 2006).  
Direct repeat erythroid-definitive (DRED) complex was initially identified as a 
definitive-stage embryonic globin gene repressor with strong affinity for direct repeat 
30 
 
elements (DR) in the human ε-globin gene promoter (Tanimoto et al., 2000). DR 
elements are found in both the embryonic and foetal globin gene promoters but are 
absent in the adult globin gene promoters. The DRED complex is composed of a 
heterodimer of the orphan nuclear receptors TR2 and TR4, which bind to the DR 
elements in the ε-globin promoter with higher affinity than the single DR element in 
each of the γ-globin promoters (Tanabe et al., 2002). Silencing of the embryonic and 
foetal globin genes was delayed in definitive erythroid cells of Tr2-Tr4-null mutant 
mice suggesting a direct repression of embryonic and foetal globin gene expression in 
definitive erythroid cells (Tanabe et al., 2007a). In addition, lysine-specific histone 
demethylase 1 (LSD1) and DNA methyltransferase 1 (DNMT1) act as cofactors to form 
the tetrameric core of DRED complex, which in turn can interact with HDAC 1 & 2, 
NuRD, Corepressor of element-1-silencing transcription factor (CoREST), Tripartite 
motif-containing 28 (TRIM28) and HDAC3 (Cui et al., 2011). A point mutation at -117 
of the HBG1 (
Aγ) promoter disrupts the DR element leading to reduced TR2/TR4 
binding and increased HbF expression (Tanabe et al., 2002). TR2 and TR4 can also 
bind to the DR element within the GATA1 haematopoietic enhancer which leads to 
repression of GATA1 transcription, proposing a mechanism of TR2/TR4-mediated 
silencing of GATA1 during terminal erythroid maturation (Tanabe et al., 2007b).  
Genetic association analysis led to the identification of an intergenic region between 
HBS1L and MYB genes on chromosome 6q23 as a quantitative trait locus (QTL) 
controlling foetal globin gene expression in adults (Thein et al., 2007). A follow-up 
study proposed that this intergenic region contains an erythroid-specific enhancer that 
acts as a major regulatory element controlling the expression of HBS1L and MYB genes 
(Wahlberg et al., 2009).  HBS1L was excluded from having a role in regulating HBG 
(γ-globin) expression when a patient with complete loss of function of the HBS1L gene 
had a normal distribution of haemoglobin subtypes (Sankaran et al., 2013). Stadhouders 
et al. (2012) showed the presence of binding sites for GATA1, LDB1, TAL1 and KLF1 
within the HSB1L/MYB intergenic region and in close proximity to the MYB gene 
promoter. Reduction of LDB1 levels in erythroid progenitors resulted in a decrease in 
Myb promoter-enhancer interaction and transcription without affecting the 
transcriptional levels of Hbs1l (Stadhouders et al., 2012, Stadhouders et al., 2014).  The 
Myb gene encodes a transcription factor that is critical for haematopoietic progenitors 
but decreases as erythroid cells mature (Emambokus et al., 2003). Suzuki et al. (2013) 
demonstrated that Hbs1l-Myb intergenic region was responsible for the persistent 
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expression of embryonic globins and that despite the reduced expression of both Hsb1l 
and Myb genes, knock-out of Myb resulted in elevated expression of embryonic globin 
genes. Myb can also activate the DRED complex (Suzuki et al., 2013), a repressor of 
embryonic and foetal globin genes in adults (Tanabe et al., 2002) suggesting an indirect 
regulation of γ-globin transcription by this gene. Some patients with trisomy 13 have a 
delayed foetal-to-adult haemoglobin switch and persistence of foetal haemoglobin 
(Sankaran et al., 2011). Sankaran et al. (2011) showed that the extra copy of genes 
(present in chromosome 13) encoding miR-15a/16-1, mediated the down-regulation of 
MYB transcription factor that was responsible for the increased HbF in these patients.   
Among the ubiquitous trans-acting transcription factors, Sp1, is a zinc-finger protein 
belonging to the Kruppel-like factors known as Sp1/XKLF transcription factor family 
(Bouwman and Philipsen, 2002). Sp1 binds to the consensus sequences of GC and GT 
boxes in ubiquitously expressed proximal promoters, including the β-globin gene 
promoter, as well as to distal enhancers of housekeeping genes (Mastrangelo et al., 
1991). Feng and Kan (2005) suggested that binding of Sp1 to the GC and GT boxes 
results in the recruitment of HDAC1 that deacetylates histones and keeps the chromatin 
structure closed thus preventing recruitment of histone acetyltransferases (HAT) by 
FKLF2. Phosphorylation of Sp1 at threonine 579 results in inactivation of Sp1 and β-
globin gene expression (Feng and Kan, 2005). Sp1 has been suggested to be a repressor 
of γ-globin expression due to the increased binding of Sp1 to the stage selector element 
in the human γ-globin gene promoters upon site-specific cytosine methylation (Jane et 
al., 1993, Sengupta et al., 1994).  
NRF2 is a redox-sensitive transcription factor that plays a major role in the cellular 
defence against oxidative stress through up-regulation of transcription of phase II 
defence enzymes and antioxidant stress proteins. NRF2 binds to a specific ARE 
sequence in the promoter of target genes such as NADPH quinone oxyreductase 1 
(NQO1) and haem oxygenase 1 (HO1/HMOX1). Under normoxic conditions, NRF2 is 
ubiquinated by KEAP1 resulting in proteosomal degradation of NRF2. In the presence 
of oxidative stress, KEAP1 is altered chemically by reactive oxygen species, releasing 
NRF2 from the complex leading to the translocation of NRF2 to the nucleus and 
subsequent activation of antioxidant genes (Macari and Lowrey, 2011). NRF2 is highly 
enriched in human embryonic stem cells and dramatically decreases upon differentiation 
(Jang et al., 2014).  
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HMOX1 gene encodes haem oxygenase-1, an antioxidant enzyme that breaks down the 
porphyrin ring of the haem to produce biliverdin, free iron and carbon monoxide and 
plays a vital role in the cytoprotection of tissues during oxidative stress by preventing 
apoptosis (Abraham et al., 2003, Brouard et al., 2000). Gil et al. (2013) have shown that 
a polymorphism in HMOX1 is associated with high HbF expression in Brazilian sickle 
cell patients. The authors hypothesise that reduced HMOX1 levels lead to stress-
induced erythropoiesis due to higher levels of free haem (Gil et al., 2013). This, 
however, is not proven. 
The Cyclic AMP response element binding protein (CREB) is a protein belonging to 
basic leucine zipper domain (bZIP) superfamily of transcription factors and is highly 
important for transcription of haematopoietic genes and development of the myeloid 
lineage. Phosphorylation of CREB1 at Ser133 leads to its binding to the cAMP response 
element (CRE), mediating activation of transcription (Shaywitz and Greenberg, 1999). 
CREB1 recruits CBP which acts as a bridge by recruiting the basal transcriptional 
machinery to the promoters of CREB target genes (Nakajima et al., 1997). CBP is 
important for haematopoiesis since disruption of Cbp in mice leads to reduced primitive 
and definitive haematopoiesis (Oike et al., 1999). p300, a paralogue of CBP, is 
important for erythropoiesis since mutations at the CREB-interacting domain (KIX) 
result in severe defects in erythropoiesis due to disruption of the c-Myb and CREB 
binding sites (Kasper et al., 2002). CBP stimulates c-MYb, GATA1, NF-E2 and KLF1 
through direct interaction. Moreover, Ramakrishnan and Pace (2011) demonstrated that 
knock-down of p38 MAPK and CREB in primary human erythroid cultures resulted in 
reduced γ-globin expression while enhanced expression of both resulted in increased 
levels of γ-globin expression (Ramakrishnan and Pace, 2011).   
 
1.3. Epigenetic regulators 
DNA methylation was the first described epigenetic mechanism that affects gene 
regulation. DNA methylation involved the addition of methyl groups at the 5 position of 
cytosine within CpG dinucleotides by either maintenance methylation, the addition of a 
methyl group by DNMT1 to the symmetric CpG on the unmethylated strand of DNA 
after DNA replication, or by de novo methylation, which symmetrically methylates 
cytosines in dinucleotides on both strands of unmethylated DNA by DNMT3A and B 
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(Okano et al., 1998). Globin genes of vertebrates were among the first genes to show an 
inverse relationship between cytosine methylation and transcription (van der Ploeg and 
Flavell, 1980). Methylation was therefore rendered an important factor in the regulation 
of γ-globin expression. In fact, studies on transgenic mice have demonstrated that DNA 
methylation repressed 
Aγ-globin expression (Rupon et al., 2006, Goren et al., 2006). A 
correlation between the level of DNA methylation of five CpG residues within the γ-
globin gene promoter and the level of γ-globin gene expression was established by Chin 
et al. (2009). CpG dinucleotides within the 5’ γ-globin gene are unmethylated in foetal 
liver when the genes are expressed but methylated in adult bone marrow in both human 
(Mavilio et al., 1983) and baboons (van der Ploeg and Flavell, 1980) when the genes are 
silenced.  
The presence of methyl groups generates binding sites for methyl-CpG-binding domain 
proteins (MBDs) that consequently lead to the recruitment of histone modifying 
enzyme-containing co-repressor complexes. Recruitment of these complexes results in 
the modification of histone and consequently chromatin structure, and prevents binding 
of transcription factors (Goren et al., 2006). Among the MBD proteins, MBD2 binds 
preferentially to DNA containing a high density of methylated CpGs. Knock-down of 
Mbd2 expression resulted in a large increase in the expression of the silent human γ-
globin gene in human β-globin locus-bearing transgenic mice (Rupon et al., 2006) and 
in primary human CD34
+
 precursor-derived adult erythroid cells (Gnanapragasam et al., 
2011). MBD2 was shown to mediate silencing by recruiting the NuRD complex to 
methylated DNA (Zhang et al., 1999, Feng and Zhang, 2001) by interacting with 
p66α/β, a component of the NuRD complex (Gnanapragasam et al., 2011). Although 
MBD3 does not bind to methylated or non-methylated DNA with high affinity, it can 
interact with the NuRD complex which consequently interacts with the γ-globin gene 
promoter through association with the GATA1-associated protein FOG-1 (Miccio and 
Blobel, 2010). More recently, knock-down of Mi2β component of the NuRD complex 
showed a 10-fold increase in γ-globin gene expression in primary human erythroid 
cultures but was not associated with MBD2-NuRD or MBD3-NuRD interactions 
(Amaya et al., 2013). Rather, the increase in γ-globin gene expression was partly due to 
down-regulation of BCL11A and KLF1 in Mi2β knock-down erythroid cells.   
Histone acetylation was the first described histone modification (Phillips, 1963) that 
was associated with actively transcribed genes (Allfrey et al., 1964). Acetylation of 
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lysine at histone tails results in charge neutralization and loosening of the interaction of 
nucleosomes with their associated DNA, linker DNA or adjacent histones and thus 
increasing accessibility of DNA to the transcriptional machinery (Zentner and Henikoff, 
2013). Histone acetylation can also occur at DNA double-strand breaks and thus 
increasing DNA access to repair mechanisms (Xu and Price, 2011). Lysine residues are 
acetylated by HATs such as p300/CBP (Bannister and Kouzarides, 1996), PCAF 
(p300/CBP-associated factor) and TAF(11)250 (TBP associated factor) (Mizzen et al., 
1996), which usually have low substrate specificity. Lysine deacetylation is performed 
by histone deacetylases (Kuo and Allis, 1998). Analysis of mononucleosomes from 
primitive and definitive erythrocytes in chicken embryos showed that both active and 
inactive genes were hyperacetylated suggesting a broad acetylation pattern of chromatin 
domains (Forsberg and Bresnick, 2001). In addition, hyperacetylated areas were 
associated with DNaseI sensitivity (Hebbes et al., 1994) suggesting that locus-wide 
hyperacetylation promotes the chicken β-globin locus for transcription but does not 
control β-globin gene switching. A broad hyperacetylation pattern was also observed in 
the murine β-globin locus, however, without being uniform. Hyperacetylation was 
concentrated on Histone 3 (H3) and Histone 4 (H4) at the LCR and the active β-major 
and β-minor promoters in expressing but not in non-expressing tissues, with a 
hypoacetylated subdomain encompassing the silenced embryonic genes (Forsberg et al., 
2000). Restoration of acetylation by using HDAC inhibitors was not sufficient to 
reactivate the silenced embryonic genes suggesting that requisite factors are missing in 
the definitive cells. Analysis showed the presence of a basal H3 and H4 acetylation 
throughout the human β-globin locus in MEL cells, with peaks of H3 acetylation at the 
LCR and the active promoters. Deletion of HS2-4 abolished expression of β-like globin 
genes but maintained the ability to form the remaining HS and an open chromatin 
conformation suggesting that basal H3 and H4 acetylation is correlated with DNaseI 
sensitivity (Reik et al., 1998). Based on the above observations, it can be proposed that 
the broad acetylation pattern of the β-globin locus in erythroid cells is necessary for 
transcriptional competence of the β-globin genes where other types of regulation would 
then determine whether a single gene is transcribed or not (Bresnick and Tze, 1997). 
Experimental evidence demonstrated that developmentally regulated transcription of 
intergenic regions of εγ and δβ domains has the capacity to increase chromatin structure 
accessibility above the basal state, rendering it an essential component of the 
remodelling process of chromatin domains (Gribnau et al., 2000).   
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In contrast to DNA methylation, methylation of histones at lysine residues can be 
associated with gene activation, gene silencing or a bivalent function. In particular, 
methylation of histone H3 Lysine 4 (H3K4) and histone H3 lysine 36 (H3K36) is 
associated with open chromatin and gene transcription, while histone H3 lysine 9 
(H3K9) and histone H3 lysine 27 (H3K27) methylation are involved in transcriptional 
repression and gene silencing. Histone methylation provides recognition sites for the 
recruitment of non-histone proteins and enzymes which affect downstream gene 
functions (Kiefer et al., 2008) and increase the binding affinity of many domains 
including Tudor, chromodomains, and Plant Homodomain (PHD) (Taverna et al., 
2007). Among the major writers of histone methylation is protein arginine 
methyltransferase 5 (PRMT5) which was shown to be mechanistically linked to 
silencing of γ-globin gene (Zhao et al., 2009). In addition, PRMT1, another member of 
the PRMT family, has been associated with human γ-globin gene silencing through 
association with FoP. Interestingly, PRMT1 promotes acetylation of Lys9/Lys14 by 
recruitment of dimethyl Histone 4 arginine 3 (H4R3) to PCAF and subsequent 
transcription of the adult β-globin gene (Li et al., 2010) suggesting that PRMT1 can 
silence γ-globin gene expression by increasing interactions between the LCR and the β-
globin gene. Specific lysine demethylases (LSD) were also shown to be involved with 
γ-globin gene silencing in both human and murine erythroid cells. LSD1 has been 
shown to associate with the transcription factor BCL11A through a complex containing 
the CoREST (Xu et al., 2013). Inhibition of LSD1 by RNAi or by the monoamine 
oxidase inhibitor tranylcypromine in human erythroid cells or β-globin–transgenic mice 
enhances γ-globin expression (Shi et al., 2013).   
The ability of DNA methyltransferase inhibitor drugs such as decitabine, to cause 
secondary histone modifications in addition to their primary epigenetic role, proposes 
that epigenetic regulation of globin gene expression is mediated by the interplay 
between transcription factors and coregulatory complexes that contain mediators for 
epigenetic chromatin changes. BCL11A, a dominant repressor of γ-globin gene in 
primary human erythroid progenitor cells, is shown to interact with the MBD3-NuRD 
complex, the LSD1/CoREST complex, Nuclear receptor corepressor/ Silencing 
mediator of retinoid and thyroid hormone receptors complex (NCoR/SMRT) and 
DNMT1 (Xu et al., 2013). In addition, the TR2/TR4/DRED orphan receptor complex 
was also shown to interact with the above complexes (Cui et al., 2011). Epigenetic 
regulators could also be involved in γ-globin gene silencing through epigenetic 
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regulation of the expression of the transcription factors themselves. One such example 
is the function of Mi2β/CHD4 (Chromodomain helicase-DNA-binding protein 4) in the 
regulation of KLF1 and BCL11A expression in primary human erythroid cells 
independently from NuRD complex (Amaya et al., 2013).           
 
1.4. Thalassaemias 
Thalassaemias are characterised by a reduced rate of synthesis of structurally normal 
globin chains and result from mutations in the globin genes. There are two major types 
of thalassaemias, α and β, which result from reduced or absent synthesis of α- or β-
globin chains, respectively. α- or β-thalassaemias are prevalent in areas where 
Plasmodium Falciparum malaria is or has been endemic due to a natural protection of 
heterozygote thalassaemias against the Falciparum malaria parasite (Weatherall, 1987, 
Allen et al., 1997, Weatherall, 2008). However, as a result of migration, thalassaemias 
are now the commonest inherited disorders worldwide with at least 60000 severely 
affected individuals born every year (Modell and Darlison, 2008). Although malaria 
eradication programmes in developing countries such as Cyprus have reduced the 
frequency of thalassaemias, it will probably take many generations before any 
significant change in the allele frequency occurs (Weatherall, 2010, Kyrri et al., 2013). 
Therefore, due to the economic burden of treating thalassaemic patients, developing 
countries are now reducing the incidence of β-thalassaemia by incorporating prenatal 
diagnosis and genetic counselling in their health plan (Cao et al., 1990).  
Other types of thalassaemias include rarer forms of the disease in which other β-like 
globin genes (or a combination of different globin genes) are affected (Weatherall and 
Clegg, 2001). α- and β-thalassaemias can be further sub-classified based on the variable 
effect of each mutation on globin chain synthesis. Τhalassaemias are inherited in a 
Mendelian recessive manner and are very heterogeneous in the clinical picture they 
produce, ranging from very severe anaemias to asymptomatic conditions (Weatherall 





Alpha-thalassaemias mainly arise from deletions of the α-globin gene resulting in whole 
or part of the α-globin gene missing. Occasionally point mutations in critical regions of 
the α-globin genes give rise to the non-deletional α-thalassaemia variants which lead to 
inactivation of the α-globin genes (Higgs, 2013). The normal α-globin genotype is 
αα/αα with two α-globin genes in each chromosome (α2 and α1) being inherited from 
each parent. Therefore, deletion or inactivation of all four α-globin genes abolishes α-
globin synthesis and results in the failure to produce foetal haemoglobin leading to 
severe anaemia and death in the uterus, a condition known as hydrop foetalis (Chui et 
al., 2003). If, however, three of the four α-globin genes are deleted or inactivated then 
this leads to severe to moderate anaemia in adulthood and the production of Hb Bart’s 
(γ4) in foetal life (Lorey et al., 2001, Higgs, 2013) and HbH (β4) in adult life, hence the 
term HbH disease (Chui et al., 2003, Higgs, 2013). HbH disease results in moderately 
severe microcytic, hypochromic anaemia with splenomegaly and jaundice (Origa et al., 
2007). Individuals with two defective α-globin genes (α-thalassaemic trait) may present 
with mild anaemia associated with hypochromic microcytic red blood cells, while 
individuals with one defective α-globin gene have few recognisable changes in their 
haematology (Vichinsky, 2013). There are approximately 222 different molecular 
defects currently known to cause α-thalassaemia and the clinical phenotype and severity 
of each defect depend on the degree of deficiency in α-globin chain production 
(Harteveld and Higgs, 2010, Kountouris et al., 2014). Deletions leading to a complete 
absence of alpha globin chain synthesis are known as α0-thalassaemia, while deletions 
that only reduce the synthesis of normal alpha globin chains are known as α+- 
thalassaemia (Higgs, 2013).  
 
1.4.2.  Beta-thalassaemia 
 β-thalassaemia, in contrast tο α-thalassaemia, is mainly caused by point mutations in 
the β-globin gene or its immediate flanking regions and rarely due to deletions 
(Weatherall and Clegg, 2001). More than 300 mutations have been identified so far for 
β-thalassaemia, the majority of which are point mutations (Kountouris et al., 2014). 
Point mutations include mutations within the promoter and 5’ UTR leading to defective 
β-globin gene transcription, mutations within splice-junctions, consensus sequences and 
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3’ UTR affecting messenger RNA processing; and nonsense, frameshift and initiation 
codon mutations resulting in abnormal mRNA translation (Olivieri, 1999, Cao and 
Galanello, 2010).  
Thalassaemia major, the most severe end of the disease spectrum, is characterised by 
severe reduction or complete absence of β-globin production due to the inheritance of 
two severe β-thalassaemic alleles in a homozygous or compound heterozygous state. 
The lack of β-globin chains leads to an imbalanced globin chain synthesis and 
accumulation of excess unbound α-globin chains. The excess α-globin chains precipitate 
in erythroid precursor cells causing membrane damage and premature destruction of 
erythroid precursors in the bone marrow and at extramedullary sites (Thein, 2002), a 
phenomenon termed ineffective erythropoiesis. Anaemia caused by ineffective 
erythropoiesis in the bone marrow and haemolysis in peripheral blood promotes bone 
marrow expansion to compensate for the reduced erythrocytes (Thein, 2004). In 
addition to the huge numbers of erythroid precursors, the bone marrow of a 
thalassaemic patient holds fifteen times the number of apoptotic cells at the 
polychromatic and orthochromatic stages of maturation compared to a healthy 
individual (Centis et al., 2000).  
Thalassaemia major patients present with a severe anaemia, which only becomes 
apparent at 3-6 months after birth when the switch from foetal to adult haemoglobin is 
almost complete and the predominant Hb is adult haemoglobin (Olivieri, 1999). Failure 
to transfuse these children, leads to death of the child within the first decade of life. β-
thalassaemia is a progressively debilitating disease which can involve life-long damage 
to multiple organs. Patients appear with hepatospenomegaly due to excessive red cell 
destruction, extramedullary haematopoiesis and iron overload (Thein, 2004). Iron 
overload is one of the major causes of mortality and morbidity associated with β-
thalasseamia and occurs partly from chronic blood transfusion (transfusional 
haemosiderosis) and partly due to increased intestinal iron absorption secondary to 
inhibition of hepcidin synthesis (Atanasiu et al., 2007). Iron deposition in visceral 
organs such as the heart, liver and endocrine glands, leads to tissue damage and 
ultimately organ dysfunction and failure (Rund and Rachmilewitz, 2005). Myocardial 
disease caused by transfusional siderosis is the most common life-limiting complication 
of iron overload in β-thalassaemia patients with a mortality rate of 67% (Borgna-
Pignatti et al., 2004, Cao and Galanello, 2010). 
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Individuals with milder anaemias that do not require regular transfusions have 
thalassaemia intermedia or non-transfusion dependent thalassaemia (NTDT). 
Thalassaemia intermedia comprises of a clinically and genotypically very 
heterogeneous group of thalassaemia-like disorders, ranging in severity from mild 
anaemias which are more severe than the asymptomatic carrier (thalassaemia minor) to 
delayed severe anaemia that leads to blood transfusions (Forget and Bunn, 2013). 
Patients carry homozygous or compound heterozygous alleles for β-thalassaemia and 
generally present with anaemia later in life compared to those with thalassaemia major. 
In individuals with two severe beta-thalassaemic alleles, the molecular basis for NTDT, 
include co-inheritance of α-thalassaemia that reduces the α-globin chain imbalance and 
co-inheritance of mutations associated with increased production of foetal (γ) globin 
chains in adults as the γ-globin combine with the excess α-globin chains to form 
functional foetal haemoglobin molecules (Weatherall and Clegg, 2001).  
Individuals with a single β-thalassaemia mutation are known as carriers. The clinical 
phenotype of β-thalassaemia carriers (minor) is usually asymptomatic characterised by 
hypochromic, microcytic blood picture with mild or no anaemia and an increase in 
HbA2 (Forget and Bunn, 2013). 
 
1.5. Conventional and curative therapies 
The only extensively used approach in managing β-thalassaemia is regular blood 
transfusions. Blood transfusions lead to iron overload and hence are usually 
accompanied by iron chelation therapy. Iron chelation therapy was found to double the 
life expectancy of patients with thalassaemia major (Olivieri, 1999). There are currently 
three available drugs used for iron chelation therapy. Deferoxamine, the most 
commonly used iron chelator, is administered as parenteral infusions (Brittenham et al., 
1994). Deferiprone (Aydinok et al., 2007) and deferasirox (Piga et al., 2006, Cappellini 
et al., 2006), are oral iron-chelators. Blood transfusions and chelation therapy need to be 
carried out throughout the life of the patient.  
While conventional treatment has the capacity to improve the quality of life of people 
with thalassaemia major, allogeneic haematopoietic stem cell transplantation is at the 
moment the only curative treatment for the disease. Since 1982 when the first successful 
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transplantation was performed (Thomas et al., 1982), haematopoietic stem-cell 
transplantation has greatly advanced as a treatment for thalassaemia major, with 
enormous progress made in the areas of donor identification and selection and 
development of alternative sources of haematopoietic stem cells (Rund and 
Rachmilewitz, 2005). The donor pool has been increased by the use of matched 
unrelated or haploidentical donors and using cord blood HSCs (Pinto and Roberts, 
2008). More recently, the use of peripheral blood as a source of HSCs stem cells has 
replaced the use of bone marrow for a significant proportion of allogeneic 
transplantations (Mahmoud et al., 1999, Tan et al., 2004). Therefore, haematopoietic 
stem-cell transplantation has now become a more viable approach for the treatment of 
thalassaemia. However, stem-cell transplantation is only available to those with access 
to high-technology medicine and not to all the individuals with β-thalassaemia.  
Gene therapy, which corrects the defective β-globin gene or introduces a functional β-
globin gene in autologous HSCs, is an attractive potential therapeutic alternative for 
people with β-thalassaemia (Sadelain et al., 2005). In principle, haematopoietic stem 
cells from the patient are harvested and infected with modified viruses containing the 
modified β-globin gene and its upstream regulatory elements. These autologous stem 
cells are then inserted back into the patient after myeloablation to create a niche for the 
corrected progenitors. Although this will eliminate the problem of compatible donor 
availability, limitations of the method arise in vector construction (Arumugam and 
Malik, 2010), including the safety of the vector in terms of recombination or 
mutagenesis and also the ability of the vector to accommodate all the sequences 
required for correct expression of the β-globin gene (Puthenveetil and Malik, 2004). 
Current investigations are focusing on vector production methodologies and safety 
issues aiming to minimise insertional oncogenesis (Nienhuis, 2008). A number of 
clinical trials are currently taking place to test lentiviral constructs for treatment of β-
thalassaemia.  
One approach to overcome the integration problems caused by viral vectors is the use of 
non-integrating gene editing to correct disease-causing mutations in HSC. Engineered 
nucleases composed of sequence-specific DNA-binding domains fused to a non-specific 
DNA cleavage module, induce targeted DNA double-strand breaks (DSBs) that 
subsequently stimulate the cellular DNA repair mechanisms, including error-prone non-
homologous end joining (NHEJ) and homology-directed repair (HDR) (Wyman and 
41 
 
Kanaar, 2006) to correct the mutation. Three different genome editing systems have 
been introduced; zinc finger nucleases (ZFNs) (Urnov et al., 2005), transcription 
activator-like effector nucleases (TALENS) (Miller et al., 2011) and RNA-directed 
Cas9 nucleases (Cho et al., 2013, Mali et al., 2013). In contrast to ZFNs, TALENs can 
be easily engineered to specifically recognise any given DNA sequence with high 
efficiency (Hockemeyer et al., 2011), lower off-target effects and reduced nuclease-
associated cytotoxicities (Mussolino et al., 2011). Recent studies reported the successful 
correction of HBB mutations in β-thalassaemia and sickle cell anaemia using TALENs 
(Ma et al., 2013, Sun and Zhao, 2013). However, the efficiency of TALENS can be 
hampered by DNA methylation and histone acetylation in active chromatin. In contrast, 
Cas9 nucleases are not limited by these obstacles and can be easily manipulated 
(Deltcheva et al., 2011). Xie et al. (2014a) efficiently corrected two different β-
thalassaemia mutations and converted homozygous thalassaemia to the heterozygous 
states in patient-derived iPS cells by the combinational use of CRISP/Cas9 for HBB 
cleavage and piggyback for both positive and negative selection of corrected clones. 
The piggyback transposon is a mobile genetic element that contains a bi-functional 
fusion protein between puromycin N-acetyltransferase and a truncated version of herpes 
simple virus type 1 thymidine kinase (Chen and Bradley, 2000). Two 500bp segments 
of the genomic sequences of HBB intron 1 were incorporated into piggyback transposon 
which upon recognition allow the transposon to be integrate into the chromosome via a 
‘cut and paste’ mechanism. Puromycin resistance was used for positive selection of 
clones with homologous recombination events. Upon transient transfection of 
transposase, piggyback cassette was removed from the mutation-corrected clones and 
negative selection using thymidine kinase eliminated the cells that retained the cassette.  
Stem cell research was introduced recently as an upcoming therapeutic strategy due to 
the discovery that human somatic cells can be reprogrammed to form embryonic-like 
multipotent cells by the introduction and expression of four transcription factors (Oct4, 
Sox2, KLF4 and c-Myc) (Takahashi and Yamanaka, 2006). The introduction of iPS 
cells has created opportunities for their exploitation as new human disease models, new 
methods for drug screening while offering the potential for new approaches to cell 
therapy. The proof of suitability of such a system for thalassaemia came from a study 
which generated iPS cells from somatic cells of a sickle cell mouse (Hanna et al., 2007). 
Similarly, reprogrammed human skin fibroblasts from a patient with homozygous β-
thalassaemia into iPS cells (Ye et al., 2009) had the ability to differentiate successfully 
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into red blood cells (Chang et al., 2011). Although iPS cells have opened a whole new 
approach into therapeutic approaches for haemoglobinopathies, extensive research 
needs to be done in order to overcome major challenges in this field before iPS cells can 
be considered a clinical therapeutic option. 
Epidemiological data have shown that co-existence of hereditary persistence of foetal 
haemoglobin (HPFH) in patients with β-thalassaemia ameliorates the severity of the β-
thalassaemia phenotype. HPFH is characterised by significantly high foetal 
haemoglobin production in adulthood due to deletions in the β-globin gene cluster or 
point mutations in the γ-globin gene promoters that lead to deregulation of the normal 
developmental regulation of γ-globin gene expression. Genetic studies have shown that 
the excess γ-globin chains due to HPFH, associate with the excess free α-globin chains 
accumulating due to β-thalassaemia thus increasing the synthesis of fully functional 
haemoglobin (foetal) and reducing the accumulation of free α-globin chains and 
subsequently, ameliorating the clinical symptoms of β-thalassaemia. Reactivation of 
foetal haemoglobin is therefore considered to be another therapeutic approach for β-
thalassaemia. Pharmacological therapy and gene therapy are the two methods currently 
being investigated for induction of foetal haemoglobin. Gene therapy involves the use 
of gene editing to target globin suppressors such as BCL11A or through transduction of 
γ-globin genes. While gene therapy is still at experimental stage, different classes of 
pharmacological agents able to reactivate HbF synthesis have been identified both in 
vitro and in vivo. Despite the demonstration of notworthy results for some of the agents 
in clinical trials, many of these agents have low efficacy and specificity while others are 
potentially toxic or carcinogenic (Gambari and Fibach, 2007).  
 
1.6. Pharmacological reactivation of foetal haemoglobin  
Several studies have focused on the identification of potential HbF inducers. More than 
70 agents (Appendix I) have been identified so far and can be grouped in several classes 
according to their chemical structure and molecular mechanism.  
A correlation between globin gene expression and DNA hypomethylation in human 
erythroblasts purified at various stages of differentiation (Mavilio et al., 1983) led to the 
introduction of 5-azacytidine as a potential HbF inducer. Analysis of the β- and γ-globin 
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gene promoters has shown that the γ-globin promoter was hypomethylated in foetal 
erythroid progenitors and was becoming progressively hypermethylated as erythroid 
differentiation progressed into adult erythroid progenitors (Singh et al., 2007). 
Similarly, the γ-globin gene promoter in CD34+ cells was hypomethylated at the pre-
erythroid phase and became hypermethylated at later stages of differentiation (Mabaera 
et al., 2007). Induction of γ-globin gene activation by 5-azacytidine, a DNMT inhibitor, 
was correlated with hypomethylation of a specific CpG site located 53-bp upstream of 
the γ-globin transcription initiation site (Ley et al., 1983). However, it was proposed 
that the inducing activity of the agent might be partly due to its ability to act as an S-
phase cell-cycle inhibitor rather than as a DNA hypomethylator. As a result, studies 
started investigating the use of S-phase inhibitors as potential HbF inducers. Among the 
cytostatic agents tested, hydroxyurea was identified as a highly effective HbF inducer. 
Investigation of hydroxyurea in small clinical trials demonstrated a robust HbF inducing 
response in patients with sickle cell anaemia (Platt et al., 1984). Further investigation of 
the use of hydroxyurea in larger clinical trails (Charache et al., 1995) led to FDA 
approval for its use in patients with sickle cell disease. In the meantime, the 
observations that infants born to diabetic mothers had a delayed foetal to adult 
haemoglobin switch led to suggestions that elevated hydroxybutyrate levels in utero 
could be responsible for the elevated HbF levels (Perrine et al., 1985, Bard and 
Prosmanne, 1985). These observations let to the introduction of butyrate and short chain 
fatty acids (SCFA) as potential HbF inducers. Despite promising results with these 
agents in initial studies (Perrine et al., 1994), the effect of the agents in larger clinical 
trials did  not produce a wide response in all patients (Sher et al., 1995). It was therefore 
thought that SCFA induce HbF through the inhibition of HDAC (Fathallah et al., 2007), 
leading to the study of a variety of HDAC inhibitors in vitro and in vivo for their clinical 
efficancy as HbF inducers (Cao, 2004). Later studies demonstrated the ability of DNA 
binding (Bianchi et al., 1999) and immunomodulatory drugs (Grzasko et al., 2006, List 
et al., 2006) as potential HbF inducers. While trials utilizing all the above agents have 
proven that pharmacological activation of foetal haemoglobin can be an effective 
therapeutic approach, none of these agents are optimal inducers in a clinical setting due 
to their short and long-term side effects and convenience of administration. 
Attempts to identify novel HbF inducers are based on the primary actions of specific 
classes of inducing agents such as global DNA hypomethylation by DNA 
methyltransferase inhibitors and global histone hyperacetylation by HDAC inhibitors. 
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However, none of these models can explain the ability of such a functionally diverse 
group of agents to induce HbF levels. As a result, major focus has been directed to 
investigate the role of cell signalling in the reactivation of HbF by these agents. In the 
meantime, while most of the research on HbF induction has been focused on the 
increase of γ-globin gene expression, experimental evidence suggested that post-
transcriptional processes have a role in the mechanism of HbF induction (Weinberg et 
al., 2005, Mabaera et al., 2008a).  
 
1.6.1. 5-azacytidine and decitabine 
5-azacytidine was the first agent discovered to reactivate HbF synthesis in humans. 5-
azacytidine was originally brought to the clinic as a cytotoxic cancer chemotherapy 
agent but it was later shown to be a potent DNA methyltransferase inhibitor (Christman, 
2002). DeSimone et al. (1982b) showed that 5-azacytidine increased HbF levels from 6 
to 30 times higher than those produced by bleeding alone. However, the exact 
mechanism of action of this agent is unclear as it acts both as a cytotoxic anticancer 
chemotherapy agent and as an inhibitor of DNA methyltransferase enzyme (Testa, 
2009). Due to its multiple effects, two theories have been proposed to explain the HbF 
inducing action of 5-azacytidine. The first theory suggests that the cytotoxic effect of 
the agent on erythroid progenitors stimulates a compensatory erythroid cell production 
due to erythropoietic stress, leading to an increase in HbF synthesis 
(Stamatoyannopoulos et al., 1985). The second theory involves the agent’s DNA 
methyltransferase inhibitory activity and suggests that demethylation of the γ-globin 
gene promoter leads to consequent transcriptional de-repression of the γ-globin gene 
(DeSimone et al., 1982b). More recent studies indicate that neither theory is correct as 
small interfering RNA silencing DNA methyltransferases failed to induce HbF 
synthesis. Moreover, the same studies also demonstrated no changes in growth or 
differentiation kinetics in the presence of 5-azacytidine suggesting an unknown 
mechanism of action (Mabaera et al., 2008a).  
Subsequent clinical trials of 5-azacytidine in sickle cell and thalassaemia patients have 
confirmed its ability to increase HbF synthesis and reduce anaemia (Charache et al., 
1983, Ley et al., 1982, Ley et al., 1983). However, despite its promising effects, further 
trials raised concerns over its carcinogenic potential in humans (Carr et al., 1984). A 
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safer derivative of 5-azacytidine, decitabine (5-aza-2’-deoxycytidine), was introduced 
that was able to increase HbF synthesis in both baboons and sickle cell patients at 10-
20% the concentration of 5-azacytidine (Koshy et al., 2000, Saunthararajah et al., 2003, 
Saunthararajah et al., 2008). Decitabine is a hypomethylating agent which depletes the 
chromatin modifying enzyme DNMT1 and thus hypomethylates DNA CpG nucleotides. 
In vitro experiments showed that decitabine favours erythroid and megakaryocytic 
differentiation of haematopoietic cells (Visvader and Adams, 1993). Decitabine was 
shown to increase acetylation of H3 and H4 at the γ-globin promoter specifically 
suggesting that decitabine-mediated changes in DNA methylation might be associated 
with changes in chromatin structure (Saunthararajah et al., 2003). However, 
hypomethylation of the ε-promoter did not lead to increased expression of the gene, 
suggesting that local hypomethylation is not the sole requirement for gene expression 
(Karpf et al., 2004).  
 
1.6.2. Butyrate and short chain fatty acids 
Ginder et al. (1985) was the first to demonstrate that administration of butyrate resulted 
in induction of embryonic globin gene expression in 5-azacytidine pre-treated chickens. 
Shortly after, infants born to diabetic mothers who were exposed to higher butyrate 
levels in utero were shown to have higher HbF levels at birth (Perrine et al., 1985; Bard 
et al., 1985). Moreover, administration of butyric acid in baboons resulted in the 
reversion of foetal to adult globin expression (Constantoulakis et al., 1988). Despite the 
lack of understanding of the mechanism of action of butyrate, it was proposed that the 
increase in HbF levels in the presence of the agent was due to changes in histone 
acetylation level of promoter regions due to the function of butyrate as an inhibitor of 
HDAC. Subsequent studies have shown that activation of γ-globin gene by butyrate and 
other SCFA was dependent on a duplicated CCAAT box sequence, located upstream of 
the transcription initiation site (McCaffrey et al., 1997). Due to its promising 
stimulatory effect of HbF synthesis, a pharmaceutical preparation of butyrate, arginine 
butyrate, was administered to patients with sickle cell disease and β-thalassaemia as 
infusions. Butyrate infusions were able to stimulate HbF synthesis in sickle cell patients 
(Perrine et al., 1993) but the effect observed was not sustainable, possibly due to an 
inhibitory effect of the drug on haematopoiesis (Sher et al., 1995). A major drawback of 
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the drug was the inability to stimulate HbF synthesis in all patients (Sher et al., 1995). 
Oral alternatives of the drug resulted in enhancement of HbF synthesis in β-
thalassaemia patients. Sodium phenylbutyrate promoted a response in patients with high 
endogenous erythropoietin levels with no related globin gene mutation (Collins et al., 
1995) while isobutyramide elicited a response in transfusion-dependent β-thalassaemia 
patients with high pretreatment HbF levels (Reich et al., 2000).  
Despite initial assumptions that butyrate and SCFA induce foetal haemoglobin through 
histone acetylation, not all SCFA caused global histone hyperacetylation (Boosalis et 
al., 2001). Fathallah et al. (2007) demonstrated that while butyrate increased histone 
acetylation at the γ-globin promoter, it decreased histone acetylation at the β-globin 
promoter. These findings suggest an alternative mechanism of SCFA in the stimulation 
of HbF induction.  
 
1.6.3. Hydroxyurea 
Hydroxyurea (HU) is the most widely studied HbF inducer and was initially used for 
the treatment of myeloproliferative disorders. The mechanisms underlying HU action 
still remain elusive but HU has the ability to inhibit cellular ribonucleotide reductase, 
whose role is critical for DNA synthesis in the dividing late progenitor cells. Initial 
studies carried out in 1984 in anaemic monkeys (Letvin et al., 1984) and in sickle cell 
patients (Veith et al., 1985) showed stimulation of HbF production by HU. Fibach et al. 
(1993) showed that HU increased the level of HbF synthesised by erythroblasts using 
two-phase liquid erythroid cell cultures. In addition, it was shown that HU decreased 
erythroblasts proliferation and increased cell size and haemoglobin content per cell 
(Fibach et al., 1993). Data from various studies support the hypothesis that HU is able 
to induce the nitric oxide (NO) dependent activation of soluble guanylyl cyclase (sGC) 
(Cokic et al., 2008) in primary human erythroid progenitor cells and in patients with 
sickle cell disease (Nahavandi et al., 2002). HU also increases cyclic guanosine 
monophospate (cGMP) and cyclic adenosine monophospate (cAMP) in primary human 
erythroid progenitor cells (Keefer et al., 2006). Moreover, HU was shown to stimulate 
the secretion-associated and RAS-related (SAR) GTP-binding protein, which in turn 
induces apoptosis and G1/S phase arrest by reducing phosphoinositol-3 kinase (PI3K) 
and extracellular-signal regulated kinase (ERK) phosphorylation while increasing p21 
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and GATA2 expression (Tang et al., 2005). Evidence that HU decreases vaso-
occlusion, acute chest syndrome and transfusion requirements led to its approval as a 
therapeutic agent in patients with sickle cell disease by the FDA in 1998 (Charache et 
al., 1995). A double blind randomised trial of hydroxyurea in children with sickle cell 
disease demonstrated that HU reduced acute chest syndrome, pain and dactylitis as well 
as transfusion requirements while improved haematological parameters and increased 
foetal haemoglobin levels (Wang et al., 2011). One of the major disadvantages of HU is 
that not all patients respond to the agent. Around 60-80% of the patients respond to HU 
treatment with pre-therapy HbF levels being a good predictor of response to HU. In 
patients with β-thalassaemia, HU is much less effective (Italia et al., 2009). Response to 
HU treatment was correlated with XmnI haplotypes in β-thalassaemia patients 
(Yavarian et al., 2004, Bradai et al., 2007). More positive results were reported in 
patients with NTDT (Ehsani et al., 2009, Kosaryan et al., 2014).   
 
1.6.4. Histone deacetylase inhibitors 
Histone acetylation analysis of the human β-globin locus showed that the LCR is 
acetylated at the same level in both foetal and adult erythroblasts while the level of 
acetylation in the globin gene promoters was correlated to the level of transcription 
(Kim and Dean, 2004). Based on these findings as well as the action of butyrate as a 
HDAC inhibitor, several other HDAC inhibitors including MS-275, apicidin (Witt et 
al., 2003), scriptaid (Johnson et al., 2005) and trichostatin A (Pace et al., 2003) were 
tested and shown to induce HbF synthesis both in erythroleukaemia cell lines and 
primary human erythroid cultures. Computational modelling and screening of chemical 
libraries, identified RB7 as a potent HbF inducer in cultured erythroid progenitors, by 
dissociating HDAC3 from its adaptor protein or from the γ-globin gene promoter, thus 
promoting the recruitment of RNA polymerase II to the promoter (Mankidy et al., 
2006). Several studies have shown that most of these HDAC inhibitors have an indirect 
action on the globin gene promoter through the induction of p38 MAPK pathway (Pace 
et al., 2003, Tamura et al., 2000, Wei et al., 2007) by phosphorylation of CREB1 and 
activating factor-2 (ATF-2) (Sangerman et al., 2006). The phosphorylated transcription 
factors then bind to the cyclic AMP responsive element present in the promoter region 
of the γ-globin genes and consequently activate these genes (Sangerman et al., 2006).   
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1.6.5. DNA-binding Drugs 
DNA-binding drugs (DBD) interfere with critical cellular processes such as inhibition 
of DNA and RNA polymerases, topoisomerase and nucleases. Mechanistically, DBDs 
may block the action of enzyme complexes or interfere with protein access to DNA by 
inhibiting the interaction between transcription factors and target DNA elements.  
Mithramycin, chromomycin, tallimustine and angelicin are some of the DBDs found to 
be effective in reactivating HbF synthesis. Most of these compounds have been used 
previously in therapy of other diseases such as cancer and hypercalcaemia 
(chromomycin and mithracycin), viral infections (tallimustin) and psoriasis (angelicin). 
Bianchi et al. (1999) showed that mithramycin and chomomycin were powerful 
inducers of erythroid differentiation in K562 cells, by increasing the content of foetal 
haemoglobin and increasing the γ-globin mRNA accumulation. Furthermore, 
mithramycin (Fibach et al., 2003), tallimustin (Chiarabelli et al., 2003), ciplastin 
(Bianchi et al., 2000) and angelicin (Lampronti et al., 2003) enhanced HbF synthesis in 
human erythroid progenitor cells. Interestingly, the level of induction displayed by 
mithramycin was higher and more consistent than hydroxyurea in thalassaemic 
erythroid progenitor cells while showing lower cytotoxicity than hydroxyurea (Fibach et 
al., 2003). Similarly, three DNA-binding antibiotics (doxorubicin, idarubicin and 
daunorubicin), also known as anthracyclins, increased γ-globin expression in primary 
human erythroid progenitor cells from healthy and thalassaemic cultures above the 
effect of hydroxyurea (Spyrou et al., 2010).  
 
1.6.6. Immunomodulatory drugs 
Thalidomide, originally synthesised as an anti-histaminic agent, was prescribed as a 
sedative during pregnancy. Due to its teratogenic effects, thalidomide was withdrawn 
from the market (Mcbride, 1961), but re-introduced due to is remarkable effect in 
erythema nodosum leprosum and was FDA approved as an anti-inflammatory drug 
(Nightingale, 1998). It is currently being used to treat dermatologic, infectious, 
autoimmune and haematologic disorder including multiple myeloma. Clinical trials 
have demonstrated the ability of thalidomide to improve anaemia in younger patients 
with low-risk myelodysplastic syndromes and to stimulate erythropoiesis in patients 
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with multiple myeloma (Grzasko et al., 2006). Thalidomide was able to reduce 
transfusion-dependent anaemia in patients with myelodysplasia (Raza et al., 2001). 
Preliminary data suggest that thalidomide increases expression of the γ-globin gene via 
reactive oxygen species (ROS)-dependent activation of the p38 MAPK signalling 
pathway and histone H4 acetylation (Aerbajinai et al., 2007). However, its use as an 
HbF inducer is limited by its teratogenic activity. More recently, lenalidomide and 
pomalidomide, two thalidomide analogues, were introduced as HbF inducers. 
Lenalidomide and pomalidomide were described to have immunomodulatory properties 
as well as inhibitory activities of Tumour necrosis factor (TNF)-α production (Corral et 
al., 1996). Similarly to thalidomide, lenalidomide, which was recently approved by the 
FDA as a drug for myelodysplastic syndrome (MDS), was shown to reduce and 
eliminate the need for red blood cell transfusion in patients with this disease (List et al., 
2006). Moutouh-de Parseval et al. (2008) demonstrated that pomalidomide and 
lenalidomide were able to induce HbF expression by regulating the transcription of γ- 
and β-globin genes in primary human erythroid progenitor cells from patients with 
sickle cell disease while reducing erythroid differentiation. Furthermore, these agents 
show no cytotoxicity to the erythroid progenitors but actually reduce the number of 
erythroid differentiated cells undergoing apoptosis (Verhelle et al., 2007). The 
combination of stimulating erythropoiesis and increasing erythroid progenitor survival 
makes these drugs ideal candidates for the treatment of ineffective erythropoiesis 
observed both in MDS and haemoglobinopathies (Moutouh-de Parseval et al., 2008). 
 
1.7. The role of cell signalling in HbF induction 
Initially most HbF inducing agents have been viewed as affecting γ-globin gene 
expression by altering the chromatin structure of globin gene promoters in the case of 
DNA demethylating agents and histone deacetylase inhibitors, or by altering the 
kinetics of erythroid differentiation in the case of cytotoxic agents. However, findings 
such as the ability of 5-azacytidine to increase HbF synthesis in the absence of global 
DNA methylation, the inability of the DMNT1 knock-down to induce expression of the 
γ-globin gene through hypomethylation of its promoter (Mabaera et al., 2008a), the 
ability of drugs to induce HbF in vitro without changes in the differentiation kinetics 
(Mabaera et al., 2008a), the ability of short chain fatty acids that do not affect histone 
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acetylation to induce HbF synthesis (Boosalis et al., 2001) and the ability of p38 MAPK 
inhibitors to block γ-globin and HbF induction (Witt et al., 2000), has raised questions 
about the molecular mechanism of action of these agents. In fact research into the 
mechanisms of action of some of the known HbF inducers has identified different 
signalling pathways that might be involved in γ-globin gene reactivation. The 
implicated pathways include cGMP and cAMP, NO, p38 MAPK, ROS and cytokine 
signalling. The first evidence came from Witt et al. (2000) who showed that induction 
of erythroid differentiation and haemoglobin production in K562 by butyrate was 
associated with increased p38 MAPK phosphorylation and that inhibition of p38 
activity prevented butyrate’s effect. In addition, induction of HbF by HDAC inhibitors 
was shown to be mediated not only by hyperacetylation but also due to production of 
ROS (Hsiao et al., 2006) that lead to p38 MAPK phosphorylation and subsequent 
activation of the cAMP response element binding protein (CREBP) and ATF2 (Pace et 
al., 2003; Sangerman et al., 2006). Primary human erythroid cultures (Aerbajinai et al., 
2007) demonstrated that thalidomide has the ability to increase γ-globin gene expression 
through ROS production, p38 MAPK phosphorylation and global enhancement of 
histone H4 acetylation. Moreover, Ikuta et al. (1998) demonstrated the importance of 
cGMP/sGC pathway activation in the butyrate mediated induction of γ-globin gene 
expression. However, cAMP signalling has greater importance in HbF induction than 
cGMP in in vitro primary human erythroid experiments (Keefer et al., 2006). Bailey et 
al. (2007) reported that pharmacological manipulations that increased cAMP stimulate 
HbF synthesis in primary human erythroid progenitor cells from β-thalassaemia 
intermedia patients. In addition, intracellular levels of cAMP and phosphorylated CREB 
levels correlate with foetal haemoglobin in individual patients (Bailey et al., 2007). 
Cokic et al. (2008) suggested a mechanistic link between NO, cGMP and HbF induction 
in the presence of HU since inhibition of cGMP lead to inhibition of the HU mediated 
HbF induction.  
Although each of these models has strong evidence supporting their involvement in 
HbF induction, they do not explain how such a diverse group of compounds can have 
the same effect. Mabaera et al. (2008b) introduced a mechanistic model of HbF 
induction which integrates the activation of p38 MAPK through multiple upstream 
signals including DNA damage, oxidative stress (ROS), heat shock, osmotic shock, NO 
and inhibition of protein synthesis. The ability of most agents to activate cell stress 
signalling pathways that augment γ-globin gene expression and HbF production during 
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adult erythopoiesis, has led to the proposed cell stress signalling model of foetal 
haemoglobin (Mabaera et al., 2008b). Based on the cell stress model, the dose of 
inducing agents must be high enough to activate stress signalling but not so high as to 
induce cell cycle arrest or apoptosis in haematopoietic precursor cells.  
More recently, the integrated stress response pathway has been proposed to have an 
important role in erythroid cells. Under various stress conditions such as viral infection, 
heat shock, ROS, NO (Igarashi et al., 2004) endoplasmic reticulum (ER) stress (Li and 
Holbrook, 2004), proteosome inhibition, inadequate nutrients and haem deficiency, the 
integrated stress response down-regulates general protein synthesis, through inhibition 
of mRNA translation following phosphorylation of eukaryotic translation initiation 
factor 2A (eIF2A) by kinases. Translational regulation of HRI, the only kinase to be 
activated by arsenite-induced oxidative stress, was recently shown to be essential in 
reducing excessive synthesis of globin proteins and phenotypic severities in β-
thalassaemia (Han et al., 2005). In the absence of HRI, the steady-state level of protein 
synthesis in reticulocytes is considerably increased in a haem-independent manner with 
the primary impact on the synthesis of α- and β-globin chains, suggesting an important 
role for HRI in the regulation of translational initiation in erythroid precursors (Han et 
al., 2001). Studies on thalassaemic (Hbb-/-) mice have shown that activation of HRI is 
critical in minimizing the production and the accumulation of denatured α-globin 
aggregates (Han et al., 2005). In addition to inhibition of protein synthesis, the second 
important consequence of eIF2Α phosphorylation under the integrated stress response is 
the specific increase in translation and transcription of factors that are required for stress 
response. One such transcription factor is ATF4 which is up-regulated upon 
endoplasmic reticulum stress (Harding et al., 1999), leading to the secondary 
transcriptional responses affecting other transcription factors such as C/EBP 
homologous protein-10 (Chop/GADD153) (Wang et al., 1996) which in turn activate 
additional downstream genes such as growth arrest- and DNA damage-inducible gene 
(GADD) 34, leading to the induction of either corrective pathways or apoptosis (Novoa 
et al., 2003).  Atf4-/- mice resulted in transient foetal anaemia with relatively normal 
erythropoieis in adulthood while studies on gadd34-/- mice revealed that gadd34 was 
required for haemoglobin synthesis. In addition, GADD34 expression was increased 
upon exposure to erythropoietin and DMSO-mediated differentiation in MEL cells. 
Despite the lack of experimental evidence about the direct role of the integrated stress 
response pathway in HbF induction, it should not be discarded as a possible explanation 
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of the translational effects of HbF inducers due to its importance in erythroid precursor 
cells, its ability to activate under stress conditions the production of molecules such as 
NO and ROS and its ability to activate some of the transcription factors involved in p38 
MAPK pathway (Mabaera et al., 2008b).  
 
1.8. The use of proteomics for the study of biological processes   
Molecular medicine is currently moving beyond genomics and towards proteomics 
since the function of proteins is closely associated with the cellular, tissue and 
physiological contexts that drive biological outcomes. The rate of synthesis and half-life 
of proteins (Varshavsky, 1996) is regulated not only by the abundance of mRNA but 
also by post-transcriptional mechanisms and the regulated destruction of proteins. The 
mRNA levels of a particular gene do not accurately represent the amount of the 
respective protein expressed. It is, therefore, essential to measure protein expression 
directly for genome-wide analysis of biological processes (Aebersold et al., 2000). In 
order to study biological processes at the system level, analytical tools that identify the 
components of the system and measure their responses to a changing environment are 
required. Among them proteomics, the global analysis of protein expression, is a rapidly 
developing technology (Bantscheff et al., 2007). Quantitative proteomics have the 
ability to detect steady-state gene expression and perturbation-induced changes leading 
to a more accurate representation of protein-directed biological processes (Aebersold et 
al., 2000).  
Classical proteomic quantitative methods combine protein separation by high-resolution 
two-dimensional gel electrophoresis (2DE) (O'Farrell, 1975), in combination with mass 
spectrometry (MS) or tandem mass spectrometry (MS/MS) for identification of selected 
proteins. 2DE was developed before the term proteomics was even employed and 
entails the separation of complex protein mixtures by molecular charge in the first 
dimension and by mass in the second dimension. Although it provides several types of 
information about the proteins identified including molecular weight, PI and quantity, 
large-scale protein analysis studies comparing the levels of expression of proteins from 
yeast S. cerevisiae, observed that the 2DE/MS approach is fundamentally limited by its 
ability to detect low abundance proteins and that the number of proteins detected does 
not correspond to the number of genes expressed in the cell from which the sample 
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originated (Gygi et al., 1999b). These limitations are resolved by the introduction of 
Liquid chromatography (LC)-MS/MS techniques.  
LC-MS/MS based quantitation employs stable isotope labelling of peptides which 
create a specific mass tag that can be recognised by a mass spectrometer. Since a stable 
isotope-labelled peptide is chemically identical and behaves identically to its native 
counterpart during chromatographic and mass spectrometric analysis, the mass tag 
provides the basis for quantitation of proteins. Several methods have been developed for 
stable isotope labelling used in proteomics and only differ in the method of introduction 
of tags into proteins or peptides. The tags can be introduced metabolically (Ong et al., 
2002), chemically (Gygi et al., 1999a, Ross et al., 2004) or enzymatically (Yao et al., 
2001) as internal standards (Ong and Mann, 2005), or by spiking known quantities of 
synthetic peptides into the sample as external standards (Kusmierz et al., 1990). 
Alternatively, label-free methods are available which can provide a comparison between 
two or more experiments by comparing the signal intensity for any given peptide or 
using the number of acquired spectra matching to a peptide as an indicator for its 
respective amount in a given sample. Each technique has its particular strengths and 
weaknesses. Thus careful consideration should be placed on which method is more 
suitable for the type of experiment performed.  
Proteomics have been used in a number of applications. Quantitative proteomics are 
ideally suited for the discovery of protein biomarkers in the absence of any prior 
knowledge of quantitative changes in protein levels, and for diagnosis of diseases such 
as cancers, cardiovascular diseases and diabetes among others. Comparison of the 
proteomic profile of healthy with disease state provides information on over or under-
expressed proteins or disease-induced proteins released in the serum and insights for 
therapeutic interventions. However, despite the many thousand proteomic studies 
published so far, only a minority has provided a comprehensive quantitative description 
of the biological systems under investigation (Ong and Mann, 2005). It is now widely 
recognised that the proteome is much more complex than the genome and transcriptome 
(Rappsilber and Mann, 2002) and the various challenges in proteomic investigations are 
only beginning to be determined. Several sources of potential error exist during every 
step of the process that can negatively affect the results of peptide quantitation. But 
since quantitative proteomics is a relatively new field, no standards have been agreed on 
how to perform the experiments and analyse the data with statistical confidence. 
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Therefore further research is urgently needed to ensure quality and transparency of 
quantitative proteomics (Ong and Mann, 2005).   
 
1.9. Aims and Objectives 
Despite the large number of compounds identified as HbF inducers, their clinical use is 
limited due to low HbF inducing activity, high cytotoxicity and inability to elicit a 
response in all patients. Thus identification of new agents with higher efficacy and 
reduced toxicity is imperative. A key step in developing targeted drugs is the 
identification of specific molecular targets whose function can be manipulated by 
compounds. One approach to achieve that is the identification of molecules within 
signalling pathways associated with the particular function of interest, followed by 
rational design of molecules that alter the function of the targets to produce a desirable 
effect. Despite years of research, most of the key molecules and pathways that mediate 
the induction of HbF remain to be defined. A second approach for target identification 
is to screen drug libraries or test promising compounds for the ability to produce a 
desired cellular effect and to then determine the pathways and molecules targeted by 
effective agents. However, neither the molecular mechanisms nor target molecules have 
been definitively verified for any of the 70 HbF inducing compounds described so far.  
Therefore, the most direct route to identifying specific molecules for targeted drug 
development may involve taking advantage of these lead compounds to determine their 
molecular mechanism of action.  
In the current project two approaches have been employed with the aim of identifying 
potential HbF inducers. Initially, agents that are structurally similar to compounds with 
known HbF inducing activity will be screened for identification of novel agents with 
potent HbF inducing activity. Then, the molecular pathways of a known HbF inducer 
will be investigated with the aim of identifying potential targets for therapeutic 






My immediate objectives included:  
o In vitro screening of agents belonging to the xanthine group of substances using 
a mouse erythroleukaemic cell model.  
o Screening of eleven derivatives of resveratrol in a human erythroleukaemic cell 
line with the purpose of identifying a compound which combines the HbF 
inducing activity of resveratrol with lower cytotoxicity. 
o Screening of four potent HbF inducers: (1) Lenalidomide, an immunomodulator 
drug, (2) Angelicin, a compound structurally related to psoralens, (3) 5-aza-2’-
deoxycytidine (decitabine), an antimetabolite nucleoside analogue and (4) 
Mithramycin, another DNA binding agent,  in a human erythroleukaemic cell 
line and primary human erythroid progenitor cells with the purpose of selecting 
the most effective agent with regards to HbF induction.  
o Investigation of the molecular mechanisms of action of the most effective agent 
by quantitative proteomic analysis of primary human erythroid cultures from 
healthy individuals and transfusion-dependent thalassaemic patients treated with 
the particular agent. 
o Investigation of the DNA and Histone methylation patterns of the LCR and 
globin gene promoters in primary human erythroid cultures from healthy donors 
treated with the agent using Chromatin immunoprecipitation (ChIP) assay 
o Investigation of changes in the mRNA levels of ten transcription factors 
associated with γ-globin gene expression, in primary human erythroid cultures 
from healthy donors and transfusion-dependent thalassaemic patients in the 
presence of the selected agent by quantitative PCR 
o Investigation of the effect of down-regulation of 17 significantly differentially 
expressed proteins (identified through proteomics) in primary human erythroid 



























2.1. Cell culture 
2.1.1. Cell culture materials 
 Description Supplier 
Media 
Roswell Park Memorial institute (RPMI) 1640 
Medium 
GIBCO Invitrogen Inc, Paisley UK 
Serum Foetal Bovine Serum (FBS), Heat inactivated GIBCO Invitrogen Inc, Paisley UK 
Supplement L-Glutamine 200nM (100x) GIBCO Invitrogen Inc, Paisley UK 
Supplement Penicillin-Streptomycin (10,000 U/ml) GIBCO Invitrogen Inc, Paisley UK 
Supplement Sodium Pyruvate GIBCO Invitrogen Inc, Paisley UK 
Antibiotic Gentamicin (G418) 10mg/ml GIBCO Invitrogen Inc, Paisley UK 
Dye Trypan Blue Sigma-Aldrich, St Louis USA 





 Delta treated NUNC, Roskilde Demark 
Plates 6-well plates NUNC, Roskilde Demark 
Plates 12-well plate NUNC, Roskilde Demark 
Centrifuge Eppendorf 5810 centrifuge Eppendorf, Hamburg Germany 
 
2.1.2. Culturing the MEL cell line 
Attempts to identify pharmacological reactivators of foetal haemoglobin require 
screening of agents in experimental models that replicate the in vivo regulation of β-like 
globin genes. Several groups have been using cells transfected with reporter genes 
under the transcriptional control of the γ- and β-globin gene promoters in order to 
identify more specific agents (Skarpidi et al., 2000, Vadolas et al., 2004). The 
advantage of these systems is their ability to become automated and thus be used for 
high throughput screening of HbF inducers.  
The initial screening of potential HbF inducers was performed on the mouse 
erythroleukaemia cell line GM979 (MEL). The GM979 cell line was modified by 
incorporating the μLCRβprRluc
AγproFluc construct (Figure 6) containing two luciferase 
proteins, Firefly and Renilla, under the control of the human γ- and β-globin promoters, 
respectively, as originally described by Skarpidi et al. (2000).  
Cells were cultured in RPMI medium enriched with 10% Foetal Bovine Serum (FBS), 
0.6% Glutamine, 50 U/ml of Penicillin/Streptomycin, 1% Sodium Pyruvate and 
400μg/ml G418 Geneticin reagent, an aminoglycoside related to Gentamicin for 
selection of the clones containing the μLCRβprRluc
AγproFluc construct, in T25cm
2
 flasks 
in a humidified atmosphere of 5% CO2 at 37˚C. Cells were sub-cultured every two days, 
when complete media change was performed. The cells were collected in 15ml falcon 
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tubes and centrifuged for 5 min at 1200rpm. The supernatant was discarded and cells 
were re-suspended in 12ml medium at a density of 0.4x10
6




Figure 6, Dual luciferase reporter construct (μLCRβprRluc
AγproFluc) transfected into the GM979 
cell line. Scarpidi et al.(2000)Blood 96(1):321-216 
 
2.1.3. Culturing the K562 cell line 
In 1981, Rutherford et al. (1981) was the first to suggest the use of the human cell line 
K562 as a model for studying haemoglobin switching. K562 cells, originally established 
by Lozzio and Lozzio (1975) were derived from a patient with chronic myeloid 
leukaemia in terminal blast cell crisis. Studies have shown that the K562 blasts are 
multipotential, haematopoietic malignant cells that can spontaneously differentiate into 
recognisable progenitors of the erythrocytic, granulocytic and megakaryocytic series 
(Andersson et al., 1979). 
K562 cells were cultured in RPMI medium enriched with 10% Foetal Bovine Serum 
(FBS), 0.6% Glutamine and 50 U/ml of Penicillin/Streptomycin. Cells were maintained 
at 37˚C in a humified atmosphere of 5% CO2 using Nunc T25cm
2 
tissue culture flasks. 
Every two days, the cells were collected into 15ml falcon tubes, centrifuged at 1200rpm 
for 5 min and re-suspended in new media at a density of 0.3x10
6
 cells/ml.  
 
2.2. Screening of potential agents in MEL cells 
2.2.1. Treatment of MEL cells 
For experimentation, the cells were collected in 15ml falcon tubes and centrifuged at 
1200rpm for 5min. The supernatant was discarded and cells were washed with 1X PBS 
to remove any excess antibiotic. The cell numbers were estimated by Trypan Blue 
staining on a Haemocytometer (Hausser Scientific, Horsham, USA) and cells were 
seeded in 6-well plates at 5x10
4









concentration of each compound to be studied was added to each well. Un-treated cells 
were used as negative control whereas treatment with 10mM Propionic acid was used as 
positive control. Triplicates of each culture condition were performed and plates were 
incubated at 37°C in a humified atmosphere of 5% CO2 for 4 days prior to collection of 
the cells for the luciferase assay.    
 
2.2.2. Luciferase assay 
2.2.2.1. Materials and Kits 
 Description Supplier 
Kit Dual-Luciferase Reporter Assay Promega, MAD USA 
Tubes 2.5ml Polystyrene tubes BD Biosciences, Erembodegem Belgium 
Luminometer Tube luminometer 
Berthold Detection System GmbH, Pforzheim 
Germany 
 
2.2.2.2. Measuring luciferase activity in MEL cells 
A luciferase assay was used to measure the effect of potential inducers in MEL cells. On 
day 4 of treatment, the cells from each well were collected into 15ml falcon tubes and 
centrifuged at 1200 rpm for 5 min and washed once with 1X PBS. Trypan blue staining 
was used to estimate cell number and viability of cells in each condition. The cells were 
centrifuged once more at 1200 rpm for 5min and the supernatant removed. 100μl 1x 
Passive Lysis buffer prepared from 5x stock solution in distilled water, was added to the 
re-suspended pellet and incubated at room temperature for 15 min to allow lysis of cells. 
The firefly luciferase reporter assay was initiated by adding 20μl of the lysed cells 
suspension to 100μl LARII solution (prepared by re-suspending stock LARII powder in 
10ml Buffer according to manufacturer’s instructions, Promega) in a 2.5 ml polystyrene 
tubes. The firefly luciferase activity was then measured on a tube luminometer. 
Addition of 100μl 1X Stop and Glow Solution (1X), prepared just before use from a 50x 
stock substrate, to the samples allows the quenching of firefly luciferase luminescence 
and concomitant activation of renilla luciferase. Renilla luminescence was quantitated 
with the luminometer as fast as possible.  
The increase activity of the γ-globin promoter in the presence of the agent was 
calculated by the ratio of firefly luciferase to the total luciferase activity for each sample 
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where firefly intensity represented the γ-globin promoter activation and Renilla 
intensity, the β-globin promoter activation. In the current system, firefly luciferase 
activity has approximately 50% greater luminescence than renilla luciferase activity per 
mole and therefore multiplication of the measurement of renilla luciferase activity by a 
factor of 2 will adjust for the difference in the measured activity. The ratio γF/(γF+2βR) 
therefore, represents the increase in γ-globin promoter activity relative to the total 
increase in globin gene promoter activity. 
 
2.3. Screening of potential agents in K562 cell line 
2.3.1. Treatment of K562 cells with potential agents 
Cells were counted using Trypan Blue staining and were collected in 15ml falcon tubes 
and centrifuged at 1200rpm (Centrifuge 5810, Eppendorf) for 5min. The supernatant 
was discarded and the cells were seeded in 12-well plates in 2ml per well at a density of 
2x10
4
 cells/ml. The appropriate concentration of each compound to be studied was 
added to each well. Un-treated cells were used as a negative control and treatment with 
150μM Hydroxyurea was used as a positive control. Triplicates for each culture 
condition studied were performed and the plates were incubated at 37°C in a humidified 
atmosphere of 5% CO2 for 5 days. After five days incubation with the agent, the cells 
were collected and cell viability was determined by Trypan Blue. The level of cellular 
differentiation as a result of the effect of the inducing agent was determined by 
Benzidine staining. 
 
2.3.2. Benzidine staining 
2.3.2.1. Materials and reagents  
 Description Supplier 
Dye Benzidine dihydrochloride Sigma Aldrich, St Louis USA 
Reagent Glacial acetic acid BDW VWR international Poole UK 
Reagent MilliQ Distilled water Millipore, GaA, Darmstadt Germany 




2.3.2.2. Benzidine staining procedure 
Benzidine staining is the most widely used method for scoring erythroid differentiation. 
It is highly specific for haem-containing compounds and can thus be used for the 
detection of haemoglobin (Nagy et al., 1995). Haemoglobin containing cells will stain 
blue in the presence of benzidine stain. However, benzidine staining is such a sensitive 
method that sometimes myeloid cells with high haem-containing enzyme-peroxidase 
content may stain lightly blue (Fibach, 1998).   
Stock solution of the stain was prepared by the addition of 1g benzidine dihydrochloride 
and 14.6ml glacial acetic acid to 485.4ml of distilled water. The bottle was kept in the 
dark with constant stirring for a few hours until benzidine was dissolved.  
A working solution was then prepared by the addition of 20μl of 30% H2O2 to 1ml 
benzidine stock solution. Equal volumes of the working solution and cells were 
combined and allowed to stand at room temperature for 2-3 minutes. The haemoglobin 
containing cells were stained blue and can be scored using a haemocytometer.  
 
2.4. Primary human erythroid progenitor cell culture  
2.4.1. Materials and reagents 
 Description Supplier 
Medium Αlpha MEM 2x Sigma-Aldrich, St Louis USA 
Serum 
Certified Foetal Bovine Serum US origin 
(1600044) 
GIBCO Invitrogen Inc, Paisley UK 
Supplement Cyclosporin A 1mg/ml Sigma-Aldrich, St Louis USA 
Supplement Bovine Serum Albumin (BSA) Sigma-Aldrich, St Louis USA 
Supplement β-mercaptoethanol 1mM Sigma-Aldrich, St Louis USA 
Supplement Dexamethasone 21-phosphate disodium salt Sigma-Aldrich, St Louis USA 
Supplement Glutamine 200mM GIBCO Invitrogen Inc, Paisley UK 
Supplement Lyophilised human Stem cell factor GIBCO Invitrogen Inc, Paisley UK 
Supplement Human recombinant Erythropoietin  Janssen-Cilag Lt, Bucks, UK 
Reagent PBS GIBCO Invitrogen Inc, Paisley UK 
Reagent Lympholyte M 
Tebu-Bio, Le-Perray-en-Yvelines 
France 
Tubes 50ml falcon tubes 
Greiner Bio-one, Frickenhausen, 
Germany 
Pipettes 5ml, 10ml and 25ml pipettes 
Costar, Corning Inc., New York, 
USA 
Flasks T75cm2 flasks Nuclon
TM
 Delta treated Nunc, Roskilde Denmark 
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2.4.2. Preparation of cell culture reagents 
 
10% Bovine Serum Albumin (BSA):  
25g BSA were diluted in 110ml double deionised water overnight at 4˚C in the dark 
using a magnetic stirrer. The following day, an equal volume (110 ml) of the double 
concentrated (2x) α-MEM was added to the solution. The solution was mixed for 
another hour at room temperature using a magnetic stirrer, filter-sterilised through a 
0.22μm filter and stored at 4˚C. 
 
Double concentrated (2x) alpha-MEM medium 
1 litre powder package of α-MEM was dissolved in 0.5L of distilled water. Addition of 
2.2g sodium bicarbonate changed the pH and consequently the colour of the solution 
into an orange-red colour. The pH was adjusted to 7.2-7.4 using sodium hydroxide 
solution. The medium was supplemented with 100U/100μg Penicillin/Streptomycin, 
filter-sterilised through a 0.22μm filter and stored at 4°C.     
 
Conditioned Medium from H5637 cell line  
Conditioned Medium was derived from the H5637 human bladder carcinoma cell line. 
Studies has shown that the conditioned medium contains factors including colony 
stimulating factor, that are capable of stimulating the proliferation and growth of human 
myeloid leukemic cell (Michaeli et al., 1986). H5637 cells were cultured in α-MEM 
supplemented with Glutamine, Penicillin/Streptomycin and 10% FBS (37°C, 5% CO2 
humidified atmosphere). Once a confluent monolayer was formed following a week’s 
incubation, the medium was collected and centrifuged at 1200rpm for 5 min. The 
supernatant was filter sterilised and finally stored in 15ml aliquots at -20°C.  
 






α-MEM (1x) 81% 
Glutamine 1% 
Penicillin/Streptomycin 5U/ml/5μg 
Foetal bovine serum 10% 
Cyclosporin A 1μg/ml 
Conditioned medium from H5637 cell line 10% 
Stem cell factor 10ng/ml 
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Phase II medium 
α-MEM (1x) 69% 
Foetal Bovine serum 30% 
β-mercaptoethanol 0.01mM 
Dexamethasone 0.77μM 
Recombinant Erythropoietin 1U/ml 
Stem cell factor 10ng/ml 
BSA (10% ) 1% 
Penicillin/Streptomycin 5U/ml/5μg
/ml Glutamine 2 M 
  
2.4.3. Introduction 
The two-phase method originally described by Fibach (1989) was used for culture of 
primary human erythroid progenitor cells from peripheral blood or buffy coat obtained 
from healthy individuals and thalassaemic donors.  
Fibach (1998) introduced a method where cells were grown in suspension and 
consequently overcoming many of the limitations of semi-solid method. This culture 
method has the advantage of yielding large and relatively pure populations of cells and 
can recapitulate in vivo erythropoiesis. The original two-method comprises of an 
erythropoietin-independent phase where the erythroid committed progenitors proliferate 
and differentiate into more mature progenitors in the absence of erythropoietin (EPO); 
followed by an erythropoietin-dependent phase where the progenitors from the previous 
phase differentiate in the presence of erythropoietin into orthochromatic normoblasts 
and enucleated erythrocytes (Figure 7).  
During the first phase, erythroid progenitors along with leukocytes and monocytes are 
isolated by density gradient centrifugation (Section 2.4.4) and grown in the presence of 
transcription factors such as cyclosporin A and stem cell factor (SCF) but in the absence 
of EPO. Cyclosporin A is responsible for the inhibition of proliferation of lymphocytes 
while the presence of SCF stimulates the proliferation of haematopoietic progenitors. At 
the end of Phase I, only the non-adherent cells in the supernatant, comprising mostly of 
haematopoietic progenitors, are transferred into Phase II. This ensures the elimination of 
non-haematopoietic cells such as monocytes and macrophages that have the tendency to 
attach to the culture plate. Phase II medium allows the differentiation of the erythroid 
progenitors into mature erythroblasts in the presence of a cocktail of factors containing 
dexamethasone, SCF, EPO, FBS and BSA.  
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Figure 7, Maturation stages of primary human erythroid progenitor cells defined by the 
expression of CD71 and GPA surface antigens (A) and morphology (B). Adapted from 
Lamikanra et al. (2009) PlosONE 4(12):e8446 and Wojda et al. (2002) Blood 99(8):3005-13. 
 
2.4.4. Isolation of mononuclear cells from peripheral blood 
Buffy coats from healthy donors were obtained from the National Blood Bank in 
Nicosia for the establishment of each culture. Peripheral blood (~20ml) from 
thalassaemic donors was provided by Dr Maria Sitarou (Thalassaemia Department, 
Larnaca General Hospital, Cyprus). Both the buffy coat and the peripheral blood were 
diluted 1:1 (v/v) with 1X PBS and gently layered on lympholyte (density of 
1.0777g/ml). The lympholyte layer was added as 1/3 of the volume to a 50ml falcon 
tube and topped up very slowly with diluted buffy coat or blood. The tubes were then 
centrifuged at 2000rpm for 30 min without brake (Eppendorf centrifuge 5810, 
Eppendorf) at room temperature. Density gradient centrifugation separated the diluted 
blood into three phases, the top layer (containing platelets and plasma), the interphase 
layer (containing mononuclear cells) and the bottom layer (containing the red blood 
cells). The interphase layer containing the primary human erythroid progenitor cells 
with the mononuclear white blood cells was collected with a sterile 5ml pipette and 
transferred to a new 50ml falcon tube. The cells were then topped up to 50ml with 1X 
PBS and centrifuged at 1500 rpm for 8 min. The supernatant was removed and the 
pellet re-suspended by gentle pipetting. The cells were then washed twice with 1x PBS 
and centrifuged at 1200 rpm and at 1000rpm for another 8 min after the first and second 
Day 0                             Day 4                              Day 7                            Day 10                             Day 14 
         Blasts            Preproerythroblasts      Proerythroblasts     Basophilic erythroblasts   Poly-erythroblasts    ortho-erythroblasts 
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wash respectively in order to remove any platelets and red blood cells remaining in the 
pellet. The cells can be further washed with 1x PBS if the supernatant is still not clear. 
An outline of the procedure can be seen in Figure 8. 
 
Figure 8, Outline of the process followed for isolation of mononuclear cells from peripheral 
blood or buffy coat   
 
2.4.5. Culture of isolated mononuclear progenitor cells 
Isolated mononuclear cells were re-suspended in Phase I medium (Day 0) and were 
cultured for 7 days at 37°C in 5% CO2 humidified atmosphere. During Phase I, isolated 
peripheral blood mononuclear cells grow in the presence of growth factors but in the 
absence of EPO. On day 6 of Phase I, non-adherent cells were harvested and centrifuged 
at 1200rpm for 8 min. The cells were washed once with 1X PBS and the pellet was re-
suspended in EPO-supplemented Phase II medium. Cells were incubated again at 37°C 




2.4.6. Treatment by potential agents 
For the study of potential HbF inducers, test compounds were added to the primary 
human erythroid cultures on day 6-7 of Phase II. The cultured cells were re-suspended 
by pipetting and the number of cells in each culture flask was determined by trypan blue 
staining. Primary human erythroid progenitor cells were distributed into T25m
2
 flasks at 
a concentration of ~2x10
6
 cells per ml. One T25m
2
 flask was set up for each 
concentration of the compound. The corresponding compound to be studied was then 
added to the corresponding flask and incubated at 37°C in 5% CO2 for 5-6 days. Un-
treated cells, cells without any agent, were used as negative controls, and cells treated 
with 150μM hydroxyurea or 10mM propionic acid were used as positive controls.  
On day 12 of Phase II (following 5-6 days incubation with the agent), the cultures were 
disrupted by pipetting and cell numbers determined by trypan blue staining. Cells were 
then collected in 15ml falcons and washed twice with 1x PBS. Cell pellets were either 
snap-frozen in liquid nitrogen for analysis by cation-exchange HPLC for haemoglobin 
levels and Western blot analysis, or re-suspended in 1ml TriFast reagent and stored at -
80°C for RNA extraction and analysis by real-time PCR for globin gene expression.  
 
2.5. Cytospin  
2.5.1. Materials and reagents 
 Description Supplier 
Slides Menzel-Gläser SuperFrost slides Thermo Fisher Scientific, MA USA  
Centrifuge Cellspin II cytocentrifuge Tharmac, Waldsolms, Germany 
Materials Filter paper Tharmac, Waldsolms, Germany 
Dye 
Hema ‘Gurr’ rapid staining set for 
Haematology 
BHD, VWR international, Poole, UK 
Fixative DPX mountant for histology Sigma-Aldrich, St Louis USA 
Slides Microscope cover glass Deckglaser, Germany 
 
2.5.2. Cytospin preparation 
During Phase II, the progress of the culture and the stage of differentiation of the cells 
can be assessed by cytospin preparation. Cells were seeded onto Menzel-Gläser 
SuperFrost slides by the use of Cellspin II cytocentrifuge. The slide, filter paper and 
funnel were inserted into the clip in that order and sealed in the correct position. 
Depending on the density of the cultures, 150-300μl of each culture was placed into the 
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funnel opening and the whole clip was placed in the cyto-centrifuge at an angle of 45°. 
Once the clips were arranged in balance within the chamber, the cells were centrifuged 
at 1000rpm for 3 minutes. The funnel and the filter paper were then removed from the 
slide without disrupting the cell smear and the slide was air-dried.  
 
2.5.3. Staining of cytopsins 
The dried slides were treated with Hema ‘Gurr’ rapid staining set for Haematology 
where cells were fixed using a fixative solution containing CH3OH, followed by 
staining with Gurr staining reagent 1 (Eosin Y) and staining with Gurr staining reagent 
2 (Methylene blue + Azure II). The purple colour obtained by cell nuclei after staining 
is due to molecular interaction between eosin Y and the methylene blue/azure II-DNA 
complex. After drying, the cytospin were mounted with a cover slide.  
 
2.6. Flow Cytometry 
2.6.1. Antibodies and instrumentation 
 Description Supplier 
Flow cytometer CyFlow Cube 8 Partec, Görlitz, Germany 
Antibody PE anti-human CD235a (HIR2 clone) BioLegend, CA USA 
Antibody APC anti-human CD71 (CY1G4 clone) BioLegend, CA USA 
 
2.6.2. Introduction 
The stage of differentiation of the primary human erythroid cells can be determined by 
immunostaining with fluorescently labelled monoclonal antibodies directed against the 
surface antigen Glycophorin A (CD235a) and transferrin receptor (CD71) (Figure 7). 
Anti-CD235a-PE (Phycoerythrin) is an antibody raised against Glycophorin A, a major 
sialoglycoprotein expressed on red cell membrane and erythroid precursors, and is 
useful in determining erythroid cell development. Anti-CD71-APC (Allophycocyanine) 
is an antibody raised against transferrin receptor, a homodimeric transmembrane 
glycoprotein that is expressed on proliferating cells. Analysis of cell surface antigen 
expression of differentiating erythroid progenitors and fluorescence-activated cell 
sorting of primary human samples have demonstrated that early erythroid progenitors 
such as BFU-E and CFU-E cells express CD71 marker but lack GPA expression. The 
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expression of GPA progressively increases as immature erythroblasts differentiate while 
maintaining their CD71 expression. Terminally differentiated erythroblasts show up-
regulated GPA expression and severely decreased CD71 expression (van den Akker et 
al., 2010, Li et al., 2014). The lack of expression of GPA in BFU-E or CFU-E cells and 
high expression in mature erythroblasts confirms its function as a differentiation 
marker.  
 
2.6.3. Phenotyping of Primary human erythroid cultures   
Approximately 1-2x10
6
 cells were labelled with 1.5μl anti-CD71 and anti-GPA 
monoclonal antibodies in 100μl PBS for 30 minutes in the dark. The cells were then 
washed twice with PBS at 1000rpm for 5 min, re-suspended in 1ml PBS and analysed 
based on their surface antigen positivity using CyFlow Cube 8 flow cytometry. Cells 
were excited at 488nm and detected in FL2 (PE) and in FL3 (APC) in logarithmic scale.  
 
2.7. Cation-exchange High Performance Liquid Chromatography (HPLC) 
2.7.1. Materials  
 Description Supplier 
Reagent LiChrosolv Water  Merck KGaA, Darmstadt Germany 
Reagent Bi-Tris Sigma Aldrich Co, St Louis USA 
Reagent Potassium Cyanide Sigma Aldrich Co, St Louis USA 
Reagent EMSURE NaCl Merck KGaA, Darmstadt Germany 
Centrifuge Eppendorf 5415R Eppendorf, Hamburg, Germany 
Column 20x4.6mm PolyCAT A
TM
 PolyLC, Columbia USA 
Instrument Shimadzu LCsolution instrument Shimadzu Corporation, Kyoto, Japan 
Reagent Lymphocheck
TM




 Bis-Tris KCN NaCl pH 
Phase A 10mM 1mM - 
 
6.87 






Cation-exchange chromatography has been previously used for separation of minor 
haemoglobin types including modified HbA components and was showed to be a good 
method for separation of HbF from the remaining HbA variants (Gupta and Hanash, 
1983, Ou and Rognerud, 1993). In cation exchange chromatography, positively charged 
molecules are attracted to a negatively charged solid support through ionic interactions 
and are released with increasing concentration of salt solution. Molecules with less 
charge and thus weaker interactions are eluted first.  
 
2.7.3. Procedure 
The percentage of HbF was determined by cation exchange High Performance Liquid 
Chromatography (HPLC) coupled with a 3.5x0.46cm HPLC column packed with 5μm 
silica coated porous particles, as described previously by Ou and Rognerud (1993).  
Around 3-5x10
6 
 primary human erythroid progenitor cells were collected on Day 12 of 
Phase II, washed once with PBS and the cell pellet was snap-frozen in liquid nitrogen 
and stored at -80°C. On the day of experimentation, the cell pellets were lysed in ~15μl 
HPLC water per 1x10
6
 cells by vortexing and incubated for 20 min on ice. The cell 
debri was pelleted by brief centrifugation and the supernatant was topped up with equal 
volumes of mobile phase A buffer. Samples were then ready for analysis by cation 
exchange HPLC analysis. The different haemoglobin species from the cell lysates were 
separated on a 20 x 4.6mm PolyCAT A
TM
 HPLC column fitted onto the Shimadzu 
LCsolution instrument. Elution of haemoglobin was performed by increasing the mobile 
phase B from 12% to 40% and 100% in mobile phase A at 8 and 12 min respectively, 
and reduced to 12% again at 13min. The column was re-equilibrated with 12% mobile 
phase B for at least 7 min before the application of the next sample. Haemoglobin 
proteins were detected at 217nm. Lyophilised human whole blood based control 
(Lymphocheck
TM
 haemoglobin A2 control) was used as a reference for the retention 
time of each haemoglobin type (Figure 9). The Lyophilised control contains defined 





     
 
 
2.8. RNA purification 
2.8.1. Materials  
 Description Supplier 
Kit RNeasy Mini kit Qiagen GmbH, Hilden, Germany 
Material 0.8 mm x 40mm 21G x1.5”  2ml syringe Becton Dickinson, NJ USA 
Reagent EMSURE  Ethanol Merck KGaA, Darmstadt Germany 
Reagent peqGOLD Trifast  Peqlab, Sarisbury Green, UK 
Reagent EMSURE Chloroform Merck KGaA, Darmstadt Germany 
Reagent Isopropanol Sigma Aldrich Co, St Louis USA 
Centrifuge Eppendorf 5415R  Eppendorf, Hamburg, Germany 
Instrument NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific, MA USA 
Reagent Agarose Sigma Aldrich Co, St Louis USA 
Reagent Gel loading Dye (6x) New England BiolAbs, MA USA 
Reagent 100pb DNA ladder New England BioLabs, MA USA 
Dye Ethidium Bromide BHD VWR international, Poole, UK 
 
2.8.2. RNA purification using the Qiagen RNeasy Mini Kit 
On day 12 of Phase II, primary human erythroid progenitor cells from each 
experimental condition were collected and centrifuged at 1200rpm for 5 min and the 
cells washed once with 1xPBS. RNA was extracted and purified using the RNeasy Mini 
kit according to the manufacturer’s instructions. Briefly, 600μl of guanidine 
isothiocynate-containing RLT Buffer (provided by the kit) was added to the cell pellet 
and the solution was mixed by pipetting. The solution was then homogenised by passing 
the lysate at least 5 times through a blunt 20-gauge needle fitted on an RNase-free 
Haemoglobin Retention Time Percentage 
HbF 2.343 8.8 
HbA 4.471 50.8 
HbF 7,381 25.9 
Figure 9, Analysis of the lyophilised human 
whole blood control by Cation exchange 
HPLC. The chromatograph showed the 
retention time of peaks corresponding to 
each haemoglobin (A) and the percentage of 
each haemoglobin (B) as calculated by the 
















































syringe. An equal volume of 70% ethanol was then added to the homogenised lysate 
and mixed well by pipetting. The solution was then transferred to an RNeasy spin 
column which was placed into a 2ml collection tube. The tube was then centrifuged at 
10000 rpm for 15 sec. The flow through was discarded and 700μl of Buffer RW1, a 
guanidine salt-containing buffer responsible for removal of proteins and fatty acids, was 
added to the RNeasy spin column. The column was incubated for 5 min at room 
temperature and centrifuged at 10000 rpm for 15 sec. Once the flow through was 
discarded, each RNeasy spin column was washed twice with 500μl Buffer RPE and 
centrifuged at 10000rpm for 15 sec to wash the spin column membrane effectively. 
Finally the RNeasy spin column was placed in a new 1.5ml collection tube and 50μL of 
RNase-free water was added. The columns were centrifuged at 10000rpm for 1 min and 
the RNA eluent stored at -20˚C. 
 
2.8.3. Manual RNA purification with Trifast reagent   
If the RNA extraction was not done on the same day, the cell pellets were re-suspended 
in peqGOLD Trifast reagent, a guanidine isothiocyanate and phenol containing reagent, 
and stored at -80°C. On the day of extraction, the cell pellets were defrosted and 
allowed to stand for 3 min at room temperature. 200μl of chloroform was added to each 
tube and the samples were shaken vigorously for 10-15 seconds. The samples were then 
incubated at room temperature for 3 min and centrifuged for 15 min at 1200rpm at 4°C. 
After centrifugation, the aqueous layer was collected into a new 1.5ml eppendorf and 
RNA precipitated with 500μl isopropanol. The samples were mixed by inversion and 
incubated at room temperature for 10 minutes. The samples were then centrifuged for 
10 minutes at 1200 rpm at 4°C. Isopropanol was removed and the RNA pellet washed 
with 75% ethanol overnight at -80°C. On the following day, the samples were 
centrifuged for 20min at 1200 rpm at 4°C to remove any ethanol present, the pellets 
were air-dried and re-suspended in 10μl DEPC-treated water. 
 
2.8.4. Spectrophotometric RNA quantitation  
The RNA concentration was determined by using the NanoDrop 1000 
Spectrophotometer. 1μl of the extracted RNA was loaded onto the NanoDrop and the 
concentration of the RNA was calculated automatically by the machine based on 
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absorbance calculated at 260nm and 280nm utilizing a 0.2mm path length. The purity of 
the RNA was considered acceptable when the 260/280 ratio was ~2.0 and the 260/230 
ratio was within the 1.8-2.2 range.  
 
2.8.5. Gel electrophoresis  
To check the integrity of the extracted RNA, 1μl of RNA, mixed with 8μl H2O and 1μl 
loading dye, was loaded onto 1% agarose gel and run at 95V for 50 min. Once 
electrophoresis was done, the gel was stained with Ethidium Bromide. Under exposure 
with UV light, an image of the gel was taken with the Vilber Lourmat Gel 
documentation system (Figure 10).  
                                      
                                     
Figure 10, Verification of RNA quality by gel electrophoresis. Good quality RNA will show 
two bands when loaded onto 1% agarose gel, corresponding to the 28S and 18S ribosomal 
RNAs.  
 
2.9. Reverse transcription Polymerase Chain Reaction (RT-PCR)  
2.9.1. Materials 
 Description Supplier 
Kit TaqMan Reverse Transcription Reagents Applied Biosystems, New Jersey USA 
Reagent RNase free water Sigma-Aldrich, St Louis USA 







2.9.2. cDNA synthesis 
Synthesis of cDNA from total RNA samples is the first step in the two-step process of 
quantitation of gene expression levels in primary human erythroid progenitor cells.  
Complementary DNA (cDNA) was synthesised from 1μg RNA using the TaqMan 
Reverse Transcription Reagents kit with random hexamers from Applied Biosystems. 
1μg RNA was added to 1x reaction mixture (Table 1) according to manufacturer’s 
instructions. The reaction mixture was made up to a total volume of 25μL with RNase-
free water. Reverse transcriptase PCR was performed on Thermal Cycler Veritin with 
thermal cycling of 10 min at 25˚C, 30 min at 48˚C, 5 min at 95˚C and finally cooled to 
4˚C.    
Quantitation of cDNA was performed using the NanoDrop 1000 Spectrophotometer as 
before (Section 2.8.4). The concentration of cDNA was calculated based on the 
absorbance calculated at 260nm and 280nm utilizing the 0.2mm path length. 
 
Table 1, Reverse transcription reaction mixture (1x) 
Reagent Final concentration Volume (μl)/reaction 
10X TaqMan RT buffer 1X 2.5 
25mM MgCl2 5.5mM 5.5 
Deoxyribonucleotides (dNTPs) (2.5mM) 500μM 5 
Random Hexamers (50μΜ) 2.5μM 1.25 
RNase inhibitors (20U/μL) 0.4U/μl 0.5 
MultiScribe
TM 
Reverse Transcriptase (50U/μL) 1.25U/μl 0.625 
 
                                                                                                                                                                             
2.10. Quantitative Real-time PCR  
2.10.1. Multiplex Real-time PCR 
Goblin gene expression levels in primary human erythroid progenitor cells were 
investigated using a multiplex real-time-PCR assay. Quantitative real-time PCR (qRT-
PCR) assay was performed on 50ng cDNA using the CFX96 Touch Real-time 
Detection System (BioRad laboratories Inc, CA USA) coupled with iQ
TM
 Multiplex 
Powermix (BioRad laboratories Inc, CA USA). The powermix contains an antibody 
mediated automatic hot start iTaq DNA polymerase. Upon heat activation at 95°C, the 
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antibodies which are keeping the polymerase inactive become irreversibly denatured, 
releasing in this way the fully active and unmodified iTaq DNA polymerase. This 
enables the specific and efficient primer extension with the convenience of room 
temperature reaction assembly.  
The multiplex reaction, through hydrolysis of each dual fluorescently labelled, target-
specific oligonucleotide probes, allows the detection of the α-, β- and γ-globin genes 
and the endogenous Glyceraldehyde-3-phosphotate dehydrogenase (GAPDH) gene in 
the same reaction. On the intact probe, emission of the reporter dyes (HEX, FAM, 
Texas red and Quasar) at the 5’ end is quenched by resonance energy transfer to the 
quencher dye (BHQ1-3) at the 3’ end. During hydrolysis, the reporter is released and 
separated from the quencher causing increase in the fluorescence. All the primers and 
probes (Table 2) were synthesised by Metabion GmbH (Martinsried, Germany) apart 
from the GAPDH probe which was synthesised by Biosearch Technologies (Biosearch 
Technologies, CA, USA). The gene expression data were normalised to individual 
GAPDH expression for relative quantification.  
50ng cDNA was used as a template for each reaction with 1x iQ multiplex powermix. 
α-globin primers were used at a final concentration of 0.075μΜ, β- and γ-globin gene 
primers at a final concentration of 0.3μM, GAPDH primers at a final concentration of 
0.79μM and all probes at a final concentration of 0.2μM, in a total reaction volume of 
10μl (Table 3). Samples were loaded onto a 96-well plate with triplicates for each 
reaction. 
Amplification was performed using the following cycle conditions: initial denaturation 
at 95°C for 30sec followed by 50 cycles of 10s at 95˚C and 30sec at 60˚C. Relative 
quantification was performed according to the 2
-ΔΔCT
 method (Livak and Schmittgen, 
2001). The relative expression of the target genes in the treated samples was expressed 




2.10.2. Quantitative Real-time PCR coupled with SYBR green 
The gene expression levels of 10 erythroid related genes were investigated by singleplex 
Real-time PCR on the ABI 7900HT Fast Real-time PCR System with the Fast 96-well 
block module (Applied Biosystems, New Jersey, USA) coupled with SYBR green 
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technology (Applied Biosystems, New Jersey, USA).  All primers were purchased from 
Metabion (Metabion GmbH, Martinsried, Germany) (Table 4).  
50ng of cDNA was used as template in a 25μl total volume reaction mixture (Table 5) 
with 1X SYBR Green PCR master mix. The SYBR green master mix consists of SYBR 
green I Dye, AmpliTaq Gold DNA polymerase, dNTPs, dUTP and ROX as the passive 
reference. Direct detection of PCR product formation is monitored by measuring the 
increase in fluorescence caused by the incorporation of SYBR green dye to the newly 
formed double stranded DNA in real-time.   
Amplification and real-time data acquisition was performed using the following cycle 
conditions: initial denaturation at 95˚C for 10 min, followed by 40 cycles of 15s at 95˚C 
and 1 min at 60˚C. Target quantities were normalised to the ribosomal protein GAPDH. 
Relative quantification was performed according to the 2
-ΔΔCT
 method (Livak and 
Schmittgen, 2001). The relative expression of target gene in the treated samples is 
expressed relative to the expression of the same gene in un-treated samples, rendering 
the un-treated sample as a ratio of 1.  
 






 Sequence (5’-3’) 
PCR product 
size (bp) 
γ-globin primer F TGACAAGCTGCATGTGGATC 85 
γ-globin primer R TTCTTTGCCGAAATGGATTGC  
γ-globin probe FAM-CACCAGCACATTTCCCAGGAGC-BHQ-1  
β-globin primer F GGGCACCTTTGCCACAC 124 
β-globin primer R GGTGAATTCTTTGCCAAAGTGAT  
β-globin probe TEXAS RED-ACGTTGCCCAGGAGCCTGAAG-BHQ-2  
α-globin primer F CGACAAGACCAACGTCAAGG 109 
α-globin primer R GGTCTTGGTGGTGGGGAAG  
α-globin probe HEX-ACATCCTCTCCAGGGCCYCCG-BHQ-1  
GAPDH F TGCACCACCAACTGCTTAGC 87 
GAPDH R GGCATGGACTGTGGTCATGAG  
GAPDH probe QUASAR 705-CCCCTGGCCAAGGTCATCCATG-BHQ-3  
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iQ multiplex powermix (2x) 5μl 1x 
α-globin primer pair (15μM) 0.05μl 0.075μM 
β-globin primer pair (15μM) 0.2μl 0.3μM 
γ-globin primer pair (15μM) 0.2μl 0.3μM 
GAPDH primer pair (15μM) 0.53μl 0.8μM 
α-globin probe (10μM) 0.2μl 0.2μM 
β-globin probe (10μM) 0.2μl 0.2μM 
γ-globin probe (10μM) 0.2μl 0.2μM 
GAPDH probe (10μM) 0.2μl 0.2μM 
H2O 0.24μl  
 
 
Table 4, Primer sequences used in the qRT- PCR for quantitation of the gene expression levels 
before and after treatment of primary human erythroid progenitor cells with 300nM decitabine. 
The primers were designed to span exon-exon junctions using the Refseq mRNA database in 
NCBI Primer BLAST.  
 







Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
BCL11a TGCCCCGCAGGGTATTTGTAA CCTGAAGGGATACCAACCCG 
HMOX1 TGCTGACCCATGACACCAAG GGGCAGAATCTTGCACTTTGTT 
SP1 CTATAGCAAATGCCCCAGGT TCTGGGCTGTTTTCTCCTTC 
KLF1 CCCTCCATCAGCACACTGAC GCCACCACTTGAGGAAGTCAT 
SOX6 AGTTCTTTACTGTGGGGCAAC CCGCCATCTGTCTTCATAC 
MYB CGCAGCCATTCAGAGACACTA AGCTGCATGTGTGGTTCTGT 
NFR2 GTCCCAGCAGGACATGGATTT AGCTCATACTCTTTCCGTCGC 
MBD2 TCCAAGTGGTAAGAAGTTCAGAAG CAAGTCTGGTTTACCCTTATTTTGA 
GATA1 GACACTCCCCAGTCTTTCAGG CTCAGCCGCTCTGTCTTCAA 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
Reagent Final concentration Volume (μl)/reaction 
SYBR green mastermix (2x) 1x 12.5 
Primers (5μM) 0.3μM 1.5 
RNase, DNase-free Water - 8.5μl 
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2.11. Western blotting 
2.11.1. Materials and solution composition 
  




RIPA nuclear extraction buffer 
Material Final concentration Supplier 
Tris-HCL pH 7.4 20mM Sigma Aldrich, St Louis USA 
NaCl 150mM Sigma Aldrich, St Louis USA 
NP40 1% Thermo scientific,  
SDS (20%) 0.1% Fisher Scientific, St Louis USA 
Sodium Deoxycholate 0.5% Sigma Aldrich Co, St Louis USA 
EDTA 5mM USB Corporation, OH USA 
 
 Bradford protein assay 
 







40% acrylamide 1.25ml 1.5ml BioRad laboratories Inc, CA USA 
1.5M Tris (pH8.8) 1.25ml 1.25ml Sigma Aldrich, St Louis USA 
MilliQ water 2.4ml 2.15ml EMD Millipore Darmstadt, Germany 
20% SDS 25μl 25μl Fisher Scientific, St Louis USA 
30% APS 16.7μL 16.75μl Merck KGaA, Darmstadt, Germany 
TEMED 5μl 5μl Merck KGaA, Darmstadt, Germany 
 
Stacking gel recipe and reagents (per two gels): 
Material Volumes Supplier 
MilliQ water 3.0743ml EMD Millipore Darmstadt, Germany 
40% acrylamide 0.625ml BioRad laboratories Inc, CA USA 
0.5M Tris (pH6.8) 1.26ml Sigma Aldrich, St Louis USA 
20% SDS 25μl Fisher Scientific, St Louis USA 
30% APS 16.6μl Merck KGaA, Darmstadt, Germany 
TEMED 5μl Merck KGaA, Darmstadt, Germany 
Material Final concentration Supplier 
Hepes-KOH ph 7.9 10mM Scharlau S.L., Mas d’En Cisa Spain 
MgCl2 1.5mM Sigma-Aldrich, St Louis USA 
KCL 10mM Scharlau S.L., Mas d’En Cisa Spain 
Material Description Supplier 
Reagent Commasie Plus Bradford reagent Thermo Fisher Scientific, MA USA  
Cuvettes 1.5ml semi-micro photometric  
Brand Gmbh & Co, Wertheim 
Germany 
Spectrophotometer Evolution 201/220 UV-Visible  Thermo Fisher Scientific, MA USA  
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 SDS-PAGE materials: 
 Description Supplier 
Reagent BlueStar Prestained Protein marker 
Nippon Genetics Europe GmbH, 
Düren Germany 
Material 0.45μm nitrocellulose membrane BioRad laboratories Inc, CA USA 
Stain Ponceau stain Sigma Aldrich, St Louis USA 
Reagent Bovine serum albumin Sigma Aldrich, St Louis USA 
Reagent 
ECL Western Blotting Detection 
reagent 
GE Healthcare, Buckinghamshire 
UK 
Instrument UVP BioSpectrum Imaging System UVP, Cambridge UK 
 
  1x Running Buffer 
Material Amount per 1L Supplier 
Tris 3g/L Sigma Aldrich, St Louis USA 
Glycine 14.42g/L Fisher Scientific, Leicester UK 
SDS (20%) 5ml Fisher Scientific, St Louis USA 
  
 1x Transfer buffer 




  2x Sample Buffer 
Material Final concentration Supplier 
Tris-HCL pH6.8 0.125M Sigma Aldrich, St Louis USA 
SDS (20%) 2% Fisher Scientific, St Louis USA 
Glycerol 21% Merck Chemicals Ltd, Nottingham UK 
Β-mercaptoethanol 4% Sigma-Aldrich, St Louis USA 
Bromophenol Blue 0.005% Sigma-Aldrich, St Louis USA 
 
 1x Tris-buffered saline (TBS) – 0.05% Tween 20 
Material Final concentration Supplier 
10x TBS 10% - 
Tween 20 (10%) 0.5% Sigma-Aldrich, St Louis USA 
 
  10x TBS 
Material Amount per 1L Supplier 
Tris 12.1g Sigma Aldrich, St Louis USA 
NaCl 87.7g Sigma Aldrich, St Louis USA 




Table 6, Antibodies used in Western blot analysis 







Haemoglobin γ 1o Mouse 18 1:1000 





 Mouse 37 1:1000 




mouse IgG HRP 
2
o
 Goat - 1:10000 





2.11.2. Nuclear and Cytoplasmic protein extraction 
Primary human erythroid cultures were collected at day 12 of Phase II and washed twice 
with PBS. Every 1x10
6
 primary human erythroid progenitor cells were re-suspended in 
20μl of Buffer A (Table 6) for preparation of cytoplasmic extracts. The samples were 
incubated on ice for 20min, vortexed and centrifuged at 12000rpm for 10min. Equal 
volumes of sample buffer were added to the supernatant (cytoplasmic extract) and 
stored at -20°C if not used on the same day. The residual cell pellet which comprises 
mostly of cell nuclei was then re-suspended in 8μl of RIPA buffer for every 1x106 cells. 
Samples were incubated on ice once more for 20min, vortexed and centrifuged at 
12000rpm for another 10 min. An equal volume of samples buffer was added to the 
supernatant (nuclear extract) and stored at -20°C. Cell pellets could also be stored at -
80°C before extraction. 
 
2.11.3. Protein quantitation by Bradford assay 
The protein concentration of each of the cell extracts was determined using the 
Coomassie (Bradford) Protein assay kit, a colourimetric method for total protein 
quantitation. Binding of proteins on Comassie reagent causes a shift in absorbance from 
red to blue at OD595 allowing the determination of the protein concentration for each 
sample.  
10μl of 10-fold dilutions of each sample were combined with 990μl Commasie Plus 
Bradford reagent in 1.5ml semi-micro photometric cuvettes and incubated briefly at 
room temperature. Absorbance was measured at 595nm wavelength using the Evolution 
201/220 UV-Visible Spectrophotometer. Protein concentrations were estimated by 
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reference to an absorbance standard curve obtained using a series of BSA standard 
protein dilutions (0, 0.2, 0.4, 0.6, 0.8, 1mg/ml) which were assayed alongside the 
unkown samples. Due to the non-linear colour response of coomassie with increasing 
protein concentrations, a standard curve was constructed for every assay carried out to 
ensure accurate protein determination. 
 
2.11.4. Sodium dodecyl sulphate – Polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins in the nuclear and cytoplasmic extracts were separated by Sodium dodecyl 
sulphate (SDS) - polyacrylamide gel electrophoresis (PAGE). SDS is responsible for the 
denaturation of the proteins which can then travel through the polyacrylamide polymer 
depending only on their size in the presence of electricity. The proteins were separated 
using a discontinuous gel system comprising of 5% stacking gel and 10-12% resolving 
polyacrylamide gel. Acrylamide gels were prepared from a stock solution of 40% 
acrylamide and bis-acrylamide solution in a 37.5:1 ratio. Acrylamide monomers 
polymerise in the presence of 0.01% (by volume) tetramethyl-ethylenediamine 
(TEMED) and 0.01% ammonium persulphate (APS). Casting frames were set up by 
clamping two glass plates together separated by a spacer and placed on the casting 
stand. The resolving gel was prepared as described in section 2.11.1 and was used to fill 
the space between the two glass plates on the casting frames. The gel was allowed to 
polymerise for 15-30min. The stacking gel was prepared as described in section 2.11.1. 
Once the resolving gel was set, the stacking gel was poured on top and the comb used to 
form the wells was immediately inserted between the glass plates.   
10-15μg of nuclear and 5-10μg cytoplasmic extracts were diluted with equal volumes of 
2x sample buffer and boiled for 10min at 95°C before being loaded onto the SDS-
PAGE gel along with 4μl of BlueStar Prestained Protein marker. The gels were then run 
at a constant current of 45mA until the bromophenol blue in the sample buffer reached 
the bottom of the gel. Proteins were then transferred onto a 0.45μm nitrocellulose 
membrane using the Criterion Blotter Tank transfer. The transfer sandwich containing 
the gel and the nitrocellulose membrane was set up submerged into the transfer buffer to 
allow equilibration of the membrane and gel and to reduce the formation of air bubbles. 
Pieces of filter paper and nitrocellulose membrane, cut to the size of the gel, were pre-
soaked in transfer buffer and added to the transfer cassette starting from the 
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black/cathode in the following order: pad, filter paper, gel, membrane, filter paper and 
pad. Protein transfer was performed at 300mA for 2 hours on ice. Following the 
transfer, the membrane was stained with Ponceau stain for quick quantitation of the 
protein load of each sample and then washed with dH2O and 1x TBS/0.05% Tween 20. 
The membrane was then blocked for 1 hour in 1% BSA in 1xTBS/0.05% Tween 20 and 
incubated in primary antibody overnight at 4°C. On the following day, the membrane 
was washed 3 times for 10min in TBS/0.05% Tween20 on a shaker and was incubated 
with the secondary antibody in TBS/0.05% Tween 20 with 5% (w/v) non-fat dry milk 
for 1 hour at room temperature. The membrane was washed 3 times for 10min in 
TBS/0.05% Tween 20 and developed using the ECL Western Blotting Detection 
reagent. Equal volumes of the ECL buffer A and buffer B were mixed and allowed to 
reach room temperature before being applied on the membrane for 3 min. Once the 
membrane was developed, quantitation was performed using the UVP BioSpectrum 
Imaging System.  
 
2.12. Chromatin Immunoprecipitation (ChIP) 
2.12.1. Materials 
Materials Description Supplier 
Reagent Formaldehyde 37% (w/w) Scharlau S.L., Mas d’En Cisa Spain 
Kit Shearing ChIP kit Diagenode s.a., Ougree, Belgium 
Reagent 
Complete Protease inhibitor 
cocktail 
Diagnostics, Basel Switzerland 
Enzyme Proteinase Diagenode s.a., Ougree, Belgium 
Beads 
Protein A Agarose/Salmon sperm 
DNA beads 
Millipore, GaA, Darmstadt Germany 
Reagent Bovine serum albumin Sigma-Aldrich, St Louis USA 
Reagent Phenol/chloroform Sigma-Aldrich, St Louis USA 
Reagent Glycogen (20μg/ml) Invitrogen Inc, Paisley UK 
Reagent Isopropanol Sigma-Aldrich, St Louis USA 
Reagent EMSURE Ethanol Merck KGaA, Darmstadt Germany 









    Low salt wash buffer: 
Material Final concentration 
SDS (20%) 0.1% 
Triton X-100 1% 
EDTA  2mM 
Tris-HCL pH8.1 20mM 
NaCl 150mM 
 
   High salt wash buffer: 
Material Final concentration 
SDS (20%) 0.1% 
Triton X-100 1% 
EDTA 2mM 
Tris-HCL pH8.1 20mM 
NaCl 200mM 
 
  Tris-EDTA (TE) buffer: 
Material Final Concentration 
Tris-HCL ph*.1 10mM 
EDTA 1mM 
   
 Lithium Cloride (LiCl) wash buffer:  







  Elution Buffer: 
Material Final concentration 





Decitabine, a DNA methyltransferase inhibitor, was found to hypomethylate CpG 
nucleotides in the foetal globin genes in baboons (Saunthararajah et al., 2004) and was 
initially suggested that γ-globin induction was due to DNA hypomethylation by the 
agent. We therefore investigated DNA and histone methylation in primary human 
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erythroid cultures from healthy donors in the presence and absence of decitabine, using 
antibodies against Methyl-CpG-binding protein 2 (MeCP2) and Histone 3 Lysine 4 
dimethylation (H3K4me2), respectively. Dimethylation of Histone 3 at Lysine 4 
represents a marker of active chromatin along with H3 Lysine 36 methylation and H3 
acetylation (Kiefer et al., 2008) and usually peaks early in active genes (Kim et al., 
2007). MeCP2 binds to a single symmetrically methylated CpG pair and methylated 
DNA and is thus capable of inhibiting transcription in gene promoters. It is a single 
polypeptide that contains a MBD and a transcriptional repression domain (TRD). 
MeCp2 binds to methylated DNA via its MBD and recruits the Sin3-histone deacetylase 
complex via its TRD, leading to deacetylation of methylated chromatin and subsequent 
transcriptional repression (Hendrich and Bird, 1998).  
 
2.12.3. Chromatin shearing 
Approximately 20x10
6 
primary human erythroid progenitor cells were cross-linked 
using 1% formaldehyde for 10 minutes at room temperature. Cross-linking was stopped 
by the addition of 1.25M Glycine and incubating for 5 min at room temperature. The 
cross-linked cells were centrifuged at 1500rpm for 5 min and washed twice with ice 
cold 1x PBS at 1500rpm for 5 min. The cell pellet was re-suspended in 3ml Buffer B for 
every 10x10
6
 cells, for cell lysis, centrifuged at 1500rpm for 5 min and the supernatant 
was discarded. The cell pellet was then diluted in 300μl sonication buffer, Buffer D 
supplemented with 1x Complete Protease inhibitor Cocktail per 20x10
6 
cells and kept 
on ice until sonication. Both Buffer B and D are SDS-based buffers provided by the 
Shearing ChIP kit. The cells were then sonicated using the Bioruptor Pico sonicator for 
20 cycles of 30 sec ON and 30 sec OFF, to achieve sonication of chromatin to DNA 
fragment sizes ranging between 200 and 500 base pairs. The sonicated chromatin was 
then centrifuged at 12000rpm for 10 min to remove any cell debris and stored at -80°C 
in aliquots.  
 
2.12.4. Immunoprecipitation 
Chromatin was centrifuged at 13000 rpm for 10 min at 4°C to remove any remaining 
cell debris. 25μL per 300μl of chromatin was stored at -20˚C as Input control. Pre-
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clearing of chromatin prior to binding to the primary antibody was done using 60μl 
BSA blocked Protein A Agarose/Salmon sperm DNA beads for 30 minutes at 4°C. The 
supernatant was collected and was incubated with 10μg of the antibody (Table 7) and 
10μg of the corresponding IgG overnight at 4°C on a rotator wheel. All the beads were 
blocked with 10mg/ml BSA for 45 minutes at room temperature. The following day, 
chromatin was incubated with 75μl blocked Protein A Agarose/Salmon sperm DNA 
beads for 1 hr at 4°C on a rotator wheel. The beads were then washed sequentially once 
with 1mL of Low salt, once with 1ml High salt, once with 1ml LiCl and twice with 1ml 
TE wash buffers for 3 min each at 4°C. The beads were recovered with 30sec 
centrifugation at 2000rpm at 4°C. Bound chromatin was eluted by incubating the beads 
in 250μl Elution buffer for 15 min at room temperature. This was repeated twice with 
the total volume of eluted chromatin reaching 500μl. Input was also re-suspended in 
Elution buffer up to a final volume of 500μl.  
 
2.12.5. De-cross Linking and Purification of chromatin 
20μl 5M NaCl was used for chromatin de-cross linking at 65°C overnight. The 
decrosslinked samples were deproteinised with 10mg/ml Proteinase K, 0.5M EDTA and 
20μl Tris-HCL pH 6.5 for 1 hr at 45°C. The DNA was recovered by phenol/chroloform 
extraction followed by isopropanol precipitation and washed with 75% ethanol with 1μl 
20μg/ml Glycogen as carrier. The DNA was diluted into 40μl HPLC grade water for all 
samples apart from the Input samples that were diluted in 160μl HPLC grade water.  
 
2.12.6. Gel electrophoresis 
Gel electrophoresis was used to assess the chromatin shearing efficiency of sonication. 
10μl of the sonicated chromatin was de-cross linked and the DNA was purified as 
described in section 2.12.5. Half of the DNA was then loaded onto a 1.5% agarose gel 




2.12.7. Real-time PCR with SYBR green 
Real-time PCR was carried out in the 7900HT Real-time PCR machine using SYBR 
green master mix. Primers (Table 8) were synthesised by Metabion GmHB (Metabion, 
Germany). 1μl of each de-cross linked sample was used as a template for the reaction 
with 1x SYBR green mix as described in section 2.10.2. 
Enrichment for a specific DNA sequence was calculated using the comparative CT 
method where target quantities were normalised relative to the PCBP2 gene. Data 
collection was analysed and plotted using Microsoft Excel. The fold difference of a 
given target sequence precipitated by a specific antibody was determined by dividing 
the amount of target sequence in the immunoprecipitation (IP) fraction by the amount of 
target sequence in input DNA. Therefore, for each reaction, the ratio of IP to input DNA 
is calculated by subtracting the CT determined for the target sequence of the IP samples 
from the CT determined for the target sequence of the reference sample and taking the 
resulting value to the power of 0.5. 
 
Table 7, Antibodies used in Chromatin immunoprecipitation experiments 
Antibody Concentration Supplier Catalogue No 
Dimethyl Histone H3 (Lys4) 10μg Millipore, GaA, Darmstadt Germany 07-030 
MeCP2 10μg/ChIP Abcam, Cambridge UK Ab2828 
 
Table 8, Primer sequences used in real-time PCR following ChIP 
Gene Forward primer (5’-3’) Reverse Primer (5’-3’) Product 
γ-promoter ACATTTCACAATCCCTGAAC TAGCCTTTGCCTTGTTCCG 206 
β-promoter CAATTTGTACTGATGGTATGG GGTGTCTGTTTGAGGTTGC 280 
ε-promoter CACAAACTTAGTGTCCATCCATCAC CCCTGTTCTCCATGGTACTTAAAA 111 
δ-promoter ATCTCAGGGCAAGTTAAGGG GTAAGCAACAGTCGACTCTG 152 
Intergenic ε-γ TCCCACTCTGTGGGTTGTCTGTTT CCCTTCTACACATTGGCTTAGGAAAGG 158 
Cyclin D1 TGCCACACACCAGTGACTTT ACAGCCAGAAGCTCCAAAAA 60 
HS1 CAAGCGTGGGGACTGAGAAGG TGCTGAGCTGTGATG 85 
HS2 GCTTACAGGGCAGATGGCAAAA GATGCCGTTTGAGGTGGAGTTTTA 48 
HS3 TAGGTGGTTAGGTCAGGTTGGTGG AATGCTGCTATGCTGTGCCTCC 122 
HS4 TGGCATCTAGCGCAATGACTT GGGCAAGCCATCTCATAGCTG 194 







 Description Supplier 
Kit iTRAQ reagent – 8plex box AB Sciex, MA USA 
Sonicator Vibra cell sonicator Sonics & Materials Inc, Newtown, USA  
Reagent Bradford reagent BioRad laboratories Inc, CA USA 
Reagent Trypsin Roche Diagnostics, Basel Switzerland 
Reagent Ultrapure water Sigma Aldrich Co, St Louis USA 
Reagent Isopropanol Sigma Aldrich Co, St Louis USA 
Concentrator Savant SpeedVac kit ISS1110 Thermo Scientific, MA USA 
Column 
150 x 4.6mm, 3m5μm XBridge 
C18 column 
Water SAS, Saint-Quentin En Yvelines 
Cedex, France 
Mass Spec 
nano-ESI Orbitrap-XL mass 
spectrometer 
Thermo Scientific, MA USA 
Reagent Acetonitrile Sigma Aldrich Co, St Louis USA 
Reagent Ammonium hydroxide Sigma Aldrich Co, St Louis USA 
Column 
the Acclaim PepMap 100, an 
100μm  x 2cm C18, 5μm 100 Å 
trapping column 
Thermo Scientific, MA USA 
Column Acclaim PepMap RSLC Thermo Scientific, MA USA 




Mobile Phase composition used for High-pH Reverse Phase (RP) Peptide 
Fractionation 
 Acetonitrile (v/v) Ammonium hydroxide (v/v) 
Phase A 2% 0.05% 
Phase B 100% 0.05% 
 
Mobile Phase composition used for Liquid chromatography–Mass spectroscopy 
analysis  
 Acetonitrile (v/v) Formic acid (v/v) 
Phase A 2% 0.1% 




Whole cell lysates of primary human erythroid cultures before and after treatment with 
300nM decitabine underwent peptide quantitation based on the iTRAQ label 
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quantitation method. Isobaric tags for relative and absolute quantitation (iTRAQ) 
provide a non-gel based multiplex protein quantitation technique for identification of 
differentially expressed peptides/proteins as a function of different biological conditions 
including disease or drug-treated states. As the name suggests the iTRAQ technology 
utilises isobaric reagents to label the primary amines of peptides and proteins. The 
labelling reagent (Figure 11) consists of an N-methylpiperazine reporter group that is 
unique to each iTRAQ reagent, a neutral balance group and an N-hydroxyl succinimide 
ester group that reacts with the N-terminal amino groups of peptides. The tags are 
designed so that on analysis of the labelled samples by collision-induced dissociation 
(CID), the label is released to give rise to a reporter ion with a specific mass-to-charge 
ratio (Thompson et al., 2003). The balance groups present in each of the iTRAQ 
reagents function to make the labelled peptides from each sample isobaric (i.e. to have 
the same mass). iTRAQ is one of the methods that allows the comparison of proteins 
between experiments as isobaric labelled proteins can co-migrate in liquid 
chromatography acting as a more precise reciprocal internal standard. All the tags have 
the same overall mass and are distinguished only upon fragmentation by MS 
(Thompson et al., 2003) (Figure 12). This allows the simultaneous determination of 
both identity and relative abundance of peptides in tandem-mass spectra. Moreover, 
iTRAQ allows the multiplex quantitation of proteins in up to eight different samples 
which is useful in comparing different parameters within the same experiment, while 
eliminating any biases due to the experimental procedures. 
 
          
 
Figure 11, Structure of the iTRAQ 
reagent consisting of a reporter group, 
a balance group and an amine specific 
peptide reactive group. The reporter 
group ranges in mass from m/z 114.1 
to 117.1, while the balance group 
ranges in mass from 28 to 31Da, such 
that the combined mass remains 
constant (145.1Da) for each of the 
reagents. Ross P L et al. Mol Cell 




iTRAQ workflow (Figure 13) outlines the preparation of peptide samples for analysis. 
Samples to be quantified are initially lysed to extract proteins. After using a standard 
protein assay to estimate the protein concentration of each sample, proteins are treated 
for bisulphide bond reduction and block of cysteine residues in proteins. Reduced and 
blocked proteins are then digested using an enzyme, such as trypsin, to generated 
proteolytic peptides and are labelled with a different iTRAQ reagent. Once labelled, the 
different labelled digests are combined into one sample mixture and analyzed by LC-
MS/MS for both identification and quantitation. The sequence of a peptide is 
determined by the production of ions that are generated from cleavage of peptide 
interresidue bonds. Relative quantitation of iTRAQ-tagged peptide in each sample is 
facilitated through analysis of the intensity of the reporter groups that are generated 
upon fragmentation in the mass spectrometer. The experiments were performed by Dr 
Konstantinos Vougas at the Academy of Athens under the supervision of Dr Elena 
Katsantoni. The list of proteins generated from the proteomic experiments was then 
given to me for data analysis.   
 
       
Figure 12, Outline of the procedure followed by quantitative iTRAQ proteomic approach. 
Adapted from http://www.ias.ac.in/meetings/myrmeet/21mym_talks/rmadhubala/img39.html 













Figure 13, Workflow of the sample preparation, labelling and analysis followed in the 
quantitative iTRAQ proteomic approach 
  
2.13.3. Samples dissolution and protein quantitation 
Frozen cell pellets corresponding to each sample were re-suspended in 200-300μl 
Dissolution Buffer containing 0.5M Triethylammonium bicarbonate (TEAB) and 0.05% 
SDS (provided by the iTRAQ kit) for every 4x10
6
 cells. Effective pellet disruption and 
homogenisation were ensured by pulse probe sonication at an amplitude of 29% with 
pulse ON for 0.1sec and pulse OFF for 0.2sec for a total sonication time of 0.5-1 min.  
Non-homogenised cellular debris was separated from the protein solution with 
centrifugation at 13000rpm for 10min. The amount of protein in each sample was 
measured with the Bradford protein assay as described in Section 2.11.3. For each 
sample, a total of 100μg protein was then diluted with dissolution buffer to a final 
volume of 20μl.   
 
2.13.4. Reduction of disulfide bonds and Blocking cysteines  
Cysteine disulfide bonds were reduced with tris(2-carboxyethyl)phosphine (TCEP) 
using 2μl 50mM TCEP for every 20μl sample, followed by incubation at 60°C for an 
Sample 1 Sample 2 
Bisulphide bridge reduction, 
cysteine block and trypsin 
digestion 
Bisulphide bridge reduction, 
cysteine block and trypsin 
digestion 
Label with an iTRAQ reagent – 8plex Label with an iTRAQ reagent – 8plex 
Combine the iTRAQ labelled sample 
digest into one sample mixture 
High-resolution fractionation 
Analysis of the mixture by LC/MS/MS for protein 
identification and quantitation 
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hour. Cysteine residues were blocked by the addition of 1μl 200mM Methyl 
methanethiosulfonate (MMTS) in isopropanol for 10min at room temperature.  
 
2.13.5. Protein digestion and iTRAQ labelling 
Samples were then diluted with 14μl ultrapure water and 6μl of 500ng/μl proteomics 
grade trypsin solution resulting in an enzyme:substrate ratio of 30:1 (v/v) following 
which they were incubated with trypsin overnight at room temperature. After tryptic 
digestion, the peptide samples were labelled with isobaric tags. For isobaric labelling, 
each label (8μl) was diluted in a total volume of 100μl with isopropanol. Once the labels 
were ready, one label was added to each digested sample and incubated at room 
temperature for two hours. The 8 different labelled samples were then pooled and 
vacuum dried overnight using the Savant speedvac concentrator.  
 
2.13.6. High-pH Reverse Phase (RP) Peptide Fractionation 
High-pH RP C18 fractionation of the iTRAQ 8-plex labelled peptides was performed on 
the Dionex P680 pump coupled with the PDA-100 photodiode array detector using the 
150 x 4.6mm, 3m5μm XBridge C18 column. Peptide pellets were dissolved in 200μl 
mobile phase A by bath sonication. Samples were centrifuged at 13000rpm for 5min 
and the supernatant was injected into the column through a 200μl sample loop. The 
peptide separation was performed as follows: 10 min isocratic 5% phase B, 50min 
gradient up to 50% of phase B, 10min gradient up to 70% of phase B, followed by 
10min gradient up to 95% phase B at a flow rate of 0.4ml/min. The signal was 
monitored at 280, 254 and 215nm while maintaining a temperature of 30˚C. Peptide 
fractions were collected every minute and were finally dried with speedvac concentrator 
for 4-5 hours and stored at -20˚C before being analysed by LC-MS.    
 
2.13.7. Liquid chromatography–Mass spectroscopy (LC-MS) analysis  
All LC-MS experiments were performed on the Dionex Ultimate 3000 UHPL system 
coupled with the high resolution nano-electrospray ionization (ESI) Orbitrap-XL mass 
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spectrometer. Individual high-pH RP peptide fractions were reconstituted in 30μl 
loading solution composed of 2% acetonitrile and 0.1% formic acid. 2μl sample volume 
was injected and loaded for 8 min onto the Acclaim PepMap 100, an 100μm x 2cm C18, 
5μm 100 Å trapping column, coupled with the ulPickUP Injection mode and the loading 
pump operating at 5μl/min flow rate. For peptide separation the Acclaim PepMap 
RSLC, a 75μm x 25cm nanoViper C18, 2μm, 100Å column retrofitted to a PicoTip 
emitter (FS360-20-10-D-20-C7) was used for multi-step gradient elution. The gradient 
elution method was as follows: gradient up of phase B to 40% for 80 min and up to 85% 
for the next 5 min, followed by 5 min of isocratic 85% phase B, a drop of phase B to 
3% in 2 min and finally 8 min isocratic equilibration at 3% of phase B. The flow rate 
was maintained at 300nL/min and the column temperature at 35˚C. Gaseous phase 
transition of the separated peptides was achieved with positive ion electrospray 
ionization by applying a voltage of 2.5kV. For every Mass Spectrometry (MS) survey 
scan, the top 10 most abundant multiply-charged precursor ions between mass/charge 
(m/z) ratio 350 and 1900 and intensity threshold 500 counts were selected with FT mass 
resolution of 15,000 and subjected to high-energy collisional dissociation (HCD) 
fragmentation with an isolation window of 1.2Da. Tandem mass spectra were acquired 
with FT resolution of 7500 within m/z range of 100-1900. The normalised collision 
energy was set to 45 and already targeted precursors were dynamically excluded for 
further isolation and activation for 45sec with 5ppm mass tolerance.     
            
2.13.8. Database search 
The HCD tandem mass spectra collected from RP fractions were analysed through the 
Proteome Discovered software (v1.4) for peptide and protein identifications. All spectra 
were searched against a UniProt Fasta file containing 20,200 human reviewed entries. 
The search parameters included Precursor Mass Tolerance of 10ppm, Fragment Mass 
Tolerance of 0.05Da, Dynamic Modifications were Oxidation of M (+15.995Da), 
Deamidation of N, Q (+0.984Da), Phosphorylation of S,T,Y (+79.966Da) and Static 
Modifications at any N-terminus, K Y (+304.205Da) and Methylthio at C (+45.988Da). 
iTRAQ quantitation was also performed through the same software. Protein ratios were 
normalised to protein median and peptides with missing iTRAQ channels were 
excluded from relative protein quantitation.  
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2.13.9. Data Analysis  
Normalization and quantitation of the proteins led to the generation of differentially 
expressed proteins, where the expression levels of each protein and their intensity was 
calculated. The final list of proteins was an average of the protein ratios of all three 
experiments and included proteins that were expressed in all three experiments.  
Functional annotation analysis of differentially expressed proteins was carried out using 
two bioinformatic resources, the Database of Annotation, Visualization and Integrated 
Discovery (DAVID) (Huang da et al., 2009) and GeneCodis (Carmona-Saez et al., 
2007, Nogales-Cadenas et al., 2009, Tabas-Madrid et al., 2012). Both resources use GO 
terms to annotate the proteins into functional groups.   
 
2.14. Lentivirus shRNA-mediated knock-down 
2.14.1. Materials  
 Description Supplier 
Buffer NEB CutSmart buffer New England Biolab, MA USA 
Media Luria Broth Invitrogen Inc, Paisley UK 
Antibiotic Ampicillin Sigma Aldrich, St Louis USA 
Broth Agar Granulate Melford, Sulffock UK 
Enzyme StuI (10000U/ml) New England Biolab, MA USA 
Kit 
NucleoSpin Plasmid DNA 
purification   
Macherey-Nagel GmbH, Duren Germany 
Reagent Isopropanol Sigma Aldrich, St Louis USA 
Reagent EMSURE ethanol Merck, Darmstadt Germany 
Reagent Sodium Acetate Sigma Aldrich, St Louis USA 
Kit NucleoBond Xtra Maxi Columns Macherey-Nagel GmbH, Duren 
Media DMEM GIBCO Invitrogen Inc, Paisley UK 
Supplement FBS GIBCO Invitrogen Inc, Paisley UK 
Reagent Polyethylenimine 
Polysciences GmbH, Eppelheim, 
Germany 
Media RPMI GIBCO Invitrogen Inc, Paisley UK 
Instrument SW28 rotor Bechman Coulter Inc, California USA 
 
Buffer 1:  







Buffer 2:  





Material Final concentration 
KAc 3M 
Glacial Acetic Acid 5M 
 
 
HBS solution:  
Material Final concentration Supplier 
NaCl 280mM Merck KGaA, Darmstadt Germany 
HEPES 50mM Scharlau S.L., Mas d’En Cisa Spain 
Na2HPO4.7H2O (pH7.05) 1.42mM Scharlau S.L., Mas d’En Cisa Spain 
 
2.14.2. Introduction 
RNA interference (RNAi) is an evolutionarily conserved mechanism of post-
transcriptional gene silencing induced by introducing the double-stranded RNAs into 
cells. Several methods of RNA interference (RNAi) have evolved over time, among 
them are the widely used exogenously synthetic and endogenously expressed small 
interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs). Although the simplest 
approach involves the transduction of chemically synthesised siRNAs oligonucleotides 
directly into the cytosol, siRNA-mediated RNAi are limited to only cells capable of 
transduction due to the variable transduction efficiencies of different cell types (Moore 
et al., 2010). The shRNAs are more efficient than siRNAs on the induction of gene 
silencing and currently have evolved as an extremely powerful and the most popular 
gene silencing reagent (Cheng and Chang, 2007). shRNAs are synthesised within the 
cell by DNA vector-mediated production. They can be transduced as plasmid vectors 
encoding shRNAs transcribed by RNA pol III or modified pol II promoters, or through 
infection of the cell with virally produced vectors. The shRNA sequence consists of two 
complementary 19-22bp RNA sequences linked by a short loop of 4-11 nucleotide 
similar to the hairpin found in naturally occurring miRNA. Following transcription, the 
shRNA sequence is exported to the cytosol where it is recognised by an endogenous 
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enzyme, Dicer, which processes the shRNA into the siRNA duplexes which are able to 
bind to the target mRNA and is thus incorporated into the RISC complex for target-
specific mRNA degradation. There are multiple methods of introducing siRNA and 
shRNA into cells depending on whether transient or stable expression is desired as well 
as on the model system. Lentiviral-mediated transduction provides a convenient method 
of introducing shRNA into dividing or non-dividing cells and in general is less toxic to 
the cells than adenoviral-mediated transduction (Moore et al., 2010).  
   
2.14.3. Experimental Design 
Lentiviral-mediated transduction of shRNAs was used in the current study to knock-
down the mRNA levels of 17 genes identified by proteomic analysis of primary human 
erythroid cultures as potential genes involved in the reactivation of γ-globin expression 
following treatment by decitabine. shRNA-containing vectors were obtained from the 
TRC Mission human and mouse library from Sigma in the form of glycerol stocks. 
Packing was done as described by the Sigma Mission library protocol. shRNAs were 
cloned into pLK0.1 vector using EcoRI and AgeI and verified by sequencing. The 
pLK0.1-TRC cloning vector contains a stuffer that is released upon digestion with 
EcoRI and AgeI. The oligos contain the shRNA sequence flanked by sequences that are 
compatible with the sticky ends of EcoRI and AgeI. The forward and reverse primers of 
each shRNA are annealed and ligated into the PLK0.1 vector, producing a final plasmid 
that expresses the shRNA of interest (Figure 14). 
Glycerol stocks were streaked onto LB agar plates for generation of single colonies. 
Isolated single cell derived colonies for each construct were then used as source 
inoculums for miniprep preparation. The plasmid DNA was isolated from the miniprep 
preparation and was digested with StuI restriction enzyme to check for the presence of 
shRNA. The remaining miniprep was used for preparation of Midi and Maxi preps for 
generation of large quantities of plasmid DNA, necessary for the production of lentiviral 
particles containing the shRNA vector. Lentivirus was produced by transient 
transduction of 293T cells and was further used for transduction in primary human 
erythroid progenitor cells in the presence and absence of the drug. The efficiency of 
each shRNA was determined by quantitative Real-time PCR. The effect of each shRNA 
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on γ-globin expression was determined by quantitative real-time PCR and Western blot 
analysis.  
 
                    
Figure 14, Map of the pLKO.1 vector containing an shRNA insert. The pLK0.1-TRC cloning 
vector contains a stuffer that is released upon digestion with EcoRI and AgeI. shRNAs, 
consisting of two complementary 19-22bp RNA sequences linked by a short loop of 4-11 
nucleotides, are then cloned into pLK0.1 vector using EcoRI and AgeI sticky ends. The forward 
and reverse primers of each shRNA are annealed and ligated into the pLK0.1 vector, producing 
a final plasmid that expresses the shRNA of interest upon transcription by Pol II.  
 
2.14.4. Single colony generation from glycerol stock and preparation of bacterial 
miniprep cultures 
Glycerol stocks harbouring sequenced verified shRNA cloned into the pLKO.1 vectors, 
were obtained from the TRC Mission Sigma library (Appendix II). Five glycerol stocks 
corresponding to clones for five different shRNA constructs were purchased for each of 
the 17 genes under investigation, each clone targeting different regions of the gene 
sequence. The glycerol stocks were streaked on LB agar plates containing 10μg/ml 
Ampicillin for generation of single cell derived colonies. Glycerol stocks were diluted 
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with 10μl LB medium containing 1x ampicillin. Using a sterile pipette, 10μl of the 
diluted glycerol stocks were streaked onto LB agar plates and incubated overnight at 
37˚C.   
Isolated single colonies for each construct was then used as a source inoculum for 5ml 
miniprep preparation where each colony was grown in LB medium containing 10μg/ml 
ampicillin at 37˚C overnight.  
 
2.14.5. Extraction of miniprep plasmid DNA and screening for inserts 
Plasmid DNA was extracted from minipreps by re-suspension of bacterial pellets 
derived from 1.5ml miniprep cultures into 250μl Buffer 1. 250μl of Buffer 2 were added 
to the re-suspended bacteria, followed by 250μl of 3M KAC. The solution was then 
centrifuged for 10min at 13000rpm at room temperature and the pellet was re-suspended 
in 0.7x volume isopropanol. After centrifugation at 13000rpm for 10 min, the pellet was 
washed with 70% ethanol and the air-dried DNA was dissolved in 40μl TE 
supplemented with 40μg/μl RNase. 2μg of the plasmid DNA was screen for the 
presence of inserts by restriction enzyme digestion with StutI for 30min at 37°C. The 
digested DNA was separated on 1% agarose gel resulting in two fragments of 995bp 
and 6.08kb sizes.  
 
2.14.6. Midi preparation and DNA purification 
The remaining miniprep was grown into 100ml LB supplemented with 10μg/ml 
ampicillin at 37°C overnight with shaking. The bacterial cell culture was centrifuged at 
4500xg for 20min at 4 °C. The cell pellet was re-suspended in 8ml Buffer 1 and lysed 
with the addition of 8ml Buffer 2 and mixed well by inversion. For neutralization, 8ml 
KAC was added to the lysate and mixed well by inversion. The lysate was then 
centrifuged for 30 min at 4°C and the supernatant was collected. 0.7 x volumes of 
isopropanol was added to the supernatant, mixed and then centrifuged at 4000rpm for 
20min at 4°C. The pellet was then air dried and re-suspended into 200μl TE buffer 
supplemented with 20μg/ml RNAse. The plasmid DNA was then purified using the 
NucleoSpin Plasmid DNA purification kit according to the manufacturer’s instructions. 
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Two volumes of Buffer A3 was added to the DNA solution and mixed well by 
inversion. The mixture was then loaded onto a NucleoSpin Plasmid column and 
centrifuged at 11000xg for 1 min. The supernatant was discarded and the column 
washed with 600μl Buffer A4. The column was centrifuged at 11000xg for 1min and 
supernatant was discarded. In order to remove excess ethanol wash buffer from the 
column, the column was centrifuged for 2 mins at 11000xg. The DNA was then eluted 
using 50μl of Buffer AE. For maximum yield, the column was incubated for 1 min at 
room temperature and then centrifuged at 11000xg for 1 min. The DNA concentration 
was determined by NanoDrop spectrophotometer as noted in Section 2.8.4. The plasmid 
DNA was once more tested for the presence of the insert by restriction enzyme 
digestion as in Section 2.14.5. 
 
2.14.7. Maxi preparation and DNA purification 
For generation of large amounts of plasmid DNA, in particular for scramble plasmid 
vector and psPAX2 packing plasmid, maxi prep amounts of cultures were produced. 
Plasmid DNA purification was carried out using the Plasmid DNA purification 
NucleoBond Xtra Maxi kit according to the manufacturer’s instructions. Glycerol stocks 
were used as a source of inoculums for preparation of a 400ml bacterial culture in LB 
medium supplemented with 10μg/ml ampicillin at 37°C overnight. Bacterial cell culture 
was centrifuged at 4500xg for 20min at 4 °C. The cell pellet was re-suspended with 
12ml Resuspension buffer and lysed with the addition of 12ml Lysis buffer followed by 
12ml Neutralization buffer. The column filter was equilibrated with 25ml Equilibration 
buffer before being loaded with the lysate. The filter was washed with 15ml 
equilibration buffer and at this point the first filter was removed. The second filter was 
then washed with 25ml Wash buffer (containing ethanol) and the DNA eluted with 
15ml Elution buffer and purified using 0.7 x volume of isopropanol followed by 100% 
ethanol precipitation and 0.1x volume of Sodium Acetate. The DNA was washed once 
with 70% ethanol at full speed for 5min at 4°C on a benchtop centrifuge and the DNA 
pellet re-suspended in 200-400μl H2O. The DNA concentration was determined by 
NanoDrop spectrophotometer as noted in Section 2.8.4.   
The scramble Plasmid DNA was tested by restriction enzyme digestion with StuI as 
described in 2.14.5. The psPAX2 packing plasmid DNA was tested by BamHI, EcoRI 
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and XmnI restriction enzymes. The fragment sizes expected following digestion with 
the above enzymes are shown in Table 9. 
 
Table 9, Restriction enzyme digestion of psPAX2 packing plasmid with BamHI, EcoRI and 
XmnI. The table lists the fragment sizes expected following digestion with the above enzymes  
BamHI EcoRI XmnI 
9373bp 6329bp 4902bp 
1007bp 4374bp 2151bp 
337bp  1805bp 
  1411bp 
  434bp 
 
 
2.14.8. Lentiviral production of plasmid DNA 
Lentivirus was produced by transient transduction of 293T cells. A day before viral 
transduction, 293T cells were cultured in 10cm plates to 30% confluence in DMEM 
supplemented with 10% foetal bovine serum. On the day of transduction, once the cells 
have reached ~80% confluence, the medium was discarded and replaced by 6ml DMEM 
supplemented with 1% FBS. For vector preparation, 5μg of Env plasmid 
(pMD2_VSVG), 15μg of packing plasmid (psPAX2) and 20μg of transfer vector 
(pLK0.1/TRC clone) were added to 1ml filtered sterilised 1xHBS. 100μg 
Polyethylenimine (PEI) diluted in 1ml HBS were added in the DNA/HBS solution in a 
slow dropwise manner and incubated at room temperature for 15-20min. The virus/PEI 
precipitate was added in a slow dropwise manner. After 3-4 hours, the medium was 
replaced with 8ml DMEM supplemented with 10% FCS and incubated at 37°C. The 
culture medium containing the virus was harvested on the first three consecutive days of 
transduction by aspiration and stored at 4°C and was replaced by 8ml of fresh DMEM 
supplemented with 10% FBS. The 24ml viral supernatant was filter sterilised through 
0.45μm filter units and then ultra-centrifuged for 4 hours at 20000rpm at 4°C using an 




2.14.9. Viral Transduction of primary human erythroid progenitor cells  
Primary human erythroid cultures from healthy donors were transduced on Day 4 of 
Phase II in 24-well plates. 1x10
6
 cells were seeded in each well in 500ml Phase II media 
(Section 2.4.2). Each well was transduced by the addition of 25μl virus and incubated 
for 8 days. Four wells were transduced with the same virus. The cells from two of the 
wells were used for western blot analysis and the cells from the remaining two wells for 
RNA extraction. On Day 5 of Phase II, another 500μl Phase II media were added to 
each well. On Day 6 of Phase II, two wells of each virus were incubated with 300nM 
decitabine and incubated for 6 days. Four wells were transduced with virus containing 
the sramble construct vector and four wells were incubated without any virus as 
negative controls.  
On Day 12 of Phase II, the cells were collected and washed once with PBS. Whole cell 
lysates were prepared from two wells transduced with each virus, one with and one 
without the agent, with 8μl RIPA buffer (Section 2.12.1) for every 1x106 cells. Equal 
volumes of sample buffer (Section 2.12.1) were added to the samples and stored at -
20°C. Half of the sample (~16μl) was loaded onto an SDS-PAGE gel and were 
quantified for HBG and GAPDH proteins by western blotting as described in Section 
2.12.4.  
The two wells destined for RNA extraction, one with and one without the agent, were 
diluted in 1ml TriFast solution for RNA extraction as described in Section 2.8.3. The 
RNA concentration was determined by NanoDrop as described in Section 2.8.4 and 1μg 
RNA was used for cDNA production as described in Section 2.9.  
 
2.14.10. Quantitative Real-time PCR  
Real-time PCR on the ABI 7900HT Fast Real-time PCR System with Fast 96-well 
block module (Applied Biosystems, New Jersey, USA) coupled with SYBR green 
technology (Applied Biosystems, New Jersey, USA) was used for determining the level 
of knock-down of each mRNA with each shRNA construct. All primers were purchased 
from Metabion (Metabion GmbH, Martinsried, Germany) (Table 10). 37.5ng of cDNA 
was used as template in a 12.5μl total volume reaction mixture (Table 11) with 1xSYBR 
Green PCR master mix. Amplification and real-time data acquisition was performed 
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using the following cycle conditions: initial denaturation at 95˚C for 10 min, followed 
by 40 cycles of 15s at 95˚C and 1 min at 60˚C. Target quantities were normalised to the 
endogenous GAPDH gene. Relative quantification was performed according to the 
comparative CT calculation method. The relative expression of target gene in the treated 





Table 10, Primer sequences used for quantitation of mRNA levels of genes following knock-
down with shRNA constructs in the presence and absence of 300nM decitabine in primary 
human erythroid cultures.  
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Product size 
USP11 TTGAGGGGCGTCTTCCAATC CACAAGGAACCAGCTTTCGC 245 
PPP5C CGAGAGCATGACCATTGAGGA TGAGTGTGGTTTCCACGAGC 194 
TACC3 GATGCAGTGGTAAAGGCGAC GGCCTGGTACACAACCTCTT 126 
SMARCD3 CAAAGGATTCGGGAGCTGGT GCTTTTGCTTCATGGGCCTC 136 
PSMB10 GTTCCAAGACGGGGTCATTCT GCAGTAGATTTTGGGGGCGA 109 
RCBTB2 AGACACGGGGGAGGTCTAT CCAAGCATACACTTGGCCTTC 181 
TAF9 AGCTCGAGAAGTCTGATCATCG TCGGAAGGCAAACTCCAACA 163 
TMEM19 GTGGCGTTGGCTGTTTTCTG TCCAACGACTAGCCCTCCTA 106 
CHUK AGCGAGCAGATGACGTATGG GGCACGCTGTTCCAGAGATT 210 
EGLN2 GGGTACGTAAGGCACGTTGA GACAGTGATGGCGTACCTGG 240 
BAZ1B TGATGGCAACCAGGAGCTTT TGAAATGACCCGGGCTTCAA 124 
HTATIP2 AGGCCTGGAGTTCTGTTATGTG CAGGTCATGGATGGCCTTGT 204 
PYCARD AGCCAGGCCTGCACTTTAT GCATCTTGCTTGGGTTGGTG 153 
HEXIM1 CCAAGAAGAAGCGGCATTGG GGAGTACAGGCCGGTTTTGA 206 
ARHGA4 GAGGAGCAGGAGGTGTCTTG TGGCCTGAGCTCTGGATAAAC 134 
CHD5 ACATGATCCTCAACGAGCCC GCCTGCTCCAGCAGCTTAAA 103 
S100A8 AAGGGGAATTTCCATGCCGT GCCACGCCCATCTTTATCAC 176 
 
 
Table 11, Real time PCR reaction mixture used for quantitation of mRNA levels of genes 







Reagent Final concentration Volume (μl)/reaction 
SYBR green mastermix (2x) 1x 6.25 
Primers (5μM) 0.3μM 0.75 


























3.1. Defining the correct parameters for in vitro screening in primary human 
erythroid progenitor cells 
3.1.1. Introduction 
Major part of the project, including screening of potential agents and delineation of the 
molecular mechanism of action of an HbF inducer, was performed in primary human 
erythroid progenitor cell cultures. Initial primary human erythroid cultures set up for the 
study had a high baseline HbF level in the un-treated mature erythroblasts, and 
demonstrated differences in the level of response to known agents compared to the 
literature. In order to ensure that the most optimal conditions were used for the 
preparation of the primary human erythroid cultures, different parameters were 
investigated before proceeding with any experiments.    
Primary human erythroid progenitor cell cultures are generally thought to be the best 
available in vitro model of human erythopoiesis due to their resemblance with in vivo 
erythropoiesis. For several years the semi-solid erythroid colony technique was the 
main method of preparation of primary human erythroid progenitor cells. The semi-
solid colony technique is suitable for enumeration and study of clonal erythropoiesis. 
However, immobilization of cells on semi-solid medium results in several 
disadvantages, including low cell yield and difficulty in manipulation of cells for 
biochemical, molecular and immunological characterisation. Fibach et al. (1989) 
introduced the first liquid culture system to support erythropoiesis in vitro. This system 
has many advantages over the other experimental models including the use of peripheral 
blood cells as a source of CD34
+
 cells and ability of the system to recapitulate many 
aspects of the in vivo erythropoiesis.  
Following the introduction of the liquid culture by Fibach et al. (1989) (Section 2.4), a 
large number of methods has emerged for culture of primary human erythroid 
progenitor cells ranging from single-phase to hanging drop protocols, each providing a 
different approach for a more precise in vitro representation of erythropoiesis. Van den 
Akker et al. (2010) demonstrated that CD34
-
 peripheral blood mononuclear cells 
(PBMC) yielded 10-20 times more erythroblasts than CD34
+
 cells purified by immuno-
magnetic bead technology from the same amount of peripheral blood. Sonoda (2008) 
suggested that peripheral blood has various progenitor types that have the capacity to 
differentiate into erythroblasts with only a minority being CD34
+ 
cells suggesting that 
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the environment has a major role in the correct differentiation of progenitors into 
erythroblasts (Sonoda, 2008). Fibach et al. (1989) pointed out the importance of EPO 
for the maturation of the erythroid-committed progenitors into mature erythrocytes. Dai 
et al. (1991) later showed that SCF was essential for BFUe proliferation and maturation 
without the need for accessory cells. In contrast, SCF was not necessary for maturation 
of erythrocytes once they have developed into CFUe-like cells (Dai et al., 1991). The 
combination of SCF and EPO results in the stimulation of glucocorticoid receptors that 
promote proliferation of erythroblasts and inhibit erythroid differentiation, while at the 
same time inhibiting activation of T cell lymphocytes that might be present in the 
culture (von Lindern et al., 1999).  
In addition, globin gene expression patterns, which change during various ontogenic 
stages, are significantly influenced by culture conditions. Foetal calf serum (FCS) was 
shown to stimulate γ-globin mRNA and γ-globin production (Constantoulakis et al., 
1990). This result in significantly higher HbF levels in erythroid cells cultured in FCS-
containing medium than those in the peripheral blood of corresponding donors. 
Furthermore, Gabbianelli et al. (2003) showed that c-kit alone or in combination with 
dexamethasone induces expansion of effective erythropoiesis and stimulates HbF levels 
to foetal levels in cultures from thalassaemic patients’ peripheral blood.   
 
3.1.2. Characterisation of HbF levels and differentiation pattern in primary 
human erythroid cultures  
Primary human erythroid cultures were set up from buffy coats obtained from the 
National blood bank in Nicosia. A buffy coat usually originates from 500ml whole 
blood and is the byproduct of the processing of peripheral blood donation. The buffy 
coat consists of white blood cells and platelets. By using buffy coats, we ensured that 
the yield of erythroblasts at the end of the cultures will be in the range of millions, 
rendering screening of potential agents achievable and efficient.  
The progress of erythroid differentiation in Phase II, the erythropoietin-dependent phase 
that promotes the differentiation of progenitors, was investigated by cytospin 
preparations (Section 2.5) where the morphology of the different stages of maturation 
(Figure 15) were monitored along with benzidine staining. As can be seen by the 
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morphological changes, erythroid progenitors undergo differentiation throughout Phase 
II, terminating in the orthochromatic normoblast stage by the end of Phase II. On day 3 
of Phase II, erythroid blasts predominate in the culture. First signs of maturation are 
observed on day 5, when the blasts have matured into pre-pro and pro-erythroblasts. 
From that point onwards, maturation moves much faster onto polychromatic and 
orthochromatic normoblasts on day 6-10. By day 13, the percentage of differentiated 
cells has reached an average of 67% of the total cell population as determined by 
benzidine staining. Cytospins show that  maturation of blasts is not always synchronised 
and homogeneous and that the culture can be sometimes contaminated with other types 
of cells such as lymphocytes and monocytes. These provide a possible explanation as to 
why the percentage of benzidine positive cells was below the 90% levels suggested in 
the literature.  
As erythroblasts mature, they accumulate haemoglobin (Figure 16), with gradual 
increase in HbF levels, reaching a maximum value on day 7 of Phase II. In a similar 
manner to in vivo erythropoiesis, HbF levels dropped as the erythroblasts reached the 
orthochromatic stage, mimicking the foetal to adult switch. Although the percentage of 
HbF was observed to decrease at the end of the culture period, the final percentage of 
HbF observed on day 13 of Phase II (~5%) was higher than the percentages observed in 
the peripheral blood of healthy donors (1-2%). This may be attributed to factors present 







                               Day 3                                                      Day 5                                                                  Day 6                                                        Day 7                                             
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Figure 15, Characterisation of morphological stages 
of erythropoiesis in vitro. Cytospin preparations 
correspond to day 3, 5, 6, 7, 8 and 13 of Phase II of 
primary human erythroid progenitor cell cultures from 
healthy donors. The cytospins were stained with eosin 
red and methylene blue. Cytospins show how the 
erythroid blasts (day 3) progress and mature into 
orthochromatic erythroblasts by day 13 in Phase II of 
the two phase method by Fibach (1998). Red arrows 
indicate the cells that correspond to each maturation 




                                   
 
        
Figure 17, Investigation of the time (A) and duration (B) of treatment on the expression of HbF 
in primary human erythroid progenitor cell cultures using hydroxyurea as the inducing agent. 
The highest average HbF induction was observed when the agent was added on day 6 of Phase 
II and left in the cultures for 7 days. The results are the average of 1-5 experiments with error 
bars corresponding to the standard deviation. Paired t-test shows that the effect observed when 
the cultures were treated for 6 and 4 days is highly significant with p-value 0.05<0.01 (*).   
 
 
Figure 16, Foetal and adult haemoglobin 
expression during Phase II of primary 
human erythroid progenitor cell cultures 
from healthy donors. HbA (A) and HbF 
(B) levels were measured on day 1, 3, 4, 
5, 6, 7, 8, 10 and 13 of Phase II by cation 
exchange chromatography. HbF can be 
detected from day 3 of phase II, peaks on 
day 7 of Phase II and drops as 
erythroblasts mature. The HbF and HbA 
levels are presented as percentages of the 
total haemoglobin present in the cells. The 
results represent the average of 5 
experiments with error bars corresponding 
to the standard deviation.  
 *                  * 
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3.1.3. Optimisation of time and duration of treatment of primary human 
erythroid cultures 
To identify the optimal time point and duration of treatment, we treated primary human 
erythroid progenitor cells from healthy donors with hydroxyurea.  Treatment of cultures 
with 150μM HU on different days of Phase II (Day 4-8) (Figure 17A) showed that the 
inducing activity was highest when the agent was added on day 6, i.e. once the 
progenitors had reached the basophilic stage. Furthermore, treatment of primary human 
erythroid cultures with HU for 4 and 6 days increased the expression of HbF 
significantly when compared to the un-treated control (p-value<0.05, paired t-test) 
(Figure 17B). However, there was no significant increase in the level of HbF following 
5 or 7 days of treatment with HU. Since the induction observed was higher (~1.7) after 
6 days of incubation with the HU than after 4 days (~1.5) with similar cytotoxicity (p-
value>0.05, paired t-test), we decided to use a treatment period of 6 days in subsequent 
experiments to obtain the highest possible effect.   
The percentage of HbF in primary human erythroid cultures ranged between 2-14%, 
levels, which were higher than the percentage of HbF found normally in the peripheral 
blood of adults (<1%). The high baseline of HbF level in primary human erythroid 
culture can be a limiting factor in the screening of HbF inducers. To demonstrate 
considerable activity, an agent needs to increase the percentage of HbF by more than 2-
fold, i.e. the agent has the ability to increase the percentage of HbF by 100% above the 
un-treated control. Such a percentage is not achievable with most inducers and thus the 
effect of moderate inducers may not be considered as significant, and potential HbF-
inducing agents could be missed during screening in primary human erythroid 
progenitor cell cultures. We, therefore, investigated variable concentrations of EPO to 
define the concentration in Phase II that will provide good differentiation and 
progression of the culture without over-stimulating HbF levels. Results from a single 
experiment (Figure 18) show no major changes in cell survival, benzidine staining, 
CD235a
+
 percentage, HbF and HbA levels when cells were grown in 0.5U/ml, 1U/ml or 









Figure 18, The effect of variable concentrations of EPO on the progression of primary human 
erythroid progenitor cell cultures during Phase II. Erythroid progenitors were grown in three 
concentrations of EPO, 0.5U/ml, 1U/ml and 1.5U/ml, in Phase II and the effect on cell survival 
(A), haemoglobinization (B),  differentiation (C), HbF (D) and HbA (E) levels was investigated 
on days 5, 7, 9, 12 and 13 of Phase II. Similar patterns were observed for all parameters 
investigated despite the different concentrations of EPO used. The results are from a single 









Constantoulakis et al. (1990) suggested that FCS contains factors that possess HbF 
inducing activity. We thought that this might also be true for the FBS used in the current 
study, and thus proceeded to investigate whether changes in the percentage of FBS in 
Phase II will affect the HbF levels at the end of the culture (Figure 19). A reduction in 
cell numbers was observed when cells were grown in 45% FBS after 3 and 6 days in 
Phase II, possibly due to inhibition of cell proliferation. No major differences can be 
observed in the percentage of Hb containing cells between the different percentages of 
FBS. The percentage of HbF remains around similar levels when cells are grown in 
30% or 45% FBS during the first 3 and 6 days of Phase II. At day 12 of Phase II, 30% 
FBS was shown to stimulate cell survival as seen by the increase in cell numbers but at 
the same time showing lower HbF levels than 45% FBS. The results are in agreement 
with the original protocol of the two-phase method by Fibach (1998), suggesting 30% 
FBS to be most efficient. 
Studies have also suggested that foetal sheep serum or charcoal treated FCS results in 
lower HbF levels in BFUe cultures (Constantoulakis et al., 1990). As a result, we 
investigated the effect of three types of FBS; a heat-inactivated FBS (FBS 10500), a 
well characterised and certified FBS with low endotoxin and haemoglobin levels (FBS 
16000) and a qualified, EU-approved FBS (FBS 10270) on HbF levels in primary 
human erythroid cultures from healthy donors (Figure 19) at 30% concentration. 
FBS16000 promoted cell survival and differentiation as shown by the increase in 
benzidine positive cells and cell numbers compared to the other two types of FBS. 
Furthermore, the use of FBS16000 resulted in lower HbF levels through Phase II than 
any of the two other types of FBS. As a result FBS16000 was chosen as the most 





    
   
          
Figure 19, The effect of different FBS parameters on the progression of primary human 
erythroid progenitor cell cultures. Erythroid progenitors were grown in three concentrations of 
FBS, 15%, 30% and 45%, (A-C) and in three types of FBS, FBS 16000, FBS 102700 and FBS 
10500, at 30% (D-F) in Phase II. The effect on cell survival (A+D), haemoglobinization (B+E) 
and HbF levels (C+F) was investigated on days 3, 6 and 12 of Phase II. 30% FBS promotes cell 
survival but limits haemoglobinization and HbF stimulation within median levels between 15 
and 45% of FBS (A-C). The results are the average of 2-3 experiments with error bars 
corresponding to the standard deviation. None of the changes are statistically significant 





Liquid cultures of primary human erythroid progenitor cells is an in vitro model that 
recapitulate many aspects of the in vivo erythropoiesis including globin RNA 
metabolism (Dalyot et al., 1992), cell cycle kinetics (Dalyot et al., 1993), expression of 
cell surface antigens, iron and ferritin metabolism (Vaisman et al., 1997). In contrast to 
the colony based assay, the liquid method allows easy manipulation of culture 
conditions at various stages without termination of the cultures, and at the same time 
improved cell yield per culture (Fibach et al., 1989). Furthermore, cells in suspension 
cultures undergo morphological changes and haemoglobin synthesis patterns parallel to 
those in marrow (Wojda et al., 2002). The use of liquid cultures is, however, sometimes 
limited either by the production of mixed erythroid and myeloid cells or by weak or 
absent terminal enucleation. 
In the current study, we investigated the growth kinetics of the two-phase culture 
protocol by Fibach using different parameters with respect to their effect on HbF levels. 
The use of buffy coat as starting material, has led to the generation of a very high cell 
yield, reaching a total of around 2x10
8
 cells at the end of Phase II. Although the 
haemoglobin containing erythrocytes in our culture do not reach the 90% level 
suggested in the literature, the cultures progress correctly towards erythroblast 
maturation as indicated by cytospin preparations. Erythroid blasts are predominant at 
early stages of phase II and mature into orthochromatic normoblasts within two weeks. 
The pattern of maturation was similar to the one described by Wojda et al. (2002) 
despite the different protocol used. 
The lower percentage of benzidine-positive cells can be attributed to the contamination 
of cultures with non-haematopoietic cells such as lymphocytes and monocytes. The 
presence of such cells can be observed in the cytospin preparations. Pope et al. (2000) 
showed that the majority of lymphocytes undergo apoptosis in Phase II and that the 
small numbers observed in the cultures are expendable to in vitro erythropoiesis in this 
two-phase culture system. Nathan et al. (1978) further suggested that activated T 
lymphocytes and monocytes served as sources of SCF in vitro. In order to produce more 
homogeneous and pure cultures, a number of studies have used suspension cultures with 
CD34
+
 progenitors as the starting material. However, CD34
- 
peripheral blood 
mononuclear cells yield larger numbers of erythroblasts than CD34-selected progenitors 
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(van den Akker et al., 2010). This can be attributed to the fact that CD34
+ 
selection 
misses a significant portion of peripheral blood mononuclear cells with erythroid 
potential as suggested by Sonoda (2008).  
HPLC analysis have shown that the percentage of HbF increases in the early stages of 
Phase II, peaks on day 6-7, and then decreases as the cells move towards more mature 
stages of erythropoiesis. Similarly, Dalyot et al. (1992) showed that γ-globin mRNA 
levels peak on day 6 of the two phase protocol. The drop in HbF percentage along with 
the concurrent increase in the percentage of HbA recapitulates expression patterns in the 
foetal to adult haemoglobin switch during ontogeny. However, despite the fall in HbF 
percentage at the end of Phase II, the percentage of HbF in erythroid cultures is still 
higher than the percentage in the peripheral blood of the same donor, a finding that was 
also documented by previous studies (Constantoulakis et al., 1990, Hall and Motulsky, 
1968, Papayannopoulou et al., 1977).  
Many studies point towards the presence of serum as the main cause of inconsistency in 
the liquid cultures, suggesting it as a source of undefined biochemical factors which can 
be inhibitory or stimulatory to haematopoiesis in cultures (Lebkowski et al., 1995). 
Constantoulakis et al. (1990) suggested that foetal calf serum contains activity that 
increases the relative synthesis of HbF in erythroid cultures. Therefore, we investigated 
the percentage of FBS used in Phase II with the aim of identifying optimal FCS 
concentration associated with low percentage of HbF in adult cultures. During the early 
stages of phase II (day 3 and 6), higher percentage of FBS (45%) compromised cell 
survival, a finding that was not observed with 15% and 30% FBS, while maintaining 
similar percentages of haemoglobin containing cells and HbF. During later stages of 
phase II (day12), cultures with 30% FBS showed no major change in cell survival and 
haemoglobin containing cells compared to cultures grown in 15% and 45% FBS but 
showed lower percentage of HbF compared to the 45 % FBS. As a result, 30% FBS was 
chosen as the most suitable concentration of FBS. We further investigated three 
different types of FBS on their effect to modulate the ratio of γ-globin production. We 
have shown that indeed the type and treatment of FBS can have an effect on HbF levels.  
In contrast to the characterised and certified FBS, the heat inactivated FBS reduced cell 
survival and haemoglobinization while increasing the HbF percentage. Cheung et al. 
(2007) demonstrated that consistent failure of their serum-free cultures supplemented 
with IL-3, IL-6, SCF and EPO, to reproduce the high BFU-E expansion obtained by 
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others, suggests that the composition of the added serum can significantly influence cell 
growth in such cultures.  
The effect of variable concentrations of EPO on the levels of HbF in primary human 
erythroid cultures was also investigated. It can be observed that different amounts of 
erythropoietin within the range of 0.1-1.5U/ml, does not affect the levels of HbF and 
HbA, as reported previously by Friedman et al. (1985). It was suggested that EPO 
stimulated the terminal differentiation of progenitors rather than promote HbF synthesis 
(Clarke et al., 1979).  
To identify the optimal treatment parameters that will generate the highest response to 
HU, we investigated the time point and length of duration of HU treatment in primary 
human erythroid cultures. HU exhibited the highest HbF inducing activity when added 
on day 6 of Phase II when erythroblasts have reached the basophilic stage. Treatment 
with the HU for 6 days showed a significant increase in HbF levels with minimal effect 
on cell survival when compared to shorter periods of treatment (4 days). Thus treatment 
of primary human erythroid cultures on day 6 of Phase II for 6 days was chosen as the 












3.2. Screening of caffeine and analogues in GM979 cells as potential HbF inducers 
3.2.1. Introduction 
Most HbF inducers have been identified based on their effect on γ-globin gene 
expression by altering local promoter chromatin or by altering the kinetics of erythroid 
differentiation. However, over the past few years, a number of cell signalling pathways 
have been demonstrated to have a role in regulating HbF induction. Among the 
implicated pathways include cyclic cGMP, cAMP, NO, p38 MAPK, ROS and cytokine 
signalling (Mabaera et al., 2008a). In 2008, Mabaera et al. (2008b) proposed a cell 
stress signalling model of foetal haemoglobin induction involving a potential 
mechanistic link between CREB activation by p38 MAPK and cAMP-activated protein 
kinase A.  
Caffeine, the most popular xanthine, is now known to have a wide range of biological 
effects due to its ability to target a range of molecules. At low concentrations, the main 
effect of caffeine is in the central nervous system through the inhibition of adenosine 
receptors. At higher concentrations, blockage of GABAA receptors and inhibition of 
phosphodiesterase activity, lead to increased cellular cAMP levels and release of Ca
2+
 
from intracellular ryanodine sensitive stores (Daly, 2007). Moreover, increase in 
intracellular Ca
2+
 by caffeine, activates CREB through the binding of Ca
2+
/cAMP 
response element (CRE) in the promoter of CREB-dependent genes (Connolly and 
Kingsbury, 2010). Based on the above data, it was decided that caffeine and related 
analogues should be investigated as potential inducers of HbF production, and thus 
eleven xanthines were selected for screening.  
 
3.2.2. Screening of eleven xanthines in GM979 cells 
Eleven xanthines with different molecular targets were chosen for screening using the 
modified GM979 cell line (Table 12). The GM979 cell line is a modified mouse 
erythroleukaemic cell line incorporating the μLCRβprRluc
AγproFluc construct (Figure 6) 
which contains firefly luciferase gene expression under the control of the human γ- and 
the renilla luciferase gene expression under the β-globin promoter (Skarpidi et al., 
2000). Four of the xanthines tested, caffeine, paraxanthine, theophylline and 
theobromine, are found naturally. Paraxanthine is a human metabolite of caffeine, 
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theophylline is found in tea leaf infusions while theobromine is derived from cocoa 
beans. The remaining xanthines tested include three A1-adenosine receptor selective 
antagonists (DPCPX, KW-3902, DPSPX), an A2A-adenosine receptor selective 
antagonist (CSC), an A2B-adenosine receptor selective antagonist (PSB1115), an A3-
adenosine selective antagonist (PSB-11) and a phosphodiesterase (PDE) inhibitor 
(Zaprinast). 
Varying concentrations ranging from 0.01mM to 10mM were tested for each xanthine. 
The concentrations used for each xanthine were selected based on the active 
concentrations of each agent used in the literature. Major problems were encountered 
during identification of a suitable solvent for these agents. Most xanthines are only 
soluble in organic solvents such as dimethyl sulfoxide (DMSO) and absolute ethanol 
which are highly toxic to the cells. Due to the lack of alternatives, three solvents 
(DMSO, NaOH and ethanol) were used for solubilisation of the xathines but were used 
at lower non-toxic final concentrations. Table 12 shows the solvent used for each 
xathine.  
The effect of each agent was investigated by measuring the firefly and renilla luciferase 
luminescence corresponding to the increase in γ- and β-globin promoter activity, 
respectively, in the presence and absence of the drug. Due to the lower luminescence of 
the renilla luciferase activity, the total promoter activity is calculated by the equation 
(γF+2βR) to normalise for the difference in the activity of the two enzymes (Section 
2.2.2.2) (Skarpidi et al., 2000). An agent was considered to be effective if the ratio of γ-
promoter activity relative to the total globin promoter activity was increased by >2 fold 
relative to the un-treated control. None of the agents showed higher induction than the 
positive control, proprionic acid, which showed an average increase of 10.9 at a 
concentration of 10mM (Table 13). As shown by the dose response curve for each agent 
(Figure 20), theophylline, paraxanthine, DPCPX , KW-3902, DPSPX, PSB115, and 
CSC reduced the expression of γ-globin promoter relative to the total globin promoter 
activity (<1 fold change) when compared to the un-treated control. Caffeine and 
theobromine showed an increase in the activation of γ-globin promoter compared to the 
un-treated control but the induction observed was less than the defined threshold of >2. 
Caffeine showed the highest induction (1.9-fold) at 10mM, a concentration that was 
very cytotoxic (3.9% cell survival). Treatment with PSB11 and zabrinast showed an 
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increase of more than 2-fold change in the ratio of γ-globin over the total globin 
promoter activity but the increase was accompanied by high cytotoxicity.   
 
Table 12, Eleven xanthines were tested as potential HbF inducers. All agents have a different 
target and based on their structural differences, show varying solubility to solvents. The target 
of each agent and the solvent used for the preparation of working concentrations of each agent 
are shown in this table.  
 
 
Table 13, Summary of the effect of the 11 xanthines in GM979 cell line. The table presents the 
concentration of each agent that gave the highest γF/(γF+2βR) change with minimum cytotoxicity 
(≥50% cell survival). The change in γF/(γF+2βR) is expressed as fold change relative to the un-
treated control as measured by luciferase assay.  
 
 
Agent Function Solvent 
Caffeine Natural xanthine H2O 
Theophylline Natural xanthine 0.1M NaOH 
Theobromine Natural xanthine 0.1M NaOH 
Paraxanthine Natural metabolite H2O 
DPCPX (8-cyclopentyl-1,3-dipropylxanthine) A1-adenosine antagonist DMSO 
KW-3902 A1-adenosine antagonist 100% ethanol 
DPSPX (1,3-dipropyl-8-sulfopropyl xanthine) A1-adenosine antagonist 0.1M NaOH 
CSC (8-3-chlorostyryl caffeine) A2A-adenosine antagonist DMSO 
PSB1115 A2B-adenosine antagonist H2O 
PSB11 A3- adenosine antagonist DMSO 




Fold change in γF/(γF+2βR) 
ratio relative to un-treated 
control 
Cell survival 
(% relative to un-treated 
control) 
Caffeine 1 1.28 95.9 
Theophylline 0.01 0.9 103.4 
Theobromine 1 1.35 118.9 
Paraxanthine 0.01 1.03 55 
DPCPX 0.01 0.86 103.4 
KW-3902 0.01 0.37 48.2 
DPSPX 1 0.74 94.7 
CSC 0.1 0.77 71.1 
PSB1115 0.01 0.93 68.9 
PSB11 0.01 0.97 69.1 
Zaprinast 0.025 1.3 127.7 
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Figure 20, Dose response curves for the 11 xanthines tested in the GM979 murine cell line. The 
effect of each agent was tested at varying concentrations ranging between 0.01mM to 10mM 
and their effect on γF/(γF+2βR) ratio (bar graph) and cell survival (line graph) were investigated 
after 4 days of treatment with the agent by luciferase assay and trypan blue staining, 
respectively. The results represent the average of triplicates of single experiments for each 
agent.   
 
Although the agents were generally toxic (<50% cell survival) at high concentrations, 
there was a peak in cell survival above the un-treated samples in most of the agents at 
concentrations 0.1-1mM that might suggest a proliferating effect of the agents. We 
concluded that the toxicity observed can be a result of the solvent alone or it can be 
attributed to the combination of the toxic effect of the agent and the solvent together. 
 
3.2.3. Investigation of the effects of six caffeine analogues in K562 cells 
Although the dual luciferase reporter GM979 cell line gives a good representation of the 
effect of each potential agent on HbF induction, measurement of luciferase activity by 
an enzymatic assay is limited by the significant degree of variability between 
experiments performed on different days (Skarpidi et al., 2000). Furthermore, the 
particular model can only identify agents that act at the promoter region of the globin 
genes since the luciferase genes within the construct are under the influence of the γ-
globin and β-globin promoters. In addition, only a small part of the μLCR locus is found 
within the construct that may not replicate full activity of β-globin LCR in the control of 
the globin gene expression.   
We therefore decided to investigate the effect of the caffeine analogues in K562 cell 
line, an erythroleukaemic cell line that can spontaneously differentiate into recognisable 
progenitors of the erythrocyte lineage, therefore providing a more suitable environment 
for investigation of potential HbF inducers. Due to limited availability of the xanthines, 
only six of the caffeine analogous tested in the GM979 cell line could be tested in K562 
cells.   
Based on the results obtained from GM979 cells, the effect of the six xanthines was 
investigated in concentrations ranged from 0.01 to 1mM. The effect of each agent was 
defined by the increase in the percentage of haemoglobin (Hb) containing cells as 
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determined by benzidine stain along with the corresponding cell survival levels. 
Benzidine staining is the most widely used method for scoring erythroid differentiation. 
Haemoglobin containing cells will stain blue in the presence of benzidine stain and can 
be counted using a haemocytometer (Section 2.3.2.2). Therefore, an increase in the 
percentage of blue-stained cells represents an increase in haemoglobin production and 
thus erythroid differentiation.  
As can be observed by the dose response curves (Figure 21), almost all of the xanthines 
tested in K562 cells show similar trends to the ones observed in GM979 cells. None of 
the natural xathines show any major increase in the percentage of Hb containing cells. 
Furthermore, the percentage of Hb containing cells appears to drop below the level 
observed in the un-treated control at high concentrations of the agents. DPCPX 
increased the percentage of Hb containing cells 4.7 fold above the levels observed in the 
un-treated control but this can be attributed to the high cytotoxicity observed, resulting 
in 28% cell survival at 0.01mM, a relatively low concentration.  
Moreover, the increase observed was no more than that observed for the positive control 
(HU) which increased the percentage of Hb containing cells at an average of 4.9-fold 
relative to the un-treated control (Figure 21).  DPSPX was the only xathine that showed 
an increase of 3.6-fold with moderate cytotoxicity (~60% cell survival) but again the 
effect observed was not better than the effect seen with the positive control. 
Interestingly, all of the natural xathines (caffeine, theobromine, paraxanthine and 
theophylline) showed an increase in cell survival at 0.1mM (theophilline and 
paraxanthine) or 1mM concentrations (caffeine and theobromine), a finding which was 
also observed in MEL cells suggesting a proliferative property of these agents at the 





        
 
    
    
               
Figure 21, Dose response curves for six xanthine analogues in K562 cell line. The effect of 
each agent was represented as the fold change in the percentage of Hb containing cells relative 
to un-treated control as determined by benzidine staining (bar graph). Trypan blue staining was 
used to determine the cell survival as a percentage relative to the un-treated control (line graph). 
Each experiment had a positive control (150μM HU) and a negative control (un-treated control). 
The results represent the average of triplicate repeats of single experiments for each of the 
agents, and the average of three experiments for the positive control with error bars 





Previous correlation of cAMP pathway to HbF induction led us to study the ability of 
caffeine and xathine analogues to induce HbF levels in GM979 cells containing a 
construct where luciferase gene expression was placed under the control of the β- and γ-
globin gene promoters.  
Caffeine, a natural xanthine, was initially isolated from coffee as a behaviour stimulant. 
It was not until the 1980s that its stimulant properties were fully understood. It is now 
known to be the most popular psychostimulant in the world with a wide range of 
molecular targets including adenosine receptors, where xanthines act as antagonists; 
phosphodiesterases (PDE), where xanthines act as inhibitors; calcium release ryanodine-
sensitive channels in the sarcoplasmic and endoplasmic reticulum, where xanthines act 
to sensitise channels to the activation by calcium; and GABAA receptors, as antagonists 
at the benzodiazepine-positive modulatory site (Daly, 2007). At low doses, caffeine acts 
by inhibition of adenosine receptors in the central nervous system while at higher 
concentrations it blocks the GABAA receptors, inhibits phosphodiesterase activity 
leading to increased cellular cAMP levels and the release of Ca
2+
 from intracellular 
ryanodine sensitive stores stimulating Ca
2+ 
signalling in a number of cell types (Ferre, 
2008). Caffeine was recently demonstrated to stimulate CREB-dependent transcription 
in neurons mediated by the release of Ca
2+ 
from ryanodine sensitive stores (Connolly 
and Kingsbury, 2010) and consequently increase the transcription of CREB target genes 
such as Bdnf. Moreover, caffeine was shown to have anti-tumour activity by affecting 
cell cycle progression and inducing apoptosis by activating the p38MAPK/c-Jun 
pathway and suppressing the ERK/c-Fos pathway (Liu and Chang, 2010).   
Due to the poor solubility of the agents, a wide range of solvents was used for the 
preparation of the working solution for each agent. In the cases where DMSO and 
ethanol was used, working concentrations of the compounds were prepared in very low 
final concentrations of the solvents to minimise cytotoxicity to the cells. Apart from 
zabrinast and PSB11, all the xanthines tested either reduced the activity of γ-globin 
promoter over the total globin promoter activity or minimally increased the γ-globin 
promoter activity (<2-fold threshold). Zabrinast and PSB11 were the only two xathines 
that increased the γ-globin promoter activity above the 2-fold threshold but this increase 
was attributed to the cytotoxicity of the compounds. Furthermore, although most of the 
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xathines tested were shown to be cytotoxic, some of the agents, including KW-3902, 
DPCPX, PSB11 and CSC were very cytotoxic. This can be attributed to the increased 
number of carbons in the alkyl chain at R1and R3. This is in agreement with Rogozin et 
al. (2008) where they showed that xathine derivatives exhibited increased inhibition of 
neoplastic colony formation as the number of carbons increased at groups 1 or 3.  
GM979 cells are characterised by a large variability due to the instability of the reporter 
gene expression and heterogeneity of the mixed culture system (Skarpidi et al., 2000) 
and are limited due to the absence of many of the endogenous β-globin locus regulatory 
sequences from the reporter construct (Vadolas et al., 2004). Therefore, in order to 
confirm the effect observed in the above model, the effect of six xanthines was also 
investigated in K562 cells, a human erythroleukaemic cell line. The response observed 
in K562 cells was very similar to the effect observed in GM979 cells for the xathines, 
showing very low levels of globin gene induction. The occasional moderate HbF 
induction observed was attributed to the cytotoxic effects of the compounds or their 
solvents and did not exceed the induction caused by the positive control (HU). 
Interestingly, despite most of the agents being cytotoxic, some stimulated an increase in 
cell survival above that seen for the un-treated control at concentrations of 0.1 and 1mM 
in both cell lines. Most studies have shown that caffeine promotes apoptosis and DNA 
damage-induced G2 arrest, but Tiwari et al. (2014) demonstrated that caffeine has a 
differential concentration-specific effect on cell cycle progression, checkpoint 
activation, cell viability and oxidative stress in human and murine pulmonary epithelial 
cells. Moreover, caffeine was shown to have a protective effect against oxidant–induced 
damage both in vivo and in vitro with antioxidant effect being prominent at low doses as 
shown in human skin fibroblasts. Therefore, one possible explanation for the increase in 
cell survival might be the intrinsic antioxidant activity of some of this xathines. Further 
investigation on this pattern of response would be interesting to define and understand 






3.3. Screening of Resveratrol and its derivatives as potential HbF inducers 
3.3.1. Introduction 
Oxidative stress has been observed in various types of thalassaemia as well as in other 
hereditary and acquired haemolytic anaemias. This can be mainly attributed to the iron 
overload due to increased iron absorption in the gastrointestinal tract (Papanikolaou et 
al., 2005), and multiple blood transfusions (Fibach and Rachmilewitz, 2010), as well as 
to increased intracellular denaturation of unbalanced haemoglobin subunits resulting in 
dissociation of haem from globin and iron from haem (Rund and Rachmilewitz, 2005; 
Fibach and Rachmilewitz, 2010). The excess iron levels eventually exceed the iron-
binding capacity of transferrin, leading to circulation of labile non-transferrin bound 
iron species that undergo chemical reactions that generate ROS. ROS subsequently 
affect various cell components, particularly the cell membrane, damage vital organs 
including the heart, liver and endocrine system (Hershko et al., 1998, Rachmilewitz et 
al., 2005). In addition, endogenous antioxidant mechanisms are depleted due to the 
increased need to neutralise the oxidative stress (Kushner et al., 2001). Oral 
administration of vitamin E in transfusion-independent beta thalassaemia patients was 
shown to decrease ROS production and increase glutathione reductase levels in red 
blood cells (Tesoriere et al., 2001). Moreover, natural antioxidants were further studied 
for their potential use towards elimination of antioxidant stress. Curcumin, a natural 
herb used as food additive, was found to decrease iron induced lipid peroxidation in 
vitro (Grinberg et al., 1996) while administration of fermented papaya preparation has 
shown decreased ROS generation, membrane lipid peroxidation and increased 
glutathione in β-thalassaemia/HbE disease patients (Fibach and Rachmilewitz, 2010).  
Resveratrol is a natural phytoalexin found in a variety of human dietary products such 
as in the skin of red grapes, peanuts and red wines as well as in medicinal plants where 
it is produced in response to infection or other stresses. Resveratrol was originally 
isolated in 1940 from the root of Veratrum grandiflorum, a poisonous medicinal plant 
(Siemann and Creasy, 1992). However, it was not until the beginning of 1990 that 
research into resveratrol intensified due to evidence of the cardioprotective effects of 
red wine (Nakata et al., 2012). Since the 1990s, evidence from several studies have 
shown resveratrol to have many biological activities including anti-inflammatory 
(Birrell et al., 2005), anti-proliferative (Schneider et al., 2000), chemopreventive effect 
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(Berge et al., 2004, Jang et al., 1997), antioxidant (Fremont et al., 1999, Pandey and 
Rizvi, 2010) and lifespan enhancement activities (Howitz et al., 2003, Valenzano et al., 
2006, Viswanathan et al., 2005). Resveratrol also has the ability to limit or prevent 
progression of cerebral ischaemic injuries (Hung et al., 2002, Ray et al., 1999), 
cardiovascular injuries (Lekakis et al., 2005, Wang et al., 2002), cancer progression 
(Jang et al., 1997, Kimura and Okuda, 2001, Tessitore et al., 2000), arthritis (Elmali et 
al., 2007, Tian et al., 2013), diabetes (Su et al., 2006), neurodegernerative disorders 
(Gupta et al., 2002, Zhao et al., 2013) and a number of other aging-associated and stress 
resistance disorders. The mechanisms by which resveratrol is able to exert such a wide 
range of effects is not fully understood but studies have led to the identification of a 
large number of direct targets for this compound including cyclooxygenase (COX) 
enzyme (Jang et al., 1997, Subbaramaiah et al., 1998), silent mating type information 
regulation 2 homolog 1 (SIRT1) (Xia et al., 2013), Forkhead box protein O (FOXO) 
(Franco et al., 2014, Roy et al., 2011), haem oxygenase 1(HMOX1) (Quincozes-Santos 
et al., 2013). Many of its biological actions have been attributed to its antioxidant 
properties.  
Apart from its antioxidant activities, resveratrol was found to inhibit ribonucleotide 
reductase more efficiently than HU, the bench mark HbF inducer which is clinically 
used in patients with sickle cell disease (Rodrigue et al., 2001). Fibach et al. (2012) 
were the first to show that resveratrol, in addition to its antioxidant activity, can also 
stimulate the expression of γ-globin genes and increase HbF. The above properties 
render the compound a promising agent for use in the pharmacological reactivation of 
foetal haemoglobin. 
In the current section, we investigated the ability of resveratrol and nine new 
hydroxystilbenic derivatives of resveratrol, to increase HbF levels in K562 cell line and 
primary human erythroid progenitor cells, with the aim of identifing a novel agent that 
will combine potent HbF inducing activity with low cytotoxicity while maintaining the 




3.3.2. Screening of resveratrol and 9 hydroxystilbenic derivatives in K562 cell line 
Initially the effect of resveratrol was investigated in vitro using K562 cell line. Due to 
its low water solubility, the initial stock solution of resveratrol was prepared in 100% 
methanol. Subsequent working concentrations were prepared in 50% methanol in order 
to reduce the final percentage of methanol added to the cells. Based on the literature, 
varying concentrations of resveratrol were chosen for screening, ranging from 1-100μM 
final concentrations. The effect of each concentration was determined by benzidine 
staining after five days of treatment with the agent as described previously (Section 
2.3). Results showed resveratrol to be a highly active HbF inducer resulting in an 
average of 5.7-fold increase in the percentage of Hb containing cells and 50% cell 
survival relative to the un-treated control when used at a concentration of 5μM. This 
was higher than the average effect observed with 150μM HU, the positive control which 
showed an average of 4.78-fold increase in the percentage of Hb positive cells at a 
concentration 30-fold higher than resveratrol (Table 14). However, resveratrol was also 
found to be slightly cytotoxic with cell survival reduced to 35% at 10μM concentration 
relative to the un-treated control (Figure 22). Although the cytotoxicity of resveratrol 
increased in a dose-dependent manner, the increase in the percentage of Hb containing 
cells did not show a linear relationship to increasing concentrations of the agent (Figure 
22). Rather, resveratrol gradually increased the percentage of Hb containing cells, 
reaching the highest effect at 5μM followed by a reduction in the percentage of Hb 
containing cells between 10-15μM concentrations and a second peak at 20μM after 
which the effect plateaued. However, the effect observed at 20μM of resveratrol was 
compromised by the high cytotoxicity, corresponding to around 11% cell survival 
(Figure 22). Therefore, 5μM concentration was selected as the best concentration of 
resveratrol for its highest Hb inducing activity with a cell survival of 50%.   
Since, the use of resveratrol might be limited due to this cytotoxicity, nine 
hydroxystilbenic derivatives of resveratrol were synthesised by our collaborators at the 
University of Modena and Reggio Emilia (Italy), with the aim of identifying an agent 
that retains the potent HbF inducing activity but with relatively lower cytotoxicity than 
the parent compound. All nine derivatives had the same backbone structure to the parent 
compound but had small substitutions on the othro, meta and para positions of the two 
aromatic rings (Figure 23). Initial stock solutions of each agent were prepared in 100% 
methanol to avoid any dissolution problems. Working solutions were again prepared in 
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50% methanol when possible, except when the compound was showing signs of 
precipitation in the presence of water.  
                
Figure 22, The effect of resveratrol in K562 cell line. After 5 days incubation with the agent, 
cell survival (line graph), presented as a percentage relative to the un-treated control and 
benzidine stain (bar graph), presented as a fold change in the percentage of Hb containing cells 
relative to the un-treated control. The results presented are the average of four experiments with 
error bars corresponding to the standard deviation.  
      
Figure 23, Structures of resveratrol and its nine hydroxystilbenic derivative analogues. In 
contrast to its derivatives, resveratrol, the parent compound is commercially available.  
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Initial screening of the nine derivatives was performed at different concentrations in 
K562 cell line after five days of treatment with the agents. Based on the results obtained 
by resveratrol and the limited compound stock concentration of each derivative, all 
derivatives were investigated at concentrations 1, 5, 10, 20, 40μM at the first round of 
screening. The best concentration of each agent was selected as the concentration that 
gave the highest increase in Hb induction with ≥50% cell survival. The dose response 
curves for each agent can be found in the Appendix III. 
Derivatives P1, P2, P3, P4 and P9 showed similar cytotoxicity to resveratrol, reducing 
cell survival to approximately 50% at 5μΜ concentration (Table 14). P5, P7, P8 and 
P11 showed lower cytotoxicity than resveratrol, where cell survival approached to 50% 
at relatively higher concentrations of the agents (10-20μM) (Table 14). However, only 
P1, P4 and P11 exhibited Hb inducing activity comparable to the parent compound, 
with a 3.8, 2.9 and 3.3-fold increase in the percentage of Hb-containing cells relative to 
un-treated control, respectively (Table 14). Among the latter three compounds, P11 had 
the lowest cytotoxicity while maintaining comparable haemoglobin inducing activity to 
the rest of the compounds. This difference in cytotoxicity was apparent at 
concentrations of 5μM and above (Figure 24).            
 
Table 14, Investigation of the haemoglobin inducing ability (Benzidine stain) and cytotoxicity 
(Trypan blue) of each resveratrol derivative in K562 cell line. The concentration of each agent 
resulting in approximately 50% cell survival and the corresponding effect in haemoglobin 
production is presented in this table. 150μM hydroxyurea was used as a positive control in all 
experiments. The values shown represent the average of three experiments. 
Agent 




(% relative to un-
treated) 
Benzidine stain 





HU 150 38.9 4.78 
P1 5 43 3.8 
P2 5 48.8 2.3 
P3 5 44 2.8 
P4 5 48 2.9 
P5 20 65.5 2.56 
P7 20 41.2 2.86 
P8 20 48.9 1.9 
P9 5 51.7 1.9 
P11 10 52 3.3 
Resveratrol 5 47.3 5.7 
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Figure 24, Investigation of haemoglobin inducing activity (A) and cytotoxicity (B) of 
compounds P1, P4 and P11 and resveratrol for a range of concentrations in K562 cell line. P1, 
P4 and P11 showed haemoglobin inducing levels similar to resveratrol, the parent compound, 
with P11 being less cytotoxic. The results are the average of three experiments with error bars 
corresponding to the standard deviation.   
                                                                
3.3.3. Screening of the three derivatives ex vivo in primary human erythroid 
progenitor cell cultures 
The three derivatives (P1, P4 and P11) along with resveratrol were further studied in 
primary human erythroid cultures from healthy donors. The effect of each compound 
was investigated by cation exchange HPLC where the percentage of HbF was 
determined in the presence or absence of the agent. A wider range of concentration was 
set up for each agent in primary human erythroid cultures, in order to ensure the 
identification of the most effective concentration in the new system. Resveratrol was 
investigated at concentrations ranging between 10nM-100μM, P11 at concentrations 
1nM-40μM, P4 at concentrations 10nM-40μM and P1 at concentrations 1-40μM.  
HPLC analysis showed only a minimal change in the HbF percentage with all the agents 
(Figure 25). Resveratrol and P11 increased HbF levels by 6 and 18% at 1μM and 
0.01μM respectively which were not statistically significant (p-value > 0.05, paired t-
test) (Figure 25A & B). At higher concentrations of P11, 10 and 20μM, there was a 28 
and 38% decrease in the HbF levels, respectively, when compared to the un-treated 
control (p-value < 0.05, paired t-test) (Figure 25B). P4 showed higher induction with 
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~40% increase in the HbF levels at 0.01μM (Figure 25C). Similarly, P1 showed a ~40% 
increase in HbF levels at 20μM (Figure 25D). The increase in the percentage of HbF 
observed in primary human erythroid cultures when treated with P4 and P1, however 
was not statistically significant (p-value > 0.05, paired t-test). Again this can be 
attributed to the large variability in the response observed in the relatively small sample 
size employed.  
Although the HbF induction was minimal, resveratrol, derivative P4 and P11 were 
shown to be less toxic in primary human erythroid cultures than in K562 cells with no 
major reduction in cell survival for any of the concentrations of resveratrol tested, for 
concentrations below 20μM for P4 and for concentrations below 40μM for P11 (Figure 
25). P1 showed higher cytotoxicity than resveratrol (Figure 25D) with cell survival 
dropping to less than 50% at concentrations of 5μM and above, and was therefore 
considered inappropriate as a therapeutic HbF inducer. Interestingly, induction with low 
concentrations of derivatives P11 was found to significantly increase cell numbers 
above those seen in the un-treated (negative) control (p-value<0.05, paired t-test) 
(Figure 25B). Although this was observed with resveratrol as well, the increse in cell 
numbers observed with both agents were not significantly elevated above those 
observed in cells treated with the vehicle alone (methanol) (p-value>0.05, paired t-test) 
(Figure 25). This was not however, true for P4, since cell numbers significantly (p-
value<0.05, paired t-test) increased above those observed with methanol alone at 10nM 
of P4 suggesting a proliferating role at low concentrations of the agent.   
150μM HU was used as positive control in all cultures which showed an average of 70-
80% increase in the percentage of HbF. Therefore, although the three derivatives had 
shown a good response in K562 cell line, none of the agents showed an ability to 
increase HbF levels in primary human erythroid cultures. Moreover, the response 






        
             
                    
Figure 25, Treatment of primary human erythroid progenitor cells from healthy donors with 
resveratrol (A), P11 (B), P4 (C) and P1 (D). Cell survival (line graph), measured by trypan blue 
staining, and HbF levels (bar graph), measured by cation exchange HPLC, were investigated 
after 6 days treatment with the agent. 150μM HU was used as a positive control and un-treated 
cells were used a negative control. 0.005% methanol was the solvent for all agents. The results 
obtained are the average of 12-15 cultures for Resveratrol, P11 and P4 and the average of 2 
experiments for P1 with error bars corresponding to the standard deviation. * corresponds to 
statistically significant changes in cell survival according to the paired t-test (p-value<0.05), * 
corresponds to statistically significant changes in HbF levels according to the paired t-test (p-
value<0.05) 
 
3.3.4. Effect of resveratrol on erythroid maturation  
The lack of HbF inducing ability of resveratrol, prompted us to investigate its effect on 
erythroid maturation as a mechanism for its HbF inducing ability in primary human 
erythroid cultures. Flow cytometry analysis (CD71 proliferation and GPA 
differentiation markers) and cytospins for morphological changes were used as 
described in Sections 2.5 and 2.6. Staining of cytospin preparations from primary 
* 
 *  * 
* 
 
* * * 
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human erythroid cultures treated with 1μM resveratrol showed an increase in the 
percentage of basophilic and polychromatic normoblasts compared to the un-treated 
cells (Figure 26A & B). Flow cytometry analysis of primary human erythroid cultures 
from healthy donors showed an average increase of 22.2% in the percentage of GPA
+
 
cells in the presence of resveratrol (Figure 26C) and a right shift in the mean intensity of 
the cells. In contrast, CD71 expression remained around the same levels with and 
without 1μM resveratrol (Figure 26C). These results suggest that resveratrol might be 
able to promote differentiation of primary human erythroid progenitor cells but without 
affecting their proliferation. 
 
       
 
Figure 26, Investigation of the effect of resveratrol on erythroid differentiation in primary 
human erythroid cultures. Cytopsin preparation with eosin red and methylene blue staining of 
primary human erythroid cultures from healthy donors on day 12 of Phase II (A & B) show that 
resveratrol increases the percentage of basophilic and polychromatic normoblasts (B) compared 
to the un-treated cells (A). Flow cytometry shows the increase in the percentage of GPA 
positive cells in the presence of resveratrol but no major change in the CD71 proliferation 
marker (C). The red circles highlight the basophilic erythroblasts.   






3.3.5. Combining the activities of resveratrol and decitabine in K562 cell line 
Since none of the agents were found to be potent HbF-inducers in primary human 
erythroid cultures at non-toxic concentrations, the use of resveratrol in combination 
with another agent, was considered as a potential therapeutic approach to enhance the 
HbF-inducing activity. The antioxidant activity of resveratrol was combined with the 
strong HbF inducing activity of decitabine, a known HbF inducer, in K562 cell line. 
Screening of decitabine alone in this cell line showed a 5.3-fold increase in the 
percentage of Hb positive cells at 100nM concentration (50% cell survival) compared to 
the un-treated control (Figure 27). The combined use of decitabine with resveratrol 
increased Hb production significantly above the effect of resveratrol alone (p-value< 
0.05) at all concentrations. The increase in the percentage of Hb containing cells in the 
presence of the combination was also greater than the effect observed with decitabine 
alone but this increase was not consistently statistically significant (p-value>0.05). The 
strongest response was obtained when administering 100nM decitabine with 5μM 
resveratrol, resulting in a 6.5-fold increase in the percentage of haemoglobin containing 
cells, an increase that was significantly higher than the 1.83 observed with resveratrol 
alone. The increase was also higher than the 5.2-fold increase observed with decitabine 
alone, but this was not statistically significant (p-value>0.05). However, the 
combinatorial effect observed was significantly lower than the additive effect of both 
agents together (p-value<0.05, paired t-test) at all concentrations (Figure 27), suggesting 
competition between the two agents for common down-stream targets or saturation of 
common targets. Additionally, the cytotoxicity of the combinatorial regime was not 
significantly different from the additive toxicity of the two agents alone (p-value>0.05, 
paired t-test) and not always significantly greater than the cytotoxicity of each agent (p-
value <0.05, paired t-test). Although the increased haemoglobin from the combined 
therapy was below the additive effect of the agents, the non-significant increase in 
cytotoxicity of the combination still renders the combinatorial approach as beneficial. 
Moreover, the small increase in Hb production exhibited by the combinatorial therapy 
might be attributed to the use of a very potent HbF inducing agent (decitabine) that 




   
Figure 27, Dual treatment with resveratrol and decitabine in K562 cell line. Cell survival (A) 
and haemoglobin induction (B) were measured for each agent alone and in combination with the 
second agent. The results represent the average of three experiments with error bars 
corresponding to the standard deviation. * corresponds to statistically significant changes in cell 
survival according to the paired t-test (p-value<0.05), * corresponds to statistically significant 
changes in Hb induction according to the paired t-test (p-value<0.05).A significant increase in 
haemoglobin production (p-value< 0.05, paired t-test) was observed between the combined 
regime and concentrations of 1μM and 5μM resveratrol alone, but not significantly above all of 
the concentrations of decitabine alone. Cytotoxicity was not statistically increased above the 
additive effect of the agents and was not always significantly (p-value<0.05) increased above 
the toxicity of each agent alone.  
 
3.3.6. Discussion 
Studies have shown that resveratrol not only exhibit antioxidant activity, but can also 
stimulate the expression of the γ-globin genes (Fibach et al., 2012). In the current study, 
*     *              *                      *   *                *    *               *    *             
*    *              *                      *                    *    *                *    *               *    
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we have shown that increasing concentrations of resveratrol in the K562 cell line result 
in a dose dependent reduction in cell survival confirming its anti-proliferative effect, 
possibly through cell cycle arrest and induction of ER stress as shown by Liu et al. 
(2010). The anti-proliferative effect of resveratrol prompted the identification of 
derivatives which exhibit potent HbF-inducing properties with lower cytotoxicity. Out 
of the nine derivatives tested in K562 cells, only three (P1, P4 and P11) exhibited 
haemoglobin inducing activity comparable to the parent compound, with only one (P11) 
being less cytotoxic. Treatment of primary human erythroid cultures with these three 
agents had minimal effects on HbF levels when compared to the un-treated control. 
Although less cytotoxic than resveratrol, P11 increased the percentage of HbF only to a 
non-significant level when used at low concentrations while it caused a significant 
decrease in the percentage of HbF compared to the un-treated cells at concentrations 
above 10μM. In contrast, administration of P4 at 10nM increased the percentage of HbF 
levels by ~40% above that in the un-treated cells but lacked statistical significance due 
to the high variability in the response observed between cultures. Moreover, P4 also 
significantly increased cell numbers above those observed with vehicle-treated cultures 
at 10nM, a finding that was not observed for the other two derivatives. The three 
derivatives, although similar in structure, have important differences. One of the most 
easily observed structural differences which could explain some of the biological effects 
seen, is the lack of substituents on the aromatic ring in the case of P4 compared to the 
presence of ortho, para and meta substituents on resveratrol and the other derivatives. It 
would be interesting therefore to investigate whether this effect could be attributed to 
the structural differences. Despite its HbF-inducing activity, the high cytotoxicity of P1 
renders it inappropriate as a therapeutic agent.  
Although previous studies (Fibach et al., 2012) have shown that resveratrol has an HbF 
inducing activity, our results show that none of the derivatives tested, including the 
parent compound, have a potent HbF inducing activity in primary human erythroid 
cultures from healthy donors. The lack of activity of resveratrol in primary human 
erythroid cultures, despite the high activity observed in K562 cell line, might be 
attributed to the different effects observed in the two systems. In K562 cells, resveratrol 
is shown to promote differentiation that might not necessarily correspond to an increase 
in the percentage of HbF in primary human erythroid cultures. In fact, the agent was 
shown to increase the percentage of basophilic and polychromatic normoblasts as well 
as the percentage of GPA
+
 cells suggesting promotion of erythroid differentiation but 
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not proliferation as can be seen by the insignificant change in CD71 expression in the 
presence of the agent. This is in agreement with Franco et al. (2014) where they showed 
that resveratrol accelerates erythroid cell maturation through up-regulation of FOXO3a 
rather than increasing the expression of γ-globin gene expression. Furthermore, the 
results obtained in primary human erythroid progenitor cell cultures could be explained 
by the limited bioavailability of resveratrol in the current experimental model. Lancon 
et al. (2004) demonstrated that cellular uptake of resveratrol is reduced by two fold in 
medium containing 10% serum as compared to serum-free medium. Additionally, the 
authors showed that increasing concentrations of BSA reduced the uptake of resveratrol 
by two fold at a concentration of 3.5g/L albumin (Lancon et al., 2004). The primary 
human erythroid cultures used for our screening experiments were grown in 30% serum 
and 11.3g/L BSA in Phase II. As a result, the lack of effect observed might also be 
attributed to the low uptake of the agent by the cells in the current experimental model, 
reducing the concentration of available drug. Our data therefore suggest that the effect 
of each agent should be confirmed in an alternative ex vivo experimental model.  
Pharmacological attempts to find a suitable HbF inducer are limited by the insufficient 
HbF induction observed with current agents. We therefore investigated the combined 
administration of two agents as a therapeutic approach. Decitabine is a hypomethylating 
agent that is known to have a chemopreventive rather than carcinogenic effect while 
increasing HbF levels (DeSimone et al., 2002). In contrast, resveratrol has an anti-
oxidant activity, a crucial property in beta-thalassaemia, and can inhibit ribonucleotide 
reductase in a similar manner to hydroxyurea (Rodrigue et al., 2001). Combining the 
two properties using a combination of resveratrol and decitabine in K562 cells increased 
HbF levels significantly above the effect of resveratrol alone. The combinatorial therapy 
increased Hb inducing activity above the effect exhibited by decitabine alone but only 
non-significantly. However, the Hb level observed with the combination was lower than 
the additive effect of the two agents suggesting competition between the two agents for 
common down-stream targets or saturation of common targets. Despite the minimal 
induction in haemoglobin production offered by the combinatorial regime, the 
combination should be investigated further in primary human erythroid cultures and 
thalassaemic mouse models to investigate the effect of the combinatorial therapy on 
HbF levels and clinical phenotype. The use of a combinatorial approach as a method for 
pharmacological reactivation of HbF is still interesting as can be seen by the increase in 
HbF levels in CD34
+
 erythrocytes when treated with pomalidomide and HU (Moutouh-
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de Parseval et al., 2008). In the current study, the effect observed with the combined 
therapy might be overshadowed by the use of a strong inducer such as decitabine and 
thus alternative agents should be considered for this approach. Furthermore, studies 
regarding the HbF inducing activity of resveratrol are still controversial and thus further 
investigation of resveratrol and its derivatives as a therapeutic approach of β-





















3.4. Screening of four pre-selected HbF inducers in K562 cell line and primary 
human erythroid progenitor cells 
3.4.1. Introduction 
Attempts to identify novel HbF inducers are generally limited by our poor 
understanding of the mechanisms of action of these agents. One approach to overcome 
this limitation would be to better define the molecular mechanisms of already identified 
potent HbF inducers to allow the design of new therapeutic HbF inducers in a 
mechanism-based approach. Four promising HbF-inducing agents were thus selected 
based on the bibliography and preliminary studies with the aim of identifying the most 
active agent for delineation of its molecular mechanism of action. The four agents 
selected were: (1) Lenalidomide, member of a class of immunomodulators used as 
anticancer agents, (2) Angelicin, a DNA binding compound structurally related to 
psoralens, (3) 5-aza-2’-deoxycytidine (decitabine), an antimetabolite nucleoside 
analogue and (4) Mithramycin, another DNA-binding agent.  
Several in vitro experimental systems have been utilised for screening of potential HbF 
inducers including immortalised cell lines, somatic cell hybrids, cultures of bone 
marrow- or peripheral blood-derived progenitors and thalassaemic mice models (Fibach, 
1998).  Rutherford et al. (1981), was the first to suggest the use of the human cell line 
K562 as a model for studying haemoglobin switching. K562 cell line has the ability to 
provide a reproducible, uniform, large population of cells that undergo stable and 
synchronised pattern of differentiation in the presence of chemical inducers such as 
haem (Rutherford et al., 1981). It is this innate ability, the immortality and accessibility 
that renders the cell line an important model for the study of HbF inducers. K562 cell 
line was used for initial screening of the four pre-defined agents with the aim of 
confirming their HbF inducing potential and then selecting the agent with the highest 
activity.   
 
3.4.2. Screening of the four pre-selected agents in K562 cell line 
Based on the literature and previous experiments, a range of concentrations were 
selected for the investigation of each agent, to identify the concentration at which each 
agent will have maximun inducing activity with minimum cytotoxicity. Dose-response 
curves for each agent were prepared where the effect of each agent was determined as 
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an increase in the percentage of Hb containing cells by benzidine staining as described 
previously (Section 2.3).  
Stock solutions of decitabine and mithramycin were prepared in H2O, angelicin in 
ethanol and lenalidomide in DMSO. Working concentrations were prepared in such a 
way as to ensure a final concentration of 2-4% of ethanol and DMSO in the cells in 
order to eliminate any biases in the response due to the presence of the solvents. 
The dose response curves (Figure 28) obtained in K562 cells showed that mithramycin 
and decitabine are the two agents with the highest Hb inducing activity, increasing the 
percentage of Hb containing cells by 9.91 and 8.66-fold above the un-treated negative 
control, respectively (Table 15). In addition, both mithramycin and decitabine showed a 
higher inducing activity than the positive control, HU, which increased the percentage 
of Hb containing cells by a 4.37-fold at 150μM (Table 15). Mithramycin showed the 
highest levels of induction at 10nM with a 24% cell survival, and decitabine at 400nM 
with a 15.7% cell survival (Figure 28). However, those concentrations are considered 
cytotoxic since they reduced cell survival below 50%. As a compromise, 5nM and 
50nM were selected as the most efficient concentrations for mithramycin and 
decitabine, respectively (Figure 28), at which the HbF inducing ability is at highest with 
cell survival at no more than 50%. Angelicin and lenalidomide showed an average of 
2.12 and 2.65-fold increase in the percentage of Hb containing cells, respectively, over 
the negative un-treated control, an effect which is lower than the Hb inducing ability of 
the positive control, HU (Table 15). Lenalidomide and angelicin were found to be active 
at higher concentrations (μM) than mithramycin and decitabine. Lenalidomide showed 
the highest inducing activity (7.3-fold increase over the un-treated control) at 300μM 
concentration, but cytotoxicity was unacceptable at that concentration dropping cell 
survival to ~3%. Angelicin showed the highest inducing activity (2.12-fold increase) at 
300μM concetration with a 55.4% cell survival. 
The results showed that mithramycin and decitabine had higher Hb inducing activities 
compared to angelicin and lenalidomide at a thousand–fold lower concentration 





Table 15, Screening of the four pre-selected agents in K562 cell line. The most efficient 
concentration for each agent was defined as the concentration that resulted in the highest Hb 





(% relative to un-treated 
control) 
Benzidine stain 
(Fold change relative to un-
treated control) 
Hydroxyurea 150 46.13 4.37 
Decitabine 0.05 46.1 8.66 
Angelicin 300 55.4 2.12 
Mithramycin 0.005 80.9 9.91 




       
        
                
Figure 28, Investigation of the effect of the four pre-selected agents; (A) mithramycin, (B) 
decitabine, (C) lenalidomide and (D) angelicin in K562 cell line. Cell survival (line graph) and 
haemoglobin inducing activity (bar graph) were investigated after five days of treatment with 
each agent. Cell survival is presented as a percentage of the living cells in the presence of the 
inducer compared to cell numbers in the un-treated control while the haemoglobin inducing 
activity is presented as a fold increase in the percentage of haemoglobin containing cells relative 
to the un-treated negative control. The results are the average of 3-6 experiments, with error 




3.4.3. Screening of the four pre-selected HbF inducers in primary human 
erythroid progenitor cells 
Although K562 cells are the most highly used model for screening of potential agents, 
Rutherford et al. (1981) showed that the K562 cell line does not recapitulate all aspects 
of erythropoiesis. The cell line lack adult haemoglobin production despite the presence 
of an intact β-globin gene within the cells, suggesting that the cell line originated from 
very immature progenitors (Rutherford et al., 1981). Cioe et al. (1981) suggested that 
different lines of K562 cells respond differently to inducers, probably due to their 
variable karyotype. In addition, Testa et al. (1982) demonstrated a large heterogeneity 
in the type of haemoglobin produced by different clones of K562 cell line. The presence 
of an intact β-globin gene in the absence of β-globin chain synthesis in K562 cells led 
Rutherford et al. (1981) to suggest that the predominant synthesis of foetal and 
embryonic globins in K562 cells might be a consequence of epigenetic control 
analogous to that present in the normal embryonic erythroblasts. The epigenetic changes 
might result in a block of the embryonic to foetal haemoglobin switch and expression of 
mostly embryonic globins with minimal expression of foetal and absent adult globins 
even in the presence of haemoglobin inducers. Moreover, agents identified in this model 
as effective haemoglobin inducers, are not always effective in primary human erythroid 
cultures, thus raising questions about the reliability of the model. 
Due to the presence of these limitations of K562 cell line, the effect of the four pre-
selected HbF inducers was also investigated in primary human erythroid cultures, to 
determine whether the inducing activity of the agents in K562 cells corresponds to an 
increase in HbF production in primary human erythroid cultures.  
The effect of the four agents was determined as a percentage increase in HbF levels 
relative to the un-treated control, measured by cation exchange chromatography. For 
each agent, dose-response curves were prepared in primary human erythroid cultures 
using the same concentration range used in K562 cells. Screening of the four agents in 
primary human erythroid cultures from healthy donors (Figure 29) confirmed the results 
obtained in K562 cell line. Decitabine and mithramycin showed the highest HbF 
inducing activity raising the percentage of HbF by 95 and 62 % above the HbF levels of 
the un-treated negative control at 400nM and 20nM, respectively (Figure 29A & B). 
The increase in the percentage of HbF observed with decitabine increased with 
increasing concentration of the agent. Although, cell survival decreased with increasing 
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concentrations of decitabine, the agent was shown to be the least cytotoxic among the 
four agents in primary human erythroid cultures; cell survival was reduced to only 71% 
at 400nM concentration. In contrast, despite using 10-fold lower concentrations, 
mithramycin was relatively more cytoxic reaching a 50% cell survival at a concentration 
of 15nM. In contrast to decitabine and mithramycin, increasing concentrations of 
lenalidomide decreased HbF induction. The highest increase in the percentage of HbF 
was seen (46%) at 5μM of lenalidomide (Figure 29C). The highest HbF inducing 
activity of angelicin was observed at 400μM where the agent increased the percentage 
of HbF relative to the un-treated control by 52% but reduced the cell survival to 44% 
(Figure 29D).  
 
      
        
                    
Figure 29, Dose response curves for decitabine (A), mithramycin (B), lenalidomide (C) and 
angelicin (D) in primary human erythroid progenitor cells from healthy donors. The effect of 
each agent on the percentage of HbF (bar graph) was determined by cation exchange HPLC and 
on cell survival (line graph) by trypan blue staining. Decitabine and mithramycin have the 
highest HbF inducing activity with decitabine exhibiting lowest cytotoxicity. The results are the 




The effect of the agents were also investigated in primary human erythroid progenitor 
cells from thalassaemic patients and dose-response curves were prepared for decitabine 
and mithramycin (Figure 30). Decitabine was once more shown to have higher HbF-
inducing activity compared to mithramycin while showing lower cytotoxicity. The 
highest inducing activity for decitabine was observed at a concentration of 300nM 
where the percentage of HbF was increased by 68% and cell survival reduced to 81% 
relative to the un-treated control (Figure 30A). Mithramycin had the highest inducing 
activity at 20nM concentration, but at this concentration cytotoxicity was unacceptably 
high with cell survival dropping to 33.3% (Figure 30B).  
 
    
                   
Figure 30, Dose response curves of decitabine (A) and mithramycin (B) in primary human 
erythroid cultures from thalassaemic donors. The effect of each agent on the percentage of HbF 
(bar graph) was determined by cation exchange HPLC and on cell survival (line graph) by 
trypan blue staining. The results are the average of 3 experiments with error bars corresponding 
to the standard deviation.  
 
Decitabine was therefore selected as the agent with the highest inducing activity and 
lowest cytotoxicity profile in primary human erythroid progenitor cells from both 
healthy and thalassaemic donors at the optimal concentration of 300nM.    
 
3.4.4. Discussion 
Initial screening of the four pre-selected agents in K562 cells led to the identification of 
mithramycin and decitabine as the two agents with the highest HbF inducing activity, 
resulting in approximately 9-fold increase in the percentage of Hb-containing cells 
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relative to the un-treated control. The effect observed was higher than that observed 
with HU (at 1000-fold lower concentration than HU). Decitabine was shown to increase 
Hb-inducing activity with increasing agent concentration, while compromising cell 
survival at high concentrations. This is in agreement with Pinto et al.(1984) who 
showed dose-dependent haemoglobinization and differentiation of K562 cells with 
increasing concentrations of decitabine. Mithramycin, a DNA binding drug that targets 
G+C rich nucleotide sequences, was suggested as a promising HbF inducer. 
Mithramycin induced erythroid differentiation of K562 cells in a dose-dependent 
manner, peaking at 10nM, but inhibited cell proliferation by >50% at that concentration, 
a finding that was also observed by Bianchi et al. (1999).  
In contrast, angelicin and lenalidomide exhibited lower HbF inducing activities 
compared to HU at much higher concentrations than mithramycin and decitabine. 
Angelicin was active at 300μM with an average cell survival of ~60%. Similarly, 
Lampronti et al. (2003) also demonstrated that the highest inducing activity of angelicin 
was at 200-400μM, but still lower than that of mithramycin. Lenalidomide increased 
erythroid differentiation by 2.65-fold at 50μM but was not cytotoxic until 100μM. 
Despite the low cytotoxicity, lenalidomide’s Hb inducing ability was below that 
observed with mithramycin and decitabine. Based on these results, mithramycin and 
decitabine were selected as the two agents with the highest inducing activity at lower 
concentrations than any of the other selected agents in K562 cell line.  
Screening of the agents in primary human erythroid cultures confirmed the effect 
observed in K562 cells with decitabine and mithramycin showing the highest HbF 
inducing activity. In contrast to the literature, mithramycin was shown to be highly 
cytotoxic at 10-20nM. Survival of primary human erythroid cultures was at 50% at only 
15nM concentration. The increase in the percentage of HbF observed at 15nM of 
mithramycin was similar to the effect observed by Fibach et al. (2003) when primary 
human erythroid cultures were treated with the agent on day 4 of Phase II. However, the 
authors in the latter study showed higher induction at higher concentrations of 
mithramycin, concentrations that were found to be very cytotoxic in the current study. 
Lenalidomide and angelicin were found to have moderate HbF-inducing activity in 
primary human erythroid cultures, causing an increase of 46% and 52%, respectively, in 
the HbF level over the un-treated negative control. In contrast to Moutouh-de Parseval 
et al. (2008), we showed that cell survival decreased with increasing concentrations of 
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lenalidomide. We observed the highest inducing activity of lenalidomide at 5μM with 
increasing concentrations of the agent resulting in decreasing HbF levels. Moutouh-de 
Parseval et al. (2008) did not investigate the effect of the agent at concentrations higher 
than 10μM, therefore failing to observe the dose-dependent decrease in HbF levels.  
In agreement with the literature (Lampronti et al., 2003, Lampronti et al., 2009) 
angelicin had a lower HbF inducing activity than mithramycin but higher than 
hydroxyurea in primary human erythroid cultures from healthy donors. However, in 
contrast to Lampronti et al. (2003), the effect observed did not reach a 10-fold increase 
relative to un-treated control.  
Based on the results obtained in the current experiments, decitabine had the highest HbF 
inducing activity among the four agents in primary human erythroid cultures from both 
healthy and thalassaemic donors. Decitabine had been previously shown to stimulate 
HbF production in patients with sickle cell disease that did not respond to HU (Koshy et 
al., 2000, Saunthararajah et al., 2003). Olivieri et al. (2011) demonstrated that 
decitabine can also increase HbF levels in β-thalassaemia intermedia patients without 
being cytotoxic. The only notable side effect of decitabine in clinical trial was the 
increase in platelet count that did not correlate with any clinical symptoms (Olivieri et 
al., 2011). Therefore, based on the results obtained from both K562 cells and primary 
human erythroid progenitor cells, decitabine was selected for further study and 




3.5. Characterisation of primary human erythroid cultures in the absence and 
presence of decitabine 
On selection of decitabine as the most efficient HbF inducer, we moved on to 
characterise its effect in primary human erythroid progenitor cells from healthy and 
transfusion-dependent thalassaemic donors. Following the previously defined protocol 
(Section 3.1), primary human erythroid cultures were treated with the agent on day 6 of 
phase II and incubated with the agent for 6 days for maximum HbF induction. The 
effect of the agent on globin gene expression was initially investigated using HPLC 
analysis, qRT-PCR and western blot analysis, to define the changes in HbF levels and γ-
globin gene expression at the protein and mRNA levels, respectively.  
Despite the large amount of experimental data on the association of DNA 
methyltransferase inhibitors and HbF induction, the exact mechanism underlying the 
increased expression of HbF (and gamma globin genes) by such agents is still 
debatable. In order to correlate the effect of decitabine on globin gene expression with 
its hypomethylating function, we investigated the changes in DNA and histone 
methylation patterns caused by decitabine in primary human erythroid progenitor cells 
from healthy donors. In addition, the expression of ten erythroid-related genes known to 
have a role in γ-globin gene reactivation (BCL11A, KLF1, GATA1, SP1, MYB, NRF2, 
SOX6, MBD2, HMOX1 and CREB) was investigated in primary human erythroid 
progenitor cells from healthy and transfusion-dependent thalassaemic donors treated 
with decitabine as an approach to derive some insight on the mechanism of action of 
decitabine.  
 
3.5.1. Investigation of the effect of decitabine on globin gene expression in 
primary human erythroid cultures  
The effect of decitabine on γ-globin gene expression was studied in primary human 
erythroid cultures from twelve healthy donors and twelve IVS1-110/IVS1-110 
transfusion-dependent thalassaemia patients with the aim to select the cultures with the 
highest increase in the percentage of HbF for proteomic analysis. HPLC analysis (Table 
16) showed that decitabine increased the percentage of HbF by an average of 17.34 and 
62.68% after 3 and 6 days of treatment, respectively, in cultures from healthy donors 
and by an average of 33.8 and 43.9%, after 3 and 6 days of treatment, respectively, in 
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thalassaemic cultures. The increase in HbF percentage ranged between 24.6-114.2% in 
healthy cultures and between no response to 149% in thalassaemic cultures (Table 16), 
suggesting different susceptibility of each individual to the agent. Furthermore, the 
response of some cultures to the agent increased with increasing incubation time while 
in others the response decreased with increasing length of treatment with the agent. This 
variability in the response was also prominent in thalassaemic cultures. The increase in 
both healthy and thalassaemic cultures was statistically significant (p-value<0.05) 
(Table 17) only after 6 days of treatment with decitabine. Although the HbF induction 
in thalassaemic cultures treated with the agent was at lower levels than those observed 
in cultures from healthy donors, the HbF levels obtained in the presence of decitabine 
(14-45%) might be sufficient and clinically beneficial.  
In addition, decitabine increased the expression of γ-globin gene at the mRNA level 
both in healthy and thalassaemic patients (Figure 31). γ-globin expression increased by 
an average of 2.97 and 3.69-fold relative to the un-treated control in healthy and 
thalassaemic cultures, respectively, after 6 days of treatment. Similar to HbF, γ-globin 
mRNA levels increased with increasing length of treatment in both healthy and 
thalassaemic cultures. A concurrent increase in α-globin gene expression was also 
observed in healthy cultures following both 3 and 6 days of treatment with the agent. In 
constrast, in thalassaemic cultures, α-globin gene expression dropped to half after three 
days of treatment, while its expression increased to 1.5-fold following 6 days of 
treatment. There is a small decrease in β-globin expression in healthy cultures but no 
major change in β-globin gene expression in thalassaemic cultures following treatment 
with decitabine. 
In concordance with HPLC results, western blot analysis of primary human erythroid 
cultures showed a general increase in HBG expression in both healthy and thalassaemic 
cultures (Figure 32). The increase was more pronounced in healthy cultures. The 
average increase of HBG expression in healthy cultures based on western blot analysis 
was 2.63-fold relative to the un-treated counterpart compared to an average of 1.33 in 
thalassaemic cultures (Figure 32) after 6 days of treatment. 
Although there is a large variation in the response between individual cultures as 
demonstrated by all methods (HPLC, qRT-PCR and western blot analysis), the results 
broadly demonstrated a general increase in γ-globin expression both at the protein and 
mRNA level after 6 days of treatment with the agent. The lack of statistical significance 
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is probably due to the large variation in the response to the agent between individual 
cultures.  
 
Table 16, The percentage increase of HbF in twelve primary human erythroid cultures from 
healthy donors and twelve primary human erythroid cultures from thalassaemic donors after 3 
and 6 days of treatment with 300nM decitabine. The percentage increase in HbF was calculated 








Healthy donors HbF percentage 
Increase in 
HbF 
















6 days of 
treatment 
1 974   
 
3.74 8.01 114.20 
2 965   
 
10.30 19.65 90.89 
3 242 8.12 13.48 65.98 13.46 16.77 24.65 
4 245 4.50 6.44 43.06 5.65 8.86 56.83 
5 888 3.05 1.63 -46.57 3.18 5.81 83.12 
6 165 4.51 5.09 12.87 5.31 7.00 31.93 
7 208 12.35 12.62 2.16 11.99 19.36 61.49 
8 280 3.48 4.62 32.57 5.07 9.10 79.51 
9 367 1.94 2.12 9.49 2.53 4.22 66.79 
10 844 8.37 6.06 -27.64 7.37 9.30 26.33 
11 885 7.69 12.25 55.27 12.83 19.73 53.78 
12 882 6.08 7.62 26.18   
 














(% relative to 
un-treated ) 
6 days No ID 
Un-
treated 




6 days of 
treatment 
1 675214 15.99 23.54 47.21 21.36 28.58 33.78 
2 724636 22.58 30.48 34.99 23.48 36.67 56.13 
3 704965 13.61 16.24 19.33 13.74 18.21 39.81 
4 730099   
 
15.39 20.62 34.00 
5 784676   
 
15.80 22.65 43.35 
6 838990   
 
9.87 15.46 56.64 
7 665190   
 
18.21 20.61 13.17 
8 739392   
 
17.61 26.99 53.29 
9 710148   
 
18.11 45.21 149.68 
10 754964   
 
12.82 14.10 9.99 
11 754676   
 
21.79 31.35 43.88 
12 822141   
 
26.03 24.20 -7.02 
 Average 17.39 23.42 33.84 17.85 25.39 43.89 
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Table 17, The increase in HbF percentage in primary human erythroid cultures from healthy 
and thalassaemic donors as quantified by HPLC after 3 and 6 days of treatment with 300nM 
decitabine. The values are the average of twelve healthy cultures and twelve thalassaemic 
cultures and are presented as the average increase of HbF levels relative to the un-treated 
negative control ± standard deviation. The p-values demonstrate the presence (p-value<0.05) or 
absence (p-value>0.05) of statistical significance in HbF induction after 3 and 6 days of 
treatment according to the paired t-test.  
 
Figure 31, Globin gene expression in primary human erythroid cultures treated with 300nM 
decitabine. The α-, β- and γ-globin mRNA levels were determined by quantitative real-time 
PCR after 3 and 6 days of treatment with decitabine in cultures from healthy (A) and 
thalassaemic (B) donors. The results are the average of twelve healthy cultures and eleven 
thalassaemic cultures with error bars corresponding to the standard deviation. Statistically 
significant changes are noted by * as determined by a paired t-test with p-value<0.05.  
Samples 
Increase in HbF 
(% relative to un-treated control) 
p-value 
(Paired t-test +/- Dec) 
3 days 6 days 3 days 6 days 
Healthy 17.34 ± 35.27 62.68 ± 28.66 0.177 0.00003 




            









Healthy 2.63 ± 2.6 0.15 
Thalassaemic 1.33 ± 0.833 0.20 
Figure 32, Western blot analysis of the primary 
human erythroid cultures from thalassaemic (A) 
and healthy (B) donors in the presence and 
absence of 300nM decitabine (dec). Results 
demonstrate the levels of HBG along with the 
endogenous control GAPDH. Quantitation (C) of 
the results showed an increase in HBG 
expression both in healthy and thalassaemic 
cultures in the presence of 300nM decitabine 
relative to the un-treated control, which was not 
statistically significant.  
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3.5.2. Investigation of methylation patterns on globin gene promoters before and 
after treatment with decitabine 
DNA and histone methylation at the promoters of the ε-, γ-, β- and δ-globin genes and 
the five hypersensitive sites (HS) of the LCR in the β-globin locus (Figure 33A) was 
analysed by quantitative real-time PCR associated with chromatin immunoprecipitation 
assay (Section 2.12). Primary human erythroid cultures from three healthy donors were 
set up according to the previously defined protocol (Section 3.1) and were treated with 
300nM decitabine. Confirmation of the effect of the agent in each of the cultures was 
once more validated by HPLC, in order to ensure that all cultures used for the 
methylation studies were all responders to decitabine. HPLC analysis (Table 18) 
showed that all three donors were responsive to the agent with variation in the degree of 
response.  
 
Table 18, HbF levels of primary human erythroid progenitor cells from healthy donors used for 
methylation studies. The HbF percentage of the primary human erythroid cultures was 
determined in the absence and presence of decitabine by HPLC. The table also presents the 
percentage increase in HbF levels in the presence of the agent. 
Healthy 
donor 
HbF level (%) % increase in 
HbF Un-treated 300nM Dec 
1 4.89 9.29 90.03 
2 2.72 5.98 119.85 
3 4.12 5.21 26.7 
 
Analysis of histone methylation patterns showed a low Histone 3 lysine 4 dimethylation 
(H3K4me2) in all globin gene promoters (Figure 33B) in the absence of decitabine. 
H3K4me2 represents a marker of active chromatin along with H3 Lysine 36 
methylation and H3 acetylation (Kiefer et al., 2008) and usually peaks early in active 
genes (Kim et al., 2007). Among the globin gene promoters, β- and δ-globin promoters 
had higher H3K4me2 than foetal (γ) and embryonic (ε) globin promoters, suggesting 
the active expression of adult haemoglobins and the reduced expression of foetal and 
embryonic haemoglobins. In the LCR region, almost all the HS apart from HS2 show 
higher H3K4me2 than any of the globin gene promoters in the absence of the drug, 
suggesting high activity of the LCR (Figure 33B). Following treatment with decitabine, 
there was a non-significant (p-value>0.05) increase in H3K4me2 levels at the δ-globin 
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gene promoter, a marked but not significant (p-value>0.05) decrease in H3K4me2 
levels at the β-globin gene promoter while H3K4me2 at γ- and ε-globin genes was 
maintained at approximately the same levels. Interestingly, there was a significant (p-
value<0.05) decrease in H3K4me2 in HS3 and HS5 with a marked but not significant 
(p-value>0.05) increase in HS1 and HS4. H3K4me2 at the ε-γ intergenic region, which 
served as our negative control, was found to be low both in the absence and presence of 
the agent as expected (Figure 33B). Based on the above findings it can be suggested that 
decitabine might affect globin gene expression through modulation of H3K4me2 levels 
at the HS sites. 
Analysis of DNA methylation patterns (Figure 33C) at the globin gene promoters in the 
absence of decitabine showed that γ-, ε-, β- and δ-globin gene promoters have very low 
MeCP2 binding, with similar levels to our negative control Cyclin D1. MeCP2 binds to 
methylated DNA and is thus capable of inhibiting transcription in gene promoters. In 
the presence of decitabine, the MeCP2 levels dropped substantially at the β-globin gene 
promoter but remained relatively unchanged at the other globin gene promoters. After 
treatment with the drug there is a non-significant (p-value>0.05) increase at the HS1 
MeCP2 levels and a non-significant (p-value>0.05) decrease at the HS3 and HS5. The 
findings are controversial with regards to the correlation of DNA methylation and open 
chromatin since all HS show similar patterns of H3K4m2 (open chromatin) and MeCP2 











                  
                  
Figure 33, Patterns of Histone and DNA methylation in primary human erythroid cultures from 
three healthy donors with and without treatment with 300nM decitabine. (A) shows a schematic 
representation of the β-globin locus and the sites (-) under investigation for methylation status 
by qRT-PCR assay. H3K4me2 (B) and MeCP2 (C) binding were investigated in all five 
hypersensitive sites in the LCR and ε-,γ-, β- and δ-globin gene promoters. The results represent 
the average of three experiments with error bars corresponding to the standard deviation. The 
MeCP2 results of the β-promoter were the average of two experiments because the third 
experiment was an extreme outlier and was therefore exluded from calculation. * corresponds to 
statistically significant changes in methylation patterns according to the paired t-test (p-





3.5.3. The effect of decitabine on gene expression levels of ten erythroid related 
genes in primary human erythroid cultures  
Primary human erythroid cultures from healthy donors and transfusion-dependent 
patients set up previously (Section 3.5.1) were used for the investigation of the mRNA 
levels of ten erythroid-related genes. Changes in the mRNA levels of the above genes 
were investigated in eleven primary human erythroid cultures from healthy donors and 
eleven from thalassaemic patients after 3 and 6 days of treatment with 300nM 
decitabine. The differential expression of the above genes in the absence and presence 
of decitabine, was investigated by quantitative Real-time PCR (Section 2.10.2). The 
results were presented as fold changes in gene expression relative to the corresponding 
un-treated negative controls.  
In healthy erythroid cultures, expression of almost all ten genes increased to ~1.5 fold 
over the un-treated control after 3 days of treatment with decitabine but the expression 
levels dropped to un-treated equivalents after 6 days with decitabine (Figure 34A). γ-
globin gene expression increased by a 2.5 and 3-fold after 3 and 6 days of treatment 
with decitabine, respectively, relative to the un-treated control (Figure 34A).  
In thalassaemic cultures, expression levels of HBG (Figure 34B) increased significantly 
by 2.3-fold (p-value<0.05) above the un-treated control after 3 days of treatment with 
the agent, and non-significantly by 3.2-fold after 6 days of treatment. In addition, 
decitabine reduced the expression levels of BCL11A to 0.64 that of un-treated control 
after 3 days of treatment, a difference that was statistically significant (p-value<0.05). 
After 6 days of treatment with decitabine, expression levels of almost all genes 
increased relative to the un-treated control. The expression levels of KLF1, SP1, SOX6 
and CREB were close to 2-fold while that of MBD2 approached a 3-fold increase 










                               Healthy cultures                                                                        Thalassaemic cultures  
    
Figure 34, Investigation of the mRNA levels of γ-globin and ten erythroid-related genes in 
primary human erythroid cultures from eleven healthy (A) and eleven transfusion-dependent 
thalassaemic donors (B) treated with 300nM decitabine. The results represent the average levels 
of mRNA after three and six days of treatment with the agent. Error bars correspond to the 
standard deviation. * corresponds to statistically significant changes in mRNA levels relative to 
the un-treated control according to the paired t-test (p-value<0.05).   
  
Based on their increase in HbF percentage following treatment with decitabine, primary 
human erythroid cultures could be grouped into high responders (Figure 35A & C) and 
low responders (Figure 35B & D). High responders had >50% increase in HbF levels 
(as measured by HPLC) whereas in low responders, the HbF increase was <50% 
following treatment with decitabine. There were 8 high responders and 3 low 
responders for the healthy cultures; and 7 high responders and 4 low responders in the 
thalassaemic cultures. The values are the average of triplicates from one biological 
experiment for each culture.  
Among the high responders in healthy cultures (Figure 35A) after 3 days of treatment 
with the agent, the expression of BCL11A, KLF1, NRF2, HMOX1 and CREB increased 
by ~1.5-fold  relative to the un-treated control (Table 19). After 6 days incubation with 
the agent, expression levels of most of the above genes were at similar levels expect for 
CREB which showed a moderate but non-significant drop to almost half (Figure 35B, 
Table 19). In contrast to high responders, the expression of BCL11A, GATA1 and 
HMOX1 increased non-significantly to 1.6, 2.48 and 1.86 respectively in low responders 
after 3 days treatment with decitabine. In addition, the expression of MYB and SOX6 in 








                                                        Healthy High responders                                                                                          Healthy Low responders 
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Figure 35, mRNA levels of γ-globin and ten erythroid-related genes in primary human 
erythroid cultures from healthy (A+B) and thalassaemic donors (C+D). Primary human 
erythroid cultures were divided into high responders (A+C) and low responders (B+D) to 
decitabine based on the increase in HbF percentage determined by HPLC analysis following 
treatment with decitabine. The results are the average of 2-8 cultures. Error bars correspond to 
the standard deviation. Statistically significant changes according to the paired t-test (p-
value<0.05), are marked with *.  
 
Table 19, mRNA levels of the ten erythroid-related genes in primary human erythroid cultures 
from healthy (A) and thalassaemic (B) donors in the presence of decitabine. Primary human 
erythroid cultures were divided into high responders and low responders to decitabine based on 
the increase in HbF percentage (HPLC) following treatment with decitabine. The values 
represent the fold change in mRNA level of each gene, as measured by Real-time PCR, in the 
presence of decitabine relative to the un-treated control. The results are the average of 2-8 




Day 3 Day 6 
High responders Low responders High responders Low responders 
Genes Average Average Average Average 
BCL11A 1.427 ± 0.827 1.603 ± 0.308 1.313 ± 0.817 1.011 ± 0.666 
KLF1 1.533 ± 0.809 1.028 ± 0.534 1.423 ± 0.841 1.975 ± 2/019 
GATA1 1.123 ± 0.814 2.475 ± 2.119 1.170 ± 0.866 1.012 ± 0.692 
SP1 1.233 ± 1.017 1.406 ± 0.443 1.590 ± 1.42 1.661 ± 0.099 
HBG 2.204 ± 1.5 3.267 ± 2.99 3.927 ± 5.288 1.009 ± 0.829 
MYB 1.080 ± 0.618 1.252 ± 0.029 1.029 ± 0.863 0.971 ± 0.579 
NRF2 1.428 ± 1.098 1.189 ± 0.34 0.994 ± 0.717 1.878 ± 1.77 
SOX6 0.958 ± 0.514 1.204 ± 0.0012 1.148 ± 0.886 1.347 ± 0.841 
MBD2 1.276 ± 0.624 1.263 ± 0.118 1.144 ± 0.866 1.731 ± 0.395 
HMOX1 1.561 ± 1.211 1.861 ± 1.536 1.222 ± 0.695 0.746 ± 0.458 




Day 3 Day 6 
High responders Low responders High responders Low responders 
Genes Average Average Average Average 
BCL11A 0.591 ± 0.1545 0.697 ± 0.1341 0.905 ± 0.819 1.521 ± 1.552 
KLF1 1.245 ± 0.363 0.869 ± 0.7891 2.980 ± 2.793 1.542 ± 1.7422 
GATA1 0.446 ± 0.236 0.954 ± 0.4651 0.689 ± 0.627 1.908 ± 1.483 
SP1 0.708 ± 0.043 1.034 ± 0.6475 1.447 ± 0.758 1.733 ± 1.769 
HBG 2.567 ± 0.753 1.906 ± 0.0328 6.076 ± 5.59 1.338 ± 1.2105 
MYB 1.252 ± 0.477 1.183 ± 0.2921 0.820 ± 0.677 1.378 ± 0.8012 
NRF2 1.157 ± 0.035 1.352 ± 0.7493 1.028 ± 0.470 1.463 ± 1.0321 
SOX6 0.966 ± 0 0.870 ± 0.0294 1.423 ± 0.76 1.745 ± 1.576 
MBD2 0.896 ± 0.701 1.111 ± 0.1836 2.990 ± 3.219 2.218 ± 1.3304 
HMOX1 0.993 ± 0 1.144 ± 0.3876 0.9439 ± 0.629 1.001 ± 0.819 
CREB 1.00 ± 0.22 0.819 ± 0.232 3.196 ± 4.915 0.940 ± 0.650 
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Following 6 days of treatment with decitabine, HMOX1 and GATA1 expression in low 
responders decreased to un-treated levels while that of KLF1, NRF2 and MBD2 showed 
a non-significant increase. SP1 expression was increased significantly (p-value<0.05) in 
low responders after 6 days of treatment. In low responders of healthy cultures, the 
increase in HBG expression was higher after 3 days of treatment with the agent (Figure 
35B), rather than after 6 days of treatment as observed in the high responders (Figure 
35A).    
In thalassaemic cultures, high responders (Figure 35C) showed a decrease in BCL11A 
and GATA1 expression to ~0.5-fold after 3 days of treatment, which later increased to 
un-treated levels after 6 days of treatment for both genes (Table 19). High responders 
showed a substantial increase in KLF1, MBD2 and CREB expression of ~3-fold after 6 
days of treatment with decitabine although the increase was not statistically significant 
(Figure 35C, Table 19). Among the low responders in thalassaemic cultures (Figure 
35D), the expression of most genes under investigation apart from HBG, was similar to 
the un-treated levels, after 3 of treatment. After 6 days of treatment with decitabine, low 
responders showed an increase in GATA1, SP1, SOX6 and MBD2 expression of ~2-fold. 
Similarly to the cultures from healthy donors, induction of the γ-globin gene in low 
responders of thalassaemic cultures was higher after 3 days of treatment while in the 
high responders higher induction was observed after 6 days of treatment with the agent.  
Although there is a lack of statistical significance in most of the changes in mRNA 
levels, some changes are substantial with expression levels changing by 2-fold. The lack 
of significance might be attributed to the variation in response between individuals. 
 
3.5.4. Discussion 
HbF levels in all primary human erythroid cultures increased with increasing length of 
incubation with the agent in both healthy and thalassaemic cultures as determined by 
HPLC. The increase in HbF percentage was statistically significant only after 6 days of 
incubation with the agent. The increase in γ-globin expression was also confirmed by 
real-time PCR. However, in contrast to HPLC analysis, real-time PCR has shown a 
greater increase in γ-globin gene expression in thalassaemic compared to that in healthy 
cultures. A concurrent increase in the α-globin gene expression was noted in healthy but 
not in thalassaemic cultures after 3 days of treatment suggesting a difference in the 
response to the agent in the presence of the disease state. Western blot analysis 
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confirmed the HPLC results, showing that the increase in HbF levels was greater in 
healthy rather than in thalassaemic cultures. This might be attributed to the high 
baseline HbF percentage already present in thalassaemic cultures. However, although 
induction of HbF was lower in thalassaemic cultures, the HbF percentage in the 
presence of the agent reached levels that might be clinically beneficial. 
Despite the general increase in γ-globin expression as demonstrated by all the 
techniques, a large variation in the response to the agent was observed between 
individuals. This variation in response was also observed in relation to HU (Pourfarzad 
et al., 2013). The most common genetic predictor predisposing the beneficial effect by 
HU was demonstrated to be the baseline HbF level that was associated with the 
presence of HbF-associated SNPs in BCL11A gene or to the XmnI restriction site 
polymorphism of the γ-globin gene promoter (Ronchi and Ottolenghi, 2013, 
Stamatoyannopoulos, 2005). Menzel et al. (2007) suggested that quantitative trait loci 
variation in thalassaemia might affect the erythropoietic stress response and thus 
underlie the variability in clinical severity and capacity of individuals to respond to HbF 
inducers.  
Since decitabine is a hypomethylating agent, the effect of the agent on DNA and histone 
methylation was investigated in primary human erythroid cultures. Analysis of histone 
methylation patterns in primary human erythroid cultures demonstrated that apart from 
HS2 in the β-globin LCR, all HS sites in primary human erythroid cultures from healthy 
donors show high H3K4me2. Since methylation of H3K4 and H3K36 is associated with 
open chromatin and gene transcription, higher H3K4me2 at the LCR might support the 
dependence of transcriptional activation of globin genes on the β-globin LCR. This 
coincides with the idea that LCR controls the sequential human globin gene expression 
during development. Kim et al. (2007) also showed that the H3K4me2 is present 
throughout the LCR and at the coding sequence of the transcribed γ-globin gene. 
H3K4me2 was moderate in the β- and δ-globin gene promoters and minimal in the γ- 
and ε-globin gene promoters in the absence of induction. This coincides with previous 
reports that show the δβ domain to be highly enriched for H3K4me2 along with 
H3K4me3 and H3ac while the εγ domain lacked these histone modifications in adult 
cells from anaemic spleen of transgenic mice and in primary human erythroid 
progenitor cells (Miles et al., 2007).  
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Treatment of primary human erythroid cultures with decitabine resulted in a significant 
decrease of the H3K4me2 at the HS3 and HS5, with a non-significant increase in 
H3K4me2 levels at the HS1 and HS4. Following decitabine treatment, small non-
significant increases in H3K4me2 at the γ- and δ-globin gene were observed. Similar to 
our findings, Lavelle et al. (2006) demonstrated higher H3K4me2 levels at the β-globin 
promoter than in the γ-and ε-globin gene promoters in un-treated baboon bone marrow 
erythroid cells with no significant change in those levels after decitabine treatment. 
Chin et al. (2009) showed that erythroid progenitor cells from the bone marrow of adult 
baboons with reactivated HbF, had increased levels of H3K4me3 at the γ-globin gene 
comparable to the levels observed at the β-globin gene, suggesting similar levels of 
expression of the two genes. In contrast, we have shown a marked decrease in the 
expression of H3K4me2 at the β-globin promoter. Although not statistically significant, 
the drop in H3K4me2 levels in the β-globin promoter suggests the decrease in 
transcription of β-globin by decitabine. This is supported by the small decrease in β-
globin mRNA levels after 6 days of treatment with decitabine (Section 3.5.1). A 
decrease in β-globin expression along with an increase in γ-globin expression was also 
reported by Mabaera et al. (2008a) following treatment of CD34
+
 cells with 5-
azacytidine.  
Investigation of DNA methylation in the absence of decitabine showed low levels of 
MeCP2 binding at all globin gene promoters but high at all five HS sites. Treatment of 
primary human erythroid cultures with decitabine caused no significant changes in the 
MeCP2 levels throughout the β-globin locus with the exception of a marked decrease in 
the MeCP2 levels at the β-globin promoter. Similar to the patterns observed with 
H3K4m2, decitabine reduced the levels of MeCP2 at the HS3 and HS5 while increasing 
MeCP2 at HS1. However, these results are in contrast to the function of MeCP2, since a 
drop of MeCP2 levels at the β-globin promoter would represent a demethylated 
promoter and active gene while a drop in H3K4m2 would represent reduced 
transcription of the gene. We suggest that the MeCP2 might act as an activator rather 
than a repressor of transcription. In fact, studies have shown that gene silencing due to 
DNA methylation does not depend solely on the binding of MeCP2 (Hendrich and Bird, 
1998). It was also suggested that the ability of MeCP2 to repress transcription was 
dependent upon the density of methyl CpG residues (Nan et al., 1997) which induces 
assembly of chromatin-condensing secondary structures in the absence of methylation 
(Georgel et al., 2003). Moreover, Chahrour et al. (2008) demonstrated that MeCP2 can 
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act as both activator and repressor of transcription, with 85% of the genes being 
activated by MeCP2 in hypothalamus of mice. They further showed that in contrast to 
repressed genes, gene promoters of MeCP2-activated genes were enriched in CpG 
islands that were not heavily methylated (Chahrour et al., 2008). It can be therefore 
concluded that a more specific and accurate approach should have been considered for 
determination of DNA methylation patterns of globin gene promoters, such as bisulfite 
sequence analysis.    
However, recent studies investigating the potential mechanisms of action of 5-
azacytidine suggest that hypomethylation is only a secondary effect of the agent. 
Mabaera et al. (2008a) showed a decrease in γ-globin promoter methylation with no 
major change in global DNA demethylation in the presence of the agent. In addition, the 
authors demonstrated that inhibition of DNMT1 expression by RNAi did not induce γ-
globin expression sufficiently (Mabaera et al., 2008a). This was confirmed by Chin et 
al. (2009) where they demonstrated that increased γ-globin expression does not 
correlate with DNA hypomethylation of the γ-globin promoter in decitabine-treated 
baboons. Based on the above findings, it was suggested that demethylation by 5-
azacytidine is a secondary localised effect related to gene activation by other 
mechanism. It is possible that such a mechanism of action is also relevant to decitabine. 
In fact, studies have shown that decitabine acts by increasing transcription of γ-globin 
genes by transcriptional and post-transcriptional processes (Akpan et al., 2010, Chin et 
al., 2009).  
In order to determine whether γ-globin induction by decitabine might be associated with 
gene activation by other mechanisms, we investigate the differential expression of ten 
erythroid-related genes after treatment with decitabine in primary human erythroid 
cultures from healthy and transfusion-dependent thalassaemic donors. Apart from the 
increase in HBG levels following decitabine treatment of primary human erythroid 
cultures from healthy donors with decitabine, no marked changes were observed in the 
remaining genes. We grouped the cultures based on their HbF response to decitabine; 
high responders has >50% increase in the HbF percentage and low responders <50%. In 
the high responders, there was an increase in BCL11A, KLF1, NRF2, HMOX1 and 
CREB expression relative to the un-treated control after 3 days of treatment. Changes in 
the levels of expression of these genes are likely to be downstream effect of decitabine. 
For examples, the increase in HMOX1 can be mediated by the increase in NRF2 
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expression which in turn might induce γ-globin expression. Induction of HMOX1 was 
previously shown to be regulated at the transcription level by the stress response 
element/NRF2 transcription factor pathway (Alam and Cook, 2003). Macari and 
Lowery (2011) showed that tert-butylhydroquinone increase γ-globin mRNA levels 
through increased cellular levels of NRF2 and increased binding of the transcription 
factor to the γ-globin promoter. Recent studies have demonstrated regulation of γ-globin 
gene expression by p38 MAPK-mediated activation of CREB (Ramakrishna and Pace, 
2011), thus supporting the increase in CREB expression observed in this study. In 
contrast, there was a significant increase in MYB and SOX6 expression after 3 days of 
treatment with decitabine in low responders. After 6 days of treatment, low responders 
showed a significant increase in SP1 expression.  
In thalassaemic cultures, expression levels of BCL11A and GATA1 are reduced after 3 
days of treatment, but their expression levels returned to un-treated levels after 6 days of 
treatment. High responders of thalassaemic cultures showed a substantial increase in 
KLF1, MBD2 and CREB expression of ~3-fold after 6 days of treatment with the agent. 
However, the increase in KLF1 expression is not consistent with the increase in HBG 
expression. We speculate that its high expression in thalassaemic cultures might be due 
to the increased expression of CREB since CREB can activate KLF1 by direct 
interaction. Moreover, the increase in MBD2 gene expression suggests stimulation of 
methylation within thalassaemic cultures which is not consistent with the function of 
decitabine as hypomethylating agent but coincides with the effect observed by ChIP 
analysis that shows increase in methylation pattern at the δ-promoter and HS after 
treatment with decitabine (Section 3.5.2). In contrast, low responders increased BCL11A 
and GATA1 expression after 6 days of treatment, and maintained low levels of CREB. 
The increase in BCL11A coincides with the low HBG expression since BCL11A is a 
silencer of γ-globin gene. Both low and high responders showed an increase in KLF1, 
SP1 and MBD2 levels after 6 days of treatment with decitabine. 
Based on the above findings, treatment of primary human erythroid cultures with 
decitabine seems to have a wide effect on gene expression of a number of genes known 
to be associated with γ-globin regulation. However, most of the changes in gene 
expression following treatment with decitabine are only subtle and lack statistical 
significance. This lack of statistical significance might be attributed to the large 
variation in the response to the agent in the presence of a relatively small sample size. It 
162 
 
is obvious though that the cultured erythroblasts treated with decitabine express γ-
globin at much higher levels than any of the other genes tested. Comparing the changes 
in mRNA levels of genes in high responders of healthy and thalassaemic cultures, it can 
be observed that KLF1 levels are the highest in both groups after 6 days of treatment. 
Whereas, SP1 and MBD2 expression are among the highest in low responders of both 
healthy and thalassaemic cultures after 6 days of induction with the agent. Apart from 
the above common findings, most changes in the expression levels of the genes 
investigated were different in healthy and thalassaemic cultures. This suggests that 
decitabine might act through different mechanisms in healthy and disease environment. 
However, these are only assumptions and need to be further investigated in a more 




















3.6. Differential proteomic analysis of primary human erythroid cultures treated 
with decitabine 
3.6.1. Introduction 
Emerging evidence suggest that the mRNA expression patterns are not sufficient to 
describe biological systems. Post-transcriptional mechanisms, controlling the protein 
translation rate and half-life of proteins, and regulated destruction of proteins that 
control the turnover of proteins and molecular association of protein products, are 
among the mechanisms that affect protein abundance. These render the measurement of 
protein levels essential for analysis of biological processes since proteins are the direct 
mediators of cellular behaviour. Quantitative proteomics provide a method to measure 
the relative amounts of proteins in a biological system of interest and to determine how 
the quantities of those proteins vary in response to particular stimuli such as decitabine.  
To further enhance our understanding of how decitabine induces HbF production in 
primary human erythroid cultures, we compared the proteomes of primary human 
erythroid cultures before and after decitabine. We adopted an isobaric tag for relative 
and absolute quantitation (iTRAQ) proteomic approach coupled with mass 
spectrometry. iTRAQ proteomic approach is a powerful technique for protein 
expression profiling studies due to its ability to identify and quantitate different proteins 
simultaneously as well as due to its ability to allow multiplex analysis. Six primary 
human erythroid cultures from healthy donors and six from thalassaemic patients (Table 
20) were selected from Section 3.5.1 for proteomic analysis based on their high increase 
in the percentage of HbF after both 3 and 6 days of treatment with decitabine, as 
determined by HPLC analysis.   
 
3.6.2. Quantitative proteomic analysis of primary human erythroid cultures in the 
presence of decitabine 
Proteomic analysis was performed on each of the twelve primary human erythroid 
cultures individually, in three 8-plex experiments. For each 8-plex experiment, the un-
treated and treated (300nM decitabine) samples of two primary human erythroid 
cultures from healthy subjects (i.e. 4 samples), and from two thalassaemic subjects (i.e. 
4 samples) were lysed, labelled and analysed by the Dionex Ultimate 3000 UHPL 
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system coupled with the high resolution nano-ESI Orbitrap-XL mass spectrometer. 
Results from the three experiments were then combined resulting in a total of 2188 
proteins being detected. Around 61.3% of the proteins (1341 out of 2188) were 
identified with at least two peptide matches per protein. All proteins were identified 
with an average of 4.25 matched peptides per protein. Consistent with the values 
reported in the literature, we observed a protein sequence coverage of 0.25-92% with 
less than 50% of the proteins having a coverage of at least 10% and 8.5% having 
sequence coverage of more than 40%. Haemoglobin subunits fell within the 10% 
category of proteins with high coverage. Both gamma globin proteins had a sequence 
coverage of 88.4%, β-globin a sequence coverage of 91.16% and α-globin a coverage of 
76.6%. Haemoglobin subunit delta, theta, mu and zeta were also detected by the 
proteomic analysis.   
The identified proteins span a wide spectrum of molecular weights (MW), ranging from 
5 to 632kDa. Around 14.2% of the proteins identified have a molecular weight of 
<20kDa while the majority of the proteins (~32%) have a molecular weight between 20 
and 40kDa. As expected, the proteins with <20kDa MW have a smaller sequence 
coverage, on average 25%, due to the reduced number of cleavage sites. As previously 
shown, the iTRAQ approach can identify proteins at the extreme spectrum of molecular 
weight, in this case 8.6% of the proteins identified had a MW of >120kDa.  
Only 3 (KLF1, MBD2 and HMOX1) out of the 10 genes investigated by real-time PCR 
in primary human erythroid cultures from healthy donors (Section 3.5.3), were detected 
in the proteomic analysis. KLF1 and MBD2 proteins were identified with a sequence 
coverage of <10% and a single matched peptide whereas HMOX1 was identified with a 
sequence coverage of 12% and two unique matched peptides.   
In order to understand and interpret these data and to generate testable hypotheses on 
the systemic response of the proteome to decitabine, the proteins identified have to be 
further classified and filtered. Quantitation and comparison of the levels of each protein 
in the different erythroid cultures were presented as four ratios:  
(1) The first ratio provided a comparison of the levels of the proteins in the treated 
healthy cultures versus the levels of the proteins in the un-treated healthy 
cultures (healthy treated/healthy un-treated cultures) 
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(2)  the second ratio was a comparison of the protein levels in the treated 
thalassaemic cultures versus those in the un-treated thalassaemic cultures 
(thalassaemic treated/thalassaemic un-treated cultures)  
(3) the third ratio compared protein levels in the un-treated thalassaemic cultures 
versus those in the un-treated healthy cultures (thalassaemic un-treated/healthy 
un-treated cultures) 
(4) the final ratio was a comparison of protein levels in the treated thalassaemic 
cultures versus those in the treated healthy samples (thalassaemic treated/healthy 
treated cultures)  
 
Table 20, Data on the six primary human erythroid cultures from healthy donors and six 
primary human erythroid cultures from thalassaemic patients selected for proteomic analysis. 
For each culture, the HbF levels before and after 6 days of treatment with decitabine were 
determined by HPLC analysis. The table shows the HbF percentage before and after treatment 




HbF (%) Increase in HbF iTRAQ 
Experiment 
No 
un-treated 300nM Dec 
(% relative to un-
treated ) 
974 3.74 8.01 114.20 1 
965 10.30 19.65 90.89 1 
245 5.65 8.86 56.83 2 
885 12.83 19.73 53.78 2 
280 5.07 9.1 79.51 3 
367 2.53 4.22 66.78 3 





HbF (%) Increase in HbF iTRAQ 
Experiment 
No 
un-treated 300nM Dec 
(% relative to un-
treated ) 
754676 21.79 31.35 43.88 1 
784676 15.80 22.65 43.35 1 
710148 18.11 45.21 149.68 2 
724636 23.48 36.67 56.13 2 
838990 9.87 15.46 56.64 3 
739392 17.61 27.00 53.29 3 
Average 17.78 29.72 67.16  
 
As expected, the expression levels of most proteins did not change in the presence of 
decitabine. For the majority of proteins, the values of all four ratios were around 1, with 
only ≤5% of the proteins being up- or down-regulated by more than 1.5-fold. In order to 
determine if the proteins are significantly differentially expressed, the ratios were 
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transformed into log2 values for each protein in order to normalise the negatively 
skewed distribution of the proteins for accurate statistical analysis. The proteins within 
each ratio were then sorted based on their log2 value and their p-values were calculated. 
As expected, the p-value distribution of the log2 values within each ratio is positively 
skewed towards a p-value of 1 (Figure 36) confirming once more that the expression 
levels of the majority proteins did not change in the presence of decitabine. A p-value of 
<0.05 for each log2 value was used as a cut-off threshold to select the significantly 
differentially expressed proteins for further analysis. Applying the cut-off threshold 
narrowed down the differentially expressed proteins to 105 proteins for the healthy 
treated/healthy un-treated ratio, 110 proteins for the thalassaemic treated/thalassaemic 
un-treated ratio, 66 proteins for the thalassaemic un-treated/healthy un-treated and 98 
proteins for the thalassaemic treated/healthy treated ratio (Appendix IV).  
 
                
Figure 36, The p-value distribution of the log2 values of the 2188 proteins identified by 
proteomic analysis. The expression levels of each protein within each ratio was transformed into 
log2 value with a corresponding p-value. Using a p-value<0.05 as a threshold, only a minority of 








3.6.2.1. Ratio 1- Healthy cultures: Treated versus Un-treated 
Among the 105 significantly differentially expressed proteins (p-value<0.05) in healthy 
cultures (ratio 1), 47 proteins were up-regulated in the presence of decitabine, 95.7% of 
them with an average expression ratio of over 1.2 and 4.3% with an average expression 
ratio of over 2 (Appendix IV). 58 proteins were significantly down-regulated by less 
than two fold, i.e. with an expression ratio of more than 0.5 in the presence of 
decitabine. Bioinformatics analysis by DAVID (Figure 37A) and GeneCodis (Figure 
37B), demonstrated that the significantly differentially expressed proteins in healthy 
cultures are involved in transcription factor binding, regulation of cell proliferation, 
protein stabilization, chromatin organization and protein complex assembly. In addition, 
four differentially expressed proteins were associated with regulation of NF-κB 
signalling pathway. Looking into the function of the up-regulated and down-regulated 
proteins directly, it can be suggested that decitabine might affect caspase-mediated 
apoptotic pathways and ubiquitin ligase complexes due to activation of oxidative or ER 
stress (Figure 38). This can be supported by the up-regulation of proteins like 
PYCARD, a mediator of caspase 8 and 9-mediated apoptosis (Hasegawa et al., 2007), 
COPS2, a regulator of cullin-based ubiquitin E3 ligase complexes that mediates p53 
degradation (Bech-Otschir et al., 2001), DNAJA3, modulator of apoptotic signal 
transduction (Syken et al., 1999) and HTATIP2, a tumor suppressor involved in cellular 
oxidative stress surveillance which induces p53-mediated apoptosis (Lee et al., 2012, 
Zhao et al., 2008). Transcriptional inhibitors, including DR1, a TATA-binding protein-
associated phosphoprotein inhibitor of basal and activated gene transcription (Inostroza 
et al., 1992), CNOT8, a subunit of CCR4-NOT complex which regulates RNA 
polymerase II transcription (Aslam et al., 2009, Kruk et al., 2011) and HEXIM1, an 
inhibitor of positive transcription elongation factor (Lew et al., 2013), were down-
regulated. At the same time proteins that promote transcription such as MYBL1 (Ma 
and Calabretta, 1994) are up-regulated. These findings support the positive regulation of 













Count P-value Benjamini 
transcription factor binding MF 1.56 11 0.0045 0.7500 
regulation of cell growth BP 1.4 5 0.0081 0.9400 
regulation of cellular component size BP 1.4 7 0.0150 0.8900 
regulation of protein localisation BP 1.32 5 0.0120 0.8800 
lipid transport BP 1.32 6 0.0027 0.9400 
focal adhesion CC 1.13 5 0.0200 0.7400 
kinase inhibitor activity MF 0.89 3 0.0680 0.9100 
protein stabilization BP 0.92 4 0.0092 0.9100 
protein kinase cascade BP 0.79 6 0.0350 0.9800 
chromatin organization BP 0.74 8 0.0470 0.9600 
transcription cofactor activation MF 0.72 8 0.0120 0.8300 
macromolecular complex assembly BP 0.7 15 0.0380 0.9700 
regulation of I-kappaB kinase/NF-
kappaB cascade 
BP 0.66 4 0.0550 0.9700 




Figure 37, Bioinformatic analysis of the 105 significantly differentially expressed proteins in 
primary human erythroid cultures from healthy donors treated with decitabine (ratio 1). 
Functional analysis by DAVID (A) and GeneCodis (B) of significantly differentially expressed 
proteins (ratios with p-value<0.05) using a reference list of all 2188 proteins identified, grouped 
proteins according to their biological process (BP), molecular function (MF) and cellular 
component (CC). In DAVID, protein groups are categorised according to their enrichment 
scores and corresponding p-value and Benjamini values.        
 




Figure 38, Schematic diagram demonstrating the possible effect of decitabine in primary human 
erythroid progenitor cells from healthy donors. Decitabine promotes apoptosis through 
activation of stress responses, and increases transcriptional activity by down-regulation of 
transcriptional repressors. Proteins in red circle are some of the differentially expressed proteins 
identified in ratio 1 (i.e. healthy treated/healthy un-treated cultures). The red arrows 
demonstrated whether the encircled proteins are up- or down-regulated by decitabine.  
 
3.6.2.2. Ratio 2 – Thalassaemic cultures: treated versus un-treated 
The comparison of proteins in treated versus un-treated thalassaemic cultures (ratio 2), 
indicated that 54.5% of the 110 significantly differentially expressed proteins (p-
value<0.05) were up-regulated (Appendix IV); by less than 1.2-fold in 45.5%; by a ratio 
of greater than 1.2-fold in 25.5% and by more than 2-fold in 9% of the proteins. Among 
the significantly down-regulated proteins, 92.7% are down-regulated by more than 1.4 
times while the remaining proteins are down-regulated by more than 2-fold (expression 
ratio <0.5) (Appendix IV). Functional annotation analysis of the differentially expressed 
proteins (p-value<0.05) in thalassaemic cultures (Figure 39) showed that the 
differentially expressed proteins in the presence of decitabine are involved in protein 
and metal ion binding, DNA binding and chromatin modifications, transcription and 
positive regulation of NF-κB cascade. Functional clustering of differentially expressed 
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proteins, as well as looking into the function of individual proteins directly, suggested 
that decitabine favours production of immature erythrocytes (Figure 40) as can be seen 
by the down-regulation of proteins involved in erythroid maturation such as PICALM, a 
clathrin assembly lymphoid myeloid leukemia protein involved in erythroid maturation 
and transferin internalization in mice (Suzuki et al., 2012), ABCB6, a glycoprotein 
expressed in the membrane of mature erythrocytes and in exosomes released from 
reticulocytes at the final steps of erythroid maturation (Kiss et al., 2012) and up-
regulation of TACC3, a protein highly expressed in haematopoietic progenitors 
(Garriga-Canut and Orkin, 2004). Moreover, results suggest that decitabine affects 
transcriptional activation of genes downstream of oxidative stress pathways such as 
HMOX1, a target gene of the central regulator of cellular oxidative stress response Nrf2 
(Fer et al., 2010) and up-regulation of THOC5, a key protein in the maintenance of 
haematopoietic stem cells which is phosphorylated in the presence of oxidative stress 
(Griaud et al., 2013), and PPP5C, a negative regulator of hypoxia-induced activation of 
apoptosis signal-regulating kinase 1 (Morita et al., 2001) (Figure 40). Proteins such as 
RBM10, an RNA binding regulator of splicing (Wang et al., 2013), XRN2, a 5’-3’ 
exonuclease that promotes transcriptional termination (Kaneko et al., 2007, West et al., 
2004), were up-regulated while HEXIM, a regulator of transcriptional elongation of 
RNA polymerase II (Lew et al., 2013) was down-regulated. These findings suggest that 
decitabine promotes transcriptional termination and post-transcriptional processes 
(Figure 40). Decitabine also appears to regulate chromatin remodelling as can be 
observed by the up-regulation of SMARCD3, a subunit of SWI/SNF complex that 
promotes DNA-histone dissociation (Forcales et al., 2012), and down-regulation of 
CHD5, a chromatin remodelling, helicase and DNA-binding protein which is activated 














Counts P-value Benjamini 
transition metal ion binding MF 1.52 19 1.70E-02 9.90E-01 
zinc finger MF 1.52 10 2.00E-02 9.80E-01 
cerebral cortex development BP 1.35 3 2.50E-02 9.80E-01 
chromatin organization BP 1.35 12 2.00E-04 1.70E-01 
transcription BP 1.29 14 2.10E-02 9.90E-01 
gamete generation BP 1.13 6 4.10E-02 9.50E-01 
chromatin modification BP 0.98 6 2.30E-02 9.90E-01 
positive regulation of I-kappaB 
kinase/NF-kappaB cascade 
BP 0.95 4 3.60E-02 9.50E-01 
                          
Figure 39, Functional annotation of the 110 significantly differentially expressed proteins in 
primary human erythroid cultures from thalassaemic donors treated with decitabine (ratio 2). 
Functional analysis by DAVID (A) and GeneCodis (B) of the significantly differentially 
expressed proteins (ratios with p-value<0.05) using a reference list of all 2188 proteins 
identified, grouped proteins according to their biological process (BP), molecular function (MF) 
and cellular component (CC). In DAVID, protein groups are categorised according to their 















Figure 40, Schematic diagram demonstrating the possible effects of decitabine on primary 
human erythroid progenitor cells from thalassaemic donors. Decitabine promotes transcription 
through down-regulation of transcriptional repressors and through chromatin modifications, 
rather than activation of oxidative stress-induced pathways. In addition, decitabine favours 
immature erythroblasts and protects them against stresses. Proteins in red circle are some of the 
differentially expressed proteins in thalassaemic cultures treated with decitabine (ratio 2). The 
red arrows demonstrated whether the encircled proteins are up- or down-regulated by 
decitabine.    
 
3.6.2.3. Ratio 3 – Thalassaemic un-treated versus healthy un-treated 
Analysis of the ratio of proteins of un-treated thalassaemic samples over un-treated 
healthy samples (ratio 3) resulted in the identification of 66 significantly differentially 
expressed proteins (p-value<0.05), 36.3% of which are up-regulated. 87.5% of the up-
regulated proteins were expressed with a ratio greater than 2 while the remaining 
proteins were expressed with a ratio of 1.5 to 2. Among the down-regulated proteins, 
57% were down-regulated by more than 1.6 fold and the remaining were down 
regulated by more than 2 fold (Appendix IV). Differentially expressed proteins were 
found to be involved in steroid metabolic processes, defence responses, metal ion 
transport, oxidation-reduction processes and haematopoiesis as shown by the functional 








Count P-value Benjamini 
Glycoprotein Keyword 3.19 17 1.10E-04 2.40E-02 
extracellular region CC 3.19 11 3.50E-03 4.10E-01 
steroid metabolic process BP 1.62 4 2.40E-02 9.80E-01 
defence response BP 1.19 7 1.00E-02 1.00E+00 
acute-phase response BP 1.19 3 1.90E-02 1.00E+00 
metal ion transport BP 1.13 4 4.10E-02 9.90E-01 
tyrosine protein kinase MF 0.49 4 5.60E-03 7.00E-01 
                    
Figure 41, Functional annotation of the 66 significantly differentially expressed proteins of un-
treated thalassaemic samples over un-treated healthy samples (ratio 3). Functional analysis by 
DAVID (A) and GeneCodis (B) of the significantly differentially expressed proteins (ratios with 
p-value<0.05) using a reference list of all 2188 proteins identified, grouped proteins according 
to their biological process (BP), molecular function (MF) and cellular component (CC). In 
DAVID, protein groups are categorised according to their enrichment scores and corresponding 
p-value and Benjamini values.    
 
 
3.6.2.4. Ratio 4 – Thalassaemic treated versus healthy treated 
98 proteins were found to be significantly differentially expressed when comparing 
thalassaemic and healthy cultures treated with decitabine (ratio 4) (Appendix IV). 50% 
of the significantly differentially expressed proteins (p-value<0.05) were up-regulated, 
85.7% of which had an expression ratio of greater than 1.2 while 4.3% had a ratio of 
greater than 2. Among the significantly down-regulated proteins, 57% were reduced by 
less than 2 fold, while the remaining 43% were reduced by more than 2-fold. Functional 
clustering of differentially expressed proteins (Figure 42), demonstrated that the 
differentially expressed proteins are involved in lipid transport, platelet activation and 
degranulation, immune defence and cell adhesion.  
 









Count P-value Benjamini 
Glycoprotein keyword 4.51 7 2.70E-04 2.20E-01 
lipid transport BP 1.72 6 1.80E-03 5.60E-01 
sex differentiation BP 1.42 5 1.40E-02 9.60E-01 
integral to plasma membrane CC 1.34 20 2.80E-02 5.50E-01 
defence response BP 1.22 8 2.20E-02 9.90E-01 
ion transport BP 0.86 8 3.60E-02 9.90E-01 
             
     
Figure 42, Functional annotation of the 98 significantly differentially expressed proteins in 
thalassaemic cultures treated with decitabine over healthy cultures treated with decitabine (ratio 
4). Functional analysis by DAVID (A) and GeneCodis (B) of the significantly differentially 
expressed proteins (ratios with p-value<0.05) using a reference list of all 2188 proteins 
identifed, grouped proteins according to their biological process (BP), molecular function (MF) 
and cellular component (CC). In DAVID, protein groups are categorised according to their 
enrichment scores and corresponding p-value and Benjamini values.    
 
Comparison of the functional clusterings of the differentially expressed proteins of each 
ratio (Table 21), demonstrate that differentially expressed proteins of ratio 1 and 2 fall 
commonly into three functional annotations: chromatin organization and modification, 
transcription and regulation of the NF-κB cascade. Differentially expressed proteins of 
ratio 3 and 4 are commonly involved with steroid metabolism, defence response, 
haematopoiesis and vitamin D metabolism; biological processes that are involved with 
the disease state.  
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Table 21, Comparison of the functional clustering of the significantly differentially expressed 
proteins of each ratio. Functional analysis by DAVID and GeneCodis, categorised the 
differentially expressed proteins of each ratio (ratios with p-value<0.05) according to their 
Biological process (BP), Molecular function (MF) and cellular component (CC). The table 
shows the number of differentially expressed proteins within each ratio that belong to each 
















regulation of cell growth BP 5 
  
2 
regulation of cellular component size BP 7 
   
regulation of protein localisation BP 5 
   
protein stabilization BP 4 
   




chromatin organization BP 8 12 
  




transcription BP 8 14 
  
lipid transport BP 6 
  
6 
lipid metabolic process BP 
   
5 
fatty acid oxidation BP 2 
   




regulation of transferase activity BP 6 
   
regulation of I-kappaB kinase/NF-
kappaB cascade  
BP 4 4 
  









steroid metabolic process BP 
  
4 6 
defense response BP 3 
 
7 8 











vitamin D metabolic process BP 
  
2 2 
platelet activation BP 
   
7 
cell adhesion BP 
   
5 
transcription factor binding  MF 11 
   
kinase inhibitor activity MF 3 
   



























focal adhesion CC 5 
   
 
In order to narrow down the list of differentially expressed proteins to those that are 
solely associated with the function of decitabine and not due to the disease state, we 
further compared the four sets of significantly differentially expressed proteins between 
the four ratios (ratio 1: healthy treated/healthy un-treated samples, ratio 2: thalassaemic 
treated/thalassaemic un-treated cultures, ratio 3: thalassaemic un-treated/healthy un-
treated cultures and ratio 4: thalassaemic treated/healthy treated cultures). Comparison 
of ratio 1 and 2 indicated 23 common, differentially expressed proteins (Figure 43A, 
gray area). Comparison of proteins derived from ratio 3 and ratio 4 identified 40 
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proteins that were commonly differentially expressed (Figure 43B, gray area). 
Comparison of proteins derived from ratio 2 and 3, identified 17 common, differentially 
expressed proteins (Figure 43C, gray area). 21 protein were common when comparing 
differentially expressed proteins in ratios 1 and 3 (Figure 43D, gray area). 17 proteins 
were commonly differentially expressed when comparing proteins in ratios 1 and 4 (i.e. 
healthy treated/healthy un-treated samples and thalassaemic treated/healthy treated 
samples) (Figure 43E, gray area). 10 commonly, differentially expressed proteins were 
identified when comparing ratios 2 and 4 (i.e. thalassaemic treated/thalassaemic un-
treated cultures and thalassaemic treated/healthy treated samples (Figure 43F, gray area) 
and 2 proteins were commonly differentially expressed among  all of the four ratios 
(Figure 43G, gray area).  
Differentially expressed proteins following treatment with decitabine in healthy (105 
proteins) and thalassaemic (110 proteins) cultures represent proteins whose expression 
levels change in the presence of decitabine. In contrast, proteins that are associated with 
the disease state are proteins whose expression differs between thalassaemic and healthy 
cultures in the absence of the agent (i.e. proteins in the ratio thalassaemic un-
treated/healthy un-treated samples, ratio 3). However, proteins that are shown to be 
differentially expressed by the ratio of thalassaemic treated over healthy treated samples 
(ratio 4) but not by the ratio of thalassaemic un-treated/healthy un-treated samples (ratio 
3) might include proteins that are up- or down-regulated at higher levels in thalassaemic 
compared to healthy cultures due to the agent. Therefore, in order to identify the 
proteins that are solely associated with the presence of decitabine (Figure 44), proteins 
that were attributed to the disease state were removed from the list of commonly 
differentially expressed proteins between the treated over un-treated ratios of healthy 
and thalassaemic cultures. Among the 23 common proteins between thalassaemic and 
healthy cultures whose expression is altered in the presence of decitabine (Figure 43A 
and 44), 8 proteins associated with the disease state were removed (Figure 44), resulting 
in 15 proteins that were solely attributed to the presence of decitabine. 6 proteins that 
were differentially expressed in thalassaemic cultures due to the presence of decitabine 
(thalassaemic treated/thalassaemic un-treated cultures, ratio 2) but were also 
differentially expressed in thalassaemic treated over healthy treated cultures (ratio 4) 
can be considered as proteins being affected by the agent, since they might represent 
proteins that are affected more in thalassaemic rather than in healthy cultures following 
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Figure 43, Venn diagrams representing overlaps of significantly expressed proteins among the 
four ratios. (A) common proteins between treated/un-treated ratio in healthy (ratio 1) and 
thalassaemic (ratio 2) cultures. (B) common proteins between thalassaemic un-treated/healthy 
un-treated ratio (ratio 3) and thalassaemic treated/healthy treated ratio (ratio 4). (C) common 
proteins of thalassaemic treated/thalassaemic un-treated ratio (ratio 2) and thalassaemic un-
treated/healthy un-treated ratio (ratio 3). (D) common proteins between healthy treated/healthy 
un-treated ratio (ratio 1) and thalassaemic un-treated/healthy un-treated ratio (ratio 3). (E) 
common proteins between healthy treated/healthy un-treated ratio (ratio 1) and thalassaemic 
treated/healthy treated ratio (ratio 4). (F) common proteins between thalassaemic 
treated/thalassaemic un-treated ratio (ratio 2) and thalassaemic treated/healthy treated ratio 
(ratio 4). (G) common proteins between all four ratios, (H) proteins that are differentially 























Figure 44, Schematic diagram of the process followed to identify the proteins that are 
differentially expressed due to decitabine 

















8 proteins due to disease 










6 proteins affected by the agent more 
in thalassaemic than in healthy cultures  
(part of Figure 43F) 










6 proteins affected by the agent more in 
healthy than in thalassaemic cultures  






























2A 56 kDa regulatory subunit delta 






Ubiquitin carboxyl-terminal hydrolase 
11 
inhibits degradation of target proteins by proteosome, 




Q9UDX4 SEC14-like protein 3 transport hydrophobic ligands like tocophenol SEC14L3 ↑ ↓ 
 
Q9NP58 
ATP-binding cassette sub-family B 
member 6, mitochondrial 
binds haem and porphyrins and mediate with ATP-




Q8N183 Mimitin, mitochondrial 





P40306 Proteasome subunit beta type-10 
involved in antigen processing to generate class I binding 




P60983 Glia maturation factor beta stimulate neural regeneration GMFB ↑ ↑ 
 
O95199 
RCC1 and BTB domain-containing 
protein 2 





Phosphatidylinositol transfer protein 
alpha isoform 





Signal recognition particle 54 kDa 
protein 




Q9C0D2 Centrosomal protein KIAA1731 centriole formation of stability KIAA1731 ↓ ↓ 
 
Q16594 
Transcription initiation factor TFIID 
subunit 9 
involved in transcriptional activation, gene regulation 




Table 22, The 27 differentially expressed proteins identified to be potentially involved with the action of decitabine based on the comparative analysis of the 
differentially expressed protein of the four ratios. The process followed that led to the identification of these 27 proteins is outlined in Figure 44.  
 
  
Table 22, continues 
 
Q8N960 Centrosomal protein of 120 kDa 





Q14563 Semaphorin-3A involved in development of olfactory system SEMA3A ↓ ↓ 
 
Q96HH6 Transmembrane protein 19 Possibly involved in NRF2/KEAP1 pathway TMEM19 ↓ ↑ ↑ 
O60888 Protein CutA 






P61201 COP9 signalosome complex subunit 2 
Regulator of cullin RING ubiquitin ligases, involved in 







NADH dehydrogenase (ubiquinone) 
iron-sulfur protein 6, mitochondrial 
sensory subunit of mitochondrial membrane respiratory 





Q96KS0 Egl nine homolog 2 
Cellular oxygen sensor that catalyses under normoxic 















Inhibitor of nuclear factor kappa-B 
kinase subunit alpha 
Phosphorylates inhibitors of NF-κB – allows 
ubiquitination of inhibitors of NF-κB and translocation of 






39S ribosomal protein L42, 
mitochondrial 













Q7LDG7 RAS guanyl-releasing protein 2 
functions as calcium ad DAG regulated nucleotide 




P16989 Y-box-binding protein 3 










Similarly, 6 proteins that are commonly differentially expressed in healthy cultures due 
to the presence of decitabine (healthy treated/healthy un-treated, ratio 1) and in treated 
samples of thalassaemic over healthy donors (ratio 4) can also be considered as proteins 
that are being affected by the agent (Figure 44). Addition of the above 12 proteins, to 
the 15 common proteins that are differentially expressed in thalassaemic and healthy 
cultures due to decitabine, results in 27 proteins (Figure 43H, gray area, and Table 22) 
that are considered as the proteins associated with decitabine.   
Functional analysis of the 27 proteins (Figure 45) by GeneCodis demonstrated that 16% 
of the proteins are involved in transport processes. Other biological processes associated 
with these proteins include negative regulation of apoptosis (6%), protein binding (3%), 
positive regulation of cell growth (3%), alternative splicing (3%) and the I-kappaB 




Figure 45, Functional analysis of the 27 proteins whose expression is affected by decitabine. 
The analysis was performed using Genecodis which categorises proteins according to the 
biological processes they are involved in.   
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Although functional annotation using the above bioinformatic tools is useful, their 
allocation to the different groups depends on the algorithm the particular software is 
using. We therefore looked into the function of each of the 27 proteins. Based on the 
function of the 27 proteins (Figure 46), it can be suggested that decitabine promotes 
transcriptional termination and post-transcriptional processes as can be observed by the 
up-regulation of SRrp53, a serine/arginine related protein 53 involved in constitutive 
and alternative splicing (Cazalla et al., 2005), and down-regulation of TAF9, a histone-
like TBP-associated factor essential in TFIID mediated transcription (Chen and Manley, 
2003). In addition, decitabine might reduce protein ubiquitination and apoptosis through 
the regulation of the NF-κB signalling pathway supported by the involvement of 3 
(COSP2, CHUK and USP11) of the 27 proteins in this pathway (Figure 46). 
Furthermore, proteins such as EGLN2, a prolyl-4-hydroxylase redox sensor involved in 
the stabilization of HIF; NDUFAF2, a molecular chaperone for mitochondrial complex 
I assembly and PSMB10, an IFN-γ mediated proteosome subunit with ATP-dependent 
proteolytic activity (Foss et al., 1998, Racape et al., 2011) were differentially expressed. 
These proteins are involved in oxidative and ER stresses possibly leading to activation 
of signal transduction pathways (Figure 46).   
Apart from the NF-κB pathway, decitabine may be involved in the MyD88 dependent 
toll-like receptor signalling pathway (PPP2R5D) and Ras signalling pathway 
(RASGRP2) (Figure 46). Activation of these pathways could be either due to 
demethylation and transcriptional activation of random genes throughout the genome by 
decitabine or through activation of specific pathways related to oxidative stress such as 




Figure 46, Schematic diagram demonstrating the various pathways potentially involved with 
the action of decitabine. Differentially expressed proteins (highlighted with red circles) 




To delineate the molecular mechanism of action of decitabine responsible for 
reactivation of foetal haemoglobin, we employed a quantitative proteomic iTRAQ 
approach where the identity and relative abundance of each protein in the experimental 
primary human erythroid cultures could be determined simultaneously. 
The major advantage of the iTRAQ technique is its applicability to primary samples 
such as human tissues. In addition, its ability to analyse multiple samples 
simultaneously facilitates time course studies or allows analysis of larger number of 
samples simultaneously, saving sample preparation and analysis time while improving 
the experimental design (Unwin et al., 2005). However, current data analysis methods 
for iTRAQ fail to report reliable relative protein abundance estimates and suffer with 
problems of precision and accuracy. Precision is affected by random errors, non-
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reproducible and unpredictable fluctuations around the true value, while accuracy is 
compromised by systemic biases arising from inconsistencies in the iTRAQ labelling 
efficiency and protein digestion.  
The logarithmic transformation has been previously suggested as a method to address 
the heterogeneity of variance for iTRAQ data (Boehm et al., 2007). For this reason, the 
abundance ratios of all of the 2188 proteins identified in the current study were 
converted into their log2 values. However, attempts to normalise these biases led to 
compression of ratios towards 1 which lead to underestimation of the ratios as 
previously shown (Bantscheff et al., 2008, Ow et al., 2009). Bantscheff et al. (2008) 
showed that ratio compression is due to contamination during ion selection, which 
occurs consistently within an experiment. However, Karp et al. (2010) demonstrated 
that like any other normalization method, logarithm transformation does not sufficiently 
stabilise the variance.  
Despite the above limitations, normalization using the logarithmic transformation 
allowed us to filter the 2188 identified proteins based on their p-value into 105 
differentially expressed proteins (p-value<0.05) in healthy cultures and 110 in 
thalassaemic cultures in the presence of decitabine. Functional annotation analysis of 
the differentially expressed proteins demonstrated that decitabine commonly affects 
proteins that are involved in protein binding, chromatin organization and regulation of 
transcription in both healthy and thalassaemic cultures. In addition, differentially 
expressed proteins in both healthy and thalassaemic primary human erythroid cultures 
treated with decitabine are involved in regulation of the NF-κB pathway.  
In order to understand and interpret these data and to generate testable hypotheses on 
the response of the proteome to decitabine, the list has to be further classified and 
filtered. 23 proteins were commonly differentially expressed in both healthy and 
thalassaemic cultures in the presence of decitabine. Filtering out the proteins attributed 
to the disease state, as defined by the proteins differentially expressed in thalassaemic 
but not in healthy cultures in the absence of the agent, reduced the potential candidates 
to 15 proteins. Proteins that were not differentially expressed in thalassaemic or healthy 
cultures in the presence of decitabine but were found to be differentially expressed 
when thalassaemic and healthy treated cultures were compared, were considered as 
proteins affected by the agent and were added to the list of 15 proteins. Functional 
annotation of the resulting 27 proteins, proteins considered to be associated with the 
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action of decitabine, showed that these proteins are involved in transport, protein 
binding and ubiquitination and regulation of cell growth among others. In addition, 
functional annotation of the above proteins also demonstrated the involvement of 
decitabine with the NF-κB pathway. NF-κB is active during the early stages of normal 
erythroid development (Zhang et al., 1998, Jeong et al., 2011) and is responsible for the 
suppression of a number of transcription factors critical for normal erythropoiesis 
including MYB, MYC and NFE2. Recently, resveratrol was shown to inhibit TNFα-
mediated NF-κB activation and promote erythropoiesis in primary human erythroid 
cells (Jeong et al., 2011).  
However, functional annotation of differentially expressed protein presents many 
drawbacks. Most of the annotations are done computationally and only a minority is 
based on experimental data. In addition, the list of terms used for functional annotation 
is not yet complete and changes with the continuous addition of new discoveries, 
making the terms redundant or obsolete (Schmidt et al., 2014). Studies have shown that 
comparison of the different algorithms used by different softwares showed high 
discrepancies in the functional grouping of the same proteins (Khatri and Draghici, 
2005).  
Examining the function of each individual protein suggested that decitabine promotes 
survival of immature erythroid progenitors in thalassaemic cultures, possibly due to 
modulation of eythropoiesis (Figure 40). Alternatively, oxidative stress in healthy 
cultures might lead to activation of signal transduction pathways and subsequent 
activation of γ-globin expression (Figure 38). This agrees with claims that increasing 
levels of stress such as in the case of haemolysis and hypoxia, lead to increased HbF 
contents per F cell due to stimulation of maturation of erythroid progenitors that retain 
the ability to produce HbF (Desimone et al., 1978, Desimone et al., 1982a). Moreover, 
the toxic effects of 5-azacytidine were suggested to be responsible for the augmentation 
of HbF synthesis due to accelerated maturation of early progenitors (Torrealbaderon et 
al., 1984). In addition, signalling pathways, such as the NF-κB pathway, might be 
activated as a result of the different responses to decitabine observed in healthy and 
thalassaemic cultures (Figure 46). The potential involvement of the NF-κB signalling 
pathway in the molecular mechanism of decitabine responsible for HbF reactivation 
merits further investigation.  
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The general perception is that MS-based proteomics have low reliability in the complete 
coverage of proteins, and complexes involved in the same signalling pathway or 
belonging to the same functional family is not usually achieved (Schmidt et al., 2014). 
Despite the high mass accuracy of mass spectrometers, challenges of the proteomic 
investigation occur at all levels, from sample preparation, raw data integration and 
database searching to the functional interpretation of large datasets (Tabb et al., 2010).   
Reproducibility in protein identification among replicates can vary between 30 and 60% 
(Liu et al., 2004, Tabb et al., 2010). In complex peptide mixtures such as cell lysates, 
the number of ions co-eluting can significantly exceed the number of ions for which 
tandem mass spectra can be acquired, showing a bias towards high abundance ion 
signals that correspond to peptides found at high levels (Liu et al., 2004). High 
abundant proteins are usually identified by multiple peptides while low abundant 
proteins by one or two. In the current study, around 60% of the proteins in the 
proteomic experiments performed were identified with at least two peptide matches. 
This percentage coincides with quantitative iTRAQ analysis of Escerichia coli cells 
(Aggarwal et al., 2005). Although protein identification based on multiple peptide 
matches improves confidence of the identification and quantitation, more than one-third 
of the proteins in most iTRAQ studies conducted so far have been identified using only 
one peptide (Aggarwal et al., 2006).  
Despite the ability of iTRAQ to detect low abundance proteins, incomplete MS spectra 
and the use of overly stringent identification criteria would result in missed 
identifications (Bell et al., 2009). Another commonly encountered issue encountered in 
iTRAQ is the non-random missingness. Missingness refers to the loss of data when 
peptides are observed at different intensities in different samples (Luo et al., 2009). The 
probability that a protein is missing is not random, but depends on the abundance of the 
protein. Low abundance peptides are more likely to be missed due to the data 
acquisition of the analysis process (Liu et al., 2004). These might explain the inability 
of the iTRAQ approach in our study to detect seven of the transcription factor 
investigated by real-time PCR (Section 3.5.3).  
Surprisingly, none of the haemoglobin gamma subunits were identified among the 
differentially expressed proteins in either the healthy or thalassaemic cultures treated 
with decitabine. In fact, the expression levels of both haemoglobin gamma subunits in 
the presence of decitabine remained at similar levels to the un-treated counterparts in 
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both healthy and thalassaemic cultures. In contrast, HPLC analysis of the same cultures 
demonstrated an increase of 1.7-fold in the percentage of HbF after treatment with 
decitabine. The lack of detection of significant changes in haemoglobin gamma subunit 
levels in our proteomic analysis might be attributed to variations within biological 
replicates. While averaging of replicates to produce a single measure is acceptable, it 
leads to loss of information about variability. Averaging of replicates was performed in 
the current study which might have resulted in loss of information. In addition, both 
haemoglobin gamma subunits were identified with only a single unique peptide despite 
the large sequence coverage observed, rendering the haemoglobin gamma subunits as 
low-abundant proteins. Since peptides from more abundant proteins (haemoglobin beta 
subunit) are more frequently selected than peptides from low abundant proteins 
(haemoglobin gamma subunit) by the instrument, this questions the accuracy of the 
measurement for low abundant proteins. In addition, the limited unique peptide matches 
for haemoglobin gamma subunits might be attributed to sequence similarities between 
the haemoglobin beta and gamma subunits. Peptides that originated from the 
haemoglobin gamma subunit but were homologous to haemoglobin beta sequence 
might have been wrongly assigned (i.e. haemoglobin beta subunit).  
Despite the presence of limitations in the accuracy, precision and reproducibility of 
proteomic approaches, a global protein profiling approach eliminates the need to study 
drug-induced response of individual cellular pathways and provides a common platform 
for the simultaneous detection of thousands of drug-related changes in proteins. This 
allows the generation of new hypotheses for testing of potential pathways and targets 








3.7. Lentiviral shRNA-mediated knock-downs of selected proteins  
3.7.1. Introduction 
Proteomic analysis performed on erythroid cultures identified 27 proteins that were 
significantly differentially expressed in response to decitabine (Table 22). The aim was 
to investigate their potential role on the expression of the γ-globin genes and their 
association with the action of decitabine. Due to time constrains, the role of all 27 
proteins could not be investigated. Instead, we targeted 17 proteins (Table 23): 6 
proteins (USP11, PSMB10, RCBTB2, TAF9, TMEM19, EGLN2), from the list of 27, 
were selected with the aim of investigating the role of different biological pathways 
potentially involved in mediating HbF inducing activity of decitabine. The remaining 11 
proteins were selected based on their differential expression in the healthy treated/un-
treated and thalassaemic treated/un-treated ratios (ratio 1 & 2, Section 3.6): 5 proteins 
(CHUK, PYCARD, HTATIP2, HEXIM1, ARHGAP4) were significantly differentially 
expressed only in healthy cultures (i.e. treated/un-treated, ratio 1), 5 (BAZ1B, CHD5, 
PPP5C, SMARCD3, TACC3) only in thalassaemic cultures (i.e. treated/un-treated, ratio 
2) and 1 protein (S100A8) was expressed at higher levels in healthy treated over 
thalassaemic treated cultures (ratio 4). In order to investigate the effect of each protein, 
lentiviral shRNA-mediated knock-down experiments were performed for each protein 
in primary human erythroid progenitor cells from healthy donors in the presence and 
absence of decitabine.  
 
3.7.2. The effect of lentiviral shRNA-mediated knock-down of 17 target proteins on 
γ-globin expression 
Five different shRNAs were screened simultaneously for each protein to ensure that at 
least two of the shRNAs would be successful in knocking-down gene expression. All of 
the shRNAs were incorporated in the pLKO.1 vector. As a negative control and 
reference sample, the pLKO.1 vector containing a scrambled insert was used to 
eliminate any transduction-mediated effects. Primary human erythroid cultures from 
healthy donors were set up according to the previously defined protocol (Section 3.1). 
On the fourth day of the EPO-dependent phase II of the cultures, transduction of 







Table 23, List of differentially expressed proteins that were selected for further investigation of their effect on γ-globin gene expression in the presence and 
absence of decitabine. Ratios of up- or down-regulation of the proteins are presented along with the function of each protein. The ratios represent the fold change 
in expression of proteins between different cultures as described in section 3.6.2. The arrows demonstrate whether the protein is up- (↑) or down- (↓) regulated 
in each ratio. 


















P51784 Ubiquitin carboxyl-terminal hydrolase 11 USP11 ↑ 1.652 ↓ 0.706 
    
ubiquitin/NF-κB 
P40306 Proteasome subunit beta type-10 PSMB10 ↑ 1.289 ↓ 0.687 
    
ER stress 
O95199 RCC1 and BTB domain-containing protein 2 RCBTB2 ↑ 1.248 ↓ 0.682 
    
unknown 
Q16594 Transcription initiation factor TFIID subunit 9 TAF9 ↓ 0.805 ↓ 0.598 
    
transcription 
activation/repression 
Q96HH6 Transmembrane protein 19 TMEM19 ↓ 0.544 ↑ 2.099 
    
NRF2/KEAP1 (?) 
Q96KS0 Egl nine homolog 2 EGLN2 ↓ 0.758 ↓ 0.905 
  
↑ 1.567 
activation of NF-κB/oxygen 
sensor 
O15111 
Inhibitor of nuclear factor kappa-B kinase 
subunit alpha 
CHUK ↓ 0.703 
    
↑ 1.588 NF-κB/CREBBP activation 
Q9UIG0 Tyrosine-protein kinase BAZ1B BAZ1B 
  




Apoptosis-associated speck-like protein 
containing CARD 
PYCARD ↑ 1.289 
      
apoptosis/inhibit CHUK 
Q9BUP3 Oxidoreductase HTATIP2 HTATIP2 ↑ 1.262 
      






HEXIM1 ↓ 0.666 
      
RNA polymerase II 
transcription inhibitor 
P98171 Rho-GTPase activating protein4 ARHGAP4 ↓ 0.766 
      
Rho-like GTPase 
Q8TD10 Chomodomain-helicase binding protein 5 CHD5 
  
↓ 0.545 
    
chromatin remodelling/NURD-
like complex 
P53041 Serine/threonine-protein phosphatase 5 PPP5C 
  
↑ 1.111 
    
inhibits ASK1/MAP3K5/ERK 
Q6STE5 
SWI/SNF related matrix associated actin 





    
ATP dependent nucleosome 
remodelling 
Q9Y6A5 





    
FOG1interacting protein 
P05109 Protein S100-A8 S100A8 






In order to allow recovery of the cultures and maximum knock-down of the proteins, 
decitabine was added on the sixth day of EPO-dependent phase II, i.e. two days after 
transduction of primary human erythroid cultures, at a concentration of 300nM.  HPLC 
analysis confirmed that both of the primary human erythroid cultures set up from 
healthy donors for lentiviral shRNA-mediated knock-downs, were good responders to 
decitabine (Table 24). The HbF percentage doubled after decitabine treatment in both 
cultures.    
 
Table 24, Levels of HbF induction in primary human erythroid cultures treated with 300nM 
decitabine. The HbF percentage of the primary human erythroid cultures used for lentiviral 
shRNA-mediated knock-downs was determined before and after the addition of the decitabine 





Before investigating the effect of knocking-down each of the above 17 proteins, the 
effectiveness of each shRNA in reducing the mRNA levels of each corresponding gene 
was investigated by real-time PCR. Knock-down of each gene was considered 
successful when more than one shRNA clone was capable of reducing the mRNA levels 
of that gene. This will allow the elimination of false positive results. A threshold of 20% 
was used as an effective reduction level in the gene expression for an shRNA. The 
number of effective shRNAs for each protein is listed in Figure 47. 
The shRNAs destined for four genes were not considered successful in knocking-down 
their respective gene expression. In the case of TACC3 and RCBTB2 genes, in fact, 
there was an increase rather than a decrease in the expression levels of the genes relative 
to the pLKO.1 scramble control (ratio of 1) as shown by qRT-PCR (Figure 47). In the 
case of PSMB10 and PYCARD genes, shRNAs were able to decrease gene expression 





                                                                                                       
Healthy 
donors 
HbF levels (%) % increase in 
HbF un-treated 300nM Dec 
1 11.14 26.38 136.80 
2 3.32 20.28 510.80 
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                                                                                                                   0                50             100 
Figure 47, Heat map showing the reduction in gene expression of the 16 proteins mediated by 
each of their 5 shRNAs. Each row of the heat map represents the 5 shRNAs used for knock-
down of each protein and the percentage reduction in their mRNA. The scale of reduction is 
indicated from 0 for no reduction in mRNA levels, to 100 for complete loss of mRNA 
production. The last column to the right indicates the number of successful shRNAs for each 
protein; a 20% reduction in mRNA levels was used as the threshold for successful protein 
knock-down. The data represent the average of triplicates of one biological replicate for each 
shRNA in primary human erythroid cultures from healthy donors. Note: Only 16 of the 17 
genes are shown, since it was not possible to examine the expression levels of CHD5 due to 
failure of two sets of primers to detect any products by quantitative real-time PCR.  
 
For the remaining 12 proteins (S1000A8, TAF9, ARHGAP4, EGLN2, TMEM19, 
CHUK, SMARCD3, USP11, PPP5C, HTATIP2, HEXIM1 and BAZ1B) that could be 
knocked-down, we initially assessed the changes in mRNA levels of the genes under 
investigation in un-transduced (without knock-down) but decitabine treated primary 
human erythroid cultures (Figure 48A), followed by the effect of the shRNAs with and 
without decitabine treatment on the expression of the gene itself (Figure 48B) and on γ-






 1 2 3 4 5 
 S100A8 51.17983758 -12.26222 -240.55422 50.25217 
 
2 
PSMB10 -162.3595853 -92.422566 6.4945734 -77.027869 
 0 
TAF9 87.03744514 59.35947 83.47049 50.94225 73.3780252 5 
ARHGAP4 70.27614792 23.428523 100 58.508794 86.26573129 5 
EGLN2 57.1202916 63.123682 -76.815715 55.492188 19.99716665 4 
TMEM19 -41.17459573 -46.843001 46.006019 49.367733 32.66037931 3 
CHUK 54.54843108 52.3871 -11.5416 29.57864 -1.4123251 2 
SMARCD3 35.35812279 51.269971 5.8886259 46.081379 -1.118817667 3 
USP11 45.6168358 64.871132 90.654669 91.98975 73.73688401 5 
TACC3 -240.4582752 -75.18503 -118.90266 -10.036793 -150.9557496 0 
PPP5C 63.77933347 63.61228 89.14636 60.94523 64.7460211 5 
RCBTB2 -180.1244673 -858.72131 -316.22828 -98.571696 -473.7578551 0 
HTATIP2 36.90948642 16.428149 -26.949261 21.102828 4.232137958 2 
HEXIM1 31.2566054 65.192382 37.242143 18.56505 -14.31201112 3 
PYCARD 5.273006581 -44.743895 -6.4034921 5.7689124 -3.486422685 0 
BAZ1B 21.65011838 -68.9517 -9.30194 36.12304 -43.491323 2 




                 
                                                                                          
 
                 
                                                                   
 
 
                







Un-transduced and decitabine treated 
shRNA transduced and decitabine treated 
shRNA-transduced and decitabine treated 
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Figure 48, mRNA levels of genes under investigation and γ-globin in un-transduced and 
shRNA-transduced primary human erythroid cultures from healthy donors, in the presence and 
absence of decitabine. (A) Changes in gene expression levels of the genes under investigation in 
un-transduced primary human erythroid cultures following treatment with decitabine. Lentiviral 
shRNA-mediated knock-down of each gene was carried out in primary human erythroid 
cultures, where the effect on gene expression levels of each gene under investigation (B) and γ-
globin (C) were investigated by quantitative real-time PCR. The mRNA levels in A are 
expressed as fold change relative to the un-transduced cultures (ratio of 1, dotted line) while the 
mRNA levels in B & C are expressed as fold change relative to the culture transduced with 
control shRNA (ratio of 1, dotted line). The results represent the average of all effective 
shRNAs (2-5 clones) corresponding to each protein, that were originated from a single 
experiment from one biological replicate. Error bars correspond to the standard deviation. * 
correspond to statistically significant (p-value <0.05) changes in gene expression in the presence 
of decitabine when compared to the un-treated samples transduced with the corresponding 
shRNA for each protein according to the paired t-test.  
 
        
Figure 49, Western blot analysis of HBG expression levels in primary human erythroid cultures 
from healthy donors transduced with shRNA expressing lentivirus for each of the 12 genes 
(horizontal axis) under investigation, in the absence (blue bars) and presence (red bars) of 
decitabine. HBG expression levels are expressed as a fold change relative to the culture 
transduced with control shRNA (dotted line, ratio of 1). The results represent the average fold 
change of HBG levels for all the effective shRNAs that correspond to each protein. Error bars 
correspond to the standard deviation. * corresponds to statistically significant (p-value<0.05) 






Treatment of un-transduced primary human erythroid cultures with decitabine increased 
the expression levels of ARHGAP4, EGLN2, CHUK, USP11, PPP5C, HTATIP2 and 
BAZ1B along with HBG. The expression levels of the remaining genes remained 
unaffected by decitabine, with the exception of TAF9, whose expression decreased after 
treatment (Figure 48A and Table 25).     
Looking at each of the knocked-down genes individually, it was observed that reduced 
expression of S100A8 gene did not affect HBG expression levels (Figure 48B). 
Decitabine treatment of primary human erythroid cultures already transduced with the 
effective shRNA clones, resulted in a significant (p-value<0.05) increase in the 
expression level of S100A8 itself along with a substantial increase in HBG expression 
(Figure 48B & C). This suggests that decitabine might increase expression of the gene 
enough to overcome the knock-down effect. However, this was not represented by the 
response of S100A8 to decitabine in un-transduced samples, which did not change 
relative to the un-treated control (Figure 48A). Western blot analysis, in contrast to the 
real-time PCR, showed an increase in HBG expression after reducing the expression 
levels of S100A8, which was enhanced after treatment with decitabine (Figure 49).    
Knock-down of TAF9 reduced HBG expression in the absence of decitabine. Following 
decitabine treatment, there was a significant increase in the mRNA levels of the gene to 
similar levels as the negative control (Figure 48B) and an increase in HBG expression 
(Figure 48C). Interestingly, decitabine seems to decrease TAF9 expression in the 
absence of shRNAs (Figure 48A). Western blot analysis showed completely opposite 
results to the real-time PCR analysis, with an increased HBG expression following 
knock-down of TAF9 which decreases after treatment with decitabine (Figure 49).  
Decitabine treatment of primary human erythroid cultures prior to knock-down, 
increased ARHGAP4 expression by approximately 4-fold above the levels of the un-
treated control (Figure 48A). Reduced expression of ARHGAP4 led to reduced HBG 
mRNA levels in the absence of decitabine (Figure 48C) while maintained HBG 
expression to similar levels to the negative control (Figure 49). In the presence of 
decitabine, ARHGAP4 increased slightly but still remained suppressed (Figure 48B) by 
the shRNAs while increased γ-globin expression both at the mRNA (Figure 48C) and 
protein level (Figure 49).  
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EGLN2 gene expression increased following decitabine treatment in un-transduced 
primary human erythroid cultures (Figure 48A). Knock-down of EGLN2 in the absence 
of decitabine was accompanied by an increase in HBG expression (Figure 48C). 
Following treatment with decitabine, EGLN2 expression increased slightly but remained 
suppressed in the presence of the shRNA clones (Figure 48B), while HBG mRNA 
expression increased further (Figure 48C). HBG protein expression was increased 
following reduction of EGLN2 and was further increased non-significantly in the 
presence of decitabine (Figure 49).  
TMEM19 and HEXIM1 expression remained unchanged after decitabine treatment in the 
absence of shRNAs (Figure 48A). Reduced expression of both genes resulted in a small 
reduction in HBG expression in the absence of decitabine. Treatment with the agent 
increased both the expression of the genes themselves (Figure 48B), significantly in the 
case of HEXIM1, and HBG expression (Figure 48C). At the protein level, HBG 
expression was reduced following knock-down of both genes which was increased 
above the negative control only in the case of HEXIM1 following treatment with 
decitabine (Figure 49).  
CHUK expression increased following decitabine treatment in both un-transduced 
(Figure 48A) and transduced cultures (Figure 48B). However, the increase in expression 
in the presence of shRNAs was only minimal (Figure 48B). Knock-down of CHUK 
expression was associated with a decrease in γ-globin expression at both the mRNA 
(Figure 48C) and protein level (Figure 49) in the absence of decitabine. Western blot 
analysis demonstrated an increase in HBG expression following decitabine treatment in 
the presence of CHUK knock-down (Figure 49).  
SMARCD3 was the only gene that showed further decrease in expression after shRNA 
transduction and decitabine treatment (Figure 48B), a decrease that was statistically 
significant (p-value<0.05). The decreased SMARCD3 expression was accompanied by a 
small increase in HBG expression (Figure 48C) which was not substantial at the protein 
level (Figure 49).  
USP11 showed the highest increase in expression following decitabine treatment in un-
transduced primary human erythroid cultures (Figure 48A). In the presence of 
decitabine, USP11 gene expression also increased above the levels of the negative 
control despite the successful knock-down of the gene by shRNAs (Figure 48B). The 
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increased expression of USP11 following decitabine treatment, was accompanied by a 
significant (p-value<0.05) increase in γ-globin expression (Figure 48C). Up-regulation 
of HBG expression in the presence of decitabine was also observed at the protein level 
(Figure 49). This was confirmed by the proteomic analysis which showed an increased 
expression of USP11 in healthy cultures following decitabine treatment. Interestingly, 
USP11 was significantly decreased in thalassaemic cultures treated with decitabine as 
shown by the proteomic analysis (Table 23).  
Knock-down of PPP5C expression reduced HBG expression in the absence of 
decitabine. After treatment with decitabine, PPP5C gene expression remained 
unchanged (Figure 48B). In contrast, there was a large and significant (p-value<0.05) 
up-regulation of HBG expression following decitabine treatment (Figure 48C).  
However, this was not represented at the protein level (Figure 49), where in fact a 
decrease was observed in HBG expression following treatment with decitabine.   
HTATIP2 and BAZ1B expression increased after treatment with decitabine in un-
transduced primary human erythroid cultures (Figure 48A). Knock-down of both genes 
was accompanied by reduced expression of HBG expression in the absence of 
decitabine (Figure 48C). Treatment with decitabine not only increased the expression of 
HBG (Figure 48C) but also increased both gene expression levels (Figure 48B). The 
increase in HTATIP2 expression was significant following treatment with decitabine. 
Western blot analysis showed opposite results to the real-time PCR experiments for 
both genes, with decitabine treatment resulting in decreased HBG expression (Figure 
49).    
Despite the lack of statistical significance in the changes of HBG expression by 
decitabine after transduction of primary human erythroid cultures with shRNA against 
ARHGAP4, ELGN2, HEXIM1, S100A8 and SMARCD3, western blot analysis has shown 
some interesting results (Figure 50 and 51).     
Down-regulation of ARHGAP4 with shRNA 47192 (clone 5) resulted in the up-
regulation of HBG expression in un-treated cultures. Treatment with decitabine showed 
an increase in HBG expression with shRNA 47188 (clone 1) and shRNA 47190 (clone 
3) (Figure 50A) while maintaining reduced expression of ARHGAP4 gene expression 
(Figure 49B). The high HBG expression in the presence of shRNA 47192 (clone 5) 
remained at similar levels in the presence of decitabine. All of the shRNAs for this gene 
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are targeting within the coding sequence of the gene. Proteomic analysis showed a 
decrease in ARHGAP4 protein expression in healthy cultures in the presence of 
decitabine (Table 23) suggesting an inverse association between ARHGAP4 gene and γ-
globin expression. However, this is in contrast to the increase observed in ARGHAP4 
mRNA levels after treatment with decitabine in un-transduced cultures (Figure 48A).   
Down-regulation of EGLN2 gene expression by shRNA 22324 (clone 1), 22327 (clone 
4) and 22328 (clone 5), resulted in up-regulation of HBG expression in the absence of 
decitabine (Figure 50B) suggesting an inverse relation of the protein with γ-globin 
expression. Once treated with decitabine, HBG expression was increased further for 
shRNA 22324 (clone 1) as well as for shRNA 22325 (clone 2) but was reduced for 
shRNA 22328 (clone 5). shRNA 22324 (clone 1) targets the 3’ UTR of the gene while 
shRNA 22328 is targeting the coding sequence of the gene. The reduced expression of 
HBG might be due to the removal of inhibition by decitabine through induction of 
transcription of the gene. A small increase in EGLN2 expression was observed at the 
mRNA level in the presence of decitabine (Figure 48A). However, proteomic analysis 
showed that EGLN2 protein was down-regulated in both healthy and thalassaemic 
cultures treated with decitabine (Table 23). 
Down-regulation of HEMIX1 gene expression reduced HBG expression with shRNA 
74173 (clone 1) and shRNA 74174 (clone 2) in the absence of decitabine (Figure 50C). 
HBG expression increased after treatment with decitabine in the presence of both 
shRNAs. Since there is a significant increase in HEXIM mRNA level with both shRNA 
after addition of decitabine (Figure 48B), the increase in γ-globin expression may be 
attributed to the increase in HEXIM1 (Figure 48B). In contrast, proteomic analysis 
showed reduced levels of HEXIM1 in healthy cultures when treated with decitabine 
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Figure 50, Western blot analysis investigating the HBG levels of expression in primary human 
erythroid cultures from a healthy donor transduced with shRNAs for ARHGAP4 (A), ELGN2 
(B) and HEXIM2 (C) in the absence and presence of 300nM decitabine. HBG expression was 
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Figure 51, Western blot analysis investigating the HBG levels of expression in primary human 
erythroid cultures from a healthy donor transduced with shRNAs for S100A8 (A) and 
SMARCD3 (B) in the absence and presence of 300nM decitabine. HBG expression was 
normalised to the endogenous GAPDH expression.  
 
Down-regulation of S100A8 expression with shRNAs 53774 (clone 1) and 53777 (clone 
4) (Figure 51A), resulted in a small increase in HBG expression relative to pLKO.1 
scramble in un-treated cultures, which was further enhanced in the presence of 
decitabine. Although not statistically significant, the increase in γ-globin expression was 
observed at both the mRNA (Figure 48C) and protein level (Figure 49) following 
addition of decitabine. S100A8 gene expression levels were also increased significantly 
in the presence of decitabine (Figure 48B) suggesting a loss of repression of the S100A8 
gene in the presence of decitabine. As shown by the proteomic analysis (Section 3.6), 
S100A8 protein was expressed more in healthy rather than in thalassaemic cultures 
treated with decitabine (Table 23), and was slightly increased in healthy cultures in the 

































































































































































































































































































Moreover, reduction of SMARCD3 expression by shRNA 147806 (clone 2)  and 179523 
(clone 4) (Figure 51B) resulted in reduced or similar levels of HBG with pLKO.1 
scramble suggesting no major effect of this gene on γ-globin expression. However, 
treatment with decitabine resulted in significantly lower expression levels of SMARCD3 
(Figure 48B) while maintaining or increasing slightly HBG expression (Figure 51B). 
This suggests that SMARCD3 might be an inhibitor of γ-globin expression so that when 
decitabine reduces its expression the inhibition is reversed. The small increase in γ-
globin expression might suggest that SMARCD3 might act through interaction with 
other factors and reversion of inhibition might not be high enough to promote high γ-
globin induction. In contrast to the real-time PCR, proteomic analysis showed an 
increased (although marginal) in SMARCD3 expression in thalassaemic cultures when 
treated with decitabine (Table 23) while remained unchanged in healthy cultures.     
 
Table 25, Summary of the effect of knock-down of the 12 genes under investigation on the gene 
itself and γ-globin expression in primary human erythroid cultures from healthy donors. 
Initially, the changes in mRNA levels of the genes under investigation were assessed in un-
transduced (without knock-down) but decitabine treated primary human erythroid cultures, 
followed by the effect of shRNAs with and without decitabine treatment on the expression of 
the gene itself and on γ-globin expression. The table represents the fold changes in the mRNA 
and protein levels in the presence of decitabine relative to the un-treated control. * demonstrates 
the statistically significant changes (p-value<0.05) according to the paired t-test.  
 




















S100A8 0.91 8.87* 1.18 5.72 4.88 
TAF9 0.25 4.97* 0.81 7.63 0.21 
ARHGAP4 3.60 2.05 0.77 2.03 2.00 
EGLN2 1.95 1.51 0.75 1.16 1.14 
TMEM19 1.02 2.20 0.54 2.17 1.96 
CHUK 1.95 1.49 0.70 1.17 1.97* 
SMARCD3 0.99 0.53* 1.07 1.83 1.32 
USP11 9.52 9.23 1.65 11.51* 3.96 
PPP5C 1.54 1.27 1.01 21.22* 0.38 
HTATIP2 1.72 2.54* 1.26 1.75 0.28 
HEXIM1 0.94 2.99* 0.67 2.38 3.53 
BAZ1B 2.57 6.89 1.16 5.30 0.54 
 





3.7.3. Discussion    
Based on the proteomic analysis, 17 proteins were selected for further investigation of 
their effect on γ-globin expression in primary human erythroid cultures using shRNA 
technology. Among the 17 genes, the expression of TACC3, PSMB10, RCBTB2 and 
PYCARD could not be repressed efficiently with any of the shRNA tested and were 
therefore excluded from the analysis. shRNAs within plasmids require nuclear 
penetration and translational processing to produce the hairpin shRNA for Dicer 
processing (Siolas et al., 2005). The lack of effective knock-down might be due to 
ineffective penetration of the plasmid into the cells and ineffective expression of the 
plasmids or due to the presence of a regulatory feedback for the genes that leads to 
increased mRNA levels even after transduction. In addition, quantitation of the 
expression levels of gene CHD5 was not possible. CHD5 was therefore excluded from 
the study too due to lack of confirmation of the shRNA’s effectiveness. 
Successful repression of gene expression for the remaining twelve genes was shown by 
quantitative real-time PCR. In the absence of decitabine, reduced expression of the 
genes under investigation was accompanied by either a reduction or no change in γ-
globin gene expression in primary human erythroid cultures. The only exception was 
EGLN2, whose reduction resulted in an up-regulation of γ-globin gene expression at 
both the mRNA and protein levels in the absence of decitabine. Treatment with 
decitabine resulted in a statistically significant up-regulation of S100A8, TAF9, 
HTATIP2 and HEXIM1 gene expression and a statistically significant down-regulation 
of SMARCD3 gene expression in transduced primary human erythroid cultures (Table 
25). Moreover treatment with decitabine in the presence of the shRNAs resulted in a 
significant increase in γ-globin gene expression in USP11 and PPP5C knock-down 
cultures. This effect was only confirmed at the protein level for USP11 (Table 25).  
USP11 expression increased profoundly after decitabine treatment in both un-
transduced cultures and in the presence of the shRNA (Table 25). This was confirmed 
also in the proteomic analysis where USP11 protein was significantly increased in 
primary human erythroid cultures from healthy donors treated with decitabine. USP11, 
a de-ubiquitinating enzyme, was recently shown to inhibit ΤΝFα-induced activation of 
NF-κB pathway and to regulate IKKα by a de-ubiquitination-independent mechanism 
(Yamaguchi et al., 2007a) (Figure 52).  CHUK, known as the inhibitor of nuclear factor 
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kappa-B kinase subunit alpha (IKKα), was the only gene whose down-regulation 
resulted in a statistically significant, yet small, increase in HBG expression in the 
presence of decitabine (Table 25). In contrast to the real-time PCR results, proteomic 
analysis demonstrated a decrease in CHUK expression in healthy cultures treated with 
decitabine. Apart from its involvement in NF-κB pathway, IKKα was recently shown to 
regulate the ROS-induced activation of the p53 tumour suppressor following activation 
by the protein kinase Cδ (Yamaguchi et al., 2007b) (Figure 52). 
Western blot analysis suggests that ARHGAP4, EGLN2, HEXIM1, S100A8 and 
SMARCD3 genes might be involved in the mechanisms of action of decitabine in 
reactivating γ-globin expression.  
ARHGAP4 (p115 RhoGAP) encodes for RhoGTPase activating protein 4 that prevents 
the association of MEKK1 with components of the JNK MAP kinase (Christerson et al., 
2002) and promotes PRL-1 mediated ERK1/2 and RhoA activation (Bai et al., 2011) 
(Figure 53). ARHGAP4 is a potent inhibitor of cell and axon motility (Vogt et al., 
2007) that is known to inhibit the formation of stress fibres. In addition, ARHGAP4 has 
been found to be highly expressed in cells of haematopoietic origin including the K562 
cell line (Tribioli et al., 1996). ARHGAP4 gene was one of the genes found to be 
induced after hydroxyurea administration leading to signal transduction and 
transcriptional activation of down-steam targets (Costa et al., 2007). Reduced 
expression of ARHGAP4 leads to activation of MEKK1 which in turn activates 
transcriptional regulator AP-1 and NF-κB, MAP kinase cascades, the c-Jun-N-terminal 
kinase/stress activated protein kinases and to a lesser extent ERK1/2. In the current 
study, decitabine treatment increased the mRNA levels of ARHGAP4 in un-transduced 
cultures but down-regulated ARGHAP4 protein in proteomic analysis of healthy 
cultures treated with decitabine. Knock-down of ARHGAP4 gene expression resulted in 
induction of HBG expression in the presence of the agent suggesting an inverse relation 
between the gene and γ-globin expression.  
EGLN2, also known as prolyl-4-hydroxylase (PHD1), is responsible for post-
translational modification of prolines on specific target proteins (Moser et al., 2013). 
Under normoxic conditions HIFa is hydroxylated by PHD1-3, which is then recognised 
by the von Hippel-Lindau protein E3 ubiquitin ligase complex and targeted for 
proteosomal degradation. Hypoxia reduces the propyl-hydroxylation by PHDs resulting 
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in stabilization of the HIF complex leading to transcriptional activation of downstream 
genes including EPO (Figure 52). While inhibition of EGLN2 alone did not cause 
significant effects on EPO induction, knock-down of EGLN1 and ELGN2 have a 
synergistic effect on EPO induction in Hep3B cells (Fisher et al., 2009) and in mice 
(Minamishima and Kaelin, 2010). Moreover, Moser et al. (2013) have shown that 
EGLN2 is required for centrosome duplication and maturation through hydroxylation of 
Cep192 leading to regulation of cell cycle progression in the presence of hypoxia. Over-
expression of EGLN2 inhibited NF-κB activity through negative regulation of IKKβ 
(Cummins et al., 2006)(Figure 53), suggesting an inhibitory role of EGLN2 on NF-κB 
leading to cell cycle arrest through NF-κB-mediated regulation of cyclin D1 (Xie et al., 
2014b) (Figure 52). In the current study, treatment of primary human erythroid cultures 
from healthy and thalassaemic donors with decitabine resulted in down-regulation of the 
EGLN2 protein while it increased EGLN2 mRNA levels. Knock-down of EGLN2 in 
primary human erythroid cultures led to increased HBG expression at the protein and 
mRNA level (Table 25).    
 
 
         
 
Figure 52, Schematic diagram demonstrating the involvement of 14 shRNA-targeted proteins in 
the pathways potentially affected by decitabine. The proteins surrounded by a red circle are 
among the 17 proteins selected for shRNA-mediated knock-downs. 
204 
 
        
Figure 53, Schematic diagram demonstrating the function of ARHGAP4, EGLN2, HEXIM, 
USP11, SMARCD3 and S100A8 proteins. The red arrows demonstrate whether the proteins 
were up- or down-regulated based on the proteomic analysis of primary human erythroid 
cultures from healthy donors treated with decitabine (ratio 1).  
 
HEXIM1 gene encodes a hexamethylene bisacetamide-inducible protein 1, an inhibitor 
of positive transcription elongation factor b (P-TEFb) which controls transcription 
elongation of RNA polymerase II (Lew et al., 2013) (Figure 52 and 53). HEXIM1 
directly regulates HIF-1a protein by up-regulating hydroxylation, interacts with pVHL 
and leads to ubiquitination of HIF-1a. It can also regulate HIF-1a acetylation by 
attenuating its interaction with HDAC1. Yeh et al. (2013) showed that HEXIM1 
prevents p53 ubiquitination by competing with HDM2 binding to p53. Besides P-TEFb, 
HEXIM1 binds to histone deacetylases along with MyoD (Galatioto et al., 2010) and 
directly interacts with the p65 subunit of NF-κB and subsequently inhibits the 
transcriptional activity of NF-κB (Ouchida et al., 2003) (Figure 52 and 53). Moreover, 
Turano et al. (2006) demonstrated that induced expression of HEXIM1 leads to terminal 
differentiation of MEL cells and promotes cell cycle arrest. In the current study, 
proteomic analysis showed a decrease in HEXIM1 protein expression in healthy 
cultures treated with decitabine, while HEXIM1 mRNA levels increased in the presence 
of decitabine with a parallel increase in HBG expression (Table 25).  
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S100A8 is a low molecular weight acidic protein with two EF domains and is associated 
with chronic inflammatory diseases (Passey et al., 1999). Most S100 proteins exist in 
the form of homodimers or heterodimers within cells and interact with several effector 
proteins mostly in a Ca
2+
 dependent manner leading to regulation of enzyme activities, 
the dynamics of cytoskeleton constituents, cell growth and differentiation and Ca
2+
 
homeostasis (Donato, 2003). In particular, S100A8/A9 inhibits casein kinase II which is 
involved in phosphorylation of substrates necessary for cellular transcription and 
translation such as nuclear oncogenes, RNA polymerase II and topoisomerase (Murao et 
al., 1989) (Figure 53). In addition, S100A8/A9 complexes stimulate the production of 
proinflammatory cytokines such as TNFa, a function that is suppressed significantly by 
p38 MAPK and NF-κB inhibitors (Sunahori et al., 2006) (Figure 53). Moreover, 
S100A8/A9 down-regulates G2/M cell cycle progression and cell survival by increasing 
phosphorylation of Cdc2 by PP2A (Khammanivong et al., 2013) (Figure 52). S100A8 
and S100A9 were among the genes found to be up-regulated significantly in erythroid 
precursors in patients with sickle cell disease following treatment with hydroxyurea 
(Costa et al., 2007). In the current study, proteomic analysis showed lower expression 
of the S100A8 in treated thalassaemic cultures when compared to treated healthy 
cultures. Down-regulation of S100A8 has a minimal affect the γ-globin gene levels. 
However, treatment with decitabine resulted in up-regulation of both S100A8 and HBG 
expression (Table 25), suggesting the activation of targets bypassing S100A8 might 
lead to γ-globin induction.  
SMARCD3 (Baf60c) is a subunit of a chromatin remodelling complex known as 
SWI/SNF, that utilises energy from ATP to dissociate DNA-histone contacts therefore 
providing access to chromatin of silent loci. During myogenic differentiation, BAF60c 
is phosphorylated by p38α kinase, promoting the incorporation of MyoD-BAF60c 
complex into a Brg1-based SWI/SNF complex, remodelling of chromatin and 
subsequent activation of transcription of MyoD-target genes (Forcales, 2012) (Figure 
53). In addition, BAF60c physically interact with PPARγ and BRG1 in vivo along with 
other nuclear receptors and transcription factors leading to recruitment of SWI/SNF 
complex and induction of remodelling of their target genes (Debril et al., 2004). Here 
we show that down-regulation of SMARCD3 slightly reduced HBG gene expression 
(Table 24). Upon stimulation with decitabine, SMARCD3 expression dropped 
significantly while maintaining or increasing slightly γ-globin expression (Table 25), 
suggesting a subtle inhibitory role of SMARCD3 gene on γ-globin gene expression.  
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Our results show poor correlation between gene transcription levels with protein levels. 
Despite the development of methods for global gene expression analysis, it has been 
shown experimentally that the mRNA level of a particular gene does not reflect the 
amount of the corresponding protein expressed in the same cells (Anderson and 
Seilhamer, 1997, Gygi et al., 1999b). This was previously attributed to the inability of 
mRNA transcripts to predict post-transcriptional modifications that affect the protein 
abundance in the cells (Vogel et al., 2010, Vogel and Marcotte, 2012). Proteins are 
therefore considered as the direct effectors of cellular behaviour rather than their DNA 
and mRNA templates. For some proteins, constant translation is not required due to 
their high stability. Thus it is possible that the long half life of proteins in addition to the 
low proliferating capacity of the primary human erythroid cultures at the end of the 
experiment could explain the variability in expression between mRNA and protein 
levels. Although characterisation of protein steady state level provides the most 
immediate assessment of cellular function capacity, differences between different states 
of biological systems, i.e. presence and absence of decitabine, cannot be explained just 
by simply looking at single genes and corresponding proteins. The function and 
behaviour of biological systems are mainly governed by the interaction among proteins. 
Many of these interaction that control cellular behaviour are dependent on post-
translational modifications induced by cross-talk between canonical signalling 
pathways. 
Based on the above, further functional studies are required for confirmation of the effect 
of each protein on γ-globin expression in the presence of decitabine. In addition, the 
function of the above proteins has to be investigated further using second generation 
proteomics and interactomics in the presence of decitabine. This could provide some 
insights on the role of decitabine in the post-translational modifications and on protein-































Despite the fact that >70 compounds have been described as HbF inducers, their clinical 
use is limited due to low HbF inducing activity, high cytotoxicity and inability to elicit a 
response in all patients. Thus, identification of new agents with higher efficacy and 
reduced toxicity is imperative. In the current project two approaches have been 
employed with the aim of identifying potential HbF inducers. Initially, agents that are 
structurally similar to compounds with known HbF inducing activity were screened for 
identification of novel agents with potent HbF inducing activity. The second approach 
involved the investigation of the molecular pathways of a known HbF inducer with the 
aim of identifying potential targets for therapeutic manipulation and target based drug 
design. The conclusions of the current project are as follows: 
 
1. None of the eleven xanthines tested are effective inducers of foetal haemoglobin 
Based on the observation that intracellular levels of cAMP and phosphorylated CREB 
levels correlated with foetal haemoglobin in individual patients (Bailey et al., 2007) and 
that caffeine-mediated increase of Ca
2+
 activated CREB through the binding of   
Ca
2+
/cAMP response element in the promoter of CREB-dependent genes (Connolly and 
Kingsbury, 2010), eleven xanthines including caffeine were investigated as potential 
HbF inducers in murine and human erytholeukaemic cell lines. Most of the xanthines 
tested lacked HbF inducing activity. Only two xanthines (Zaprinast and PSB11) 
increased γ-globin promoter activity but this was accompanied by an increase in 
cytotoxicity of the compounds. As a result, none of the xanthines tested were 
appropriate HbF inducers.  
 
2. Resveratrol and its nine derivatives are not effective in reactivating foetal 
haemoglobin in primary human erythroid cultures despite the Hb inducing 
activity shown in K562 cell line. 
Apart from its antioxidant activities, resveratrol was found to inhibit ribonucleotide 
reductase more efficiently than HU, a bench mark HbF inducer (Ware and Aygun, 
2009). Resveratrol has also been shown to stimulate the expression of γ-globin gene and 
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foetal haemoglobin (HbF) (Fibach et al., 2012). We therefore investigated the role of 
resveratrol and nine of its derivatives in K562 cells and primary human erythroid 
cultures as potential HbF inducers. Despite promising results for resveratrol and three 
derivatives (P1, P4 and P11) in K562 cell line, none of the agents showed an ability to 
increase HbF levels in primary human erythroid cultures. In fact, resveratrol was shown 
to accelerate erythroid maturation rather than increasing the expression of the γ-globin 
gene. In order to enhance the HbF-inducing activity of these agents, we investigated the 
use of resveratrol in combination with another agent as a potential therapeutic approach. 
The combined use of resveratrol and decitabine increased the percentage of 
haemoglobin containing cells when compared to each agent alone but did not surpass 
the additive effect of the agents. The small increase obtained by the combination in 
addition to the non-significant change in cytotoxicity above the additive effect of the 
agents, suggests that the combined administration of two agents is a potential 
pharmacological approach to enhance their HbF-inducing activity.   
 
3. Decitabine was the most efficient HbF inducing agent among the four pre-
selected agents in both K562 cell line and primary human erythroid cultures 
Insufficient HbF induction is achieved with current pharmacological agents. In addition, 
none of the mechanisms of action of these agents is fully understood. We thus selected 
four HbF inducers (mithramycin, decitabine, angelicin and lenalidomide) and screened 
them in K562 cells and in primary human erythroid cultures to identify the most potent 
HbF inducer for delineation of its molecular mechanism of action. Screening of the four 
known HbF inducers in K562 cells indicated that decitabine was the agent with the 
highest HbF-inducing activity, while exhibiting moderate cytotoxicity. This was 
confirmed in primary human erythroid cultures from healthy and thalassaemic donors. 
Based on our results and the fact that the agent is already in use in clinical trials for the 






4. HbF induction in the presence of decitabine does not depend on the 
hypomethylating activity of the agent on the γ-globin promoter 
Since decitabine is a DNA methyltransferase inhibitor; we began characterising the 
effect of the agent on γ-globin reactivation by investigating the decitabine-mediated 
changes in DNA and histone methylation patterns of the β-globin locus. Methylation at 
Lysine 4 of H3 (H3K4me2) represents open chromatin structure and transcriptional 
activation. H3K4me2 patterns on the β-globin locus in primary human erythroid 
cultures grown in the absence of decitabine demonstrated low transcriptional activity at 
the globin gene promoters and an increased activity at the LCR. Low H3K4me2 at the 
γ-globin gene promoter with higher H3K4me2 at the β-globin promoter and LCR 
coincide with the developmental regulation of globin gene expression by the LCR 
(Figure 54). Treatment of primary human erythroid cultures with decitabine increased 
H3K4me2 levels at β-HS1 and β-HS4 but decreased β-HS3 and β-HS5 patterns, 
maintained similar levels at the γ-globin gene promoter and decreased H3K4me2 at the 
β-globin promoter. These findings suggest that modulation of globin gene expression 
occurs mainly through the HS sites rather than by direct action on the globin gene 
promoters (Figure 54). A similar pattern to histone methylation was observed for DNA 
methylation, with low MeCP2 binding at all globin gene promoters and high binding at 
the LCR. These DNA methylation patterns were in complete contrast to the function of 
MeCP2 as a transcriptional repressor, suggesting that MeCP2 acts as an activator rather 
than a repressor of transcription. DNA methylation patterns should be verified using an 
alternative method such as bisulphite sequencing.  
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Figure 54, Schematic diagram demonstrating the effect of decitabine on DNA and histone 
methylation in primary human erythroid cultures from healthy donors. In the absence of 
decitabine, moderate levels of H3K4me2 are found at the adult β-globin genes (δ and β) and 
LCR, suggesting an LCR-mediated regulation of globin gene expression. Administration of 
decitabine leads to DNA demethylation with subsequent recruitment of histone 
methyltransferases that increase H3K4me2 at HS2 and HS4 of the LCR. The decreased 
H3K4me2 at the β-globin gene was confirmed by the decrease in β-globin expression. The 
increase in γ-globin gene expression is speculated to be through interaction with the LCR.  
 
5. Despite the lack of statistical significance, decitabine has a global effect on gene 
expression of erythroid-related genes in primary human erythroid cultures. 
Healthy and thalassaemic cultures respond differently to the agent.  
Decitabine increased the expression of almost all erythroid-related genes under 
investigation in healthy cultures after 3 days of treatment, suggesting a global response 
to the agent. In contrast, decitabine decreased gene expression levels of BCL11A and 
GATA1 in thalassaemic cultures after 3 days of treatment. However, after 6 days of 
treatment, the gene expression levels of these genes returned to baseline levels. By 
classifying the individual cultures into high and low responders based on their HbF 
response to decitabine, we could demonstrate changes in mRNA levels of different 
genes in healthy and thalassaemic cultures. KLF1 was among the genes with the highest 
expression in high responders both in healthy and thalassaemic cultures after 6 days of 
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treatment, whereas MBD2 was among the genes with the highest expression in low 
responders of both groups after 6 days of treatment with decitabine. The increase in 
MBD2 gene expression suggests stimulation of methylation which is not consistent with 
the function of decitabine as a hypomethylating agent but coincides with the effect 
observed by ChIP analysis. Differences in gene expression between high and low 
responders were more prominent in thalassaemic than in healthy cultures (Figure 55). 
Increasing length of treatment of thalassaemic cultures with decitabine increased KLF1, 
MBD2 and CREB gene expression in high responders. In contrast, increasing length of 
treatment in low responders of thalassaemic cultures increased BCL11A and GATA1 
gene expression, but reduced CREB and HBG expression (Figure 55). Due to the lack of 
statistical significance of the above changes, further investigation into the effect of 
decitabine on gene expression of the above genes is necessary.  
       
                
 
 
                                                                                                                          
                                                                                               
                                                                                                            Low responders      High responders 
Figure 55, Low and high responders of thalassaemic cultures respond differently to decitabine 
treatment as shown by the changes in mRNA levels of different genes. The graph demonstrates 
some of the major changes between low responders and high responders in thalassaemic 
cultures. Low responders (blue bars) raised BCL11A and GATA1 gene expression after 6 days of 
treatment above the levels observed after 3 days with the agent, while maintained similar levels 
of CREB gene expression relative to un-treated control after both 3 and 6 days with decitabine. 
In contrast, high responders (red bars) raised KLF1, MBD2 and CREB expression substantially, 
after 6 days of treatment. Both groups increased the levels of SP1 expression following 6 days 
with decitabine, despite differences in the level of expression. However, none of the changes are 
statistically significant according to the paired t-test (p-value>0.05). Each bar represents the fold 
change in mRNA levels after 3 (bottom border) and 6 days of treatment (top border).  
6 days 







6. Decitabine induces signal transduction pathways that might lead to foetal 
globin gene activation  
Proteomic analysis of primary human erythroid cultures from transfusion-dependent 
thalassaemic patients in the presence and absence of decitabine indicated that decitabine 
promotes survival of immature erythroid progenitors in thalassaemic cultures by 
potentially modulating erythropoiesis (Figure 40, page 172). In healthy cultures, 
decitabine-mediated oxidative stress might lead to activation of signal transduction 
pathways that subsequently cause activation of γ-globin expression (Figure 38, page 
169). Functional annotation of differentially expressed proteins in healthy and 
thalassaemic cultures in the presence of decitabine demonstrated that decitabine 
modulates protein binding, transcription and chromatin structure in both groups. In 
addition, some of the differentially expressed proteins in both healthy and thalassaemic 
cultures are involved in the NF-κB pathway and HIF signalling pathways. Activation of 
γ-globin expression by decitabine might be a down-stream effect of the activation of 
these signalling pathways. Further investigation of the effect of these pathways on γ-
globin activation and their modulation by decitabine is necessary to confirm such a 
hypothesis.  
 
7. Decitabine modulates the expression of ARHGAP4, EGLN2, SMARCD3 and 
USP11 genes which are potentially associated with γ-globin expression   
Lentiviral shRNA-mediated knock-downs of 17 proteins in primary human erythroid 
cultures demonstrated the possible association of ARHGAP4, EGLN2, SMARCD3 and 
USP11 genes with γ-globin expression in the presence of decitabine. Down-regulation 
of ARHGAP4, a RhoGTPase activating protein, resulted in reduced HBG expression 
both at the mRNA and protein levels. Decitabine treatment increased HBG protein 
expression while maintained a reduced ARHGAP4 gene expression. In contrast to the 
increased mRNA levels in un-transduced cultures, proteomic analysis showed a 
decreased expression of ARHGAP4 protein in the presence of decitabine, suggesting 
that gene expression correlates inversely with γ-globin expression. Down-regulation of 
ELGN2, a prolyl-3-hydroxylase responsible for post-translational modification of 
prolines on HIF proteins, resulted in an increased HBG expression in the absence of 
decitabine. In the presence of decitabine, HBG expression was further increased while 
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maintaining a reduced EGLN2 expression. These observations suggest that EGLN2 has 
an inhibitory role on γ-globin expression. Down-regulation of the EGLN2 gene was 
confirmed by proteomic analysis in healthy and thalassaemic cultures in the presence of 
decitabine. SMARCD3 was the only gene whose expression significantly decreased in 
the presence of decitabine. The decrease in SMARCD3 expression was accompanied by 
an increase in HBG expression, again suggesting that the gene inhibits γ-globin 
expression. Finally, USP11, a de-ubiquitinating enzyme, was the only gene whose 
expression was profoundly increased by decitabine both in un-transduced healthy 
cultures at the mRNA and protein levels and in transduced cultures. The increase in 
USP11 expression was accompanied by a prominent but not statistically significant 
increase in γ-globin gene expression suggesting a direct role of the gene on γ-globin 
expression. Although the findings are sometimes contradictory between mRNA and 
protein levels, they suggest a potential role of these genes in the regulation of γ-globin 
expression and thus merit further investigation.  
 
4.2. Discussion  
Pharmacological reactivation of foetal haemoglobin is a promising therapeutic approach 
for β-thalassaemia, as foetal haemoglobin can substitute for the absent adult β-
haemoglobin. Traditionally, most HbF inducers have been identified based on their 
ability to alter local promoter chromatin (DNA methyltransferase inhibitors and Histone 
deacetylase inhibitors) or the kinetics of erythroid differentiation (cytotoxic agents). 
However, observations such as the ability of 5-azacytidine to increase HbF synthesis in 
the absence of global DNA methylation, the failure of γ-globin promoter 
hypomethylation by shRNA-mediated DMNT1 knock-down to induce expression of the 
gene (Mabaera et al., 2008a), the ability of drugs to induce HbF in vitro without 
changes in the differentiation kinetics (Mabaera et al., 2008a), the ability of short chain 
fatty acids that do not affect histone acetylation to induce HbF synthesis (Boosalis et al., 
2001) and the ability of p38 MAPK inhibitors to block γ-globin and HbF induction by 
agents (Witt et al., 2000), has raised questions about the molecular mechanism of action 
of these agents. Over the past few years, groups have redirected their research towards 
cell signalling as a way to regulate HbF induction. The pathways that have been 
demonstrated to be involved in γ-globin reactivation, so far, include cyclic guanosine 
monophosphate and cyclic adenosine monophosphate, nitric oxide, p38 MAPK, ROS 
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and cytokine signalling. Although each of these signalling pathways has strong 
evidence about their interaction with HbF induction, they do not explain how such a 
diverse group of compounds can have the same effect.  
In the current study, due to the inability to identify novel potent HbF inducers through 
screening of agents that are structurally or mechanically associated to known HbF 
inducers, an alternative approach was employed which involved the delineation of the 
molecular mechanism of action of decitabine, a known HbF inducer, with the aim of 
identifying potential targets for design of new agents. Decitabine, a DNA demethylating 
agent and a safer derivative of 5-azacytidine, was previously shown to increase HbF 
synthesis efficiently in both baboon and patients with sickle cell disease (Koshy et al., 
2000, Saunthararajah et al., 2003, Saunthararajah et al., 2008). In accordance with 
previous studies, we have demonstrated that decitabine can increase HbF percentage in 
primary human erythroid cultures from healthy and transfusion-dependent thalassaemic 
donors. The effect on γ-globin expression was also visible at the mRNA level. This 
coincides with the findings by Chin et al. (2009) which suggested that increased γ-
globin expression in baboons involved increased transcriptional activation of the γ-
globin gene. More recently, multiple studies have shown that decitabine increases γ-
globin expression by post-transcriptional and/or translational mechanisms associated 
with activation of stress-signal transduction pathways rather than through direct 
transcriptional activation (Chin et al., 2009, Mabaera et al., 2008a, Mabaera et al., 
2008b). 
A concurrent increase in the α-globin gene expression was noted in healthy but not in 
thalassaemic cultures after treatment suggesting a different response to the agent in the 
presence of the disease state. Despite the general increase in γ-globin expression as 
demonstrated by all the techniques, a large variation in the response to the agent was 
observed between individuals. This variation in response was previously demonstrated 
in relation to other HbF inducers such as HU (Pourfarzad et al., 2013) and was mainly 
attributed to the presence of HbF-associated SNPs in BCL11A gene or to the XmnI 
restriction site polymorphism of the γ-globin gene promoter (Ronchi and Ottolenghi, 
2013, Stamatoyannopoulos, 2005).  
Although DNA methyltransferase inhibitors have been known to reactivate HbF for 
more than 30 years, the mechanism of induction of γ-globin expression by these agents 
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still remains controversial. Initially, there was evidence that globin gene activation by 5-
azacytidine correlated with hypomethylation of a specific CpG site located 53-bp 
upstream of the γ-globin transcription initiation site (Ley et al., 1983). These findings 
led to the conclusion that DNA methyltransferase inhibitors increase HbF via reduction 
in the level of DNA methylation of the γ-globin gene promoter.  
Although DNA methylation was not successfully determined in the current study, we 
suggest that γ-globin induction by decitabine does not depend on hypomethylation of 
the γ-globin gene promoter but rather due to the LCR-mediated activation of γ-globin 
gene promoter (Figure 54). This was based on the observations that treatment of 
primary human erythroid cultures with decitabine led to alterations in the H3K4me2 
patterns at the LCR with no significant changes in the γ- and β-globin gene promoters. 
This pattern, together with the small decrease in the β-globin gene expression observed 
in primary human erythroid cultures from healthy donors, is consistent with the idea 
that decitabine increases γ-globin expression through modulation of its interaction with 
the LCR. Evidence that reduction of DNA methylation of the γ-globin promoter by 
RNAi targeting DNMT1 was not sufficient to induce γ-globin expression (Mabaera et 
al, 2008b), supports our hypothesis and lead to questions about the actual mode of 
action of decitabine.  
The mechanism of action of decitabine to reactivate foetal haemoglobin in primary 
human erythroid cells was investigated for the first time here. Post-transcriptional 
mechanisms that regulate the rate of synthesis and half-life of proteins suggests that the 
mRNA levels of a particular gene might not always reflect the amount of protein 
expressed and that measurement of protein levels is crucial. Here, we employed a 
quantitative proteomic approach for delineation of the molecular function of decitabine 
in primary human erythroid progenitor cells from healthy and transfusion-dependent 
thalassaemic donors. Our results demonstrated different roles of decitabine in eliciting 
HbF induction between healthy and thalassaemic primary human erythroid cultures 
(Figure 38 and 40). Decitabine promoted survival of immature erythroid progenitors in 
thalassaemic cultures as well as regulate transcriptional activation of downstream genes 
in oxidative stress pathways, an effect also shown in healthy cultures. Additionally, 
cellular stresses including oxidative and ER stress, in healthy cultures might lead to 
activation of signal transduction pathways that will lead to chromatin remodelling and 
transcription. Recently, decitabine was shown to induce ROS generation in leukaemia 
217 
 
cells. This response was found to be hypomethylation-independent but rather a 
consequence of the incorporation of decitabine into DNA and the subsequent activation 
of signalling pathways due to DNA damage (Fandy et al., 2014) (Figure 56). It might be 
this DNA damage by decitabine that leads to cellular stresses observed in the healthy 
primary human erythroid cultures. In addition, Mabaera et al. (2008a) proposed that at 
doses that strongly induce foetal gene expression, 5-azacytidine promotes low-level 
activation of DNA damage, cell stress or other signalling pathways that lead to the 
binding of positive-acting transcription complexes to the globin promoters and block 
binding of DNMT1 and other repressive factors. 
 
                 
Figure 56, The effect of decitabine incorporation on DNA structure and DNA demethylation. 
Upon uptake into the cell, decitabine is metabolised into its active form which can bind to DNA 
as a substitute for cytosine. The metabolised drug is recognised by the DNMT1 that initiates 
methylation. However, methylation is blocked in the presence of decitabine due to the 
replacement of carbon-5 of the cytosine ring with nitrogen. This blocks the methyltransferase 
activity of DNMT1 and triggers DNA damage signalling, leading to degradation of the trapped 







Comparison of the differentially expressed proteins in healthy and thalassaemic 
cultures, suggests that decitabine modulates the expression of proteins involved in 
protein binding, chromatin organization and regulation of transcription. In addition, 
differentially expressed proteins in both healthy and thalassaemic primary human 
erythroid cultures treated with decitabine are involved in the regulation of the NF-ΚB 
pathway.  
Several lines of evidence have suggested that NF-κB plays a crucial role in 
erythropoiesis. NF-κB subunits p65, p50 and p52 are all expressed during early normal 
erythroid proliferation and their levels decline during differentiation (Zhang et al., 
1998). The three subunits form complexes with κB elements in the promoters of c-myb 
and c-myc, two oncogenes required in erythroid development suggesting modulation of 
erythropoiesis by NF-κB factors through regulation of those two genes (Figure 57). Liu 
et al. (2003) demonstrated that activation of the NF-κB pathway represses the 
expression of the α-like globin genes through repression of the erythroid-specific 
subunit p45 of NF-E2, a DNA-binding transcription activator that binds to the HS-40 
enhancer and the LCR of the β-like globin gene (Figure 57). Recently, resveratrol was 
shown to inhibit TNFα-mediated NF-κB activation and promote erythropoiesis in 
primary human erythroid progenitor cells (Jeong et al., 2011). In addition, the 
immunomodulator thalidomide induces HbF production possibly through suppression of 
NF-κB induction by inflammatory cytokines such as tumour necrosis factor, a vascular 
endothelial growth factor associated with increased release of ROS. Therefore, it 
remains to be determined whether NF-κB modulates γ-globin gene expression through 
regulation of erythropoiesis by targeting c-myb, c-myc and NF-E2, or NF-κB 
modulation is a secondary response to cellular stress or upstream signal transduction 
pathways by decitabine (Figure 58).  
Among the differentially expressed proteins, ARHGAP4, EGLN2 and USP11 are 
involved with the NF-κB pathway, and SMARCD3, in chromatin modulation. 
Lentiviral-mediated shRNA knock-down of the above genes, demonstrated possible 





                   
Figure 57, Schematic diagram of the NF-κB signalling pathways. There are two major 
signalling pathways that lead to activation of NF-κB transcription factor; the canonical 
(classical) pathway and the non-canonical pathway, each activated in response to different 
stimuli. Among the down-stream targets of NF-κB activation is the c-Myb and c-Myc 
transcription factors which are involved in erythropoiesis. In addition, NF-κB inhibits 
transcription of the α-globin genes through repression of the erythroid-specific subunit p45 of 
NF-E2. 
 
Proteomic analysis of primary human erythroid cultures treated with decitabine showed 
a down-regulation of the ARHGAP4 protein in healthy donors. Reduced expression of 
ARHGAP4 gene resulted in induction of HBG expression in the presence of the agent 
suggesting an inverse effect of the gene on γ-globin expression. ARHGAP4 gene, which 
encodes for RhoGTPase activating protein 4 (p115 RhoGAP), prevents the association 
of MEKK1 with components of the c-Jun-N terminal kinase/stress activated protein 
kinases (JNK) MAP kinase cascade through its SH3 domain (Christerson et al., 2002), 
promotes ERK1/2 and RhoA activation through its interaction with PRL-1 (Bai et al., 
2011) and inhibits MEKK1-mediated activation of transcriptional regulator AP-1 and 
NF-κB (Christerson et al., 2002). Mardini et al. (2010) demonstrated that ERK1/2 
MAPK signalling pathway represses globin chain synthesis in MEL cells whereas p38 
MAPK pathway signalling acts as positive regulator of globin production. Thus, 
ARHGAP4 might activate erythroid differentiation and globin synthesis due to down 
regulation of ERK signalling pathway.  
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Proteomic analysis showed that treatment of primary human erythroid cultures from 
healthy and thalassaemic donors with decitabine down-regulated EGLN2 protein. 
Western blot analysis showed that primary human erythroid cultures with knocked-
down EGLN2 expression had increased HBG expression when treated with decitabine. 
This suggests an inhibitory effect of EGLN2 on γ-globin expression in the presence of 
the agent. These findings are in agreement with observations that a reduction in the 
expression of EGNL2 by PHD inhibitor FG-2216 increased foetal haemoglobin 
expression in primary human erythroid cells in vitro (Hsieh et al., 2007). In addition, 
reduced EGLN2 expression significantly increased erythropoiesis in rhesus macaques 
with a moderate increase of HbF-containing red cells (Hsieh et al., 2007). Loss of 
EGLN2 promotes the accumulation of FOXO3a as a result of enhanced FOXO3a 
protein stability, the FOXO3a subsequently suppresses cyclin D1 expression which 
plays a critical role in mammary proliferation (Zheng et al., 2014). Moreover, over-
expression of EGLN2 inhibited NF-κB activity through negative regulation of IKKβ 
(Cummins et al., 2006) while increased the expression of TNF-α, IL-1β and IL-8 
significantly, suggesting EGLN2 as a potential inhibitor of NF-κB (Xie et al., 2014).  
USP11, a de-ubiquitinating enzyme, is involved in several signalling pathways, 
including the NF-κB signalling pathway. USP11 gene positively regulates the 
expression of IKKα expression at the transcriptional level in an ubiquitin-independent 
manner. In parallel, USP11 was shown to negatively regulate NF-κB activity in 
response to TNF-α (Yamaguchi et al., 2007a). Following observations that upon 
oxidative stress, IKKα regulates the transcriptional activity of the p53 tumor suppressor 
(Yamaguchi et al., 2007b), USP11 was shown to be a novel regulator of p53, essential 
for p53 activation in response to DNA damage (Ke et al., 2014). In addition, USP11 has 
pro-survival functions in cellular response to DNA damage (Schoenfeld et al., 2004) 
with USP11-silenced cells demonstrating defective repair of DNA double-strand breaks 
by homologous recombination (Wiltshire et al., 2010). USP11 was the only gene whose 
expression increased profoundly after decitabine treatment in both un-transduced 
cultures and in the presence of the shRNA. This was confirmed in the proteomic 
analysis where USP11 was significantly increased in primary human erythroid cultures 




The interaction of the above genes with the NF-κB pathway and their possible role in γ-
globin expression enhances our hypothesis about the involvement of the above pathway 
in γ-globin induction by decitabine. However, further investigation is necessary to 
confirm of the role of the above genes in HbF induction and to determine whether their 
effect on γ-globin expression is indeed through modulation of the NF-κB pathway.    
Due to the fact that several agents including HU, butyrates and thalidomide were found 
to induce HbF through p38 MAPK signalling pathway, much of the research has been 
focused towards that pathway. Mabaera et al. (2008b) introduced a mechanistic model 
of HbF induction which integrates the activation of p38 MAPK kinase through multiple 
upstream signals including DNA damage, oxidative stress (ROS), heat shock, osmotic 
shock, NO and inhibition of protein synthesis. This was supported by the failure of HbF 
inducing agents to induce γ-globin expression in the presence of p38 MAPK inhibitor 
and the ability of constitutively active forms of MKK3 and MKK6, upstream activators 
of p38 MAPK, to independently increase γ-globin gene expression (Pace et al., 2003).  
The findings of this study coincide with the stress signalling model proposed by 
Mabaera et al. (2008b). However, the involvement of the p38 MAPK pathway in the 
mechanism of action of decitabine was not clearly demonstrated by the current findings 
but instead an involvement of NF-κB pathway was prominent. Whether regulation of 
the latter pathway is due to down-stream regulation of the p38 MAPK pathway needs to 
be determined (Figure 58). In addition, further investigation is required to determine 
whether the activation of the above model is by DNA demethylation of genes involved 
in stress signalling or whether decitabine does in fact induce apoptosis and DNA 
damage due to the formation of covalent DNMT-DNA adducts as suggested previously 
(Juttermann et al., 1994, Palii et al., 2008) (Figure 58). The current project has 
highlighted some important decitabine-mediated changes in the proteomics of primary 
human erythroid cultures that will provide the basis of further research into its 





Figure 58, Schematic diagram demonstrating the proposed pathways leading to γ-globin 





































5.1. Analysis of the proteomic data using an alternative statistical model 
Existing literature has emphasised that variation can occur throughout the process in the 
analytical technique, including fluctuations in the autosampler, the use of 
multidimensional separation, instrument platforms and database algorithms. Moreover, 
variation in the lists of identified peptides and proteins between replicates can impact 
the ability of these analyses to accurately represent biological states (Tabb et al., 2009). 
Thus, proper analysis of the proteomic results is of crucial importance in interpreting 
the results.  
One common approach of identifying differentially expressed proteins is to calculate the 
ratio of the observed peptide intensities between two samples and to compare the 
calculated ratios against selected upper and lower bounds for ratio thresholds. Hill et al. 
(2008) proposed an ANOVA model which integrates differential expression and 
normalization of experimental variability in a single analysis. Later, a novel Bayesian 
model was introduced where observed peptide intensities takes into account both the 
protein expression levels and peptide effects while taking into consideration the missing 
peptides (Luo et al., 2009). However, none of the current methods can employ all 
aspects of variation and missing data in a single analysis. It is thus important to choose 
the best model based on the particular objectives of the study and recourses available 
that will lead to the successful interpretation of study results.  
It is therefore important to consider the limitations of the iTRAQ approach used in the 
current study and re-analyse the data using an alternative analysis models. This can lead 
to new directions about the molecular mechanisms of action of decitabine that need to 
be considered. 
 
5.2. Investigation of the role of the NF-κB pathway in HbF reactivation and its 
association with the p38 MAPK signalling pathway 
Proteomic analysis of primary human erythroid cultures from healthy and thalassaemic 
donors treated with decitabine has demonstrated differential expression of proteins that 
are involved in the NF-κB signalling pathway. Despite identification of potent HbF 
inducers that can modulate the NF-κB pathway, major focus has been directed on the 
p38 MAPK due to the ability of a number of diverse HbF inducers to activate HbF 
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expression via that pathway. We suggest that further investigation should be done to 
determine whether NF-κB is responsible for modulating γ-globin gene expression in 
primary human erythroid cultures and whether its effect is through regulation of its 
downstream targets or whether it is a secondary response to cellular stress or upstream 
signal transduction pathways that lead to γ-globin gene activation (Figure 58).  
Verification of the role of such a pathway will require demonstration of a complete 
series of molecular events leading to the activation of γ-globin gene expression and 
increased HbF production. As a first step, investigation of the effect of selective 
inhibitors of the NF-κB pathway or agonist of negative regulatory molecules within the 
pathway, on HbF production should be carried out in primary human erythroid 
progenitor cells. Further verification of the effect can be pursued through the use of 
knock-down of specific factors along the pathway by short hairpin RNA or by the 
expression of dominant mutant signalling regulators.  
Several studies have shown that p38 MAPK regulates the transcriptional activation of 
NF-κB transcription factor rendering the NF-κB as a downstream activation of p38 
MAPK (Saha et al., 2007, Sun et al., 2013). The lack of demonstration of p38 MAPK 
activation in the current study (despite previous observations by Mabaera et al, 2008) 
and the involvement of the NF-κB pathway in the action of decitabine, necessitates 
further investigation to determine whether there is an association between the p38 and 
NF-κB signalling pathways in primary human erythroid progenitor cells.  
 
5.3. Define the role of ARHGAP4, EGLN2 and USP11 in HbF production 
Reduced expression of ARHGAP4 and EGLN2 genes increased HbF expression in 
primary human erythroid cultures treated with decitabine suggesting an inhibitory role 
of those genes on HbF production under the regulation of decitabine. In addition, 
USP11 expression was increased in the presence of decitabine along with a large 
increase in γ-globin expression suggesting a positive regulation of HbF by USP11. The 
role of these genes in HbF production should be investigated further by functional 
studies. We first need to confirm whether the results are consistent as the above findings 
are the outcomes of a single experiment. Moreover, investigation of the baseline 
expression of these genes prior to treatment in primary human erythroid cultures is also 
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necessary for confirmation of the original experiments. Finally, future work will 
determine the effect that these genes have on HbF expression in primary human 
erythroid cultures from peripheral blood of patients treated with decitabine.  
 
5.4. Investigation of the role of all differentially expressed proteins in HbF 
induction by decitabine 
Due to time constrains, not all of the 27 differentially expressed proteins associated with 
the action of decitabine identified through proteomic analysis could be investigated 
further. With the possibility of losing important proteins during selection, only 6 out of 
the 27 proteins were investigated for their role in HbF induction with and without 
decitabine. It is therefore important to investigate the effect of all of the differentially 
expressed proteins in HbF induction in the presence and absence of decitabine. 
Lentiviral-mediated shRNA knock-downs should be employed as a first attempt to 
define their effect on γ-globin expression and their response to decitabine. Interesting 
proteins could then be investigated further using functional studies.  
  
5.5. Validation of current data and further analysis of methylation patterns in 
primary human erythroid cultures in the absence and presence of decitabine 
The role of hypomethylation by decitabine and 5-azacytidine in the reactivation of 
foetal haemoglobin has been controversial among different studies (Chin et al., 2009, 
Saunthararajah et al., 2004, Mabaera et al., 2008a). Furthermore, most of the 
investigations on hypomethylation of the γ-globin promoter were done in baboons. 
Although the baboon is an important animal model due to the almost identical structure 
of the β-globin locus and developmental pattern of expression of genes within the locus 
to man (DeSimone and Mueller, 1978), differences in mechanisms of the transcriptional 
activation of γ-globin gene expression were observed between decitabine-treated 
baboons and erythroid progenitor cell cultures from decitabine-treated baboon bone 
marrow. As a result, confirmatory experiments will need to be performed in human 
primary human erythroid progenitor cells.  
Despite attempts to investigate changes in DNA methylation patterns in primary human 
progenitor cells before and after treatment with decitabine in the current study, it was 
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not possible to determine the methylation patterns at the β-globin locus accurately. The 
investigation should be repeated in order to determine the effect of decitabine on the β-
globin locus in such a system following treatment with the agent using more appropriate 
technique. Bisulphite sequencing remains the gold standard for DNA methylation 
analysis and provides readout of the methylation status of individual cytosines within a 
defined region of the genome leading to identification of differentially methylated DNA 
species within a population, a property that is not achieved by other techniques.      
 
5.6. Transcriptomic analysis of the effect of the agent in decitabine-treated 
patients 
A global protein profiling approach provides a common platform for the simultaneous 
detection of thousands of drug-related changes in proteins. However, when the drug is 
believed to act via regulation of transcription as in the case of decitabine, it might be 
more appropriate to investigate the drug-mediated changes at the gene expression level. 
This can be done by the use of microarrays for the simultaneous measurement of 
expression levels of a large number of genes. On a higher level, RNA sequencing would 
not only be qualitative but also quantitative in determining changes in gene expression 
of potential transcription factors that are involved in globin gene expression.   
In addition, observations from the peripheral blood of patients treated with decitabine 
may be more representative of the clinical effects than treatment of primary human 
erythroid cells in vitro. The use of high levels of foetal bovine serum and growth factors 
in the in vitro model might affect the action of the drug. Therefore, transcriptomic 
analysis (RNA) and proteomic analysis should be employed to investigate the effect of 
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Table I.I, List of all the agents identified as HbF inducers so far 
 Agent Reference 
DNA methyltransferase 
inhibitors 
5-azacytidine De Simone et al. (1982), Ley et al. (1982) 
Decitabine Sauthararajah et al. (2003) 
5,6 dihydro-5-azacytidine Carr et al. (1987) 
S110 Lavelle et al. (2007) 
DNA alkylators Busulfan Liu et al. (1990) 
Cisplatin Bianchi et al. (2000) 
Streptozotosin Iyamu et al. (2000) 




Ribavirin Yu et al. (1989) 
Mycophenolic acid Yu et al. (1989) 
Tiazofulin Yu et al. (1989) 
Ribonucleotide 
reductase inhibitor 
Didox Pace et al. (1994) 
Hydroxyurea Letvin et al. (1984), Charache et al. (1987) 
Resveratrol Rodrigue et al. (2001) 
Trimidox Iyamu et al. (1998) 
DNA intercalating 
agents 
Aclarubicin Delgado-Canedo et al. (2005) 
Chromomycin Bianchi et al. (1999) 
Distamycin Bianchi et al. (2001) 
Doxorubicin Delgado-Canedo et al. (2005) 
Mithramycin Bianchi et al. (1999) 
Tallimustin Bianchi et al. (2001) 
Psoralens Angelicin Lampronti et al. (2003) 
5-Metyhoxypsoralen Viola et al. (2008) 
Trimethyl angelicin Lampronti et al. (2003) 
Dihydrofolate reductase 
inhibitor 
Methotrexate Veith et al. (1989) 
Microtubule inhibitor Vinblastine Veith et al. (1985) 
Protein synthesis 
inhibitor 
Anisomycin Pace et al. (2003) 
Short chain fatty acids Butyrate Ginder et al. (1985), Perrine et al. (1985) 
Phenyl butyrate Fibach et al. (1993) 
α-aminobutyric acid Constantoulakis et al. (1988) 
2-methylbutyric acid Pace et al. (2002) 
Tributyrin Witt et al. (2000) 
Acetate Stamatoyannopoulos et al. (1994) 
Phenylacetate Fibach et al. (1993) 
Phenoxyacetic acid Torkelson et al. (1996) 
Butyryl-hydroxamate Cao et al. (2005) 
α-Methylhyrocinnamic 
acid 
Torkelson et al. (1996) 
Caproate Safarya  et al. (1994) 
Heptanoic acid Liakopoulou et al. (1995) 
Hexanoic acid Liakopoulou et al. (1995) 
Isobutyramide Perrine et al. (1994) 
Nonanoic acid Liakopoulou et al. (1995) 
Octanoic acid Liakopoulou et al. (1995) 
Pentanoic acid Liakopoulou et al. (1995) 
Propionic acid Liakopoulou et al. (1995) 
Propional hydroxamate Skarpidi et al. (2003) 
Dimethyoxyphenyl 
proprionic acid Pace et al. (2002) 
RB7 Mankidy et al. (2006) 
RB4, RB9, RB29 Bohacek et al. (2006) 
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Valproic acid Collins et al. (1994) 
Histone deacetylase 
inhibitors 
Apicidin Witt et al. (2003) 
FK228 Cao and Stamatoyannopoulos (2006) 
Compounds 24 and 29 Mai et al. (2007) 
Helminthsporium toxin McCaffrey et al. (1997) 
MS-275 Witt et al. (2003) 
SAHA (Vorinostat) Skarpidi et al. (2003) 
SBHA Skarpidi et al. (2003) 
Scriptaid Johnson et al. (2005) 
Trapoxin McCaffrey et al. (1997) 
Trichostatin A McCaffrey et al. (1997) 
Immunomodulatory 
drugs 
Thalidomide Aerbajinai et al. (2007) 
Lenalidomide (Revlimid) Moutouh-de Parseval et al. (2008) 
Pomalidomide Moutouh-de Parseval et al. (2008) 
Hormonal agents Nomegestrol Nascimento et al. (1998) 
Progesterone da Silva Santo Duarte et al. (2002) 
Cytokines Erythropoietin Al-khati et al. (1987) 
Stem cell factor  
TGF-β Bohmer (2003) 
mTOR inhibitors Rapamicin Fibach et al. (2006) 
Everolimus Zuccato et al. (2007) 
5-lipoxygenase inhibitor Zileuton Haynes et al. (2004) 
Phosphatase inhibitor Vanadate Amoyal et al. (2007) 
HIF-prolyl hydroxylase 
inhibitor 
FG-2216 Hsieh et al. (2007) 







































Table II.I, List of the shRNA obtained from the TRC Mission Library for knocking-down the proteins under investigation. 
 






TRCN0000002800 PPP5C CCGGCCAGATCACTTTCACCTCCTTCTCGAGAAGGAGGTGAAAGTGATCTGGTTTTT CDS NM_006247.x-940s1c1 1 
TRCN0000002801 PPP5C CCGGCCACGAGACAGACAACATGAACTCGAGTTCATGTTGTCTGTCTCGTGGTTTTT CDS NM_006247.x-969s1c1 2 
TRCN0000002802 PPP5C CCGGGAGACAGAGAAGATTACAGTACTCGAGTACTGTAATCTTCTCTGTCTCTTTTT CDS NM_006247.x-757s1c1 3 
TRCN0000002803 PPP5C CCGGGAAGAGAACAACCTGGACTATCTCGAGATAGTCCAGGTTGTTCTCTTCTTTTT CDS NM_006247.x-1306s1c1 4 
TRCN0000002804 PPP5C CCGGGAAGTACATCAAGGGTTATTACTCGAGTAATAACCCTTGATGTACTTCTTTTT CDS NM_006247.x-339s1c1 5 
TRCN0000007358 USP11 CCGGCCCTCCCTTCTAGTCTTTATTCTCGAGAATAAAGACTAGAAGGGAGGGTTTTT 3UTR NM_004651.2-3123s1c1 1 
TRCN0000007359 USP11 CCGGCCGTGATGATATCTTCGTCTACTCGAGTAGACGAAGATATCATCACGGTTTTT CDS NM_004651.2-1695s1c1 2 
TRCN0000007360 USP11 CCGGCCGATTCTATTGGCCTAGTATCTCGAGATACTAGGCCAATAGAATCGGTTTTT CDS NM_004651.2-653s1c1 3 
TRCN0000011089 USP11 CCGGCGGCACAATGATTTGGGCAAACTCGAGTTTGCCCAAATCATTGTGCCGTTTTT CDS NM_004651.2-607s1c1 4 
TRCN0000011090 USP11 CCGGCCGTGACTACAACAACTCCTACTCGAGTAGGAGTTGTTGTAGTCACGGTTTTT CDS NM_004651.2-1800s1c1 5 
TRCN0000062023 TACC3 CCGGCCACGGAGCCGCTGTCCCCGCCTCGAGGCGGGGACAGCGGCTCCGTGGTTTTTG 3UTR NM_006342.1-2629s1c1 1 
TRCN0000062024 TACC3 CCGGGCAGTCCTTATACCTCAAGTTCTCGAGAACTTGAGGTATAAGGACTGCTTTTTG CDS NM_006342.1-1776s1c1 2 
TRCN0000062025 TACC3 CCGGCGCACAGGATTCTAAGTCCTACTCGAGTAGGACTTAGAATCCTGTGCGTTTTTG CDS NM_006342.1-305s1c1 3 
TRCN0000062026 TACC3 CCGGGCTTGTGGAGTTCGATTTCTTCTCGAGAAGAAATCGAACTCCACAAGCTTTTTG CDS NM_006342.1-1905s1c1 4 
TRCN0000062027 TACC3 CCGGCCAGGAAGTTCTGAGAACCAACTCGAGTTGGTTCTCAGAACTTCCTGGTTTTTG CDS NM_006342.1-589s1c1 5 
TRCN0000146887 SMARCD3 CCGGCCATGACAAGGAATACATCAACTCGAGTTGATGTATTCCTTGTCATGGTTTTTTG CDS NM_003078.2-1020s1c1 1 
TRCN0000147806 SMARCD3 CCGGGAAACTGGATCAAACCATCATCTCGAGATGATGGTTTGATCCAGTTTCTTTTTTG CDS NM_003078.2-513s1c1 1 
TRCN0000147991 SMARCD3 CCGGGACAAGTATTTCCAGCAGATTCTCGAGAATCTGCTGGAAATACTTGTCTTTTTTG CDS NM_003078.2-1045s1c1 2 
TRCN0000179523 SMARCD3 CCGGGCGGAAGTTCTCTTCTTTCTTCTCGAGAAGAAAGAAGAGAACTTCCGCTTTTTTG CDS NM_003078.2-717s1c1 3 
TRCN0000180907 SMARCD3 CCGGGCTCTGGACAGTAAGATCCATCTCGAGATGGATCTTACTGTCCAGAGCTTTTTTG CDS NM_003078.2-1282s1c1 4 
  
 
TRCN0000003935 PSMB10 CCGGGATCACAAAGACTGGCGCCAACTCGAGTTGGCGCCAGTCTTTGTGATCTTTTT CDS NM_002801.x-749s1c1 1 
TRCN0000003936 PSMB10 CCGGCGGACAAGAGCTGCGAGAAGACTCGAGTCTTCTCGCAGCTCTTGTCCGTTTTT CDS NM_002801.x-298s1c1 2 
TRCN0000003937 PSMB10 CCGGATACGCGAGCCACTAACGATTCTCGAGAATCGTTAGTGGCTCGCGTATTTTTT CDS NM_002801.x-268s1c1 3 
TRCN0000010833 PSMB10 CCGGTGCAGGCTATGGAGGTGGAGTCTCGAGACTCCACCTCCATAGCCTGCATTTTT CDS NM_002801.x-901s1c1 4 
TRCN0000151756 RCBTB2 CCGGCCTGAAGAACTTTATCAGCAACTCGAGTTGCTGATAAAGTTCTTCAGGTTTTTTG CDS NM_001268.2-1976s1c1 1 
TRCN0000151907 RCBTB2 CCGGCCCTGGCAATTAAATTGTCAACTCGAGTTGACAATTTAATTGCCAGGGTTTTTTG 3UTR NM_001268.2-2639s1c1 2 
TRCN0000152592 RCBTB2 CCGGGTGAAGTATGATGCACAGGATCTCGAGATCCTGTGCATCATACTTCACTTTTTTG CDS NM_001268.2-1869s1c1 3 
TRCN0000154627 RCBTB2 CCGGCACAAACTGCTGTGGCTGTTTCTCGAGAAACAGCCACAGCAGTTTGTGTTTTTTG CDS NM_001268.2-584s1c1 4 
TRCN0000155938 RCBTB2 CCGGCCCTGGTCTCAGTATATGCTACTCGAGTAGCATATACTGAGACCAGGGTTTTTTG 3UTR NM_001268.2-2314s1c1 5 
TRCN0000014568 TAF9 CCGGCCTTGCTGAATGTAACATGTACTCGAGTACATGTTACATTCAGCAAGGTTTTT 3UTR NM_003187.3-988s1c1 1 
TRCN0000014569 TAF9 CCGGCCTTCCGATATGTGACCACAACTCGAGTTGTGGTCACATATCGGAAGGTTTTT CDS NM_003187.3-315s1c1 2 
TRCN0000014570 TAF9 CCGGCCATCATTAATCGGGTCCAAACTCGAGTTTGGACCCGATTAATGATGGTTTTT CDS NM_003187.3-833s1c1 3 
TRCN0000014571 TAF9 CCGGCCCTCACAGGTCAAAGGTTTACTCGAGTAAACCTTTGACCTGTGAGGGTTTTT CDS NM_003187.3-729s1c1 4 
TRCN0000014572 TAF9 CCGGGCCGAAAGATGCACAGATGATCTCGAGATCATCTGTGCATCTTTCGGCTTTTT CDS NM_003187.3-223s1c1 5 
TRCN0000135528 TMEM19 CCGGCTTGATAACAACGCAGTGAATCTCGAGATTCACTGCGTTGTTATCAAGTTTTTTG CDS NM_018279.2-1505s1c1 1 
TRCN0000136115 TMEM19 CCGGGCTGGATTACTAGGATCAATTCTCGAGAATTGATCCTAGTAATCCAGCTTTTTTG CDS NM_018279.2-1373s1c1 2 
TRCN0000136586 TMEM19 CCGGCCCTACTATGGTGATGATCTACTCGAGTAGATCATCACCATAGTAGGGTTTTTTG 3UTR NM_018279.2-2765s1c1 3 
TRCN0000137230 TMEM19 CCGGGATCGTCTCTAATGGCCTTAACTCGAGTTAAGGCCATTAGAGACGATCTTTTTTG CDS NM_018279.2-772s1c1 4 
TRCN0000137271 TMEM19 CCGGCCCTTAACCTTTAAGCCAGTTCTCGAGAACTGGCTTAAAGGTTAAGGGTTTTTTG 3UTR NM_018279.2-2825s1c1 5 
TRCN0000022324 EGLN2 CCGGCGCATGGCAGACAGCTTAAATCTCGAGATTTAAGCTGTCTGCCATGCGTTTTT 3UTR NM_080732.1-1498s1c1 1 
TRCN0000022325 EGLN2 CCGGGCTGCATCACCTGTATCTATTCTCGAGAATAGATACAGGTGATGCAGCTTTTT CDS NM_080732.1-1174s1c1 2 
TRCN0000022326 EGLN2 CCGGGCCACTCTTTGACCGGTTGCTCTCGAGAGCAACCGGTCAAAGAGTGGCTTTTT CDS NM_080732.1-1280s1c1 3 
  
TRCN0000022327 EGLN2 CCGGACTGGGACGTTAAGGTGCATGCTCGAGCATGCACCTTAACGTCCCAGTTTTTT CDS NM_080732.1-1207s1c1 4 
TRCN0000022328 EGLN2 CCGGCTGGGACGTTAAGGTGCATGGCTCGAGCCATGCACCTTAACGTCCCAGTTTTT UNK NM_080732.1-1208s1c1 5 
TRCN0000000504 CHUK CCGGGCATCATAAGGAGTTGGTGTACTCGAGTACACCAACTCCTTATGATGCTTTTT 3UTR NM_001278.x-2866s1c1 1 
TRCN0000000505 CHUK CCGGCCAGATTATGAAGAAGTTGAACTCGAGTTCAACTTCTTCATAATCTGGTTTTT CDS NM_001278.x-281s1c1 2 
TRCN0000000506 CHUK CCGGCCAGCCTCTCAATGTGTTCTACTCGAGTAGAACACATTGAGAGGCTGGTTTTT CDS NM_001278.x-1194s1c1 3 
TRCN0000000507 CHUK CCGGGCAAATGAGGAACAGGGCAATCTCGAGATTGCCCTGTTCCTCATTTGCTTTTT CDS NM_001278.x-2274s1c1 4 
TRCN0000000508 CHUK CCGGGCGTGCCATTGATCTATATAACTCGAGTTATATAGATCAATGGCACGCTTTTT CDS NM_001278.x-1781s1c1 5 
TRCN0000013338 BAZ1B CCGGCCCACAACAAATCTAGCTCTACTCGAGTAGAGCTAGATTTGTTGTGGGTTTTT 3UTR NM_023005.2-5516s1c1 1 
TRCN0000013339 BAZ1B CCGGGCCCTCTATGAAGTACCAGATCTCGAGATCTGGTACTTCATAGAGGGCTTTTT CDS NM_023005.2-4001s1c1 2 
TRCN0000013340 BAZ1B CCGGCGATACTTTATACGGCATAATCTCGAGATTATGCCGTATAAAGTATCGTTTTT CDS NM_023005.2-1112s1c1 3 
TRCN0000013341 BAZ1B CCGGGCAGATGACTTTGTTGGATATCTCGAGATATCCAACAAAGTCATCTGCTTTTT CDS NM_023005.2-1660s1c1 4 
TRCN0000013342 BAZ1B CCGGCGGGAAATCCAGGAAAGAGAACTCGAGTTCTCTTTCCTGGATTTCCCGTTTTT CDS NM_023005.2-2918s1c1 5 
TRCN0000059073 PYCARD CCGGGCCCACCAACCCAAGCAAGATCTCGAGATCTTGCTTGGGTTGGTGGGCTTTTTG CDS NM_013258.3-696s1c1 1 
TRCN0000059074 PYCARD CCGGCCTGCACTTTATAGACCAGCACTCGAGTGCTGGTCTATAAAGTGCAGGTTTTTG CDS NM_013258.3-573s1c1 2 
TRCN0000059075 PYCARD CCGGCGGAAGCTCTTCAGTTTCACACTCGAGTGTGAAACTGAAGAGCTTCCGTTTTTG CDS NM_013258.3-718s1c1 3 
TRCN0000059076 PYCARD CCGGGCTCAAGAAGTTCAAGCTGAACTCGAGTTCAGCTTGAACTTCTTGAGCTTTTTG CDS NM_013258.3-297s1c1 4 
TRCN0000059077 PYCARD CCGGCCTAAGGGAGTCCCAGTCCTACTCGAGTAGGACTGGGACTCCCTTAGGTTTTTG CDS NM_013258.3-780s1c1 5 
TRCN0000020349 HTATIP2 CCGGCCCATCACCAAATCGGTAATTCTCGAGAATTACCGATTTGGTGATGGGTTTTT 3UTR NM_006410.3-880s1c1 1 
TRCN0000020350 HTATIP2 CCGGGCAGAATAAATCCGTCTTTATCTCGAGATAAAGACGGATTTATTCTGCTTTTT CDS NM_006410.3-160s1c1 2 
TRCN0000020351 HTATIP2 CCGGGCAAACATTTCAACTTGCTATCTCGAGATAGCAAGTTGAAATGTTTGCTTTTT CDS NM_006410.3-483s1c1 3 
TRCN0000020352 HTATIP2 CCGGCCTCTAAAGGAGCTGATAAATCTCGAGATTTATCAGCTCCTTTAGAGGTTTTT CDS NM_006410.3-504s1c1 4 
TRCN0000020353 HTATIP2 CCGGCGTGGTTAGAGCAATGCTGAACTCGAGTTCAGCATTGCTCTAACCACGTTTTT CDS NM_006410.3-727s1c1 5 
TRCN0000074173 HEXIM1 CCGGCCCTCCTTAAACGGAGCTATACTCGAGTATAGCTCCGTTTAAGGAGGGTTTTTG 3UTR NM_006460.1-2067s1c1 1 




TRCN0000074175 HEXIM1 CCGGGCCCTATAACACCACGCAGTTCTCGAGAACTGCGTGGTGTTATAGGGCTTTTTG CDS NM_006460.1-1292s1c1 3 
TRCN0000074176 HEXIM1 CCGGGCGGCATTGGAAACCGTACTACTCGAGTAGTACGGTTTCCAATGCCGCTTTTTG CDS NM_006460.1-1172s1c1 4 
TRCN0000074177 HEXIM1 CCGGGCGGGACTTCTCGGAGACGTACTCGAGTACGTCTCCGAGAAGTCCCGCTTTTTG CDS NM_006460.1-1481s1c1 5 
TRCN0000047188 ARHGAP4 CCGGGCCAAGTTCATGGAGCACAAACTCGAGTTTGTGCTCCATGAACTTGGCTTTTTG CDS NM_001666.2-730s1c1 1 
TRCN0000047189 ARHGAP4 CCGGCGCTGCTGTCAGTAACTACTACTCGAGTAGTAGTTACTGACAGCAGCGTTTTTG CDS NM_001666.2-804s1c1 2 
TRCN0000047190 ARHGAP4 CCGGCGAAACCTTCTACCTCACGAACTCGAGTTCGTGAGGTAGAAGGTTTCGTTTTTG CDS NM_001666.2-1350s1c1 3 
TRCN0000047191 ARHGAP4 CCGGGAACATGGACTCTGTGTTTAACTCGAGTTAAACACAGAGTCCATGTTCTTTTTG CDS NM_001666.2-2661s1c1 4 
TRCN0000047192 ARHGAP4 CCGGCATTCGCTTCATCAACCTCAACTCGAGTTGAGGTTGATGAAGCGAATGTTTTTG CDS NM_001666.2-1623s1c1 5 
TRCN0000021794 CHD5 CCGGCGAATCCTGAACCATAGCTTTCTCGAGAAAGCTATGGTTCAGGATTCGTTTTT CDS NM_015557.1-1886s1c1 1 
TRCN0000021795 CHD5 CCGGCCTGGAGATGAAGAACAAGTTCTCGAGAACTTGTTCTTCATCTCCAGGTTTTT CDS NM_015557.1-5443s1c1 2 
TRCN0000021796 CHD5 CCGGCGTGTTCCTTTACTCCCTCTACTCGAGTAGAGGGAGTAAAGGAACACGTTTTT CDS NM_015557.1-2308s1c1 3 
TRCN0000021797 CHD5 CCGGGCTACAGAACATGAACGAGTACTCGAGTACTCGTTCATGTTCTGTAGCTTTTT CDS NM_015557.1-3931s1c1 4 
TRCN0000021798 CHD5 CCGGCGCAAGAAGAAGAGGATTGATCTCGAGATCAATCCTCTTCTTCTTGCGTTTTT CDS NM_015557.1-1079s1c1 5 
TRCN0000053773 S100A8 CCGGCCACAAGTACTCCCTGATAAACTCGAGTTTATCAGGGAGTACTTGTGGTTTTTG CDS NM_002964.3-103s1c1 1 
TRCN0000053774 S100A8 CCGGGTCTGGTTCAAAGAGTTGGATCTCGAGATCCAACTCTTTGAACCAGACTTTTTG CDS NM_002964.3-212s1c1 2 
TRCN0000053775 S100A8 CCGGTCAACACTGATGGTGCAGTTACTCGAGTAACTGCACCATCAGTGTTGATTTTTG CDS NM_002964.3-234s1c1 3 



























    
       
   
          
 263 
 
    
   
Figure III.I, Investigation of the haemoglobin inducing ability (Benzidine stain) and 
cytotoxicity (Trypan blue) of resveratrol and nine hydroxystilbenic derivatives in K562 cell line. 
Concentration curves were prepared for each compound in order to determine the concentration 
with the best HbF inducing activity while having a moderate cytotoxicity. The results are the 





































Table IV.I, List of proteins that are significantly differentially expressed for each of the four ratios after sorting based on their Log2 values and selection of 
proteins with a p-value<0.05. Protein ID refers to the Uniprot Assession number corresponding to each protein. Protein description lists the full name of the 
protein. Protein name refers to the acronym of the protein which usually corresponds to the gene name. Average ratio corresponds to the average of the 
differential expression of the protein from three experiments. Log2 value is the log2 value of the average ratio and the p-value states the statistical significance of 
the log2 value of each protein. The coverage is the percentage of the protein sequence that was identified through peptides and MW corresponds to the molecular 
weight of each protein.      
 
Differentially expressed protein in treated over un-treated of healthy cultures (ratio 1) 










P52564 Dual specificity mitogen-activated protein kinase kinase 6 MAP2K6 2.488 1.271828 0 7.49 37.5 
Q14738 
Serine/threonine-protein phosphatase 2A 56 kDa regulatory 
subunit delta isoform 
PPP2R5D 2.115 1.037499 5.64E-14 4.15 69.9 
Q15006 ER membrane protein complex subunit 2 EMC2 1.892 0.876753 2.13E-10 6.4 34.8 
P51784 Ubiquitin carboxyl-terminal hydrolase 11 USP11 1.652 0.681055 8.06E-07 1.66 109.7 
Q92734 Protein TFG TFG 1.642 0.672295 1.11E-06 6.5 43.4 
Q14137 Ribosome biogenesis protein BOP1 BOP1 1.526 0.566596 4.05E-05 3.08 83.6 
P42785 Lysosomal Pro-X carboxypeptidase PRCP 1.51 0.55139 6.48E-05 5.24 55.8 
Q9UDX4 SEC14-like protein 3 SEC14L3 1.468 0.510693 0.000216 5 46 
Q15363 Transmembrane emp24 domain-containing protein 2 TMED2 1.462 0.504785 0.000255 7.96 22.7 
Q494V2 Coiled-coil domain-containing protein 37 CCDC37 1.409 0.451513 0.001072 1.15 71.1 
O60888 Protein CutA CUTA 1.371 0.41207 0.002834 7.82 19.1 
Q96EY1 DnaJ homolog subfamily A member 3, mitochondrial DNAJA3 1.367 0.407855 0.00313 3.33 52.5 
Q9HBI1 Beta-parvin PARVB 1.365 0.405742 0.003289 3.85 41.7 
Q13190 Syntaxin-5 STX5 1.361 0.401508 0.003629 3.38 39.6 
  
Q9Y5Y2 Cytosolic Fe-S cluster assembly factor NUBP2 NUBP2 1.357 0.397262 0.004003 9.96 28.8 
Q00341 Vigilin HDLBP 1.343 0.382301 0.005613 1.42 141.4 
O95236 Apolipoprotein L3 APOL3 1.328 0.366096 0.007997 2.74 44.3 
Q9NP58 
ATP-binding cassette sub-family B member 6, 
mitochondrial 
ABCB6 1.323 0.360654 0.008982 4.99 93.8 
Q8TEQ6 Gem-associated protein 5 GEMIN5 1.309 0.345306 0.012365 0.93 168.5 
Q86TX2 Acyl-coenzyme A thioesterase 1 ACOT1 1.308 0.344204 0.012646 4.75 46.2 
P52888 Thimet oligopeptidase THOP1 1.307 0.3431 0.012934 2.9 78.8 
P61201 COP9 signalosome complex subunit 2 COPS2 1.3 0.335353 0.015121 7.9 51.6 
Q8N183 Mimitin, mitochondrial NDUFAF2 1.298 0.333132 0.015806 10.65 19.8 
P11216 Glycogen phosphorylase, brain form PYGB 1.297 0.33202 0.016159 0.25 632.4 
Q9NU22 Midasin MDN1 1.297 0.33202 0.016159 1.54 96.6 
P37198 Nuclear pore glycoprotein p62 NUP62 1.293 0.327564 0.017643 5.36 53.2 
Q9ULZ3 
Apoptosis-associated speck-like protein containing a 
CARD 
PYCARD 1.289 0.323094 0.01925 8.21 28.9 
P40306 Proteasome subunit beta type-10 PSMB10 1.289 0.323094 0.01925 7.33 21.6 
O60613 15 kDa selenoprotein SEP15 1.281 0.314112 0.022871 8.02 17.8 
O43264 Centromere/kinetochore protein zw10 homolog ZW10 1.28 0.312985 0.023365 1.16 88.8 
Q9BRT2 Mitochondrial nucleoid factor 1 UQCC2 1.279 0.311858 0.023868 9.52 14.9 
O15145 Actin-related protein 2/3 complex subunit 3 ARPC3 1.276 0.30847 0.025437 15.17 20.5 
P17612 cAMP-dependent protein kinase catalytic subunit alpha PRKACA 1.268 0.299396 0.030085 2.56 58.2 
Q9NP81 Serine--tRNA ligase, mitochondrial SARS2 1.268 0.299396 0.030085 2.7 40.6 
Q9Y3A6 Transmembrane emp24 domain-containing protein 5 TMED5 1.266 0.297119 0.03136 5.24 26 
Q9BUP3 Oxidoreductase HTATIP2 HTAI2 1.262 0.292553 0.034057 4.13 27 
Q9Y6M1 Insulin-like growth factor 2 mRNA-binding protein 2 IF2B2 1.261 0.29141 0.034763 4.84 66.1 
P02647 Apolipoprotein A-I APOA1 1.259 0.28912 0.036214 5.99 30.8 
  
P60983 Glia maturation factor beta GMFB 1.257 0.286826 0.037718 22.54 36.5 
Q7L5D6 Golgi to ER traffic protein 4 homolog GET4 1.257 0.286826 0.037718 4.59 16.7 
P19784 Casein kinase II subunit alpha' CSNK2A2 1.255 0.284529 0.039278 3.71 41.2 
P51157 Ras-related protein Rab-28 RAB28 1.254 0.283379 0.040079 10.86 24.8 
Q96B26 Exosome complex component RRP43 EXOSC8 1.251 0.279923 0.042571 4.71 30 
P10243 Myb-related protein A MYBL1 1.248 0.276459 0.045198 10.83 60.3 
Q8WVJ2 NudC domain-containing protein 2 NUDCD2 1.248 0.276459 0.045198 2.79 17.7 
O95199 RCC1 and BTB domain-containing protein 2 RCBTB2 1.248 0.276459 0.045198 1.45 85.8 
Q7Z5R6 
Amyloid beta A4 precursor protein-binding family B 
member 1-interacting protein 
APBB1IP 1.244 0.271828 0.048924 1.35 73.1 
O75688 Protein phosphatase 1B PPM1B 0.854 -0.27085 0.049742 3.76 52.6 
Q9NUB1 Acetyl-coenzyme A synthase 2-like, mitochondrial ACSS1 0.851 -0.27593 0.045613 2.32 74.8 
O95630 STAM-binding protein STAMBP 0.851 -0.27593 0.045613 4.01 48 
P03928 ATP synthase protein 8 ATP8 0.848 -0.28102 0.041764 23.36 11.7 
P17096 High mobility group protein HMG-I/HMG-Y O HMGA1 0.848 -0.28102 0.041764 13.24 8 
P16333 Cytoplasmic protein NCK1 NCK1 0.847 -0.28272 0.040541 3.71 42.8 
Q6B0K9 Haemoglobin subunit mu HBM 0.845 -0.28614 0.038181 45.39 15.6 
O43772 Mitochondrial carnitine/acylcarnitine carrier protein SLC25A20 0.841 -0.29298 0.033796 6.98 32.9 
Q01658 Protein Dr1 DR1 0.841 -0.29298 0.033796 7.39 19.4 
Q9BVJ6 U3 small nucleolar RNA-associated protein 14 homolog A UTP14A 0.84 -0.2947 0.032767 1.56 87.9 
Q9UFF9 CCR4-NOT transcription complex subunit 8 CNOT8 0.839 -0.29642 0.031763 2.19 40.8 
Q9Y371 Endophilin-B1 SH3GLB1 0.839 -0.29642 0.031763 3.24 48.5 
Q15645 Pachytene checkpoint protein 2 homolog TRIP13 0.839 -0.29642 0.031763 4.79 33.5 
Q00169 Phosphatidylinositol transfer protein alpha isoform PITPNA 0.836 -0.30158 0.028902 9.63 31.8 
P29590 Protein PML PML 0.836 -0.30158 0.028902 1.36 97.5 
  
Q9UP52 Transferrin receptor protein 2 TFR2 0.834 -0.30504 0.027115 2.75 88.7 
O75563 Src kinase-associated phosphoprotein 2 SKAP2 0.828 -0.31546 0.022294 2.79 41.2 
Q99496 E3 ubiquitin-protein ligase RING2 RNF2 0.825 -0.32069 0.020166 4.17 37.6 
O75380 
NADH dehydrogenase (ubiquinone) iron-sulfur protein 6, 
mitochondrial 
NDUFS6 0.824 -0.32244 0.019495 17.74 13.7 
Q99543 DnaJ homolog subfamily C member 2 DNAJC2 0.822 -0.32595 0.01821 2.74 72 
P61011 Signal recognition particle 54 kDa protein SRP54 0.817 -0.33475 0.015304 2.78 55.7 
P20339 Ras-related protein Rab-5A RAB5A 0.813 -0.34183 0.013272 30.23 23.6 
P05204 Non-histone chromosomal protein HMG-17 HMGN2 0.812 -0.34361 0.012801 24.44 9.4 
Q9C0D2 Centrosomal protein KIAA1731 KIAA1731 0.811 -0.34538 0.012345 0.88 295 
Q8TBG4 Ethanolamine-phosphate phospho-lyase ETNPPL 0.807 -0.35252 0.010655 2.66 91.8 
Q09161 Nuclear cap-binding protein subunit 1 NCBP1 0.807 -0.35252 0.010655 5.01 55.6 
Q16594 Transcription initiation factor TFIID subunit 9 TAF9 0.805 -0.3561 0.009887 8.71 29 
Q16777 Histone H2A type 2-C HIST2H2AC 0.8 -0.36509 0.008172 62.79 14 
P04264 Keratin, type II cytoskeletal 1 K2C1 0.8 -0.36509 0.008172 28.57 66 
P49247 Ribose-5-phosphate isomerase RPIA 0.797 -0.37051 0.007272 2.57 33.2 
P02533 Keratin, type I cytoskeletal 14 K1C14 0.795 -0.37413 0.00672 15.89 51.5 
P02538 Keratin, type II cytoskeletal 6A K2C6A 0.792 -0.37959 0.005961 16.49 60 
P49189 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 0.785 -0.39239 0.004473 2.43 53.8 
Q9NVR0 Kelch-like protein 11 KLHL11 0.767 -0.42586 0.002035 0.78 223 
P12883 Myosin-7 MYH7 0.767 -0.42586 0.002035 1.84 80.1 
Q9UBQ0 Vacuolar protein sorting-associated protein 29 VPS29 0.767 -0.42586 0.002035 5.49 20.5 
P98171 Rho GTPase-activating protein 4 ARHGAP4 0.766 -0.42774 0.001943 1.16 105 
Q99436 Proteasome subunit beta type-7 PSMB7 0.762 -0.4353 0.001613 3.61 29.9 
Q96KS0 Egl nine homolog 2 EGLN2 0.758 -0.44289 0.001334 2.21 43.6 
  
Q9H9J2 39S ribosomal protein L44, mitochondrial MRPL44 0.752 -0.45435 0.000996 3.92 37.5 
P62328 Thymosin beta-4 TYB4 0.737 -0.48342 0.000462 45.45 5 
P23786 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 0.736 -0.48538 0.000438 1.82 73.7 
P32455 Interferon-induced guanylate-binding protein 1 GBP1 0.736 -0.48538 0.000438 2.87 67.9 
P13807 Glycogen (starch) synthase, muscle GYS1 0.723 -0.51109 0.000213 1.9 83.7 
P08779 Keratin, type I cytoskeletal 16 K1C16 0.707 -0.54338 8.27E-05 16.07 51.2 
P13284 Gamma-interferon-inducible lysosomal thiol reductase IF130 0.706 -0.54542 7.77E-05 4.4 27.9 
O15111 Inhibitor of nuclear factor kappa-B kinase subunit alpha CHUK 0.703 -0.55156 6.45E-05 1.21 84.6 
A6NN90 Uncharacterised protein C2orf81 C2orf81 0.675 -0.6102 9.84E-06 2.75 63 
O94992 Protein HEXIM1 HEXIM1 0.666 -0.62956 5.09E-06 3.9 40.6 
Q15654 Thyroid receptor-interacting protein 6 TRIP6 0.66 -0.64262 3.23E-06 5.46 50.3 
Q9UPN9 E3 ubiquitin-protein ligase TRIM33 TRIM33 0.654 -0.6558 2.03E-06 0.62 122.5 
Q9NZZ3 Charged multivesicular body protein 5 CHMP5 0.648 -0.66909 1.25E-06 7.31 24.6 
P13647 Keratin, type II cytoskeletal 5 KRT5 0.636 -0.69606 4.59E-07 15.42 62.3 
Q8N960 Centrosomal protein of 120 kDa CEP210 0.632 -0.70516 3.25E-07 0.91 112.6 
Q8IUE6 Histone H2A type 2-B HIST2H2AB 0.62 -0.73282 1.1E-07 56.92 14 
Q93077 Histone H2A type 1-C HIST1H2AC 0.589 -0.80682 5.07E-09 62.31 14.1 
Q96HH6 Transmembrane protein 19 TMEM19 0.544 -0.92148 2.46E-11 11.01 36.4 





Differentially expressed proteins in the ratio of treated over un-treated in thalassaemic cultures (ratio 2) 
Protein ID Protein description Protein name 
Average 
ratio 
Log2 value P-value Coverage 
MW 
(kDa) 
Q8IUE6 Histone H2A type 2-B OS=Homo sapiens HIST2H2AB 3.018 1.74461743 0 56.92 14 
A6NN90 Uncharacterised protein C2orf81 C2orf81 2.525 1.48730801 0 2.75 63 
P52564 
Dual specificity mitogen-activated protein kinase 
kinase 6 
MAP2K6 2.309 1.3582928 0 7.49 37.5 
Q7Z2X4 PTB-containing, cubilin and LRP1-interacting protein PID1 2.131 1.24255522 0 2.8 28.3 
Q96HH6 Transmembrane protein 19 TMEM19 2.099 1.22072679 0 11.01 36.4 
Q93077 Histone H2A type 1-C HIST1H2AC 1.588 0.81823554 5.9641E-09 62.31 14.1 
Q8N3Y1 F-box/WD repeat-containing protein 8 FBXW8 1.505 0.74078811 1.386E-07 2.68 67.4 
Q8N183 Mimitin, mitochondrial NDUFAF2 1.427 0.66400996 2.3446E-06 10.65 19.8 
P22492 Histone H1t HIST1H1T 1.424 0.66097377 2.6066E-06 15.46 22 
P62328 Thymosin beta-4 TMSB4X 1.414 0.65080674 3.7043E-06 45.45 5 
Q96IU4 Alpha/beta hydrolase domain-containing protein 14B ABHD14B 1.41 0.64671979 4.2603E-06 6.19 22.3 
P05204 Non-histone chromosomal protein HMG-17 HMGN2 1.399 0.63542059 6.2449E-06 24.44 9.4 
Q14558 
Phosphoribosyl pyrophosphate synthase-associated 
protein 1 
PRPSAP1 1.347 0.58077447 3.6374E-05 3.93 39.4 
Q9Y6A5 Transforming acidic coiled-coil-containing protein 3 TACC3 1.331 0.56353519 6.1545E-05 2.74 90.3 
O96008 
Mitochondrial import receptor subunit TOM40 
homolog 
TOMM40 1.309 0.53948972 0.00012513 3.05 37.9 
O15533 Tapasin TAPBP 1.281 0.5082951 0.00030146 1.79 47.6 
Q13351 Kruppel-like factor 1 KLF1 1.224 0.44262818 0.00164874 5.25 38.2 
Q96RU3 Formin-binding protein 1 FNBP1 1.22 0.43790577 0.00184841 3.08 71.3 
  
Q9H3H3 UPF0696 protein C11orf68 C11orf68 1.214 0.43079305 0.00219134 4.38 27.3 
Q8TBG4 Ethanolamine-phosphate phospho-lyase ETNPPL 1.195 0.40803524 0.00371756 5.01 55.6 
Q9Y6G3 39S ribosomal protein L42, mitochondrial MRPL42 1.187 0.39834456 0.00462171 10.56 16.7 
Q92783 Signal transducing adapter molecule 1 STAM 1.179 0.38858834 0.00572879 7.96 59.1 
O00479 
High mobility group nucleosome-binding domain-
containing protein 4 
HMGN4 1.173 0.38122764 0.00671661 7.78 9.5 
P24863 Cyclin-C CCNC 1.166 0.37259241 0.00806872 3.53 33.2 
Q96RT1 Protein LAP2 ERBB2IP 1.162 0.36763469 0.00895073 1.56 158.2 
Q15413 Ryanodine receptor 3 RYR3 1.158 0.36265988 0.00992134 0.37 551.7 
Q96IZ7 Serine/Arginine-related protein 53 RSRC1 1.152 0.35516534 0.01156089 2.99 38.7 
Q8NHV1 GTPase IMAP family member 7 GIMAP7 1.148 0.35014727 0.01278896 4.33 34.5 
O00507 Probable ubiquitin carboxyl-terminal hydrolase FAF-Y USP9Y 1.145 0.34637222 0.01378755 0.39 290.9 
P16402 Histone H1.3 HIST1H1D 1.14 0.34005845 0.0156121 45.25 22.3 
Q9UJ70 N-acetyl-D-glucosamine kinase NAGK 1.13 0.3273474 0.0199396 2.03 37.4 
Q92896 Golgi apparatus protein 1 GLG1 1.13 0.3273474 0.0199396 1.1 134.5 
Q10713 Mitochondrial-processing peptidase subunit alpha PMPCA 1.12 0.31452336 0.025332 3.24 58.2 
P98175 RNA-binding protein 10 RBM10 1.12 0.31452336 0.025332 1.51 103.5 




AASDHPPT 1.119 0.31323466 0.02593798 8.41 35.8 
P04439 
HLA class I histocompatibility antigen, A-3 alpha 
chain 
HLA-A 1.117 0.31065381 0.02718933 18.08 40.8 
P61011 Signal recognition particle 54 kDa protein SRP54 1.117 0.31065381 0.02718933 2.78 55.7 
  
Q9Y263 Phospholipase A-2-activating protein PLAA 1.116 0.30936165 0.02783518 1.13 87.1 
P04004 Vitronectin VTN 1.115 0.30806833 0.02849482 4.81 54.3 
Q13769 THO complex subunit 5 homolog THOC5 1.113 0.30547822 0.02985644 1.32 78.5 
P53041 Serine/threonine-protein phosphatase 5 PPP5C 1.111 0.30288344 0.03127622 4.21 56.8 
P12955 Xaa-Pro dipeptidase PEPD 1.111 0.30288344 0.03127622 5.68 54.5 
Q93050 V-type proton ATPase 116 kDa subunit a isoform 1 ATP6V0A1 1.107 0.29767985 0.03429871 1.79 96.4 
Q14667 UPF0378 protein KIAA0100 KIAA0100 1.105 0.29507099 0.03590576 0.72 253.5 
P62820 Ras-related protein Rab-1A RAB1A 1.104 0.2937648 0.03673421 37.56 22.7 
P60983 Glia maturation factor beta GMFB 1.101 0.28983909 0.03932274 22.54 16.7 
Q96BP3 
Peptidylprolyl isomerase domain and WD repeat-
containing protein 1 
PPWD1 1.1 0.28852815 0.04022095 1.7 73.5 
Q5VUJ6 
Leucine-rich repeat and calponin homology domain-
containing protein 2 
LRCH2 1.099 0.28721601 0.04113734 1.57 84.5 
Q9H845 
Acyl-CoA dehydrogenase family member 9, 
mitochondrial 
ACAD9 1.098 0.28590268 0.04207221 4.03 68.7 
Q6ZRH9 Uncharacterised protein FLJ46347 
 
1.097 0.28458815 0.04302588 2.71 53.6 
Q6STE5 
SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily D member 3 
SMARCD3 1.096 0.28327242 0.04399865 3.52 55 
Q9H0D6 5'-3' exoribonuclease 2 XRN2 1.094 0.28063736 0.04600275 1.16 108.5 
Q7LDG7 RAS guanyl-releasing protein 2 GRP2 1.093 0.27931802 0.04703472 1.97 69.2 
Q9H2W6 39S ribosomal protein L46, mitochondrial MRPL46 1.093 0.27931802 0.04703472 7.53 31.7 
A6NF01 
Putative nuclear envelope pore membrane protein 
POM 121B 
POM121B 0.743 -0.2775413 0.0484552 3 83 
P16989 Y-box-binding protein 3 YBX3 0.743 -0.2775413 0.0484552 7.53 40.1 
P36959 GMP reductase 1 GMPR 0.738 -0.2872827 0.04109037 7.83 37.4 
  
Q8N766 ER membrane protein complex subunit 1 EMC1 0.737 -0.2892389 0.03973186 1.71 111.7 
Q9BZI7 Regulator of nonsense transcripts 3B UPF3B 0.737 -0.2892389 0.03973186 3.11 57.7 
Q5T619 Zinc finger protein 648 ZN648 0.736 -0.2911977 0.0384099 2.11 62.3 
Q6NYC1 
Bifunctional arginine demethylase and lysyl-
hydroxylase JMJD6 
JMJD6 0.735 -0.2931592 0.03712379 3.47 46.4 
O75352 Mannose-P-dolichol utilization defect 1 protein MPDU1 0.734 -0.2951234 0.03587285 4.05 26.6 
P22033 Methylmalonyl-CoA mutase, mitochondrial MUT 0.733 -0.2970903 0.03465641 2.27 83.1 
Q6P1K2 Polyamine-modulated factor 1 PMF1 0.733 -0.2970903 0.03465641 5.85 23.3 
Q8NBI5 Solute carrier family 43 member 3 SLC43A3 0.732 -0.2990598 0.03347378 1.22 54.5 
Q9UPT8 Zinc finger CCCH domain-containing protein 4 ZC3H4 0.731 -0.3010321 0.03232431 2.23 140.2 
Q9UDX4 SEC14-like protein 3 S14L3 0.73 -0.303007 0.03120732 5 46 
Q8TCD5 5'(3')-deoxyribonucleotidase, cytosolic type NT5C 0.729 -0.3049847 0.03012215 8.96 23.4 
P41223 Protein BUD31 homolog BUD31 0.727 -0.3089481 0.02804466 13.89 17 
Q96MW1 Coiled-coil domain-containing protein 43 CCDC43 0.725 -0.3129225 0.02608665 5.8 25.2 
Q00169 Phosphatidylinositol transfer protein alpha isoform PITPN1 0.724 -0.3149138 0.02515085 9.63 31.8 
Q567U6 Coiled-coil domain-containing protein 93 CCDC93 0.721 -0.3209042 0.0225088 2.06 73.2 
Q96C36 Pyrroline-5-carboxylate reductase 2 PYCR2 0.72 -0.3229066 0.02168117 4.69 33.6 
Q8IUZ5 5-phosphohydroxy-L-lysine phospho-lyase PHYKPL 0.72 -0.3229066 0.02168117 2.44 49.7 
Q9NP58 
ATP-binding cassette sub-family B member 6, 
mitochondrial 
ABCB6 0.718 -0.3269196 0.02010187 4.99 93.8 
Q92542 Nicastrin NCSTN 0.716 -0.3309439 0.01861993 1.69 78.4 
O14602 
Eukaryotic translation initiation factor 1A, Y-
chromosomal 
EIF1AY 0.713 -0.3370014 0.0165695 18.06 16.4 
  
Q9BYN0 Sulfiredoxin-1 SRXN1 0.712 -0.3390262 0.01592978 10.95 14.3 
P51784 Ubiquitin carboxyl-terminal hydrolase 11 USP11 0.706 -0.3512353 0.0125133 1.66 109.7 
Q2TAY7 WD40 repeat-containing protein SMU1 SMU1 0.702 -0.3594324 0.01060015 3.51 57.5 
P55795 Heterogeneous nuclear ribonucleoprotein H2 HNRNPH2 0.702 -0.3594324 0.01060015 17.37 49.2 
P06401 Progesterone receptor PGR 0.701 -0.361489 0.01016299 1.29 98.9 
Q9UBW5 Bridging integrator 2 BIN2 0.7 -0.3635485 0.00974136 3.01 61.8 
Q9BXJ9 N-alpha-acetyltransferase 15, NatA auxiliary subunit NAA15 0.698 -0.3676764 0.00894296 1.73 101.2 
Q9NZ63 Uncharacterised protein C9orf78 C9orf78 0.693 -0.3780481 0.00718876 4.84 33.7 
P35236 Tyrosine-protein phosphatase non-receptor type 7 PTPN7 0.688 -0.3884949 0.00574046 2.22 40.5 
P40306 Proteasome subunit beta type-10 PSMB10 0.687 -0.3905934 0.00548346 7.33 28.9 
Q13492 Phosphatidylinositol-binding clathrin assembly protein PICALM 0.686 -0.3926949 0.00523653 5.98 70.7 
P53597 
Succinyl-CoA ligase (ADP/GDP-forming) subunit 
alpha, mitochondrial 
SUCLG1 0.686 -0.3926949 0.00523653 6.94 36.2 
O95199 RCC1 and BTB domain-containing protein 2 RCBTB2 0.682 -0.4011317 0.00434316 1.45 60.3 
Q9UIG0 Tyrosine-protein kinase BAZ1B BAZ1B 0.656 -0.4572077 0.00115078 0.94 170.8 
Q9NQW7 Xaa-Pro aminopeptidase 1 XPNPEP1 0.653 -0.4638205 0.00097437 2.89 69.9 
Q8N806 Putative E3 ubiquitin-protein ligase UBR7 UBR7 0.633 -0.508698 0.00029814 3.06 48 
Q96TA2 ATP-dependent zinc metalloprotease YME1L1 YM31L1 0.628 -0.5201389 0.00021709 1.42 86.4 
P17066 Heat shock 70 kDa protein 6 HSPA6 0.627 -0.522438 0.00020352 13.69 71 
Q92734 Protein TFG TFG 0.625 -0.5270473 0.0001787 6.5 43.4 
Q14738 
Serine/threonine-protein phosphatase 2A 56 kDa 
regulatory subunit delta isoform 
PPP2R5D 0.615 -0.5503171 9.1222E-05 4.15 69.9 
P09601 Haem oxygenase 1 HMOX1 0.61 -0.5620942 6.4269E-05 12.5 32.8 
  
Q96B49 Mitochondrial import receptor subunit TOM6 homolog TOMM6 0.603 -0.5787455 3.8725E-05 18.92 8 
P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A FKBP1A 0.599 -0.5883475 2.874E-05 12.96 11.9 
Q16594 Transcription initiation factor TFIID subunit 9 TAF9 0.598 -0.590758 2.6648E-05 8.71 29 
Q96NH3 Protein broad-minded TBC1D32 0.558 -0.6906383 9.0831E-07 2.55 144.7 
Q8TDI0 Chromodomain-helicase-DNA-binding protein 5 CHDA 0.545 -0.7246472 2.5726E-07 2.71 222.9 
P02765 Alpha-2-HS-glycoprotein AHSG 0.541 -0.7352749 1.7145E-07 6.81 39.3 
Q9UHY7 Enolase-phosphatase E1 ENOPH1 0.537 -0.7459814 1.1328E-07 4.6 28.9 
Q9C0D2 Centrosomal protein KIAA1731 KIAA1731 0.486 -0.8899472 2.4894E-10 0.88 295 
Q8N960 Centrosomal protein of 120 kDa CEP120 0.464 -0.9567787 1.0259E-11 0.91 112.6 
Q14563 Semaphorin-3A SEMA3A 0.413 -1.1247617 1.2728E-15 3.63 88.8 









Differentially expressed proteins of thalassaemic un-treated / healthy un-treated samples (ratio 3) 
Protein ID Protein description Protein name 
Average 
ratio 
Log2 ratio p-value Coverage 
MW 
(kDa) 
P52564 Dual specificity mitogen-activated protein kinase kinase 6 MAP2K6 6.203 2.566164 1.65E-08 7.49 32 
Q494V2 Coiled-coil domain-containing protein 37 CCDC37 5.666 2.435528 8.43E-08 1.15 37.5 
Q92734 Protein TFG TFG 3.335 1.670884 0.000237 6.5 71.1 
P02765 Alpha-2-HS-glycoprotein AHSG 3.165 1.595403 0.000449 6.81 43.4 
Q9H8M2 Bromodomain-containing protein 9 BRD9 3.044 1.539166 0.00071 1.17 39.3 
P02787 Serotransferrin TF 2.916 1.477188 0.001156 2.01 67 
P02647 Apolipoprotein A-I APOA1 2.596 1.309488 0.003969 5.99 77 
Q7L5D6 Golgi to ER traffic protein 4 homolog GET4 2.382 1.185371 0.009118 4.59 30.8 
Q9NZD4 Alpha-haemoglobin-stabilizing protein AHSP 2.331 1.154146 0.01112 35.29 36.5 
Q9NU22 Midasin MDN1 2.259 1.108882 0.014715 0.25 11.8 
P02771 Alpha-fetoprotein AFP 2.23 1.090241 0.01647 2.96 632.4 
Q9Y5E8 Protocadherin beta-15 PCDHB15 2.21 1.077244 0.017801 3.18 68.6 
Q15006 ER membrane protein complex subunit 2 EMC2 2.209 1.076591 0.01787 6.4 86.3 
P30508 HLA class I histocompatibility antigen, Cw-12 alpha chain HLA-C 2.173 1.052886 0.02055 13.93 34.8 
Q9HBI1 Beta-parvin PARVB 2.129 1.023373 0.024371 3.85 40.9 
Q9NZJ9 Diphosphoinositol polyphosphate phosphohydrolase 2 NUDT4 2.118 1.0159 0.025432 13.33 41.7 
P02774 Vitamin D-binding protein VTDB 2.11 1.01044 0.026231 8.23 20.3 
Q8N766 ER membrane protein complex subunit 1 EMC1 2.101 1.004274 0.02716 1.71 52.9 
Q9BXD5 N-acetylneuraminate lyase NPL 2.085 0.993245 0.028893 3.44 111.7 
O15069 NAC-alpha domain-containing protein 1 NACAD 2.032 0.956098 0.035446 0.83 35.1 
Q9UHY7 Enolase-phosphatase E1 ENOPH 2.022 0.94898 0.036836 4.6 161 
  
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 1.965 0.907727 0.045844 1.18 28.9 
Q9UIG0 Tyrosine-protein kinase BAZ1B BAZ1B 1.954 0.899628 0.047815 0.94 103.3 
P42785 Lysosomal Pro-X carboxypeptidase PRCP 1.95 0.896672 0.048552 5.24 170.8 
Q10589 Bone marrow stromal antigen 2 BST2 0.564 -0.89304 0.049471 8.33 55.8 
Q5RI15 Cytochrome c oxidase protein 20 homolog COX20 0.564 -0.89304 0.049471 10.17 13.3 
Q9NWV8 BRISC and BRCA1-A complex member 1 BABAM1 0.563 -0.8956 0.048823 3.34 36.5 
P62820 Ras-related protein Rab-1A RAB1A 0.562 -0.89816 0.04818 37.56 22.7 
Q96BP3 
Peptidylprolyl isomerase domain and WD repeat-
containing protein 1 
PPWD1 0.559 -0.90588 0.046287 1.7 73.5 
P17900 Ganglioside GM2 activator SAP3 0.559 -0.90588 0.046287 3.63 20.8 
O75351 Vacuolar protein sorting-associated protein 4B VPS4B 0.559 -0.90588 0.046287 3.6 49.3 
P49821 
NADH dehydrogenase (ubiquinone) flavoprotein 1, 
mitochondrial 
NDUFV1 0.555 -0.91624 0.043846 7.76 50.8 
O15533 Tapasin TAPBP 0.554 -0.91884 0.043251 1.79 47.6 
Q13155 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 2 
AIMP2 0.553 -0.92145 0.042661 2.5 35.3 
Q96RU3 Formin-binding protein 1 FNBP1 0.55 -0.9293 0.040926 3.08 71.3 
Q92600 Cell differentiation protein RCD1 homolog RQCD1 0.548 -0.93455 0.039798 3.01 33.6 
O60684 Importin subunit alpha-7 KPNA6 0.544 -0.94512 0.037609 2.61 60 
Q99426 Tubulin-folding cofactor B TBCB 0.54 -0.95577 0.035508 4.51 27.3 
P12724 Eosinophil cationic protein RNASE3 0.537 -0.96381 0.03399 7.5 18.4 
P27816 Microtubule-associated protein 4 MAP4 0.536 -0.9665 0.033494 1.13 120.9 
O95155 Ubiquitin conjugation factor E4 B UBE4B 0.529 -0.98546 0.030172 0.69 146.1 
P17213 Bactericidal permeability-increasing protein BPI 0.529 -0.98546 0.030172 4.93 53.9 
Q9UFF9 CCR4-NOT transcription complex subunit 8 CNOT8 0.526 -0.99367 0.028825 4.79 33.5 
Q96C01 Protein FAM136A FAM136A 0.52 -1.01022 0.026264 7.25 15.6 
  
Q8TBG4 Ethanolamine-phosphate phospho-lyase ETNPPL 0.513 -1.02977 0.023494 5.01 55.6 
P03928 ATP synthase protein 8 MT-ATP8 0.511 -1.03541 0.022745 13.24 8 
Q7Z2X4 PTB-containing, cubilin and LRP1-interacting protein PID1 0.501 -1.06392 0.019262 2.8 28.3 
P13807 Glycogen (starch) synthase, muscle GYS1 0.5 -1.0668 0.018937 1.9 83.7 
P25774 Cathepsin S CTSS 0.495 -1.0813 0.017376 3.32 37.5 
P49863 Granzyme K GZMK 0.487 -1.10481 0.015084 3.41 28.9 
Q96I25 Splicing factor 45 RB<17 0.481 -1.12269 0.013522 5.49 44.9 
P35499 Sodium channel protein type 4 subunit alpha SCN4A 0.48 -1.1257 0.013275 0.54 207.9 
Q9GZT3 
SRA stem-loop-interacting RNA-binding protein, 
mitochondrial 
SLIRP 0.478 -1.13172 0.01279 9.17 12.3 
Q9UBQ0 Vacuolar protein sorting-associated protein 29 VPS29 0.477 -1.13474 0.012553 5.49 20.5 
P06239 Tyrosine-protein kinase Lck LCK 0.464 -1.17461 0.009769 3.54 58 
Q07973 
1,25-dihydroxyvitamin D(3) 24-hydroxylase, 
mitochondrial 
CYP24A1 0.448 -1.22523 0.007033 1.36 58.8 
P08779 Keratin, type I cytoskeletal 16 KRT16 0.441 -1.24795 0.006046 16.07 51.2 
O43516 WAS/WASL-interacting protein family member 1 WIPF1 0.41 -1.35311 0.002915 1.59 51.2 
Q93077 Histone H2A type 1-C HIST1H2AC 0.402 -1.38154 0.002373 62.31 14.1 
Q9BZR8 Apoptosis facilitator Bcl-2-like protein 14 BCL2L14 0.385 -1.44387 0.001492 1.83 36.6 
Q86TC9 Myopalladin MUPN 0.351 -1.57726 0.000521 2.12 145.2 
P49189 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 0.349 -1.5855 0.000487 2.43 53.8 
A6NN90 Uncharacterised protein C2orf81 C2orf81 0.346 -1.59796 0.000439 2.75 63 
P62328 Thymosin beta-4 TMSB4X 0.298 -1.81342 6.63E-05 45.45 5 
P05204 Non-histone chromosomal protein HMG-17 HMGN2 0.297 -1.81827 6.34E-05 24.44 9.4 
Q8IUE6 Histone H2A type 2-B HIST2H2AB 0.284 -1.88284 3.44E-05 56.92 14 
 
  
Differentially expressed proteins in thalassaemic treated over healthy treated samples (ratio 4) 
Protein ID Protein description Protein name 
Average 
ratio 
Log2 value P-value Coverage 
MW 
(kDa) 
P52564 Dual specificity mitogen-activated protein kinase kinase 6 MAP2K6 5.757 2.666704113 4.33209E-13 7.49 37.5 
Q494V2 Coiled-coil domain-containing protein 37 CCDC37 3.652 2.010073666 4.73824E-08 1.15 71.1 
Q9H8M2 Bromodomain-containing protein 9 BRD9 2.573 1.504838357 4.34608E-05 1.17 67 
Q96HH6 Transmembrane protein 19 TMEM19 2.442 1.429450101 0.000102982 11.01 36.4 
P02787 Serotransferrin TF 2.334 1.364191461 0.000210422 2.01 77 
Q9Y5E8 Protocadherin beta-15 PCDHB15 2.274 1.326619154 0.000313249 3.18 86.3 
Q7LDG7 RAS guanyl-releasing protein 2 RASGRP2 2.061 1.184731405 0.001288105 1.97 69.2 
P02771 Alpha-fetoprotein AFP 1.842 1.022659962 0.005464255 2.96 68.6 
Q9NZJ9 Diphosphoinositol polyphosphate phosphohydrolase 2 NUDT4 1.822 1.006909859 0.006228173 13.33 20.3 
P04004 Vitronectin VTN 1.795 0.985370744 0.007428374 4.81 54.3 
Q9Y6G3 39S ribosomal protein L42, mitochondrial MRPL42 1.777 0.970830582 0.008351912 10.56 16.7 
O75380 
NADH dehydrogenase (ubiquinone) iron-sulfur protein 6, 
mitochondrial 
NDUSFS6 1.703 0.909465335 0.013481565 17.74 13.7 
Q7L5D6 Golgi to ER traffic protein 4 homolog GET4 1.693 0.900968873 0.014376915 4.59 36.5 
P02647 Apolipoprotein A-I APOA1 1.683 0.892422077 0.015330078 5.99 30.8 
O95239 Chromosome-associated kinesin KIF4A KIF4A 1.674 0.884686428 0.016240295 3.75 51.1 
O43493 Trans-Golgi network integral membrane protein 2 TGOLN2 1.674 0.884686428 0.016240295 0.89 139.8 
P02774 Vitamin D-binding protein GC 1.67 0.881235003 0.016661503 8.23 52.9 
P20701 Integrin alpha-L ITGAL 1.662 0.874307282 0.017535995 1.62 128.7 
O15514 DNA-directed RNA polymerase II subunit RPB4 POLR2D 1.654 0.867346135 0.018454978 10.56 16.3 
Q9HBI1 Beta-parvin PARVB 1.65 0.863852925 0.018931822 3.85 41.7 
P55285 Cadherin-6 CDH6 1.644 0.858597199 0.019669556 1.77 88.3 
  
P02765 Alpha-2-HS-glycoprotein AHSG 1.634 0.849794884 0.020961424 6.81 39.3 
Q9C0B1 Alpha-ketoglutarate-dependent dioxygenase FTO FTO 1.63 0.846258865 0.021500845 3.17 58.2 
Q5VTE6 Protein angel homolog 2 ANGEL2 1.628 0.8444876 0.021775567 2.57 62.3 
Q9UBB4 Ataxin-10 ATXN10 1.606 0.824858793 0.025030383 3.16 53.5 
P04114 Apolipoprotein B-100 APOB 1.605 0.823960198 0.025188973 0.61 515.3 
Q9NPA8 Enhancer of yellow 2 transcription factor homolog ENY2 1.603 0.822161326 0.025509064 16.83 11.5 
Q9NZD4 Alpha-haemoglobin-stabilizing protein AHSP 1.598 0.817654309 0.026326538 35.29 11.8 
P02724 Glycophorin-A GYPA 1.592 0.812227236 0.027340846 20.67 16.3 
O15111 Inhibitor of nuclear factor kappa-B kinase subunit alpha CHUK 1.588 0.808597813 0.02803784 1.21 84.6 
A2RU67 Uncharacterised protein KIAA1467 KIAA1467 1.583 0.804048156 0.028933144 2.57 67 
Q13564 NEDD8-activating enzyme E1 regulatory subunit NAE1 1.582 0.8031365 0.029115474 2.81 60.2 
P02775 Platelet basic protein PPBP 1.579 0.800398071 0.029669114 18.75 13.9 
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 ITIH3 1.577 0.79856956 0.030043813 2.47 99.8 
Q96KS0 Egl nine homolog 2 EGLN2 1.576 0.797654435 0.030232863 2.21 43.6 
Q96IZ7 Serine/Arginine-related protein 53 RSRC1 1.56 0.782932929 0.033417466 2.99 38.7 
P23786 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 1.551 0.774585587 0.03534759 1.82 73.7 
Q15057 
Arf-GAP with coiled-coil, ANK repeat and PH domain-
containing protein 2 
ACAP2 1.549 0.772724044 0.035790769 2.44 88 
O14880 Microsomal glutathione S-transferase 3 MGST3 1.546 0.76992722 0.036465516 14.47 16.5 
P02768 Serum albumin ALB 1.524 0.749249803 0.041798284 9.2 69.3 
Q9BXD5 N-acetylneuraminate lyase NPL 1.522 0.747355259 0.042318342 3.44 35.1 
Q8NF50 Dedicator of cytokinesis protein 8 DOCK8 1.514 0.739752106 0.044460824 0.86 238.4 
Q93077 Histone H2A type 1-C HIST1H2AC 1.513 0.738798888 0.044735778 62.31 14.1 
Q9NU22 Midasin MDN1 1.505 0.731150387 0.046994322 0.25 632.4 
Q8IU89 Ceramide synthase 3 CERS3 1.504 0.730191467 0.047284137 5.22 46.3 
  
Q15650 Activating signal cointegrator 1 TRIP4 1.499 0.725387284 0.048758833 1.38 66.1 
Q6NZY4 Zinc finger CCHC domain-containing protein 8 ZCCHC8 1.497 0.723461122 0.049360838 1.98 78.5 
P30508 HLA class I histocompatibility antigen, Cw-12 alpha chain HLA-C 1.496 0.722497075 0.049664477 13.93 40.9 
Q0VD83 Apolipoprotein B receptor APOBR 1.495 0.721532385 0.049969885 1.38 114.8 
Q9UFF9 CCR4-NOT transcription complex subunit 8 CNOT8 0.549 -0.723735045 0.049274847 4.79 33.5 
O43427 
Acidic fibroblast growth factor intracellular-binding 
protein 
FIBP 0.547 -0.729000362 0.047646217 2.47 41.9 
Q96BW5 Phosphotriesterase-related protein PTER 0.545 -0.734284965 0.046057362 3.15 39 
Q96C01 Protein FAM136A FAM136A 0.545 -0.734284965 0.046057362 7.25 15.6 
Q14258 E3 ubiquitin/ISG15 ligase TRIM25 TRIM 0.544 -0.736934543 0.045277691 3.33 70.9 
Q96A26 Protein FAM162A FAM162A 0.543 -0.739588997 0.044507771 7.14 17.3 
P49006 MARCKS-related protein MARCKSL1 0.542 -0.742248343 0.043747538 6.67 19.5 
Q9UHL4 Dipeptidyl peptidase 2 DPP7 0.54 -0.747581787 0.042255872 8.13 54.3 
Q14997 Proteasome activator complex subunit 4 PSME4 0.54 -0.747581787 0.042255872 0.71 211.2 
Q9NYL4 Peptidyl-prolyl cis-trans isomerase FKBP11 FKBP11 0.538 -0.752935022 0.040802168 10.45 22.2 
Q8TAE8 
Growth arrest and DNA damage-inducible proteins-
interacting protein 1 
GADD45GIP1 0.536 -0.758308194 0.039385895 4.5 25.4 
Q99614 Tetratricopeptide repeat protein 1 TTC1 0.535 -0.761002303 0.038691629 4.11 33.5 
Q7L2H7 Eukaryotic translation initiation factor 3 subunit M EIF3M 0.534 -0.763701453 0.038006519 4.28 42.5 
P16989 Y-box-binding protein 3 YBX3 0.534 -0.763701453 0.038006519 4.73 18.8 
P30536 Translocator protein TSPO 0.534 -0.763701453 0.038006519 7.53 40.1 
P03928 ATP synthase protein 8 MT-ATP8 0.534 -0.763701453 0.038006519 13.24 8 
P61201 COP9 signalosome complex subunit 2 COPS2 0.533 -0.766405662 0.037330499 7.9 51.6 
O95155 Ubiquitin conjugation factor E4 B UBE4B 0.533 -0.766405662 0.037330499 0.69 146.1 
Q10589 Bone marrow stromal antigen 2 BST2 0.53 -0.774548835 0.035356294 8.33 19.8 
P27816 Microtubule-associated protein 4 MAP4 0.528 -0.780003265 0.034084354 1.13 120.9 
  
Q9UHG3 Prenylcysteine oxidase 1 PCYOX1 0.526 -0.785478395 0.032847129 2.18 56.6 
Q99426 Tubulin-folding cofactor B TBCB 0.526 -0.785478395 0.032847129 4.51 27.3 
P17900 Ganglioside GM2 activator GM2A 0.518 -0.807589097 0.028234253 3.63 20.8 
P49354 
Protein farnesyltransferase/geranylgeranyltransferase type-
1 subunit alpha 
FNTA 0.516 -0.813170129 0.027162238 4.75 44.4 
P05109 Protein S100-A8 S100AB 0.514 -0.818772835 0.026121578 56.99 10.8 
Q15075 Early endosome antigen 1 EEA1 0.509 -0.832875538 0.023653388 0.85 162.4 
P07766 T-cell surface glycoprotein CD3 epsilon chain CD3E 0.509 -0.832875538 0.023653388 6.76 23.1 
O60888 Protein CutA CUTA 0.501 -0.855730591 0.020082422 7.82 19.1 
Q96I25 Splicing factor 45 RBM17 0.5 -0.8586131 0.019667287 5.49 44.9 
O75844 CAAX prenyl protease 1 homolog ZMPSTE24 0.495 -0.873112669 0.017690792 2.11 54.8 
P48595 Serpin B10 SERPINB10 0.488 -0.893660047 0.015188658 4.03 45.4 
P04424 Argininosuccinate lyase ASL 0.482 -0.911508048 0.013273796 2.59 51.6 
P25774 Cathepsin S CTSS 0.478 -0.923530576 0.012107353 3.32 37.5 
Q07973 
1,25-dihydroxyvitamin D(3) 24-hydroxylase, 
mitochondrial 
CYP24A1 0.471 -0.944814135 0.01026353 1.36 58.8 
Q9H2U1 Probable ATP-dependent RNA helicase DHX36 DHX36 0.469 -0.950953272 0.009780335 0.89 114.7 
P12724 Eosinophil cationic protein RNASE3 0.462 -0.972648343 0.008231093 7.5 18.4 
O75351 Vacuolar protein sorting-associated protein 4B VPS4B 0.461 -0.975774444 0.008026969 3.6 49.3 
P49189 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 0.455 -0.994674649 0.006886566 2.43 53.8 
P49863 Granzyme K GZMK 0.449 -1.01382575 0.005881619 3.41 28.9 
Q99447 Ethanolamine-phosphate cytidylyltransferase PCYT2 0.442 -1.036494825 0.004864152 3.6 43.8 
P17213 Bactericidal permeability-increasing protein BPI 0.438 -1.049610325 0.004350982 4.93 53.9 
Q92600 Cell differentiation protein RCD1 homolog RQCD1 0.434 -1.062846152 0.003883349 3.01 33.6 
P06239 Tyrosine-protein kinase Lck LCK 0.433 -1.06617417 0.003773187 3.54 58 
Q92609 TBC1 domain family member 5 TBC1D5 0.427 -1.086305125 0.003165241 1.38 88.9 
  
P35499 Sodium channel protein type 4 subunit alpha SCN4A 0.415 -1.127429858 0.002191719 0.54 207.9 
Q86TC9 Myopalladin MYPN 0.41 -1.144917285 0.001868014 2.12 145.2 
O43516 WAS/WASL-interacting protein family member 1 WIPF1 0.387 -1.228207628 0.000847701 1.59 51.2 
Q9GZT3 
SRA stem-loop-interacting RNA-binding protein, 
mitochondrial 
SLIRP 0.37 -1.293015924 0.000443414 9.17 12.3 













Differentially express proteins attributed to the disease state 







Ratio 2: thal 
treated/un-
treated 
Ratio 1: healthy 
treated/un-
treated 
Q9H8M2 Bromodomain-containing protein 9 
possible role in chromatin remodelling 




responsible for transport of iron from 
sites of absorption and haem 




Q9Y5E8 Protocadherin beta-15 












role in signal transduction ↑ ↑ 
  
P02774 Vitamin D-binding protein 
carries vitamin D sterols and prevents 






chaperone to prevent the harmful 
aggregation of alpha-haemoglobin during 
normal erythroid cell developments 
↑ ↑ 
  
Q9BXD5 N-acetylneuraminate lyase 
catalyzes cleavage of sialic acid to 




HLA class I histocompatibility 
antigen, Cw-12 alpha chain 
involved in presentation of foreign 
antigens to the immune system 
↑ ↑ 
  
Q96C01 Protein FAM136A mitochondrial protein ↓ ↓ 
  
O95155 Ubiquitin conjugation factor E4 B catalyzes ubiquitin chain assembly ↓ ↓ 
  
Q10589 Bone marrow stromal antigen 2 




P27816 Microtubule-associated protein 4 promotes microtubule assembly ↓ ↓ 
  
Q99426 Tubulin-folding cofactor B 




P17900 Ganglioside GM2 activator stimulates ganglioside GM2 degradation ↓ ↓ 
  
  
Q96I25 Splicing factor 45 
involved in regulation of alternative 









maintaining calcium homeostasis ↓ ↓ 
  
P12724 Eosinophil cationic protein cytotoxin exhibiting antibacterial activity ↓ ↓ 
  
O75351 
Vacuolar protein sorting-associated 
protein 4B 














Cell differentiation protein RCD1 
homolog 
Component of CCR4-NOT complex, a 
cellular mRNA deadenylases 
↓ ↓ 
  
P06239 Tyrosine-protein kinase Lck 
important in selection and maturation of 




Sodium channel protein type 4 
subunit alpha 
mediated voltage-dependent sodium ion 
permeability of excitable membranes 
↓ ↓ 
  




family member 1 






binding protein, mitochondrial 
RNA binding protein that acts as a 




Apoptosis facilitator Bcl-2-like 
protein 14 
involved in apoptosis ↓ ↓ 
  
P02765 Alpha-2-HS-glycoprotein 
promotes endocytosis, possesses opsonic 
properties and influences the mineral 
phase of bone 
↑ ↑ ↓ 
 
P52564 
mitogen-activated protein kinase 
kinase 6 
activation of MAP kinase signal 
transduction pathway in response to 
cytokines and all kinds of stresses 
↑ ↑ ↑ ↑ 
Q93077 Histone H2A type 1-C 
component of nucleosome involved in 
transcription regulation and 
chromosomal stability 









involved in integrin signalling via ILK 





required for maturation and nuclear 




P02647 Apolipoprotein A-I 






Golgi to ER traffic protein 4 
homolog 
component of the BAT3 complex 
involved in post-translational delivery of 








CCR4-NOT transcription complex 
subunit 8 
Involved in mRNA degradation and 
translational repression during 








catalyzes the irreversible oxidation of a 





Q92734 Protein TFG 
Interacts with TANK &NEMO – 
proteins involved in the NF-κB pathway  
↑ ↓ ↑ 
P05204 
Non-histone chromosomal protein 
HMG-17 
Involved in transcription regulation of 
gene containing or in close proximity to 
AT rich regions 
 




catalyzed breakdown of 
phosphoethanolamide  
↓ ↑ ↓ 
P62328 Thymosin beta-4 involved in organization of cytoskeleton 
 
↓ ↑ ↓ 
A6NN90 Uncharacterised protein C2orf81 uncharacterised 
 
↓ ↑ ↓ 
Q8IUE6 Histone H2A type 2-B core component of nucleosome 
 
↓ ↑ ↓ 
Q15006 
ER membrane protein complex 
subunit 2 





P42785 Lysosomal Pro-X carboxypeptidase 
cleaves C-terminal amino acids linked to 








Vacuolar protein sorting-associated 
protein 29 
component of retromer complex used in 















PTB-containing, cubilin and LRP1-
interacting protein 
Over expression increase ROS 
production and significantly inhibit 
phosphorylation of IRS1 and serine 
phosphorylation of Akt which is restored 











Q96RU3 Formin-binding protein 1 
act as a link between RND2 singling and 










Peptidylprolyl isomerase domain 
and WD repeat-containing protein 1 






ER membrane protein complex 
subunit 1 





Q9UIG0 Tyrosine-protein kinase BAZ1B 
plays a central role in chromatin 
remodelling and acts as a transcription 





Q9UHY7 Enolase-phosphatase E1 
bifunctional enzyme involved in amino-











LIST OF ABBREVIATIONS 
 
2DE  Two Dimensional Electrophoresis  
ABCB6  ATP-binding Cassette subunit-family B member 6 
AFP  Alpha-haemoglobin stabilizing protein 
AMG     Aorta-Gonad-Mesonephros 
AP-1  Activator Protein 1 
APC  Allphycocyanine 
ARG1/2 Arginine 1/2 
ARHGAP4 Rho GTPase-activating Protein 4 
ATF-2  Activating Factor-2 
BAZ1B  Bromodomain Adjacent to Zinc Finger Domain, 1B 
BCL11A B-cell Lymphoma/Leukaemia 11A 
BFU-e  Burst Forming Unit, erythroid 
BHQ  Black Hole Quencher 
BP  Biological Process   
BRE   TFIIB- recognition Element 
BRG1  ATP-dependent helicase SMARCA4 
BSA  Bovine Serum Albumin 
bZIP  Basic Leucin Zipper domain 
cAMP  cyclic Adenosine Monophosphate 
CBP  CREB-binding Protein 
CC  Cellular Component 
CCR4  Chemokine (C-C motif) Receptor 4 
CD235  Glycophorin A 
CD71   Transferring receptor 
Cdc2  Cell division cycle protein 2 homolog (CDK1, cyclin-dependent kinase 1) 
cDNA  Complementary DNA 
CEP120  Centrosomal protein 120kDa 
CFU-e  Colony Forming Unit, erythroid 
cGMP  cyclic Guanosine Monophospate 
CHD4  Chromodomain-helicase DNA binding protein 4 
CHD5  Chromodomain-helicase Binding protein 5 
ChIP  Chromatin Immunoprecipitation 
Chop  C/CBP homologous protein -10   
CHUK  Conserved Helix-loop-helix Ubiquitous Kinase (IKKα) 
CID  Collision-induced Dissociation 
CML  Chronic Myeloid Leukaemia 
COPS2  COP9 signalosome complex Subunit 2 
CoREST Corepressor for Element-1-silencing Transcription factor   
COX  Cyclooxygenase   
CP1  Cleft palate, isolated 
CPT2  Carnitine O-palmitoyltransferase 2 
CRE  Ca
2+
/cAMP response element 
CREB  Cyclic AMP Response Element Binding protein  
CREBP  CREB-binding protein 
CRISPR  Clustered Regularly Interspaced Short Palidromic Repeats 
CUTA  Protein CutA 
Da   Dalton 
DBD  DNA-binding drug 
Dec  Decitabine (5-aza-2’-deoxycytidine)  
DMSO  Dimethyl Sulfoxide 
DNA  Deoxyribonucleic acid 
DNAJA3 DNAJ Homolog Subfamily A Member 3 
DNMT1  DNA Methyltransferase 1 
dNTP  deoxyribonucleotide 
DPE   Downstream Promoter Element 
DR  Direct Repeat Elements 
DR1  Down-Regulator of Transcription 1, TBP-Binding 
DRED  Direct Repeat Erythroid-definitive 
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DSB  DNA double-strand breaks 
EF  helix-loop-helix structural domain in calcium-binding proteins 
EGLN2  Egl-9 Family Hypoxia-Inducible Factor 2 
eIF2A  eukaryotic Translation Initiation Factor 2A 
EKLF (KLF1)  Erythroid Kruppel-like Factor (Kruppel-like Factor 1) 
EPC  Erythroid precursor cell 
EPO  Erythropoietin 
ER  Endoplasmic Reticulum 
ERK  Extracellular signal-regulated kinase 
ESI  Electrospray Ionisation 
FBS  Foetal Bovine Serum 
FCH  conserved region of ~60 amino acids homologous between FER and CIP4 proteins 
FCS  Foetal Calf Serum 
FOG-1  Friend of GATA1 
FOXO  Forkhead box protein O 
FOP  Fibroblast growth factor receptor 1 (FGFR1) Oncogene partner 
GABA-A γ-aminobutyric acid receptor A 
GADD  Growth arrest- and DNA damage-inducible gene 
GADD153 Growth arrest- and DNA damage-inducible gene 153 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
GATA1  GATA-binding protein 1 
GMFB  Glia Maturation Factor Beta 
GPA  Glycophorin A 
GYPA  Glycophorin A 
H3  Histone 3   
H3K27  Histone 3 Lysine 27 
H3K36  Histone 3 Lysine 36 
H3K4  Histone 3 Lysine 4 
H3K4me2 Histone 3 Lysine 4 di-methylation 
H3K9  Histone 3 Lysine 9 
H4   Histone 4 
H4R3  Histone 4 arginine 3 
HAT  Histone Acetyltransferase 
Hb  Haemoblogin   
HbA     Adult haemoglobin 
HBB  β-globin  
HbF  Foetal haemoglobin 
HBG  γ-globin 
HCD  High-energy Collisional Dissociation 
HDAC  Histone Deacetylase 
HDR  Homology-directed repair 
HEXIM1 Hemamethylene bis-acetamide-inducible protein 1 
HIF  Hypoxia-induced Factor 
HIST2H2AB/AC  Histone H2A type 2B /1C 
HMG  High Mobility Group  
HMOX1 Haem oxygenase  
HPFH  Hereditary Persistence of Foetal Haemoglobin 
HPLC  High Performance Liquid Chromatography 
HRI  Haem-regulated inhibitor kinase  
HS  Hypersensitive Sites 
HSB1L  HSB1-like (S. cerevisiae) 
HSC     Haematopoietic Stem Cell 
HTATIP2 HIV-1 Tat Interactive Protein 2 
HU  Hydroxyurea 
IFN-γ  Interferon gamma  
IKKβ  Inhibitor of nuclear factor kappa-B kinase subunit beta 
IL-3  Interluekin-3 
IL-6  Interluekin-6 
Inr   Initiation element 
IP  Immunoprecipitation 
iPS  Induced Pluripotent Stem  
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ITGAL  Integrin Alpha-L 
iTRAQ  Isobaric tags for Relative and Absolute Quantitation 
JMJD6  Jumonji domain Containing 6 
JNK  c-Jun N-terminal kinase 
KEAP1  Kelch-like ECH-associated Protein 1 
KIAA1731 Centrosomal protein KIAA1731 
LB  Luria-Bertani 
LBD1  LOB Domain-containing protein 1 
LC-MS/MS Liquid Chromatography-Tandem Mass Spectrometry 
LCR    Locus Control Region 
LMO2 LIM domain Only Protein 2   
LSD1  Lysine-specific Histone Demethylase 1 
MAP2K6 Dual specificity mitogen-activated protein kinase kinase 6 
MAPK  Mitogen-activated protein kinase 
MARE  Maf-response Element 
MBD  Methyl cytosine-binding Domain   
MBD2  Methyl cytosine-binding Domain 2 
MBD3  Methyl cytosine-binding Domain 3 
MCS   Multi-species Conserved Sequences 
MDS  Myelodysplastic syndrome 
MeCP2  Methyl CpG binding protein 2 
MEKK  MAP Kinase Kinase Kinase 
MEL  Mouse Erythroleukaemia                            
MF  Molecular Function 
MKK  Dual specificity mitogen-activated protein Kinase Kinase  
MRPL42 Mitochondrial 39S ribosomal protein L42 
MS  Mass Spectrometry 
MS/MS  Tandem Mass spectrometry 
MW  Molecular weight 
MYB  Myeloblastosis oncogene 
MYBL1  Myb-Related Protein A 
NADPH  Nicotinamide Adenine Dinucleotide Phosphate 
NCOR  Nuclear receptor co-repressor   
NDUFAF2 NADH Dehydrogenase (Ubiquinone) Complex I, Assembly Factor 2 
NDUFS6 NADH dehydrogenase (Ubiquinone) iron-sulfur protein 6 
NF-E2  Nuclear Factor, Erythroid 2 
NF-Y Nuclear transcription factor Y  
NF-κB  Nuclear Factor kappa-B 
NHEJ  Non-homologous end joining 
NO  Nitric oxide 
NQO1  NADPH Quinine Oxyreductase 1 
NRF2  Nuclear factor (erythroid-derived 2)-like 2 
NTDT  Non-transfusion depended Thalassaemia 
NuRD  Nucleosome Remodelling Deacetylase 
PAGE  Polyacrylamide Gel Electrophoresis 
PBMC  Peripheral blood mononuclear cells 
PBS  Phosphate-buffered saline 
PCAF  p300/CBP-associated Factor 
PCBP2  Poly(rC)-binding protein 2 
PCR  Polymerase Chain Reaction  
PDE  Phophodiesterases 
PE  Phycoerythrin  
PHD1  Prolyl-4-hydroxylase 1 
PI3K  Phosphatodylinositol-4,5-bisphosphate 3-kinase 
PICALM Phosphatidylinositol binding Clathrin Assembly protein 
PITPNA  Phosphatidylinositol transfer protein Alpha isoform 
PP2A  Protein phosphates 2 
PPARγ  Peroxisome Proliferator-activated receptor gamma (γ) 
PPP2R5D Serine/threonin-protein phosphatise 2A Regulatory subunit delta 
PPP5C  Serine/threonine-protein phosphatase 5 
PRL-1  Phosphatase of Regenerating Liver protein-1 
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PRMT5  Protein Arginine Methyltransferase 5 
PSMB10 Proteasome Subunit Beta type-10 
P-TEFb  Positive Transcription Elongation Factor b  
PTPN7  Protein Tyrosine Phosphatase, Non-Receptor Type 7 
pVHL  von Hippel-Lidau tumor suppressor 
PYCARD Apoptosis-associated speck-like protein containing CARD 
qRT-PCR Quantitative real-time PCR 
QTL  Quantitative Trait Locus 
RASGRP2 RAS Guanyl-releasing protein 2 
RBM10  RNA-binding protein 10 
RCBTB2 RCC1 and BTB domain-containing Protein 2 
RNA pol RNA polymerase 
RNA  Ribonucleic acid 
RNAi  RNA interference 
ROS  Reactive Oxygen Species 
RSRC1  Serine/Arginine-related Protein 53 
RT-PCR  Reverse Transcription Polymerase Chain Reaction 
RUNX1  Runt-related transcription factor 1 
S100A8  S100 Calcium Binding Protein A8 
SAR  Secretion-associated and RAS-related 
SCF  Stem Cell Factor 
SCFA  Short Chain Fatty Acids 
SCL  Stem Cell Leukemia 
SDS  Sodium Dodecyl Sulphate 
SEC14L3 SEC14-like Protein 3 (S. Cerevisiae) 
SEMA3A Semaphorin-3A 
SEPINB10 Serpin B10 
sGC  soluble Guanyl Cyclise 
shRNA  short hairpin RNA 
siRNA  small interfering RNA 
SIRT1  Silent mating type Information regulation 2 homolog 1    
SMARCD3 SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily D  
SNP  Single Nucleotide Polymorphism 
SOX6  SRY (sex determining region Y)-box 6 
SP1  Specific Protein 1 
SPF45  Splicing Factor 45 
SRP54  Signal Recognition Particle 54kDa protein 
SSE  Stage Selector Element 
SWI/SNF SWItch/Sucrose NonFermentable 
TACC3  Transforming, Acidic Coiled-Coil Containing Protein 
TAF  TBP-associated Factor 
TAF9  TBP-associated Factor 9 
Tal1 T-cell Acute lymphocytic leukemia 1 
TALEN  Transcription Activator-like Effector Nucleases 
TBC1D5 TBC1 Domain family member 5 
TBP  TATA-binding Protein 
TF  Serotransferin 
THOC5  THO complex subunit 5 homolog 
TMEM19 Transmembrane protein 19 
TNF-α  Tumour-necrosis Factor α 
TR2/4  Testicular Receptor 2/4 
TRD  Transcriptional Repression Domain 
TRIM28  Tripartite motif-containing 28 
USP11  Ubiquitin Carboxyl-terminal hydrolase 11 
UTR  Un-translated Region 
VNT  Vitronectin 
VTDB  Vitamin B Binding protein 
XRN2  5-3’ exoribonuclease 2 
YBX3  Y-box –binding protein 3 
YY1  Yin Yang 1 
ZFN  Zing Finger Nucleases 
